

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

## Overview for Request: cder\_ssq\_wp003

**Request ID:** cder\_ssq\_wp003\_nsdv\_v01

**Request Description:** In this report, we described cohorts identified by five diagnosis code-based algorithms designed to detect Coronavirus Disease 2019 (COVID-19) in the inpatient (IP) setting. We calculated the positive predictive value (PPV) and sensitivity of each algorithm to compare algorithm performance, using diagnostic nucleic acid amplification (NAA) test laboratory result as our reference standard. This report describes Phase Two of a two-phase project.

**Data Source:** We distributed this request to six Sentinel Data Partners (DPs) on October 30, 2020. These two national insurers and four integrated delivery systems (IDS) used the most current data available to them, which included a combination of adjudicated and unadjudicated claims, electronic medical records, and reports from external laboratories. Patients hospitalized between February 20, 2020 and October 17, 2020 are included in this report. See Appendix A for a list of the latest dates of available data for each Data Partner.

**Algorithms:** We developed five diagnosis code-based algorithms based on International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes to detect a COVID-19 diagnosis. See Appendices B and C for diagnosis codes.

1. U07.1 (COVID-19)
2. U07.1 or B97.29 (Other coronavirus as the cause of diseases classified elsewhere)
3. U07.1 or B97.29 or B34.2 (Coronavirus infection, unspecified)
4. U07.1 or B97.29 or B34.2 or J12.81 (Pneumonia due to SARS-associated coronavirus) or B97.21 (SARS-associated coronavirus as the cause of diseases classified elsewhere)
5. [U07.1 or B97.29] and [pneumonia or acute respiratory distress syndrome (ARDS)]

**Algorithm Cohorts:** We identified inpatient stays with diagnosis codes that met any of the five algorithms, stratified across three time periods: A) February 20, 2020 to March 31, 2020; B) April 1, 2020 to April 30, 2020; and C) May 1, 2020 to October 17, 2020. The hospital admission date was the anchor point for determining time period and assessing patient characteristics. See Appendix G for the design diagrams detailing the study parameters for this request for each of the three time periods assessed.

**Eligible Encounters:** We included only the first qualifying inpatient stay per patient per algorithm. Patients could only be counted toward a single algorithm one time, and only in a single time period, but were counted toward all fulfilled algorithms.

**Lab Result Classification:**

Within each algorithm-identified cohort, we classified patients into four categories, based on COVID NAA testing:

- Lab positive: If patient had at least one positive NAA result during  $\pm 14$  days from hospital admission
- Lab negative: If patient had only negative NAA results during  $\pm 14$  days from hospital admission
- Lab performed, no result to date
- No known lab test

**NAA-Tested Cohorts:** We identified cohorts of all patients with known COVID NAA test results within  $\pm 14$  days from any inpatient stay, and classified them according to their test result. We reported the total counts of patients with positive or negative tests, as well as the total count of tests, including multiple tests per patient. Total count of patients with a positive test was the denominator for our sensitivity calculation.

**Descriptive Characteristics:** We stratified all cohorts by sex, age category, race, and ethnicity. We additionally stratified according to clinical symptoms, identified by ICD-10-CM diagnosis codes, antibody and antigen test results, and NAA diagnostic product description where available, identified by Logical Observation Identifiers Names and Codes (LOINC) terminology. See Appendices D-F for a list of LOINC codes.

**Performance Measures:** We calculated PPV and sensitivity for each algorithm, in each time period, both overall and stratified by DP type (claims, IDS).

**Positive Predictive Value (PPV):** Among patients who fulfill each algorithm: (Count of NAA positive patients) / (Count of patients with any NAA test result)

**Sensitivity:** (Count of NAA positive patients who fulfill an algorithm) / (Total count of NAA positive patients among that time period's lab-tested cohort)

We calculated 95% confidence intervals using the exact Clopper-Pearson formula.

**Overview for Request: cder\_ssq\_wp003**

**Optional Table:** Two DPs provided counts of patients who fulfilled each of the five algorithms of interest in the outpatient setting. These results are reported in Table 3.

**Limitations:** Algorithms to define exposures, outcomes and treatments are imperfect and may be misclassified. Therefore, data should be interpreted with this limitation in mind. Death data may be incomplete and should be interpreted with caution.

**Notes:** Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document.

**Table of Contents**

<b><u>Table 1a</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020
<b><u>Table 1b</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020
<b><u>Table 1c</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020
<b><u>Table 1d</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020
<b><u>Table 1e</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020
<b><u>Table 1f</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020
<b><u>Table 1g</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020
<b><u>Table 1h</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020
<b><u>Table 1i</u></b>	Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020
<b><u>Table 2a</u></b>	Summary of Outcomes for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and October 17, 2020, by Time Period
<b><u>Table 2b</u></b>	Summary of Outcomes for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020, by Time Period
<b><u>Table 2c</u></b>	Summary of Outcomes for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and October 17, 2020, by Time Period
<b><u>Table 3</u></b>	Descriptive Summary of Outpatient Encounters Meeting the COVID-19 Claims Algorithms in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020
<b><u>Appendix A</u></b>	Most Recent Lab Data Dates for Each Data Partner (DP) up to the Request End Date (October 17, 2020)
<b><u>Appendix B</u></b>	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Pneumonia in this Request
<b><u>Appendix C</u></b>	List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Sepsis in this Request
<b><u>Appendix D</u></b>	List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Nucleic Acid Amplification (NAA) Diagnostic Tests in this Request
<b><u>Appendix E</u></b>	List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Antibody Tests in this Request
<b><u>Appendix F</u></b>	List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Antigen Tests in this Request
<b><u>Appendix G</u></b>	Design Diagrams Detailing the Study Parameters for this Request for each of the Three Time Periods Assessed

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test*****</b>				
Total Observed	1,524	2,642	1,917	3,291
Inpatient	401	208	694	606
Outpatient or Emergency Department	331	131	288	123
Other	47	7	131	65
Care Setting Reported as Unknown	385	1,898	447	2,094
<b>Demographics</b>				
Sex				
Female	615	1,026	1,022	1,709
Male	909	1,616	895	1,582
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	0	0	39	68
6-17	1	2	16	40
18-29	40	77	84	154
30-39	84	173	146	286
40-49	185	329	143	307
50-59	311	590	266	567
60-69	387	704	395	663
70-79	311	459	407	601
80-89	159	236	314	438
90+	46	72	106	166
Missing	0	0	0	0
Race				
American Indian or Alaska Native	3	3	4	4
Asian	33	38	46	50

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Black or African American	193	211	161	179
Native Hawaiian or Other Pacific Islander	2	2	1	1
White	342	387	785	871
Other/Mixed/Unknown	951	2,001	920	2,186
<b>Ethnicity</b>				
Hispanic	55	68	50	60
Non-Hispanic	256	324	608	700
Unknown	1,213	2,250	1,259	2,531
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	27	45	32	44
Contact and suspected exposure (Z20.828)	286	510	261	422
Pneumonia (see Appendix B)	1,248	2,237	831	1,403
Other viral pneumonia (J12.89)	1,071	1,923	83	241
ARDS (J80)	302	484	40	79
Sepsis (see Appendix C)	547	1,032	508	900
Bronchitis (J20.8 OR J40)	22	29	29	50
Respiratory infection (J22 OR J98.8)	239	469	45	99
Cough (R05)	404	816	349	670
Shortness of breath (R06.2)	5	13	20	53
Fever (R50.9)	502	958	337	720
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	82	7	7	0

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Test performed, only negative results	8	0	47	12
No test or unknown result	887	2,018	1,231	2,568
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	854	1,888	1,128	2,406
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	396	428	535	593
<b>Codes Observed During Inpatient Stay</b>				
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	161	316	100	192
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	223	407	27	62
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	17	17	24	24
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	107	120	134	150
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	68	19	56
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	3
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	3
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	447	997	395	1,104
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	665	1,130	757	1,263
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	31	32	345	366

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	869	55	11	2,662	924 ( 25.69% )
Inpatient	233	7	0	N/A	240
Outpatient or Emergency Department	171	7	1	N/A	178
Other	27	4	1	N/A	31
Care Setting Reported as Unknown	385	37	9	N/A	422
<b>Demographics</b>					
Sex					
Female	314	24	7	1,140	338 ( 22.76% )
Male	555	31	4	1,516	586 ( 27.83% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	0	0	0	1	0 (0.00%)
18-29	16	1	0	32	17 ( 34.69% )
30-39	30	2	1	97	32 ( 24.62% )
40-49	92	2	1	249	94 ( 27.33% )
50-59	194	4	1	500	198 ( 28.33% )
60-69	245	11	2	666	256 ( 27.71% )
70-79	192	18	3	635	210 ( 24.76% )
80-89	80	15	2	359	95 ( 20.83% )
90+	20	2	1	114	22 ( 16.06% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	1	0	0	0	1 ( 100.0% )
Asian	22	2	0	14	24 ( 63.16% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Black or African American	103	2	1	221	105 ( 32.11% )
Native Hawaiian or Other Pacific Islander	1	0	0	0	1 ( 100.0% )
White	177	14	0	262	191 ( 42.16% )
Other/Mixed/Unknown	565	37	10	2,159	602 ( 21.73% )
<b>Ethnicity</b>					
Hispanic	31	0	0	18	31 ( 63.27% )
Non-Hispanic	144	4	0	18	148 ( 89.16% )
Unknown	694	51	11	2,620	745 ( 22.07% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	16	2	0	41	18 ( 30.51% )
Contact and suspected exposure (Z20.828)	202	19	2	608	221 ( 26.59% )
Pneumonia (see Appendix B)	771	52	11	2,410	823 ( 25.37% )
Other viral pneumonia (J12.89)	728	42	10	2,123	770 ( 26.52% )
ARDS (J80)	283	13	3	864	296 ( 25.45% )
Sepsis (see Appendix C)	395	23	8	1,234	418 ( 25.18% )
Bronchitis (J20.8 OR J40)	11	0	0	55	11 ( 16.67% )
Respiratory infection (J22 OR J98.8)	149	12	2	665	161 ( 19.44% )
Cough (R05)	240	13	4	846	253 ( 22.94% )
Shortness of breath (R06.2)	5	0	0	18	5 ( 21.74% )
Fever (R50.9)	332	22	2	1,094	354 ( 24.41% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	51	1	1	120	52 ( 30.06% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Test performed, only negative results	3	1	0	7	4 ( 36.36% )
No test or unknown result	532	33	9	1,883	565 ( 23 % )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	665	50	11	2,613	715 ( 21.41% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	212	11	0	3	223 ( 98.67% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	116	10	1	418	126 ( 23.12% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	176	16	2	557	192 ( 25.57% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	68	1	-	-	69 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	11	0	0	0	11 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	272	4	0	0	276 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	362	46	1	0	408 ( 99.76% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	20	0	0	0	20 ( 100.0% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	3,597 ( 100.0% )	94.05% ( 92.32% , 95.48% )	57.02% ( 54.49% , 59.52% )
Inpatient	240 ( 6.67% )	97.08% ( 94.08% , 98.82% )	58.10% ( 53.11% , 62.98% )
Outpatient or Emergency Department	179 ( 4.98% )	96.07% ( 92.07% , 98.40% )	51.66% ( 46.13% , 57.16% )
Other	32 ( 0.89% )	87.10% ( 70.17% , 96.37% )	57.45% ( 42.18% , 71.74% )
Care Setting Reported as Unknown	1,066 ( 29.64% )	91.23% ( 88.12% , 93.75% )	100.0% ( 99.05% , 100.0% )
<b>Demographics</b>			
Sex			
Female	1,485 ( 41.28% )	92.90% ( 89.62% , 95.40% )	51.06% ( 47.03% , 55.08% )
Male	2,106 ( 58.55% )	94.71% ( 92.57% , 96.38% )	61.06% ( 57.80% , 64.24% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	3 ( 0.08% )	N/A	N/A
6-17	1 ( 0.03% )	N/A	N/A
18-29	49 ( 1.36% )	94.12% ( 71.31% , 99.85% )	40 % ( 24.86% , 56.67% )
30-39	130 ( 3.61% )	93.75% ( 79.19% , 99.23% )	35.71% ( 25.55% , 46.92% )
40-49	344 ( 9.56% )	97.87% ( 92.52% , 99.74% )	49.73% ( 42.31% , 57.16% )
50-59	699 ( 19.43% )	97.98% ( 94.91% , 99.45% )	62.38% ( 56.74% , 67.78% )
60-69	924 ( 25.69% )	95.70% ( 92.44% , 97.84% )	63.31% ( 58.29% , 68.12% )
70-79	848 ( 23.58% )	91.43% ( 86.79% , 94.84% )	61.74% ( 56.08% , 67.16% )
80-89	456 ( 12.68% )	84.21% ( 75.30% , 90.88% )	50.31% ( 42.29% , 58.33% )
90+	137 ( 3.81% )	90.91% ( 70.84% , 98.88% )	43.48% ( 28.93% , 58.89% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	1 ( 0.03% )	100.0% ( 2.50% , 100.0% )	33.33% ( 0.84% , 90.57% )
Asian	38 ( 1.06% )	91.67% ( 73 % , 98.97% )	66.67% ( 48.17% , 82.04% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Black or African American	327 ( 9.09% )	98.10% ( 93.29% , 99.77% )	53.37% ( 46.07% , 60.56% )
Native Hawaiian or Other Pacific Islander	1 ( 0.03% )	100.0% ( 2.50% , 100.0% )	50 % ( 1.26% , 98.74% )
White	453 ( 12.59% )	92.67% ( 88.01% , 95.93% )	51.75% ( 46.32% , 57.16% )
Other/Mixed/Unknown	2,771 ( 77.04% )	93.85% ( 91.63% , 95.64% )	59.41% ( 56.21% , 62.55% )
<b>Ethnicity</b>			
Hispanic	49 ( 1.36% )	100.0% ( 88.78% , 100.0% )	56.36% ( 42.32% , 69.70% )
Non-Hispanic	166 ( 4.61% )	97.30% ( 93.22% , 99.26% )	56.25% ( 49.94% , 62.42% )
Unknown	3,376 ( 93.86% )	93.15% ( 91.10% , 94.86% )	57.21% ( 54.37% , 60.02% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	59 ( 1.64% )	88.89% ( 65.29% , 98.62% )	59.26% ( 38.80% , 77.61% )
Contact and suspected exposure (Z20.828)	831 ( 23.10% )	91.40% ( 86.90% , 94.74% )	70.63% ( 64.98% , 75.84% )
Pneumonia (see Appendix B)	3,244 ( 90.19% )	93.68% ( 91.80% , 95.25% )	61.78% ( 59.02% , 64.48% )
Other viral pneumonia (J12.89)	2,903 ( 80.71% )	94.55% ( 92.70% , 96.04% )	67.97% ( 65.09% , 70.76% )
ARDS (J80)	1,163 ( 32.33% )	95.61% ( 92.61% , 97.64% )	93.71% ( 90.35% , 96.17% )
Sepsis (see Appendix C)	1,660 ( 46.15% )	94.50% ( 91.86% , 96.48% )	72.21% ( 68.25% , 75.93% )
Bronchitis (J20.8 OR J40)	66 ( 1.83% )	100.0% ( 71.51% , 100.0% )	50 % ( 28.22% , 71.78% )
Respiratory infection (J22 OR J98.8)	828 ( 23.02% )	92.55% ( 87.34% , 96.09% )	62.34% ( 55.87% , 68.51% )
Cough (R05)	1,103 ( 30.66% )	94.86% ( 91.37% , 97.24% )	59.41% ( 54.44% , 64.23% )
Shortness of breath (R06.2)	23 ( 0.64% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Fever (R50.9)	1,450 ( 40.31% )	93.79% ( 90.74% , 96.06% )	66.14% ( 61.81% , 70.27% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	173 ( 4.81% )	98.08% ( 89.74% , 99.95% )	62.20% ( 50.81% , 72.68% )



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Test performed, only negative results	11 ( 0.31% )	75 % ( 19.41% , 99.37% )	37.50% ( 8.52% , 75.51% )
No test or unknown result	2,457 ( 68.31% )	94.16% ( 91.89% , 95.95% )	59.98% ( 56.67% , 63.22% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	3,339 ( 92.83% )	93.01% ( 90.88% , 94.77% )	77.87% ( 74.93% , 80.61% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	226 ( 6.28% )	95.07% ( 91.35% , 97.51% )	53.54% ( 48.49% , 58.53% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	545 ( 15.15% )	92.06% ( 85.89% , 96.13% )	72.05% ( 64.44% , 78.83% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	751 ( 20.88% )	91.67% ( 86.82% , 95.16% )	78.92% ( 72.98% , 84.08% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.06% )	100.0% ( 15.81% , 100.0% )	11.76% ( 1.46% , 36.44% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	69 ( 1.92% )	98.55% ( 92.19% , 99.96% )	63.55% ( 53.69% , 72.64% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	11 ( 0.31% )	100.0% ( 71.51% , 100.0% )	57.89% ( 33.50% , 79.75% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	276 ( 7.67% )	98.55% ( 96.33% , 99.60% )	60.85% ( 56.15% , 65.40% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	409 ( 11.37% )	88.73% ( 85.25% , 91.63% )	54.44% ( 50.56% , 58.27% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	20 ( 0.56% )	100.0% ( 83.16% , 100.0% )	64.52% ( 45.37% , 80.77% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,328	111	22	4,459	1,439 ( 24.31% )
Inpatient	356	19	3	N/A	375
Outpatient or Emergency Department	274	15	1	N/A	289
Other	42	8	2	N/A	50
Care Setting Reported as Unknown	572	67	13	N/A	639
<b>Demographics</b>					
Sex					
Female	516	50	13	1,905	566 ( 22.79% )
Male	812	61	9	2,536	873 ( 25.54% )
Other/Missing	0	0	0	0	-
Age at Hospital Admission (Years)					
0-5	0	0	0	37	0
6-17	0	0	0	16	0
18-29	33	4	1	107	37 ( 25.52% )
30-39	79	6	3	218	85 ( 27.28% )
40-49	168	6	1	451	174 ( 27.80% )
50-59	292	14	4	833	306 ( 26.77% )
60-69	350	17	4	1,034	367 ( 26.12% )
70-79	258	33	5	975	291 ( 22.90% )
80-89	114	27	2	583	141 ( 19.42% )
90+	34	3	2	185	37 ( 16.52% )
Missing	0	0	0	0	-
Race					
American Indian or Alaska Native	2	0	0	0	2 ( 100.00% )
Asian	30	2	0	22	32 ( 59.26% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Black or African American	151	5	1	334	156 ( 31.77% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100% )
White	260	34	3	425	294 (40.72% )
Other/Mixed/Unknown	883	70	18	3,660	953 (20.58% )
<b>Ethnicity</b>					
Hispanic	47	1	0	32	48 ( 60.00% )
Non-Hispanic	226	16	4	33	242 ( 86.74% )
Unknown	1,055	94	18	4,376	1,149 ( 20.73% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	26	2	0	58	28 ( 32.56% )
Contact and suspected exposure (Z20.828)	284	28	3	886	312 ( 25.98% )
Pneumonia (see Appendix B)	1,141	93	18	3,819	1,234 ( 24.33% )
Other viral pneumonia (J12.89)	1,056	62	18	3,191	1,118 ( 25.84% )
ARDS (J80)	325	16	4	1,044	341 ( 24.55% )
Sepsis (see Appendix C)	517	40	9	1,771	557 ( 23.83% )
Bronchitis (J20.8 OR J40)	21	1	1	107	22 ( 16.92% )
Respiratory infection (J22 OR J98.8)	265	19	5	1,024	284 ( 21.63% )
Cough (R05)	388	23	9	1,504	411 ( 21.36% )
Shortness of breath (R06.2)	7	0	0	33	7 ( 17.50% )
Fever (R50.9)	494	37	7	1,785	531 ( 22.86% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	93	3	1	214	96 ( 30.87% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Test performed, only negative results	9	4	0	26	13 ( 33.33% )
No test or unknown result	823	62	17	3,195	885 ( 21.60% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	-
Test performed, only negative results	0	0	0	0	-
No test or unknown result	1,010	91	19	4,364	1,101 ( 20.08% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	320	29	1	4	349 ( 98.59% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	170	13	2	613	183 ( 22.93% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	244	18	2	780	262 ( 25.10% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14	1	-	-	15 ( 100% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	97	3	-	-	100 ( 100% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	-
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	-
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	-

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	1	0	0	20 ( 100.00% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	-
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	-
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	425	11	0	0	436 ( 100.00% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	-
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	-
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	535	78	1	0	613 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	-
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	-
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	-
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	-
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	-

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	-
Unknown	31	1	1	1	32 ( 94.12% )



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	5,920 ( 100.0% )	92.29% ( 90.78% , 93.61% )	87.14% ( 85.35% , 88.78% )
Inpatient	378 ( 6.39% )	94.93% ( 92.20% , 96.92% )	88.78% ( 85.27% , 91.70% )
Outpatient or Emergency Department	290 ( 4.90% )	94.81% ( 91.58% , 97.07% )	82.78% ( 78.27% , 86.69% )
Other	52 ( 0.88% )	84 % ( 70.89% , 92.83% )	89.36% ( 76.90% , 96.45% )
Care Setting Reported as Unknown	1,632 ( 27.57% )	89.51% ( 86.88% , 91.78% )	*****
<b>Demographics</b>			
Sex			
Female	2,484 ( 41.96% )	91.17% ( 88.52% , 93.37% )	83.90% ( 80.76% , 86.72% )
Male	3,418 ( 57.74% )	93.01% ( 91.11% , 94.61% )	89.33% ( 87.14% , 91.26% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	37 ( 0.63% )	N/A	N/A
6-17	16 ( 0.27% )	N/A	N/A
18-29	145 ( 2.45% )	89.19% ( 74.58% , 96.97% )	82.50% ( 67.22% , 92.66% )
30-39	306 ( 5.17% )	92.94% ( 85.27% , 97.37% )	94.05% ( 86.65% , 98.04% )
40-49	626 ( 10.57% )	96.55% ( 92.65% , 98.72% )	90.81% ( 85.70% , 94.56% )
50-59	1,143 ( 19.31% )	95.42% ( 92.44% , 97.48% )	93.89% ( 90.62% , 96.28% )
60-69	1,405 ( 23.73% )	95.37% ( 92.69% , 97.28% )	90.44% ( 87.06% , 93.18% )
70-79	1,271 ( 21.47% )	88.66% ( 84.44% , 92.06% )	82.96% ( 78.31% , 86.97% )
80-89	726 ( 12.26% )	80.85% ( 73.38% , 86.99% )	71.70% ( 64.02% , 78.55% )
90+	224 ( 3.78% )	91.89% ( 78.09% , 98.30% )	73.91% ( 58.87% , 85.73% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	2 ( 0.03% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
Asian	54 ( 0.91% )	93.75% ( 79.19% , 99.23% )	90.91% ( 75.67% , 98.08% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Black or African American	491 ( 8.29% )	96.79% ( 92.68% , 98.95% )	78.24% ( 71.74% , 83.84% )
Native Hawaiian or Other Pacific Islander	2 ( 0.03% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	722 ( 12.20% )	88.44% ( 84.22% , 91.86% )	76.02% ( 71.14% , 80.45% )
Other/Mixed/Unknown	4,631 ( 78.23% )	92.65% ( 90.81% , 94.23% )	92.85% ( 91.02% , 94.41% )
<b>Ethnicity</b>			
Hispanic	80 ( 1.35% )	97.92% ( 88.93% , 99.95% )	85.45% ( 73.34% , 93.50% )
Non-Hispanic	279 ( 4.71% )	93.39% ( 89.49% , 96.17% )	88.28% ( 83.69% , 91.95% )
Unknown	5,543 ( 93.63% )	91.82% ( 90.08% , 93.34% )	86.97% ( 84.95% , 88.82% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	86 ( 1.45% )	92.86% ( 76.50% , 99.12% )	96.30% ( 81.03% , 99.91% )
Contact and suspected exposure (Z20.828)	1,201 ( 20.29% )	91.03% ( 87.29% , 93.95% )	99.30% ( 97.50% , 99.92% )
Pneumonia (see Appendix B)	5,071 ( 85.66% )	92.46% ( 90.85% , 93.87% )	91.43% ( 89.73% , 92.92% )
Other viral pneumonia (J12.89)	4,327 ( 73.09% )	94.45% ( 92.95% , 95.72% )	98.60% ( 97.70% , 99.21% )
ARDS (J80)	1,389 ( 23.46% )	95.31% ( 92.49% , 97.29% )	*****
Sepsis (see Appendix C)	2,337 ( 39.48% )	92.82% ( 90.35% , 94.82% )	94.52% ( 92.26% , 96.27% )
Bronchitis (J20.8 OR J40)	130 ( 2.20% )	95.45% ( 77.16% , 99.88% )	95.45% ( 77.16% , 99.88% )
Respiratory infection (J22 OR J98.8)	1,313 ( 22.18% )	93.31% ( 89.75% , 95.92% )	*****
Cough (R05)	1,924 ( 32.50% )	94.40% ( 91.72% , 96.42% )	96.04% ( 93.65% , 97.72% )
Shortness of breath (R06.2)	40 ( 0.68% )	100.0% ( 59.04% , 100.0% )	*****
Fever (R50.9)	2,323 ( 39.24% )	93.03% ( 90.52% , 95.05% )	98.41% ( 96.88% , 99.31% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	311 ( 5.25% )	96.88% ( 91.14% , 99.35% )	*****

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Test performed, only negative results	39 ( 0.66% )	69.23% ( 38.57% , 90.91% )	*****
No test or unknown result	4,097 ( 69.21% )	92.99% ( 91.11% , 94.59% )	92.78% ( 90.88% , 94.40% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	5,484 ( 92.64% )	91.73% ( 89.95% , 93.29% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	354 ( 5.98% )	91.69% ( 88.28% , 94.36% )	80.81% ( 76.58% , 84.57% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	798 ( 13.48% )	92.90% ( 88.16% , 96.16% )	*****
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,044 ( 17.64% )	93.13% ( 89.36% , 95.88% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	15 ( 0.25% )	93.33% ( 68.05% , 99.83% )	82.35% ( 56.57% , 96.20% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	100 ( 1.69% )	97 % ( 91.48% , 99.38% )	90.65% ( 83.48% , 95.43% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	20 ( 0.34% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	436 ( 7.36% )	97.48% ( 95.53% , 98.73% )	95.08% ( 92.64% , 96.89% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	614 ( 10.37% )	87.28% ( 84.38% , 89.81% )	80.45% ( 77.23% , 83.40% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	34 ( 0.57% )	96.88% ( 83.78% , 99.92% )	100.0% ( 88.78% , 100.0% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,352	139	22	4,757	1,491 ( 23.78% )
Inpatient	357	21	3	N/A	378
Outpatient or Emergency Department	277	16	1	N/A	293
Other	42	10	2	N/A	52
Care setting reported as unknown	592	89	13	N/A	681
<b>Demographics</b>					
Sex					
Female	531	64	13	2,062	595 ( 22.28% )
Male	821	75	9	2,677	896 ( 25.01% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	52	0 (0.00%)
6-17	0	0	0	23	0 (0.00%)
18-29	33	4	1	120	37 ( 23.42% )
30-39	79	6	3	226	85 ( 27.07% )
40-49	169	8	1	469	177 ( 27.36% )
50-59	295	19	4	872	314 ( 26.39% )
60-69	359	22	4	1,082	381 ( 25.97% )
70-79	262	39	5	1,035	301 ( 22.45% )
80-89	120	34	2	648	154 ( 19.15% )
90+	35	6	2	210	41 ( 16.21% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	2	0	0	1	2 ( 66.67% )
Asian	31	2	0	23	33 ( 58.93% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Black or African American	156	6	1	352	162 ( 31.46% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	267	43	3	478	310 ( 39.19% )
Other/Mixed/Unknown	894	88	18	3,885	982 ( 20.10% )
<b>Ethnicity</b>					
Hispanic	47	1	0	35	48 ( 57.83% )
Non-Hispanic	227	18	4	34	245 ( 86.57% )
Unknown	1,078	120	18	4,670	1,198 ( 20.35% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	26	3	0	58	29 ( 33.33% )
Contact and suspected exposure (Z20.828)	286	30	3	920	316 ( 25.50% )
Pneumonia (see Appendix B)	1,159	112	18	3,997	1,271 ( 24.04% )
Other viral pneumonia (J12.89)	1,066	62	18	3,240	1,128 ( 25.72% )
ARDS (J80)	325	16	4	1,056	341 ( 24.34% )
Sepsis (see Appendix C)	521	49	9	1,854	570 ( 23.43% )
Bronchitis (J20.8 OR J40)	21	1	1	117	22 ( 15.71% )
Respiratory infection (J22 OR J98.8)	265	20	5	1,032	285 ( 21.56% )
Cough (R05)	392	31	9	1,585	423 ( 20.97% )
Shortness of breath (R06.2)	7	1	0	38	8 ( 17.39% )
Fever (R50.9)	499	43	7	1,864	542 ( 22.46% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	96	3	1	218	99 ( 31.13% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Test performed, only negative results	9	6	0	30	15 ( 33.33% )
No test or unknown result	827	75	17	3,387	902 ( 20.95% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,032	116	19	4,658	1,148 ( 19.71% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	328	34	1	4	362 ( 98.64% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	170	14	2	632	184 ( 22.49% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	244	18	2	790	262 ( 24.86% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14	1	-	-	15 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	98	4	-	-	102 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	1	0	0	20 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	430	24	0	0	454 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	552	90	1	0	642 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	31	1	1	1	32 ( 94.12% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	6,270 ( 100.0% )	90.68% ( 89.09% , 92.11% )	88.71% ( 87.02% , 90.26% )
Inpatient	381 ( 6.08% )	94.44% ( 91.63% , 96.53% )	89.03% ( 85.55% , 91.91% )
Outpatient or Emergency Department	294 ( 4.69% )	94.54% ( 91.28% , 96.85% )	83.69% ( 79.26% , 87.50% )
Other	54 ( 0.86% )	80.77% ( 67.47% , 90.37% )	89.36% ( 76.90% , 96.45% )
Care setting reported as unknown	1,771 ( 28.25% )	86.93% ( 84.17% , 89.37% )	*****
<b>Demographics</b>			
Sex			
Female	2,670 ( 42.58% )	89.24% ( 86.47% , 91.62% )	86.34% ( 83.37% , 88.96% )
Male	3,582 ( 57.13% )	91.63% ( 89.62% , 93.36% )	90.32% ( 88.21% , 92.16% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	52 ( 0.83% )	N/A	N/A
6-17	23 ( 0.37% )	N/A	N/A
18-29	158 ( 2.52% )	89.19% ( 74.58% , 96.97% )	82.50% ( 67.22% , 92.66% )
30-39	314 ( 5.01% )	92.94% ( 85.27% , 97.37% )	94.05% ( 86.65% , 98.04% )
40-49	647 ( 10.32% )	95.48% ( 91.29% , 98.03% )	91.35% ( 86.34% , 94.98% )
50-59	1,190 ( 18.98% )	93.95% ( 90.71% , 96.32% )	94.86% ( 91.78% , 97.03% )
60-69	1,467 ( 23.40% )	94.23% ( 91.39% , 96.35% )	92.76% ( 89.71% , 95.14% )
70-79	1,341 ( 21.39% )	87.04% ( 82.72% , 90.62% )	84.24% ( 79.71% , 88.11% )
80-89	804 ( 12.82% )	77.92% ( 70.54% , 84.20% )	75.47% ( 68.03% , 81.94% )
90+	253 ( 4.04% )	85.37% ( 70.83% , 94.43% )	76.09% ( 61.23% , 87.41% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	3 ( 0.05% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
Asian	56 ( 0.89% )	93.94% ( 79.77% , 99.26% )	93.94% ( 79.77% , 99.26% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Black or African American	515 ( 8.21% )	96.30% ( 92.11% , 98.63% )	80.83% ( 74.56% , 86.13% )
Native Hawaiian or Other Pacific Islander	2 ( 0.03% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	791 ( 12.62% )	86.13% ( 81.77% , 89.78% )	78.07% ( 73.30% , 82.34% )
Other/Mixed/Unknown	4,885 ( 77.91% )	91.04% ( 89.08% , 92.75% )	94.01% ( 92.30% , 95.43% )
<b>Ethnicity</b>			
Hispanic	83 ( 1.32% )	97.92% ( 88.93% , 99.95% )	85.45% ( 73.34% , 93.50% )
Non-Hispanic	283 ( 4.51% )	92.65% ( 88.64% , 95.59% )	88.67% ( 84.14% , 92.28% )
Unknown	5,886 ( 93.88% )	89.98% ( 88.14% , 91.63% )	88.87% ( 86.96% , 90.59% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	87 ( 1.39% )	89.66% ( 72.65% , 97.81% )	96.30% ( 81.03% , 99.91% )
Contact and suspected exposure (Z20.828)	1,239 ( 19.76% )	90.51% ( 86.72% , 93.50% )	100.0% ( 98.72% , 100.0% )
Pneumonia (see Appendix B)	5,286 ( 84.31% )	91.19% ( 89.49% , 92.69% )	92.87% ( 91.30% , 94.23% )
Other viral pneumonia (J12.89)	4,386 ( 69.95% )	94.50% ( 93.01% , 95.76% )	99.53% ( 98.91% , 99.85% )
ARDS (J80)	1,401 ( 22.34% )	95.31% ( 92.49% , 97.29% )	*****
Sepsis (see Appendix C)	2,433 ( 38.80% )	91.40% ( 88.79% , 93.57% )	95.25% ( 93.11% , 96.87% )
Bronchitis (J20.8 OR J40)	140 ( 2.23% )	95.45% ( 77.16% , 99.88% )	95.45% ( 77.16% , 99.88% )
Respiratory infection (J22 OR J98.8)	1,322 ( 21.08% )	92.98% ( 89.37% , 95.66% )	*****
Cough (R05)	2,017 ( 32.17% )	92.67% ( 89.76% , 94.97% )	97.03% ( 94.87% , 98.46% )
Shortness of breath (R06.2)	46 ( 0.73% )	87.50% ( 47.35% , 99.68% )	*****
Fever (R50.9)	2,413 ( 38.48% )	92.07% ( 89.46% , 94.20% )	99.40% ( 98.26% , 99.88% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	318 ( 5.07% )	96.97% ( 91.40% , 99.37% )	*****

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Test performed, only negative results	45 ( 0.72% )	60 % ( 32.29% , 83.66% )	*****
No test or unknown result	4,306 ( 68.68% )	91.69% ( 89.69% , 93.40% )	93.24% ( 91.38% , 94.80% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	5,825 ( 92.90% )	89.90% ( 88 % , 91.58% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	367 ( 5.85% )	90.61% ( 87.12% , 93.41% )	82.83% ( 78.75% , 86.41% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	818 ( 13.05% )	92.39% ( 87.56% , 95.78% )	*****
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,054 ( 16.81% )	93.13% ( 89.36% , 95.88% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	15 ( 0.24% )	93.33% ( 68.05% , 99.83% )	82.35% ( 56.57% , 96.20% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	102 ( 1.63% )	96.08% ( 90.26% , 98.92% )	91.59% ( 84.63% , 96.08% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	20 ( 0.32% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	454 ( 7.24% )	94.71% ( 92.24% , 96.58% )	96.20% ( 93.98% , 97.77% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	643 ( 10.26% )	85.98% ( 83.05% , 88.57% )	83.01% ( 79.93% , 85.79% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	34 ( 0.54% )	96.88% ( 83.78% , 99.92% )	100.0% ( 88.78% , 100.0% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,371	143	22	4,850	1,514 ( 23.71% )
Inpatient	360	22	3	N/A	382
Outpatient or Emergency Department	281	16	1	N/A	297
Other	42	11	2	N/A	53
Care Setting Reported as Unknown	602	91	13	N/A	693
<b>Demographics</b>					
<b>Sex</b>					
Female	539	66	13	2,114	605 ( 22.14% )
Male	832	77	9	2,718	909 ( 25 % )
Other/Missing	0	0	0	0	N/A
<b>Age at Hospital Admission (Years)</b>					
0-5	0	0	0	52	0 (0.00%)
6-17	0	0	0	23	0 (0.00%)
18-29	33	4	1	121	37 ( 23.27% )
30-39	79	6	3	228	85 ( 26.90% )
40-49	171	8	1	476	179 ( 27.29% )
50-59	296	20	4	883	316 ( 26.27% )
60-69	363	24	4	1,100	387 ( 25.96% )
70-79	265	39	5	1,062	304 ( 22.17% )
80-89	126	35	2	667	161 ( 19.40% )
90+	38	6	2	218	44 ( 16.67% )
Missing	0	0	0	0	N/A
<b>Race</b>					
American Indian or Alaska Native	3	0	0	1	3 ( 75 % )
Asian	31	2	0	24	33 ( 57.89% )



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Black or African American	159	6	1	362	165 ( 31.25% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	274	43	3	498	317 ( 38.75% )
Other/Mixed/Unknown	902	92	18	3,947	994 ( 20.04% )
<b>Ethnicity</b>					
Hispanic	47	1	0	35	48 ( 57.83% )
Non-Hispanic	231	18	4	35	249 ( 86.46% )
Unknown	1,093	124	18	4,762	1,217 ( 20.29% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	26	3	0	58	29 ( 33.33% )
Contact and suspected exposure (Z20.828)	291	31	3	927	322 ( 25.72% )
Pneumonia (see Appendix B)	1,176	116	18	4,077	1,292 ( 23.98% )
Other viral pneumonia (J12.89)	1,074	62	18	3,261	1,136 ( 25.73% )
ARDS (J80)	327	16	4	1,065	343 ( 24.29% )
Sepsis (see Appendix C)	531	50	9	1,884	581 ( 23.48% )
Bronchitis (J20.8 OR J40)	22	1	1	118	23 ( 16.20% )
Respiratory infection (J22 OR J98.8)	266	20	5	1,035	286 ( 21.57% )
Cough (R05)	396	33	9	1,606	429 ( 20.99% )
Shortness of breath (R06.2)	7	1	0	39	8 ( 17.02% )
Fever (R50.9)	507	45	7	1,879	552 ( 22.64% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	96	3	1	221	99 ( 30.84% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Test performed, only negative results	9	6	0	30	15 ( 33.33% )
No test or unknown result	833	78	17	3,439	911 ( 20.86% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,046	120	19	4,750	1,166 ( 19.65% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	333	34	1	4	367 ( 98.66% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	172	15	2	636	187 ( 22.67% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	247	18	2	793	265 ( 25 % )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14	1	-	-	15 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	98	4	-	-	102 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	1	0	0	20 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	434	26	0	0	460 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	562	92	1	0	654 ( 99.85% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	31	1	1	1	32 ( 94.12% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	6,386 ( 100.0% )	90.55% ( 88.97% , 91.98% )	89.96% ( 88.34% , 91.42% )
Inpatient	385 ( 6.03% )	94.24% ( 91.41% , 96.36% )	89.78% ( 86.39% , 92.56% )
Outpatient or Emergency Department	298 ( 4.67% )	94.61% ( 91.40% , 96.89% )	84.89% ( 80.57% , 88.58% )
Other	55 ( 0.86% )	79.25% ( 65.89% , 89.16% )	89.36% ( 76.90% , 96.45% )
Care Setting Reported as Unknown	1,820 ( 28.50% )	86.87% ( 84.12% , 89.29% )	*****
<b>Demographics</b>			
Sex			
Female	2,732 ( 42.78% )	89.09% ( 86.33% , 91.46% )	87.64% ( 84.78% , 90.14% )
Male	3,636 ( 56.94% )	91.53% ( 89.53% , 93.26% )	91.53% ( 89.53% , 93.26% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	52 ( 0.81% )	N/A	N/A
6-17	23 ( 0.36% )	N/A	N/A
18-29	159 ( 2.49% )	89.19% ( 74.58% , 96.97% )	82.50% ( 67.22% , 92.66% )
30-39	316 ( 4.95% )	92.94% ( 85.27% , 97.37% )	94.05% ( 86.65% , 98.04% )
40-49	656 ( 10.27% )	95.53% ( 91.38% , 98.05% )	92.43% ( 87.63% , 95.80% )
50-59	1,,203 ( 18.84% )	93.67% ( 90.39% , 96.09% )	95.18% ( 92.17% , 97.28% )
60-69	1,491 ( 23.35% )	93.80% ( 90.91% , 95.99% )	93.80% ( 90.91% , 95.99% )
70-79	1,371 ( 21.47% )	87.17% ( 82.88% , 90.72% )	85.21% ( 80.77% , 88.96% )
80-89	830 ( 13 % )	78.26% ( 71.09% , 84.37% )	79.25% ( 72.11% , 85.26% )
90+	264 ( 4.13% )	86.36% ( 72.65% , 94.83% )	82.61% ( 68.58% , 92.18% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	4 ( 0.06% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Asian	57 ( 0.89% )	93.94% ( 79.77% , 99.26% )	93.94% ( 79.77% , 99.26% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Black or African American	528 ( 8.27% )	96.36% ( 92.25% , 98.65% )	82.38% ( 76.26% , 87.48% )
Native Hawaiian or Other Pacific Islander	2 ( 0.03% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	818 ( 12.81% )	86.44% ( 82.17% , 90.01% )	80.12% ( 75.49% , 84.22% )
Other/Mixed/Unknown	4,959 ( 77.65% )	90.74% ( 88.77% , 92.47% )	94.85% ( 93.25% , 96.16% )
<b>Ethnicity</b>			
Hispanic	83 ( 1.30% )	97.92% ( 88.93% , 99.95% )	85.45% ( 73.34% , 93.50% )
Non-Hispanic	288 ( 4.51% )	92.77% ( 88.82% , 95.66% )	90.23% ( 85.92% , 93.58% )
Unknown	5,997 ( 93.91% )	89.81% ( 87.97% , 91.45% )	90.11% ( 88.29% , 91.73% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	87 ( 1.36% )	89.66% ( 72.65% , 97.81% )	96.30% ( 81.03% , 99.91% )
Contact and suspected exposure (Z20.828)	1,252 ( 19.61% )	90.37% ( 86.61% , 93.36% )	*****
Pneumonia (see Appendix B)	5,387 ( 84.36% )	91.02% ( 89.33% , 92.52% )	94.23% ( 92.79% , 95.46% )
Other viral pneumonia (J12.89)	4,415 ( 69.14% )	94.54% ( 93.06% , 95.79% )	*****
ARDS (J80)	1,412 ( 22.11% )	95.34% ( 92.54% , 97.31% )	*****
Sepsis (see Appendix C)	2,474 ( 38.74% )	91.39% ( 88.81% , 93.55% )	97.07% ( 95.29% , 98.32% )
Bronchitis (J20.8 OR J40)	142 ( 2.22% )	95.65% ( 78.05% , 99.89% )	100.0% ( 84.56% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,326 ( 20.76% )	93.01% ( 89.41% , 95.68% )	*****
Cough (R05)	2,044 ( 32.01% )	92.31% ( 89.37% , 94.65% )	98.02% ( 96.14% , 99.14% )
Shortness of breath (R06.2)	47 ( 0.74% )	87.50% ( 47.35% , 99.68% )	*****
Fever (R50.9)	2,438 ( 38.18% )	91.85% ( 89.24% , 93.99% )	*****
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	321 ( 5.03% )	96.97% ( 91.40% , 99.37% )	*****

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Test performed, only negative results	45 ( 0.70% )	60 % ( 32.29% , 83.66% )	*****
No test or unknown result	4,367 ( 68.38% )	91.44% ( 89.43% , 93.17% )	93.91% ( 92.13% , 95.39% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	5,935 ( 92.94% )	89.71% ( 87.82% , 91.39% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	372 ( 5.83% )	90.74% ( 87.29% , 93.50% )	84.09% ( 80.11% , 87.55% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	825 ( 12.92% )	91.98% ( 87.12% , 95.44% )	*****
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,060 ( 16.60% )	93.21% ( 89.48% , 95.92% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	15 ( 0.23% )	93.33% ( 68.05% , 99.83% )	82.35% ( 56.57% , 96.20% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	102 ( 1.60% )	96.08% ( 90.26% , 98.92% )	91.59% ( 84.63% , 96.08% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	20 ( 0.31% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	460 ( 7.20% )	94.35% ( 91.83% , 96.27% )	97.09% ( 95.08% , 98.44% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	655 ( 10.26% )	85.93% ( 83.03% , 88.51% )	84.51% ( 81.53% , 87.18% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	34 ( 0.53% )	96.88% ( 83.78% , 99.92% )	100.0% ( 88.78% , 100.0% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,220	93	21	3,884	1,313 ( 25.16% )
Inpatient	327	13	3	N/A	340
Outpatient or Emergency Department	259	11	1	N/A	270
Other	35	6	2	N/A	41
Care Setting Reported as Unknown	527	61	12	N/A	588
<b>Demographics</b>					
Sex					
Female	464	41	12	1,598	505 ( 23.88% )
Male	756	52	9	2,275	808 ( 26.13% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	14	0 (0.00%)
6-17	0	0	0	7	0 (0.00%)
18-29	30	4	1	76	34 ( 30.63% )
30-39	69	4	3	188	73 ( 27.65% )
40-49	152	4	1	413	156 ( 27.37% )
50-59	277	9	4	763	286 ( 27.16% )
60-69	326	15	3	917	341 ( 27.04% )
70-79	242	30	5	847	272 ( 24.20% )
80-89	100	23	2	505	123 ( 19.52% )
90+	24	3	2	142	27 ( 15.79% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	2	0	0	0	2 ( 100.0% )
Asian	28	2	0	21	30 ( 58.82% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Black or African American	146	5	1	282	151 ( 34.79% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	234	26	3	344	260 ( 42.83% )
Other/Mixed/Unknown	808	60	17	3,226	868 ( 21.11% )
<b>Ethnicity</b>					
Hispanic	42	1	0	25	43 ( 63.24% )
Non-Hispanic	208	10	4	28	218 ( 87.20% )
Unknown	970	82	17	3,820	1052 ( 21.52% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	24	2	0	50	26 ( 34.21% )
Contact and suspected exposure (Z20.828)	266	22	2	817	288 ( 26.02% )
Pneumonia (see Appendix B)	1,145	93	18	3,829	1,238 ( 24.35% )
Other viral pneumonia (J12.89)	1,060	62	18	3,200	1,122 ( 25.85% )
ARDS (J80)	325	16	4	1,046	341 ( 24.51% )
Sepsis (see Appendix C)	505	38	9	1,682	543 ( 24.31% )
Bronchitis (J20.8 OR J40)	20	1	1	84	21 ( 19.81% )
Respiratory infection (J22 OR J98.8)	233	19	5	869	252 ( 22.38% )
Cough (R05)	348	19	8	1,332	367 ( 21.50% )
Shortness of breath (R06.2)	7	0	0	28	7 ( 20% )
Fever (R50.9)	460	31	6	1,594	491 ( 23.48% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	85	3	1	188	88 ( 31.77% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Test performed, only negative results	9	1	0	21	10 ( 32.26% )
No test or unknown result	759	55	16	2,818	814 ( 22.31% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	926	78	18	3,812	1,004 ( 20.77% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	301	23	1	4	324 ( 98.48% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	154	11	1	563	165 ( 22.63% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	236	18	2	756	254 ( 25.10% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	13	1	-	-	14 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	95	3	-	-	98 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	18	1	0	0	19 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	383	7	0	0	390 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	500	70	1	0	570 ( 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	25	0	1	1	25 ( 92.59% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	5,218 ( 100.0% )	92.92% ( 91.39% , 94.25% )	80.05% ( 77.96% , 82.03% )
Inpatient	343 ( 6.57% )	96.18% ( 93.55% , 97.95% )	81.55% ( 77.40% , 85.22% )
Outpatient or Emergency Department	271 ( 5.19% )	95.93% ( 92.83% , 97.95% )	78.25% ( 73.41% , 82.57% )
Other	43 ( 0.82% )	85.37% ( 70.83% , 94.43% )	74.47% ( 59.65% , 86.06% )
Care Setting Reported as Unknown	1,426 ( 27.33% )	89.63% ( 86.87% , 91.97% )	*****
<b>Demographics</b>			
Sex			
Female	2,115 ( 40.53% )	91.88% ( 89.15% , 94.11% )	75.45% ( 71.85% , 78.80% )
Male	3,092 ( 59.26% )	93.56% ( 91.65% , 95.16% )	83.17% ( 80.57% , 85.54% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	14 ( 0.27% )	N/A	N/A
6-17	7 ( 0.13% )	N/A	N/A
18-29	111 ( 2.13% )	88.24% ( 72.55% , 96.70% )	75 % ( 58.80% , 87.31% )
30-39	264 ( 5.06% )	94.52% ( 86.56% , 98.49% )	82.14% ( 72.26% , 89.65% )
40-49	570 ( 10.92% )	97.44% ( 93.57% , 99.30% )	82.16% ( 75.87% , 87.39% )
50-59	1,053 ( 20.18% )	96.85% ( 94.11% , 98.55% )	89.07% ( 85.06% , 92.31% )
60-69	1,261 ( 24.17% )	95.60% ( 92.85% , 97.52% )	84.24% ( 80.22% , 87.72% )
70-79	1,124 ( 21.54% )	88.97% ( 84.63% , 92.43% )	77.81% ( 72.78% , 82.31% )
80-89	630 ( 12.07% )	81.30% ( 73.28% , 87.76% )	62.89% ( 54.88% , 70.41% )
90+	171 ( 3.28% )	88.89% ( 70.84% , 97.65% )	52.17% ( 36.95% , 67.11% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	2 ( 0.04% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
Asian	51 ( 0.98% )	93.33% ( 77.93% , 99.18% )	84.85% ( 68.10% , 94.89% )

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Black or African American	434 ( 8.32% )	96.69% ( 92.44% , 98.92% )	75.65% ( 68.96% , 81.52% )
Native Hawaiian or Other Pacific Islander	2 ( 0.04% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	607 ( 11.63% )	90 % ( 85.69% , 93.36% )	68.42% ( 63.20% , 73.32% )
Other/Mixed/Unknown	4,111 ( 78.78% )	93.09% ( 91.19% , 94.68% )	84.96% ( 82.53% , 87.18% )
<b>Ethnicity</b>			
Hispanic	68 ( 1.30% )	97.67% ( 87.71% , 99.94% )	76.36% ( 62.98% , 86.77% )
Non-Hispanic	250 ( 4.79% )	95.41% ( 91.73% , 97.78% )	81.25% ( 75.92% , 85.84% )
Unknown	4,889 ( 93.69% )	92.21% ( 90.42% , 93.75% )	79.97% ( 77.60% , 82.19% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	76 ( 1.46% )	92.31% ( 74.87% , 99.05% )	88.89% ( 70.84% , 97.65% )
Contact and suspected exposure (Z20.828)	1,107 ( 21.22% )	92.36% ( 88.66% , 95.15% )	93.01% ( 89.41% , 95.68% )
Pneumonia (see Appendix B)	5,085 ( 97.45% )	92.49% ( 90.88% , 93.89% )	91.75% ( 90.08% , 93.21% )
Other viral pneumonia (J12.89)	4,340 ( 83.17% )	94.47% ( 92.97% , 95.74% )	98.97% ( 98.17% , 99.49% )
ARDS (J80)	1,391 ( 26.66% )	95.31% ( 92.49% , 97.29% )	*****
Sepsis (see Appendix C)	2,234 ( 42.81% )	93 % ( 90.52% , 95 % )	92.32% ( 89.76% , 94.41% )
Bronchitis (J20.8 OR J40)	106 ( 2.03% )	95.24% ( 76.18% , 99.88% )	90.91% ( 70.84% , 98.88% )
Respiratory infection (J22 OR J98.8)	1,126 ( 21.58% )	92.46% ( 88.48% , 95.40% )	97.49% ( 94.62% , 99.07% )
Cough (R05)	1,707 ( 32.71% )	94.82% ( 92.03% , 96.85% )	86.14% ( 82.38% , 89.36% )
Shortness of breath (R06.2)	35 ( 0.67% )	100.0% ( 59.04% , 100.0% )	*****
Fever (R50.9)	2,091 ( 40.07% )	93.69% ( 91.16% , 95.67% )	91.63% ( 88.86% , 93.90% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**			
Test performed, at least 1 positive result	277 ( 5.31% )	96.59% ( 90.36% , 99.29% )	*****



**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Test performed, only negative results	31 ( 0.59% )	90 % ( 55.50% , 99.75% )	*****
No test or unknown result	3,648 ( 69.91% )	93.24% ( 91.30% , 94.87% )	85.57% ( 83.08% , 87.82% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	4,834 ( 92.64% )	92.23% ( 90.40% , 93.81% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	329 ( 6.31% )	92.90% ( 89.54% , 95.45% )	76.01% ( 71.49% , 80.13% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	729 ( 13.97% )	93.33% ( 88.38% , 96.63% )	95.65% ( 91.25% , 98.23% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,012 ( 19.39% )	92.91% ( 89.03% , 95.75% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14 ( 0.27% )	92.86% ( 66.13% , 99.82% )	76.47% ( 50.10% , 93.19% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	98 ( 1.88% )	96.94% ( 91.31% , 99.36% )	88.79% ( 81.23% , 94.07% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19 ( 0.36% )	94.74% ( 73.97% , 99.87% )	94.74% ( 73.97% , 99.87% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	390 ( 7.47% )	98.21% ( 96.34% , 99.28% )	85.68% ( 82.09% , 88.80% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	571 ( 10.94% )	87.72% ( 84.74% , 90.30% )	75.19% ( 71.72% , 78.43% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1a. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	27 ( 0.52% )	100.0% ( 86.28% , 100.0% )	80.65% ( 62.53% , 92.55% )

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINCs or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described.

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test*****</b>				
Total Observed	2,768	4,079	5,215	7,993
Inpatient	777	487	2,423	2,246
Outpatient or Emergency Department	801	366	706	349
Other	82	40	403	313
Care Setting Reported as Unknown	771	2,744	1,285	4,494
<b>Demographics</b>				
Sex				
Female	1,251	1,825	2,897	4,280
Male	1,517	2,254	2,318	3,713
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	1	1	52	80
6-17	7	8	80	141
18-29	75	117	403	586
30-39	187	269	700	990
40-49	291	434	441	764
50-59	616	953	712	1,266
60-69	703	1,094	933	1,519
70-79	493	667	936	1,347
80-89	303	414	696	950
90+	92	122	262	350
Missing	0	0	0	0
Race				
American Indian or Alaska Native	5	6	28	33
Asian	78	91	166	195
Black or African American	439	487	494	579
Native Hawaiian or Other Pacific Islander	3	5	3	3
White	474	591	2,198	2,726
Other/Mixed/Unknown	1,769	2,889	2,326	4,447
Ethnicity				

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	258	299	237	303
Non-Hispanic	503	677	2,089	2,698
Unknown	2,007	3,103	2,889	4,992
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	41	64	691	929
Contact and suspected exposure (Z20.828)	520	778	1,647	2,437
Pneumonia (see Appendix B)	2,219	3,415	1,231	2,347
Other viral pneumonia (J12.89)	2,135	3,173	249	770
ARDS (J80)	437	660	74	176
Sepsis (see Appendix C)	918	1,368	985	1,691
Bronchitis (J20.8 OR J40)	37	46	36	66
Respiratory infection (J22 OR J98.8)	231	402	44	130
Cough (R05)	544	843	443	861
Shortness of breath (R06.2)	9	10	27	47
Fever (R50.9)	669	1,031	606	1,185
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	161	24	28	4
Test performed, only negative results	9	0	72	13
No test or unknown result	1,933	3,241	3,876	6,356
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	1,566	2,677	3,313	5,608
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,048	1,074	2,307	2,635
<b>Codes Observed During Inpatient Stay</b>				

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	221	330	298	514
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	408	589	85	212
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	3	3	3	3
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	441	479	561	631
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	95	95	55	58
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	11	73	73
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	57	127	60	125
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	2	0	1
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	2	0	1
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	615	1,020	1,022	2,057
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	3	3
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	2	5
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,207	1,841	2,769	3,958
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	3	5
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	2	2
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	16	18	24	33

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	2,637	342	35	9,383	2,979 ( 24.03% )
Inpatient	709	70	13	N/A	779
Outpatient or Emergency Department	730	65	4	N/A	795
Other	71	16	2	N/A	87
Care Setting Reported as Unknown	1,018	191	16	N/A	1,209
<b>Demographics</b>					
Sex					
Female	1,186	153	13	4,385	1,339 ( 23.34% )
Male	1,451	189	22	4,982	1,640 ( 24.68% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	14	0 (0.00%)
6-17	6	1	0	28	7 ( 20 % )
18-29	66	11	1	186	77 ( 29.17% )
30-39	173	13	5	379	186 ( 32.63% )
40-49	284	21	1	690	305 ( 30.62% )
50-59	596	61	9	1,432	657 ( 31.32% )
60-69	680	81	9	2,000	761 ( 27.47% )
70-79	460	77	4	2,091	537 ( 20.40% )
80-89	284	49	4	1,808	333 ( 15.52% )
90+	88	28	2	739	116 ( 13.54% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	4	5 ( 55.56% )
Asian	75	3	1	48	78 ( 61.42% )
Black or African American	423	29	2	887	452 ( 33.71% )
Native Hawaiian or Other Pacific Islander	3	0	0	3	3 ( 50 % )
White	433	89	0	1,400	522 ( 27.16% )
Other/Mixed/Unknown	1,698	221	32	7,025	1,919 ( 21.38% )
Ethnicity					



**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	250	10	0	90	260 ( 74.29% )
Non-Hispanic	483	39	2	46	522 ( 91.58% )
Unknown	1,904	293	33	9,231	2,197 ( 19.17% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	37	20	0	126	57 ( 31.15% )
Contact and suspected exposure (Z20.828)	498	116	14	1,850	614 ( 24.78% )
Pneumonia (see Appendix B)	2,168	251	32	7,297	2,419 ( 24.82% )
Other viral pneumonia (J12.89)	2,119	164	30	6,045	2,283 ( 27.32% )
ARDS (J80)	433	38	7	1,172	471 ( 28.55% )
Sepsis (see Appendix C)	886	119	13	2,781	1,005 ( 26.45% )
Bronchitis (J20.8 OR J40)	35	1	0	105	36 ( 25.53% )
Respiratory infection (J22 OR J98.8)	233	20	4	1,086	253 ( 18.84% )
Cough (R05)	530	58	7	1,917	588 ( 23.41% )
Shortness of breath (R06.2)	9	2	0	60	11 ( 15.49% )
Fever (R50.9)	653	91	9	2,381	744 ( 23.74% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	195	17	3	292	212 ( 41.81% )
Test performed, only negative results	9	9	1	55	18 ( 24.32% )
No test or unknown result	1,833	197	30	6,052	2,030 ( 25.02% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,795	273	33	9,182	2,068 ( 18.33% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	981	130	3	14	1,111 ( 98.49% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	215	35	7	987	250 ( 20.10% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	409	48	12	1,440	457 ( 23.94% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	424	21	2	-	445 ( 99.55% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	598	48	0	0	646 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,129	218	2	0	1,347 ( 99.85% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	12,397 ( 100.0% )	88.52% ( 87.32% , 89.64% )	95.27% ( 94.41% , 96.03% )
Inpatient	792 ( 6.39% )	91.01% ( 88.78% , 92.93% )	91.25% ( 89.04% , 93.14% )
Outpatient or Emergency Department	799 ( 6.45% )	91.82% ( 89.70% , 93.63% )	91.14% ( 88.95% , 93.01% )
Other	89 ( 0.72% )	81.61% ( 71.86% , 89.11% )	86.59% ( 77.26% , 93.11% )
Care Setting Reported as Unknown	4,192 ( 33.81% )	84.20% ( 82.02% , 86.21% )	*****
<b>Demographics</b>			
Sex			
Female	5,737 ( 46.28% )	88.57% ( 86.75% , 90.23% )	94.80% ( 93.43% , 95.97% )
Male	6,644 ( 53.59% )	88.48% ( 86.83% , 89.98% )	95.65% ( 94.50% , 96.62% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	14 ( 0.11% )	N/A	N/A
6-17	35 ( 0.28% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
18-29	264 ( 2.13% )	85.71% ( 75.87% , 92.65% )	88 % ( 78.44% , 94.36% )
30-39	570 ( 4.60% )	93.01% ( 88.34% , 96.23% )	92.51% ( 87.76% , 95.85% )
40-49	996 ( 8.03% )	93.11% ( 89.67% , 95.69% )	97.59% ( 95.11% , 99.03% )
50-59	2,098 ( 16.92% )	90.72% ( 88.23% , 92.82% )	96.75% ( 95.03% , 98.01% )
60-69	2,770 ( 22.34% )	89.36% ( 86.94% , 91.46% )	96.73% ( 95.13% , 97.91% )
70-79	2,632 ( 21.23% )	85.66% ( 82.41% , 88.52% )	93.31% ( 90.73% , 95.35% )
80-89	2,145 ( 17.30% )	85.29% ( 81.02% , 88.91% )	93.73% ( 90.38% , 96.18% )
90+	857 ( 6.91% )	75.86% ( 67.04% , 83.32% )	95.65% ( 89.24% , 98.80% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	9 ( 0.07% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	127 ( 1.02% )	96.15% ( 89.17% , 99.20% )	96.15% ( 89.17% , 99.20% )
Black or African American	1,341 ( 10.82% )	93.58% ( 90.92% , 95.66% )	96.36% ( 94.15% , 97.90% )
Native Hawaiian or Other Pacific Islander	6 ( 0.05% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	1,922 ( 15.50% )	82.95% ( 79.44% , 86.08% )	91.35% ( 88.45% , 93.72% )
Other/Mixed/Unknown	8,976 ( 72.40% )	88.48% ( 86.97% , 89.88% )	95.99% ( 94.96% , 96.85% )
Ethnicity			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	350 ( 2.82% )	96.15% ( 93.04% , 98.14% )	96.90% ( 93.98% , 98.65% )
Non-Hispanic	570 ( 4.60% )	92.53% ( 89.93% , 94.63% )	96.02% ( 93.93% , 97.55% )
Unknown	11,461 ( 92.45% )	86.66% ( 85.17% , 88.06% )	94.87% ( 93.81% , 95.79% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	183 ( 1.48% )	64.91% ( 51.13% , 77.09% )	90.24% ( 76.87% , 97.28% )
Contact and suspected exposure (Z20.828)	2,478 ( 19.99% )	81.11% ( 77.78% , 84.13% )	95.77% ( 93.66% , 97.33% )
Pneumonia (see Appendix B)	9,748 ( 78.63% )	89.62% ( 88.34% , 90.81% )	97.70% ( 96.99% , 98.28% )
Other viral pneumonia (J12.89)	8,358 ( 67.42% )	92.82% ( 91.68% , 93.84% )	99.25% ( 98.79% , 99.57% )
ARDS (J80)	1,650 ( 13.31% )	91.93% ( 89.09% , 94.23% )	99.08% ( 97.67% , 99.75% )
Sepsis (see Appendix C)	3,799 ( 30.64% )	88.16% ( 86 % , 90.09% )	96.51% ( 95.11% , 97.60% )
Bronchitis (J20.8 OR J40)	141 ( 1.14% )	97.22% ( 85.47% , 99.93% )	94.59% ( 81.81% , 99.34% )
Respiratory infection (J22 OR J98.8)	1,343 ( 10.83% )	92.09% ( 88.06% , 95.10% )	*****
Cough (R05)	2,512 ( 20.26% )	90.14% ( 87.44% , 92.42% )	97.43% ( 95.72% , 98.59% )
Shortness of breath (R06.2)	71 ( 0.57% )	81.82% ( 48.22% , 97.72% )	100.0% ( 66.37% , 100.0% )
Fever (R50.9)	3,134 ( 25.28% )	87.77% ( 85.20% , 90.04% )	97.61% ( 96.15% , 98.63% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	507 ( 4.09% )	91.98% ( 87.47% , 95.26% )	*****
Test performed, only negative results	74 ( 0.60% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	8,112 ( 65.44% )	90.30% ( 88.92% , 91.55% )	94.83% ( 93.74% , 95.77% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,283 ( 91.01% )	86.80% ( 85.26% , 88.23% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,128 ( 9.10% )	88.30% ( 86.26% , 90.13% )	93.61% ( 91.95% , 95.01% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,244 ( 10.03% )	86 % ( 81.07% , 90.05% )	97.29% ( 94.18% , 99 % )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,909 ( 15.40% )	89.50% ( 86.32% , 92.15% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.02% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	447 ( 3.61% )	95.28% ( 92.88% , 97.06% )	96.15% ( 93.90% , 97.74% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 0.73% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.10% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.49% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	646 ( 5.21% )	92.57% ( 90.27% , 94.47% )	97.24% ( 95.61% , 98.38% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,349 ( 10.88% )	83.82% ( 81.74% , 85.74% )	93.54% ( 92 % , 94.86% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassav	N/A	N/A	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: IP Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassav	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen Bv NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassav	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassav	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 0.19% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	2,640	353	35	9,500	2,993 ( 23.89% )
Inpatient	709	74	13	N/A	783
Outpatient or Emergency Department	731	68	4	N/A	799
Other	71	16	2	N/A	87
Care Setting Reported as Unknown	1,021	195	16	N/A	1,216
<b>Demographics</b>					
Sex					
Female	1,188	159	13	4,436	1,347 ( 23.24% )
Male	1,452	194	22	5,048	1,646 ( 24.51% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	14	0 (0.00%)
6-17	6	1	0	28	7 ( 20 % )
18-29	66	11	1	191	77 ( 28.62% )
30-39	173	15	5	381	188 ( 32.75% )
40-49	284	21	1	697	305 ( 30.41% )
50-59	596	62	9	1,455	658 ( 31.01% )
60-69	681	86	9	2,023	767 ( 27.40% )
70-79	463	78	4	2,118	541 ( 20.32% )
80-89	283	51	4	1,832	334 ( 15.39% )
90+	88	28	2	745	116 ( 13.44% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	4	5 ( 55.56% )
Asian	75	3	1	49	78 ( 60.94% )
Black or African American	425	31	2	901	456 ( 33.55% )
Native Hawaiian or Other Pacific Islander	3	0	0	3	3 ( 50 % )
White	434	93	0	1,411	527 ( 27.19% )
Other/Mixed/Unknown	1,698	226	32	7,116	1,924 ( 21.21% )
Ethnicity					



**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	250	10	0	90	260 ( 74.29% )
Non-Hispanic	483	41	2	46	524 ( 91.61% )
Unknown	1,907	302	33	9,348	2,209 ( 19.06% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	37	21	0	128	58 ( 31.18% )
Contact and suspected exposure (Z20.828)	499	123	14	1,881	622 ( 24.71% )
Pneumonia (see Appendix B)	2,171	256	32	7,374	2,427 ( 24.68% )
Other viral pneumonia (J12.89)	2,121	166	30	6,085	2,287 ( 27.22% )
ARDS (J80)	433	39	7	1,177	472 ( 28.50% )
Sepsis (see Appendix C)	887	127	13	2,806	1,014 ( 26.45% )
Bronchitis (J20.8 OR J40)	35	1	0	107	36 ( 25.17% )
Respiratory infection (J22 OR J98.8)	233	20	4	1,089	253 ( 18.80% )
Cough (R05)	530	62	7	1,933	592 ( 23.38% )
Shortness of breath (R06.2)	9	2	0	60	11 ( 15.49% )
Fever (R50.9)	653	97	9	2,404	750 ( 23.71% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	195	17	3	294	212 ( 41.65% )
Test performed, only negative results	9	9	1	55	18 ( 24.32% )
No test or unknown result	1,834	205	30	6,138	2,039 ( 24.84% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,798	278	33	9,297	2,076 ( 18.20% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	984	134	3	14	1,118 ( 98.50% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	215	39	7	1,000	254 ( 20.14% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	410	49	12	1,452	459 ( 23.87% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	425	25	2	-	450 ( 99.56% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	598	48	0	0	646 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,132	223	2	0	1,355 ( 99.85% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	12,528 ( 100.0% )	88.21% ( 87 % , 89.34% )	95.38% ( 94.53% , 96.13% )
Inpatient	796 ( 6.35% )	90.55% ( 88.28% , 92.51% )	91.25% ( 89.04% , 93.14% )
Outpatient or Emergency Department	803 ( 6.41% )	91.49% ( 89.34% , 93.33% )	91.26% ( 89.09% , 93.12% )
Other	89 ( 0.71% )	81.61% ( 71.86% , 89.11% )	86.59% ( 77.26% , 93.11% )
Care Setting Reported as Unknown	4,228 ( 33.75% )	83.96% ( 81.78% , 85.98% )	*****
<b>Demographics</b>			
Sex			
Female	5,796 ( 46.26% )	88.20% ( 86.35% , 89.87% )	94.96% ( 93.60% , 96.11% )
Male	6,716 ( 53.61% )	88.21% ( 86.56% , 89.73% )	95.72% ( 94.57% , 96.68% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	14 ( 0.11% )	N/A	N/A
6-17	35 ( 0.28% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
18-29	269 ( 2.15% )	85.71% ( 75.87% , 92.65% )	88 % ( 78.44% , 94.36% )
30-39	574 ( 4.58% )	92.02% ( 87.18% , 95.47% )	92.51% ( 87.76% , 95.85% )
40-49	1,003 ( 8.01% )	93.11% ( 89.67% , 95.69% )	97.59% ( 95.11% , 99.03% )
50-59	2,122 ( 16.94% )	90.58% ( 88.08% , 92.70% )	96.75% ( 95.03% , 98.01% )
60-69	2,799 ( 22.34% )	88.79% ( 86.34% , 90.93% )	96.87% ( 95.30% , 98.03% )
70-79	2,663 ( 21.26% )	85.58% ( 82.34% , 88.43% )	93.91% ( 91.43% , 95.86% )
80-89	2,170 ( 17.32% )	84.73% ( 80.42% , 88.41% )	93.40% ( 89.99% , 95.92% )
90+	863 ( 6.89% )	75.86% ( 67.04% , 83.32% )	95.65% ( 89.24% , 98.80% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	9 ( 0.07% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	128 ( 1.02% )	96.15% ( 89.17% , 99.20% )	96.15% ( 89.17% , 99.20% )
Black or African American	1,359 ( 10.85% )	93.20% ( 90.49% , 95.33% )	96.81% ( 94.71% , 98.25% )
Native Hawaiian or Other Pacific Islander	6 ( 0.05% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	1,938 ( 15.47% )	82.35% ( 78.82% , 85.51% )	91.56% ( 88.69% , 93.90% )
Other/Mixed/Unknown	9,072 ( 72.41% )	88.25% ( 86.73% , 89.66% )	95.99% ( 94.96% , 96.85% )
Ethnicity			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	350 ( 2.79% )	96.15% ( 93.04% , 98.14% )	96.90% ( 93.98% , 98.65% )
Non-Hispanic	572 ( 4.57% )	92.18% ( 89.53% , 94.33% )	96.02% ( 93.93% , 97.55% )
Unknown	11,590 ( 92.51% )	86.33% ( 84.83% , 87.74% )	95.02% ( 93.97% , 95.93% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	186 ( 1.48% )	63.79% ( 50.12% , 76.01% )	90.24% ( 76.87% , 97.28% )
Contact and suspected exposure (Z20.828)	2,517 ( 20.09% )	80.23% ( 76.87% , 83.29% )	95.96% ( 93.89% , 97.48% )
Pneumonia (see Appendix B)	9833 ( 78.49% )	89.45% ( 88.16% , 90.65% )	97.84% ( 97.14% , 98.40% )
Other viral pneumonia (J12.89)	8,402 ( 67.07% )	92.74% ( 91.60% , 93.77% )	99.34% ( 98.90% , 99.64% )
ARDS (J80)	1,656 ( 13.22% )	91.74% ( 88.88% , 94.06% )	99.08% ( 97.67% , 99.75% )
Sepsis (see Appendix C)	3,833 ( 30.60% )	87.48% ( 85.28% , 89.45% )	96.62% ( 95.24% , 97.69% )
Bronchitis (J20.8 OR J40)	143 ( 1.14% )	97.22% ( 85.47% , 99.93% )	94.59% ( 81.81% , 99.34% )
Respiratory infection (J22 OR J98.8)	1,346 ( 10.74% )	92.09% ( 88.06% , 95.10% )	*****
Cough (R05)	2,532 ( 20.21% )	89.53% ( 86.78% , 91.88% )	97.43% ( 95.72% , 98.59% )
Shortness of breath (R06.2)	71 ( 0.57% )	81.82% ( 48.22% , 97.72% )	100.0% ( 66.37% , 100.0% )
Fever (R50.9)	3,163 ( 25.25% )	87.07% ( 84.45% , 89.39% )	97.61% ( 96.15% , 98.63% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	509 ( 4.06% )	91.98% ( 87.47% , 95.26% )	*****
Test performed, only negative results	74 ( 0.59% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	8,207 ( 65.51% )	89.95% ( 88.56% , 91.22% )	94.88% ( 93.80% , 95.82% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,406 ( 91.04% )	86.61% ( 85.07% , 88.05% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,135 ( 9.06% )	88.01% ( 85.97% , 89.86% )	93.89% ( 92.27% , 95.27% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,261 ( 10.07% )	84.65% ( 79.61% , 88.85% )	97.29% ( 94.18% , 99 % )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,923 ( 15.35% )	89.32% ( 86.13% , 92 % )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.02% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	452 ( 3.61% )	94.44% ( 91.91% , 96.37% )	96.37% ( 94.17% , 97.91% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 0.73% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.10% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.49% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	646 ( 5.16% )	92.57% ( 90.27% , 94.47% )	97.24% ( 95.61% , 98.38% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,357 ( 10.83% )	83.54% ( 81.46% , 85.48% )	93.79% ( 92.27% , 95.08% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassav	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen Bv NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassav	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassav	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 0.18% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	2,647	364	35	9,617	3,011 ( 23.78% )
Inpatient	711	76	13	N/A	787
Outpatient or Emergency Department	732	70	4	N/A	802
Other	71	16	2	N/A	87
Care Setting Reported as Unknown	1,025	202	16	N/A	1,227
<b>Demographics</b>					
Sex					
Female	1,192	166	13	4,489	1,358 ( 23.17% )
Male	1,455	198	22	5,112	1,653 ( 24.36% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	1	0	0	16	1 ( 5.88% )
6-17	6	1	0	28	7 ( 20% )
18-29	66	11	1	194	77 ( 28.31% )
30-39	173	16	5	386	189 ( 32.59% )
40-49	285	24	1	705	309 ( 30.44% )
50-59	596	62	9	1,465	658 ( 30.86% )
60-69	684	90	9	2,049	774 ( 27.33% )
70-79	464	79	4	2,144	543 ( 20.18% )
80-89	284	53	4	1,859	337 ( 15.32% )
90+	88	28	2	755	116 ( 13.29% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	4	5 ( 55.56% )
Asian	75	3	1	49	78 ( 60.94% )
Black or African American	425	32	2	914	457 ( 33.28% )
Native Hawaiian or Other Pacific Islander	3	0	0	3	3 ( 50% )
White	435	93	0	1,436	528 ( 26.88% )
Other/Mixed/Unknown	1,704	236	32	7,195	1,940 ( 21.16% )
Ethnicity					



**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	250	11	0	91	261 ( 74.15% )
Non-Hispanic	483	41	2	46	524 ( 91.61% )
Unknown	1,914	312	33	9,464	2,226 ( 18.99% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	37	21	0	132	58 ( 30.53% )
Contact and suspected exposure (Z20.828)	499	127	14	1,897	626 ( 24.67% )
Pneumonia (see Appendix B)	2,175	263	32	7,441	2,438 ( 24.60% )
Other viral pneumonia (J12.89)	2,124	167	30	6,093	2,291 ( 27.23% )
ARDS (J80)	433	39	7	1,177	472 ( 28.50% )
Sepsis (see Appendix C)	890	129	13	2,823	1,019 ( 26.43% )
Bronchitis (J20.8 OR J40)	35	1	0	109	36 ( 24.83% )
Respiratory infection (J22 OR J98.8)	233	20	4	1,089	253 ( 18.80% )
Cough (R05)	531	64	7	1,955	595 ( 23.27% )
Shortness of breath (R06.2)	9	2	0	62	11 ( 15.07% )
Fever (R50.9)	655	100	9	2,428	755 ( 23.65% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	195	17	3	296	212 ( 41.49% )
Test performed, only negative results	9	9	1	56	18 ( 24 % )
No test or unknown result	1,838	213	30	6,205	2,051 ( 24.75% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,805	288	33	9,413	2,093 ( 18.14% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	986	137	3	15	1,123 ( 98.42% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	215	40	7	1,011	255 ( 20.03% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	410	50	12	1,455	460 ( 23.87% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	425	25	2	-	450 ( 99.56% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	601	51	0	0	652 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,136	230	2	0	1,366 ( 99.85% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	1,2663 ( 100.0% )	87.91% ( 86.69% , 89.05% )	95.63% ( 94.80% , 96.36% )
Inpatient	800 ( 6.32% )	90.34% ( 88.06% , 92.32% )	91.51% ( 89.32% , 93.37% )
Outpatient or Emergency Department	806 ( 6.37% )	91.27% ( 89.10% , 93.13% )	91.39% ( 89.22% , 93.24% )
Other	89 ( 0.70% )	81.61% ( 71.86% , 89.11% )	86.59% ( 77.26% , 93.11% )
Care Setting Reported as Unknown	4,286 ( 33.85% )	83.54% ( 81.34% , 85.57% )	*****
<b>Demographics</b>			
Sex			
Female	5,860 ( 46.28% )	87.78% ( 85.92% , 89.47% )	95.28% ( 93.96% , 96.39% )
Male	6,787 ( 53.60% )	88.02% ( 86.36% , 89.55% )	95.91% ( 94.79% , 96.85% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	17 ( 0.13% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
6-17	35 ( 0.28% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
18-29	272 ( 2.15% )	85.71% ( 75.87% , 92.65% )	88 % ( 78.44% , 94.36% )
30-39	580 ( 4.58% )	91.53% ( 86.62% , 95.08% )	92.51% ( 87.76% , 95.85% )
40-49	1,015 ( 8.02% )	92.23% ( 88.66% , 94.96% )	97.94% ( 95.57% , 99.24% )
50-59	2,132 ( 16.84% )	90.58% ( 88.08% , 92.70% )	96.75% ( 95.03% , 98.01% )
60-69	2,832 ( 22.36% )	88.37% ( 85.90% , 90.55% )	97.30% ( 95.81% , 98.37% )
70-79	2,691 ( 21.25% )	85.45% ( 82.20% , 88.31% )	94.12% ( 91.66% , 96.03% )
80-89	2,200 ( 17.37% )	84.27% ( 79.94% , 87.99% )	93.73% ( 90.38% , 96.18% )
90+	873 ( 6.89% )	75.86% ( 67.04% , 83.32% )	95.65% ( 89.24% , 98.80% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	9 ( 0.07% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	128 ( 1.01% )	96.15% ( 89.17% , 99.20% )	96.15% ( 89.17% , 99.20% )
Black or African American	1,373 ( 10.84% )	93 % ( 90.26% , 95.16% )	96.81% ( 94.71% , 98.25% )
Native Hawaiian or Other Pacific Islander	6 ( 0.05% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	1,964 ( 15.51% )	82.39% ( 78.86% , 85.54% )	91.77% ( 88.92% , 94.08% )
Other/Mixed/Unknown	9,167 ( 72.39% )	87.84% ( 86.30% , 89.26% )	96.33% ( 95.34% , 97.15% )
Ethnicity			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	352 ( 2.78% )	95.79% ( 92.58% , 97.88% )	96.90% ( 93.98% , 98.65% )
Non-Hispanic	572 ( 4.52% )	92.18% ( 89.53% , 94.33% )	96.02% ( 93.93% , 97.55% )
Unknown	11,723 ( 92.58% )	85.98% ( 84.47% , 87.40% )	95.37% ( 94.35% , 96.24% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	190 ( 1.50% )	63.79% ( 50.12% , 76.01% )	90.24% ( 76.87% , 97.28% )
Contact and suspected exposure (Z20.828)	2,537 ( 20.03% )	79.71% ( 76.35% , 82.80% )	95.96% ( 93.89% , 97.48% )
Pneumonia (see Appendix B)	9,911 ( 78.27% )	89.21% ( 87.91% , 90.42% )	98.02% ( 97.35% , 98.56% )
Other viral pneumonia (J12.89)	8,414 ( 66.45% )	92.71% ( 91.57% , 93.74% )	99.48% ( 99.08% , 99.74% )
ARDS (J80)	1,656 ( 13.08% )	91.74% ( 88.88% , 94.06% )	99.08% ( 97.67% , 99.75% )
Sepsis (see Appendix C)	3,855 ( 30.44% )	87.34% ( 85.14% , 89.32% )	96.95% ( 95.62% , 97.96% )
Bronchitis (J20.8 OR J40)	145 ( 1.15% )	97.22% ( 85.47% , 99.93% )	94.59% ( 81.81% , 99.34% )
Respiratory infection (J22 OR J98.8)	1,346 ( 10.63% )	92.09% ( 88.06% , 95.10% )	*****
Cough (R05)	2,557 ( 20.19% )	89.24% ( 86.47% , 91.62% )	97.61% ( 95.95% , 98.72% )
Shortness of breath (R06.2)	73 ( 0.58% )	81.82% ( 48.22% , 97.72% )	100.0% ( 66.37% , 100.0% )
Fever (R50.9)	3,192 ( 25.21% )	86.75% ( 84.13% , 89.09% )	97.91% ( 96.51% , 98.85% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	511 ( 4.04% )	91.98% ( 87.47% , 95.26% )	*****
Test performed, only negative results	75 ( 0.59% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	8,286 ( 65.43% )	89.61% ( 88.21% , 90.90% )	95.09% ( 94.03% , 96.01% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,539 ( 91.12% )	86.24% ( 84.69% , 87.69% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,141 ( 9.01% )	87.80% ( 85.74% , 89.66% )	94.08% ( 92.48% , 95.43% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,273 ( 10.05% )	84.31% ( 79.26% , 88.55% )	97.29% ( 94.18% , 99 % )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,927 ( 15.22% )	89.13% ( 85.92% , 91.82% )	
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.02% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	452 ( 3.57% )	94.44% ( 91.91% , 96.37% )	96.37% ( 94.17% , 97.91% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 0.72% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.09% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.48% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	652 ( 5.15% )	92.18% ( 89.84% , 94.12% )	97.72% ( 96.21% , 98.75% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,368 ( 10.80% )	83.16% ( 81.07% , 85.11% )	94.12% ( 92.64% , 95.38% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 0.18% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	2651	369	35	9676	3020 ( 23.72% )
Inpatient	711	79	13	N/A	790
Outpatient or Emergency Department	735	70	4	N/A	805
Other	71	16	2	N/A	87
Care Setting Reported as Unknown	1026	204	16	N/A	1230
<b>Demographics</b>					
Sex					
Female	1196	168	13	4516	1364 ( 23.15% )
Male	1455	201	22	5144	1656 ( 24.27% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	1	0	0	16	1 ( 5.88% )
6-17	6	1	0	28	7 ( 20 % )
18-29	66	12	1	195	78 ( 28.47% )
30-39	174	16	5	389	190 ( 32.53% )
40-49	285	25	1	707	310 ( 30.45% )
50-59	597	63	9	1475	660 ( 30.78% )
60-69	685	90	9	2061	775 ( 27.24% )
70-79	464	80	4	2155	544 ( 20.13% )
80-89	285	54	4	1875	339 ( 15.28% )
90+	88	28	2	759	116 ( 13.23% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	4	5 ( 55.56% )
Asian	75	3	1	49	78 ( 60.94% )
Black or African American	425	32	2	926	457 ( 33 % )
Native Hawaiian or Other Pacific Islander	3	0	0	3	3 ( 50 % )
White	436	93	0	1445	529 ( 26.80% )
Other/Mixed/Unknown	1707	241	32	7233	1948 ( 21.14% )
Ethnicity					



**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	250	12	0	91	262 ( 74.22% )
Non-Hispanic	483	41	2	46	524 ( 91.61% )
Unknown	1918	316	33	9523	2234 ( 18.95% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	37	22	0	133	59 ( 30.73% )
Contact and suspected exposure (Z20.828)	499	129	14	1906	628 ( 24.65% )
Pneumonia (see Appendix B)	2179	266	32	7491	2445 ( 24.53% )
Other viral pneumonia (J12.89)	2124	167	30	6097	2291 ( 27.22% )
ARDS (J80)	433	39	7	1179	472 ( 28.47% )
Sepsis (see Appendix C)	891	132	13	2837	1023 ( 26.41% )
Bronchitis (J20.8 OR J40)	35	1	0	110	36 ( 24.66% )
Respiratory infection (J22 OR J98.8)	233	20	4	1089	253 ( 18.80% )
Cough (R05)	533	65	7	1962	598 ( 23.30% )
Shortness of breath (R06.2)	9	2	0	62	11 ( 15.07% )
Fever (R50.9)	655	103	9	2438	758 ( 23.65% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	197	17	3	298	214 ( 41.55% )
Test performed, only negative results	9	9	1	57	18 ( 23.68% )
No test or unknown result	1839	217	30	6231	2056 ( 24.72% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1809	292	33	9470	2101 ( 18.11% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	987	138	3	15	1125 ( 98.43% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	215	41	7	1016	256 ( 20.02% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	410	50	12	1458	460 ( 23.83% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	425	25	2	-	450 ( 99.56% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	602	54	0	0	656 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1139	231	2	0	1370 ( 99.85% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	12731 ( 100.0% )	87.78% ( 86.56% , 88.93% )	95.77% ( 94.96% , 96.49% )
Inpatient	803 ( 6.31% )	90 % ( 87.69% , 92 % )	91.51% ( 89.32% , 93.37% )
Outpatient or Emergency Department	809 ( 6.35% )	91.30% ( 89.14% , 93.16% )	91.76% ( 89.64% , 93.57% )
Other	89 ( 0.70% )	81.61% ( 71.86% , 89.11% )	86.59% ( 77.26% , 93.11% )
Care Setting Reported as Unknown	4319 ( 33.93% )	83.41% ( 81.22% , 85.45% )	*****
<b>Demographics</b>			
Sex			
Female	5893 ( 46.29% )	87.68% ( 85.82% , 89.38% )	95.60% ( 94.32% , 96.67% )
Male	6822 ( 53.59% )	87.86% ( 86.19% , 89.40% )	95.91% ( 94.79% , 96.85% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	17 ( 0.13% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
6-17	35 ( 0.27% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
18-29	274 ( 2.15% )	84.62% ( 74.67% , 91.79% )	88 % ( 78.44% , 94.36% )
30-39	584 ( 4.59% )	91.58% ( 86.68% , 95.11% )	93.05% ( 88.41% , 96.25% )
40-49	1018 ( 8 % )	91.94% ( 88.33% , 94.71% )	97.94% ( 95.57% , 99.24% )
50-59	2144 ( 16.84% )	90.45% ( 87.95% , 92.59% )	96.92% ( 95.23% , 98.13% )
60-69	2845 ( 22.35% )	88.39% ( 85.92% , 90.56% )	97.44% ( 95.98% , 98.48% )
70-79	2703 ( 21.23% )	85.29% ( 82.03% , 88.16% )	94.12% ( 91.66% , 96.03% )
80-89	2218 ( 17.42% )	84.07% ( 79.73% , 87.80% )	94.06% ( 90.77% , 96.44% )
90+	877 ( 6.89% )	75.86% ( 67.04% , 83.32% )	95.65% ( 89.24% , 98.80% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	9 ( 0.07% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	128 ( 1.01% )	96.15% ( 89.17% , 99.20% )	96.15% ( 89.17% , 99.20% )
Black or African American	1385 ( 10.88% )	93 % ( 90.26% , 95.16% )	96.81% ( 94.71% , 98.25% )
Native Hawaiian or Other Pacific Islander	6 ( 0.05% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	1974 ( 15.51% )	82.42% ( 78.90% , 85.57% )	91.98% ( 89.16% , 94.26% )
Other/Mixed/Unknown	9213 ( 72.37% )	87.63% ( 86.08% , 89.06% )	96.50% ( 95.53% , 97.30% )
Ethnicity			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	353 ( 2.77% )	95.42% ( 92.14% , 97.61% )	96.90% ( 93.98% , 98.65% )
Non-Hispanic	572 ( 4.49% )	92.18% ( 89.53% , 94.33% )	96.02% ( 93.93% , 97.55% )
Unknown	11790 ( 92.61% )	85.85% ( 84.34% , 87.27% )	95.57% ( 94.57% , 96.42% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	192 ( 1.51% )	62.71% ( 49.15% , 74.96% )	90.24% ( 76.87% , 97.28% )
Contact and suspected exposure (Z20.828)	2548 ( 20.01% )	79.46% ( 76.08% , 82.55% )	95.96% ( 93.89% , 97.48% )
Pneumonia (see Appendix B)	9968 ( 78.30% )	89.12% ( 87.82% , 90.33% )	98.20% ( 97.55% , 98.71% )
Other viral pneumonia (J12.89)	8418 ( 66.12% )	92.71% ( 91.57% , 93.74% )	99.48% ( 99.08% , 99.74% )
ARDS (J80)	1658 ( 13.02% )	91.74% ( 88.88% , 94.06% )	99.08% ( 97.67% , 99.75% )
Sepsis (see Appendix C)	3873 ( 30.42% )	87.10% ( 84.89% , 89.09% )	97.06% ( 95.75% , 98.05% )
Bronchitis (J20.8 OR J40)	146 ( 1.15% )	97.22% ( 85.47% , 99.93% )	94.59% ( 81.81% , 99.34% )
Respiratory infection (J22 OR J98.8)	1346 ( 10.57% )	92.09% ( 88.06% , 95.10% )	*****
Cough (R05)	2567 ( 20.16% )	89.13% ( 86.36% , 91.51% )	97.98% ( 96.41% , 98.99% )
Shortness of breath (R06.2)	73 ( 0.57% )	81.82% ( 48.22% , 97.72% )	100.0% ( 66.37% , 100.0% )
Fever (R50.9)	3205 ( 25.17% )	86.41% ( 83.76% , 88.77% )	97.91% ( 96.51% , 98.85% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	515 ( 4.05% )	92.06% ( 87.59% , 95.30% )	*****
Test performed, only negative results	76 ( 0.60% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	8317 ( 65.33% )	89.45% ( 88.04% , 90.74% )	95.14% ( 94.08% , 96.05% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11604 ( 91.15% )	86.10% ( 84.55% , 87.55% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1143 ( 8.98% )	87.73% ( 85.67% , 89.59% )	94.18% ( 92.59% , 95.52% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1279 ( 10.05% )	83.98% ( 78.91% , 88.26% )	97.29% ( 94.18% , 99 % )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1930 ( 15.16% )	89.13% ( 85.92% , 91.82% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.02% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	452 ( 3.55% )	94.44% ( 91.91% , 96.37% )	96.37% ( 94.17% , 97.91% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 0.71% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.09% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.48% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	656 ( 5.15% )	91.77% ( 89.40% , 93.76% )	97.89% ( 96.41% , 98.87% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1372 ( 10.78% )	83.14% ( 81.05% , 85.09% )	94.37% ( 92.91% , 95.60% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 0.18% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	2,291	267	32	7,507	2,558 ( 25.33% )
Inpatient	595	45	13	N/A	640
Outpatient or Emergency Department	651	55	3	N/A	706
Other	64	11	1	N/A	75
Care Setting Reported as Unknown	884	156	15	N/A	1,040
<b>Demographics</b>					
Sex					
Female	974	108	12	3,369	1,082 ( 24.24% )
Male	1,317	159	20	4,125	1,476 ( 26.26% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	2	0	0	12	2 ( 14.29% )
18-29	40	6	1	119	46 ( 27.71% )
30-39	130	9	4	269	139 ( 33.74% )
40-49	247	17	1	581	264 ( 31.21% )
50-59	539	47	8	1,223	586 ( 32.25% )
60-69	616	70	9	1,671	686 ( 28.99% )
70-79	403	60	4	1,671	463 ( 21.66% )
80-89	241	39	3	1,398	280 ( 16.66% )
90+	73	19	2	547	92 ( 14.35% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	4	0	0	3	4 ( 57.14% )
Asian	69	3	1	36	72 ( 66.06% )
Black or African American	374	28	2	679	402 ( 37.12% )
Native Hawaiian or Other Pacific Islander	2	0	0	3	2 ( 40 % )
White	343	66	0	1,024	409 ( 28.54% )
Other/Mixed/Unknown	1,499	170	29	5,749	1,669 ( 22.41% )
Ethnicity					



**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	217	8	0	72	225 ( 75.76% )
Non-Hispanic	412	26	2	35	438 ( 92.21% )
Unknown	1,662	233	30	7,387	1,895 ( 20.35% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	33	13	0	98	46 ( 31.94% )
Contact and suspected exposure (Z20.828)	472	91	13	1,605	563 ( 25.81% )
Pneumonia (see Appendix B)	2,180	258	32	7,422	2,438 ( 24.65% )
Other viral pneumonia (J12.89)	2,130	168	30	6,127	2,298 ( 27.18% )
ARDS (J80)	436	39	7	1,187	475 ( 28.46% )
Sepsis (see Appendix C)	858	99	12	2,532	957 ( 27.34% )
Bronchitis (J20.8 OR J40)	22	0	0	82	22 ( 21.15% )
Respiratory infection (J22 OR J98.8)	207	17	4	882	224 ( 20.18% )
Cough (R05)	481	51	7	1,651	532 ( 24.29% )
Shortness of breath (R06.2)	9	2	0	53	11 ( 17.19% )
Fever (R50.9)	616	74	9	2,061	690 ( 25% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	170	14	3	264	184 ( 40.80% )
Test performed, only negative results	9	7	1	38	16 ( 29.09% )
No test or unknown result	1,619	154	27	4,992	1,773 ( 26.10% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,555	212	30	7,341	1,767 ( 19.34% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	831	102	2	14	933 ( 98.31% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	205	29	7	870	234 ( 21.06% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	407	48	12	1,417	455 ( 24.15% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	380	20	2	-	400 ( 99.50% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	79	4	-	-	83 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	10	1	-	-	11 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	52	6	0	0	58 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	534	35	0	0	569 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	958	171	2	0	1,129 ( 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	11	0	0	7	11 ( 61.11% )

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	10,097 ( 100.0% )	89.56% ( 88.31% , 90.72% )	82.77% ( 81.31% , 84.16% )
Inpatient	653 ( 6.47% )	92.97% ( 90.70% , 94.83% )	76.58% ( 73.44% , 79.51% )
Outpatient or Emergency Department	709 ( 7.02% )	92.21% ( 89.98% , 94.08% )	81.27% ( 78.40% , 83.92% )
Other	76 ( 0.75% )	85.33% ( 75.27% , 92.44% )	78.05% ( 67.54% , 86.44% )
Care Setting Reported as Unknown	3,254 ( 32.23% )	85 % ( 82.68% , 87.12% )	*****
<b>Demographics</b>			
Sex			
Female	4,463 ( 44.20% )	90.02% ( 88.08% , 91.74% )	77.86% ( 75.45% , 80.13% )
Male	5,621 ( 55.67% )	89.23% ( 87.53% , 90.76% )	86.82% ( 85.01% , 88.48% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	3 ( 0.03% )	N/A	N/A
6-17	14 ( 0.14% )	100.0% ( 15.81% , 100.0% )	28.57% ( 3.67% , 70.96% )
18-29	166 ( 1.64% )	86.96% ( 73.74% , 95.06% )	53.33% ( 41.45% , 64.95% )
30-39	412 ( 4.08% )	93.53% ( 88.06% , 97 % )	69.52% ( 62.38% , 76.03% )
40-49	846 ( 8.38% )	93.56% ( 89.89% , 96.20% )	84.88% ( 80.24% , 88.79% )
50-59	1817 ( 18 % )	91.98% ( 89.48% , 94.05% )	87.50% ( 84.63% , 90.01% )
60-69	2,366 ( 23.43% )	89.80% ( 87.28% , 91.96% )	87.62% ( 84.96% , 89.97% )
70-79	2,138 ( 21.17% )	87.04% ( 83.64% , 89.96% )	81.74% ( 78.05% , 85.06% )
80-89	1,681 ( 16.65% )	86.07% ( 81.45% , 89.90% )	79.54% ( 74.55% , 83.94% )
90+	641 ( 6.35% )	79.35% ( 69.64% , 87.08% )	79.35% ( 69.64% , 87.08% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	7 ( 0.07% )	100.0% ( 39.76% , 100.0% )	80 % ( 28.36% , 99.49% )
Asian	109 ( 1.08% )	95.83% ( 88.30% , 99.13% )	88.46% ( 79.22% , 94.59% )
Black or African American	1,083 ( 10.73% )	93.03% ( 90.09% , 95.32% )	85.19% ( 81.52% , 88.38% )
Native Hawaiian or Other Pacific Islander	5 ( 0.05% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
White	1,433 ( 14.19% )	83.86% ( 79.93% , 87.29% )	72.36% ( 68.10% , 76.34% )
Other/Mixed/Unknown	7,447 ( 73.75% )	89.81% ( 88.26% , 91.22% )	84.74% ( 82.98% , 86.38% )
Ethnicity			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Hispanic	297 ( 2.94% )	96.44% ( 93.11% , 98.45% )	84.11% ( 79.07% , 88.35% )
Non-Hispanic	475 ( 4.70% )	94.06% ( 91.42% , 96.09% )	81.91% ( 78.26% , 85.18% )
Unknown	9,312 ( 92.23% )	87.70% ( 86.14% , 89.15% )	82.81% ( 81.09% , 84.44% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	144 ( 1.43% )	71.74% ( 56.54% , 84.01% )	80.49% ( 65.13% , 91.18% )
Contact and suspected exposure (Z20.828)	2,181 ( 21.60% )	83.84% ( 80.53% , 86.78% )	90.77% ( 87.95% , 93.12% )
Pneumonia (see Appendix B)	9,892 ( 97.97% )	89.42% ( 88.13% , 90.61% )	98.24% ( 97.61% , 98.75% )
Other viral pneumonia (J12.89)	8,455 ( 83.74% )	92.69% ( 91.55% , 93.72% )	99.77% ( 99.45% , 99.92% )
ARDS (J80)	1,669 ( 16.53% )	91.79% ( 88.95% , 94.10% )	99.77% ( 98.73% , 99.99% )
Sepsis (see Appendix C)	3,501 ( 34.67% )	89.66% ( 87.55% , 91.51% )	93.46% ( 91.67% , 94.98% )
Bronchitis (J20.8 OR J40)	104 ( 1.03% )	100.0% ( 84.56% , 100.0% )	59.46% ( 42.10% , 75.25% )
Respiratory infection (J22 OR J98.8)	1,110 ( 10.99% )	92.41% ( 88.13% , 95.52% )	89.61% ( 84.94% , 93.23% )
Cough (R05)	2,190 ( 21.69% )	90.41% ( 87.59% , 92.78% )	88.42% ( 85.43% , 90.99% )
Shortness of breath (R06.2)	64 ( 0.63% )	81.82% ( 48.22% , 97.72% )	100.0% ( 66.37% , 100.0% )
Fever (R50.9)	2,760 ( 27.33% )	89.28% ( 86.72% , 91.48% )	92.08% ( 89.77% , 94.01% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	451 ( 4.47% )	92.39% ( 87.56% , 95.78% )	*****
Test performed, only negative results	55 ( 0.54% )	56.25% ( 29.88% , 80.25% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	6,792 ( 67.27% )	91.31% ( 89.91% , 92.58% )	83.76% ( 82.03% , 85.37% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	9,138 ( 90.50% )	88 % ( 86.40% , 89.48% )	99.30% ( 98.75% , 99.65% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	949 ( 9.40% )	89.07% ( 86.89% , 91 % )	79.29% ( 76.71% , 81.71% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	Total Patient Count	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number (Percent)	Percent	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,111 ( 11 % )	87.61% ( 82.69% , 91.54% )	92.76% ( 88.51% , 95.81% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,884 ( 18.66% )	89.45% ( 86.26% , 92.12% )	99.75% ( 98.64% , 99.99% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual Differential WBC Count	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.02% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	402 ( 3.98% )	95 % ( 92.38% , 96.92% )	86.17% ( 82.59% , 89.25% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	83 ( 0.82% )	95.18% ( 88.12% , 98.67% )	83.16% ( 74.10% , 90.06% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11 ( 0.11% )	90.91% ( 58.72% , 99.77% )	90.91% ( 58.72% , 99.77% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	58 ( 0.57% )	89.66% ( 78.83% , 96.11% )	91.23% ( 80.70% , 97.09% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	569 ( 5.64% )	93.85% ( 91.55% , 95.68% )	86.83% ( 83.90% , 89.40% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,131 ( 11.20% )	84.85% ( 82.63% , 86.90% )	79.37% ( 76.98% , 81.62% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1b. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
<b>Unknown</b>	<b>18 ( 0.18% )</b>	<b>100.0% ( 71.51% , 100.0% )</b>	<b>68.75% ( 41.34% , 88.98% )</b>

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINC or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test*****</b>				
Total Observed	4,811	6,698	57,044	90,681
Inpatient	1,090	1,034	21,010	22,351
Outpatient or Emergency Department	1,973	943	11,230	6,747
Other	337	382	5,834	7,967
Care Setting Reported as Unknown	690	3,482	10,927	44,441
<b>Demographics</b>				
Sex				
Female	2,293	3,245	32,911	51,014
Male	2,518	3,453	24,133	39,667
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	18	27	469	725
6-17	20	42	789	1,282
18-29	294	533	5,205	8,143
30-39	439	682	8,076	12,156
40-49	639	905	4,487	8,131
50-59	1,019	1,428	7,087	13,412
60-69	1,063	1,402	10,768	17,728
70-79	747	938	11,171	16,203
80-89	429	556	6,932	9,903
90+	143	185	2,060	2,998
Missing	0	0	0	0
Race				
American Indian or Alaska Native	23	28	229	326
Asian	267	318	1,779	2,217
Black or African American	862	971	6,223	7,711
Native Hawaiian or Other Pacific Islander	3	3	45	63
White	1,192	1,383	27,234	35,127
Other/Mixed/Unknown	2,464	3,995	21,535	45,237
Ethnicity				



**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	654	753	2,323	2,892
Non-Hispanic	1,327	1,611	24,118	33,220
Unknown	2,830	4,334	30,603	54,569
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	94	211	9,293	14,321
Contact and suspected exposure (Z20.828)	509	714	15,169	24,670
Pneumonia (see Appendix B)	3,479	4,468	5,287	10,312
Other viral pneumonia (J12.89)	3,274	4,053	641	2,006
ARDS (J80)	444	605	204	569
Sepsis (see Appendix C)	1,230	1,748	5,132	10,281
Bronchitis (J20.8 OR J40)	57	79	97	202
Respiratory infection (J22 OR J98.8)	181	240	104	321
Cough (R05)	516	682	1,348	2,929
Shortness of breath (R06.2)	12	17	131	340
Fever (R50.9)	682	968	2,707	5,982
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	89	40	74	25
Test performed, only negative results	16	3	565	286
No test or unknown result	3,653	5,498	42,476	75,211
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	1	0	0	0
Test performed, only negative results	1	0	26	0
No test or unknown result	2,548	4,172	35,287	66,113
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	3,094	2,391	31,744	32,890
<b>Codes Observed During Inpatient Stay</b>				

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	227	308	1,640	3,019
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	368	463	245	757
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	526	571	2,840	3,219
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	640	649	2,272	2,407
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	6	7
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	146	149	3,474	3,775
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	1	1
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	36	305	534
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	1
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	1
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	280	600	7,031	15,096
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	1	2
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	1	5	15
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,867	4,126	36,433	58,596
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	2	92	94
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	5	205	268
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	6	11	78	120
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	4	8	23	68
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	7	7
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7	11	160	238
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	1	1
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	2	2
Unknown	48	48	95	199

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	4,564	1,060	28	20,249	5,624 ( 21.71% )
Inpatient	1,029	97	4	N/A	1,126
Outpatient or Emergency Department	1,816	373	12	N/A	2,189
Other	314	30	5	N/A	344
Care Setting Reported as Unknown	1,225	554	7	N/A	1,779
<b>Demographics</b>					
Sex					
Female	2,153	545	10	9,839	2,698 ( 21.50% )
Male	2,411	515	18	10,347	2,926 ( 22.01% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	12	4	0	79	16 ( 16.84% )
6-17	18	5	1	128	23 ( 15.13% )
18-29	280	74	1	900	354 ( 28.21% )
30-39	418	89	3	1,280	507 ( 28.32% )
40-49	614	117	1	2,035	731 ( 26.42% )
50-59	978	172	4	3,321	1,150 ( 25.70% )
60-69	1,019	200	8	4,132	1,219 ( 22.75% )
70-79	698	217	6	4,020	915 ( 18.52% )
80-89	399	136	3	3,077	535 ( 14.80% )
90+	128	46	1	1,214	174 ( 12.53% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	23	1	0	14	24 ( 63.16% )
Asian	263	16	0	62	279 ( 81.82% )
Black or African American	826	94	0	1,201	920 ( 43.38% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	1,107	272	1	2,898	1,379 ( 32.23% )
Other/Mixed/Unknown	2,342	677	27	16,010	3,019 ( 15.84% )
Ethnicity					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	634	43	0	186	677 ( 78.45% )
Non-Hispanic	1,276	69	1	181	1,345 ( 88.08% )
Unknown	2,656	946	27	19,819	3,602 ( 15.36% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	66	45	1	403	111 ( 21.55% )
Contact and suspected exposure (Z20.828)	438	248	6	3,339	686 ( 17.02% )
Pneumonia (see Appendix B)	3,419	636	21	13,644	4,055 ( 22.88% )
Other viral pneumonia (J12.89)	3,269	420	20	10,980	3,689 ( 25.11% )
ARDS (J80)	433	50	3	1,374	483 ( 25.97% )
Sepsis (see Appendix C)	1,198	271	6	4,773	1,469 ( 23.51% )
Bronchitis (J20.8 OR J40)	57	9	0	217	66 ( 23.32% )
Respiratory infection (J22 OR J98.8)	178	33	1	963	211 ( 17.96% )
Cough (R05)	506	139	4	2,723	645 ( 19.13% )
Shortness of breath (R06.2)	11	4	0	80	15 ( 15.79% )
Fever (R50.9)	659	218	6	3,453	877 ( 20.23% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	97	28	0	232	125 ( 35.01% )
Test performed, only negative results	17	18	0	90	35 ( 28% )
No test or unknown result	3,502	636	26	14,525	4,138 ( 22.14% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	3,028	887	27	19,802	3,915 ( 16.49% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	2,952	607	11	47	3,559 ( 98.40% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	210	111	3	1,424	321 ( 18.36% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	351	115	5	2,112	466 ( 18.04% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	485	45	-	-	530 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	44	-	-	606 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	256	85	5	0	341 ( 98.55% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,711	794	3	0	3,505 ( 99.91% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	25,901 ( 100.0% )	81.15% ( 80.11% , 82.17% )	94.87% ( 94.20% , 95.47% )
Inpatient	1,130 ( 4.36% )	91.39% ( 89.59% , 92.96% )	94.40% ( 92.87% , 95.69% )
Outpatient or Emergency Department	2,201 ( 8.50% )	82.96% ( 81.32% , 84.51% )	92.04% ( 90.76% , 93.20% )
Other	349 ( 1.35% )	91.28% ( 87.78% , 94.04% )	93.18% ( 89.94% , 95.62% )
Care Setting Reported as Unknown	7209 ( 27.83% )	68.86% ( 66.65% , 71.01% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	12,547 ( 48.44% )	79.80% ( 78.23% , 81.30% )	93.89% ( 92.84% , 94.84% )
Male	13,291 ( 51.31% )	82.40% ( 80.97% , 83.76% )	95.75% ( 94.89% , 96.50% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	95 ( 0.37% )	75 % ( 47.62% , 92.73% )	66.67% ( 40.99% , 86.66% )
6-17	152 ( 0.59% )	78.26% ( 56.30% , 92.54% )	90 % ( 68.30% , 98.77% )
18-29	1,255 ( 4.85% )	79.10% ( 74.48% , 83.21% )	95.24% ( 92.14% , 97.37% )
30-39	1,790 ( 6.91% )	82.45% ( 78.85% , 85.66% )	95.22% ( 92.78% , 97.01% )
40-49	2,767 ( 10.68% )	83.99% ( 81.13% , 86.58% )	96.09% ( 94.28% , 97.45% )
50-59	4,475 ( 17.28% )	85.04% ( 82.85% , 87.06% )	95.98% ( 94.58% , 97.10% )
60-69	5,359 ( 20.69% )	83.59% ( 81.39% , 85.63% )	95.86% ( 94.48% , 96.98% )
70-79	4,941 ( 19.08% )	76.28% ( 73.39% , 79.01% )	93.44% ( 91.42% , 95.11% )
80-89	3,615 ( 13.96% )	74.58% ( 70.67% , 78.22% )	93.01% ( 90.17% , 95.23% )
90+	1,389 ( 5.36% )	73.56% ( 66.36% , 79.95% )	89.51% ( 83.29% , 94.01% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	38 ( 0.15% )	95.83% ( 78.88% , 99.89% )	100.0% ( 85.18% , 100.0% )
Asian	341 ( 1.32% )	94.27% ( 90.85% , 96.69% )	98.50% ( 96.21% , 99.59% )
Black or African American	2,121 ( 8.19% )	89.78% ( 87.64% , 91.66% )	95.82% ( 94.26% , 97.06% )
Native Hawaiian or Other Pacific Islander	4 ( 0.02% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	4,278 ( 16.52% )	80.28% ( 78.08% , 82.35% )	92.87% ( 91.26% , 94.26% )
Other/Mixed/Unknown	19,056 ( 73.57% )	77.58% ( 76.04% , 79.05% )	95.05% ( 94.12% , 95.87% )
<b>Ethnicity</b>			



**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	863 ( 3.33% )	93.65% ( 91.54% , 95.37% )	96.94% ( 95.32% , 98.12% )
Non-Hispanic	1,527 ( 5.90% )	94.87% ( 93.55% , 95.99% )	96.16% ( 94.98% , 97.13% )
Unknown	23,448 ( 90.53% )	73.74% ( 72.27% , 75.17% )	93.85% ( 92.90% , 94.71% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	515 ( 1.99% )	59.46% ( 49.73% , 68.68% )	70.21% ( 59.90% , 79.21% )
Contact and suspected exposure (Z20.828)	4,031 ( 15.56% )	63.85% ( 60.13% , 67.45% )	86.05% ( 82.73% , 88.94% )
Pneumonia (see Appendix B)	17,720 ( 68.41% )	84.32% ( 83.16% , 85.42% )	98.28% ( 97.79% , 98.68% )
Other viral pneumonia (J12.89)	14,689 ( 56.71% )	88.61% ( 87.55% , 89.62% )	99.85% ( 99.64% , 99.95% )
ARDS (J80)	1,860 ( 7.18% )	89.65% ( 86.58% , 92.22% )	97.52% ( 95.61% , 98.76% )
Sepsis (see Appendix C)	6,248 ( 24.12% )	81.55% ( 79.47% , 83.50% )	97.40% ( 96.35% , 98.21% )
Bronchitis (J20.8 OR J40)	283 ( 1.09% )	86.36% ( 75.69% , 93.57% )	100.0% ( 93.73% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,175 ( 4.54% )	84.36% ( 78.74% , 88.98% )	98.34% ( 95.23% , 99.66% )
Cough (R05)	3,372 ( 13.02% )	78.45% ( 75.07% , 81.56% )	98.06% ( 96.46% , 99.07% )
Shortness of breath (R06.2)	95 ( 0.37% )	73.33% ( 44.90% , 92.21% )	91.67% ( 61.52% , 99.79% )
Fever (R50.9)	4,336 ( 16.74% )	75.14% ( 72.14% , 77.97% )	96.63% ( 94.98% , 97.85% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	357 ( 1.38% )	77.60% ( 69.28% , 84.57% )	*****
Test performed, only negative results	125 ( 0.48% )	48.57% ( 31.38% , 66.01% )	*****
No test or unknown result	18,689 ( 72.16% )	84.63% ( 83.49% , 85.72% )	95.87% ( 95.17% , 96.49% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.02% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	23,744 ( 91.67% )	77.34% ( 76 % , 78.65% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	3,617 ( 13.96% )	82.94% ( 81.67% , 84.17% )	95.41% ( 94.61% , 96.12% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,748 ( 6.75% )	65.42% ( 59.94% , 70.62% )	92.51% ( 88.28% , 95.58% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,583 ( 9.97% )	75.32% ( 71.15% , 79.17% )	95.38% ( 92.71% , 97.29% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	530 ( 2.05% )	91.51% ( 88.80% , 93.74% )	92.21% ( 89.57% , 94.35% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	606 ( 2.34% )	92.74% ( 90.38% , 94.68% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 0.60% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	346 ( 1.34% )	75.07% ( 70.13% , 79.58% )	91.43% ( 87.51% , 94.43% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	3,508 ( 13.54% )	77.35% ( 75.92% , 78.72% )	94.56% ( 93.66% , 95.36% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.02% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 0.68% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	4,568	1,071	28	20,412	5,639 ( 21.62% )
Inpatient	1,029	102	4	N/A	1,131
Outpatient or Emergency Department	1,819	374	12	N/A	2,193
Other	314	30	5	N/A	344
Care Setting Reported as Unknown	1,226	559	7	N/A	1,785
<b>Demographics</b>					
<b>Sex</b>					
Female	2,156	550	10	9,929	2,706 ( 21.40% )
Male	2,412	521	18	10,419	2,933 ( 21.94% )
Other/Missing	0	0	0	0	N/A
<b>Age at Hospital Admission (Years)</b>					
0-5	12	4	0	79	16 ( 16.84% )
6-17	18	6	1	133	24 ( 15.19% )
18-29	280	75	1	924	355 ( 27.73% )
30-39	419	89	3	1,296	508 ( 28.11% )
40-49	614	117	1	2,058	731 ( 26.20% )
50-59	978	175	4	3,345	1,153 ( 25.61% )
60-69	1,019	203	8	4,159	1,222 ( 22.68% )
70-79	701	217	6	4,040	918 ( 18.49% )
80-89	399	138	3	3,092	537 ( 14.79% )
90+	128	47	1	1,222	175 ( 12.52% )
Missing	0	0	0	0	N/A
<b>Race</b>					
American Indian or Alaska Native	23	1	0	14	24 ( 63.16% )
Asian	263	16	0	62	279 ( 81.82% )
Black or African American	826	94	0	1,203	920 ( 43.33% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	1,107	274	1	2,908	1,381 ( 32.19% )
Other/Mixed/Unknown	2,346	686	27	16,160	3,032 ( 15.78% )
<b>Ethnicity</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	635	44	0	186	679 ( 78.50% )
Non-Hispanic	1,276	70	1	181	1,346 ( 88.09% )
Unknown	2,659	955	27	19,981	3,614 ( 15.30% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	66	46	1	412	112 ( 21.33% )
Contact and suspected exposure (Z20.828)	438	253	6	3,396	691 ( 16.88% )
Pneumonia (see Appendix B)	3,420	639	21	13,701	4,059 ( 22.83% )
Other viral pneumonia (J12.89)	3,270	421	20	11,006	3,691 ( 25.08% )
ARDS (J80)	433	50	3	1,375	483 ( 25.95% )
Sepsis (see Appendix C)	1,198	271	6	4,812	1,469 ( 23.37% )
Bronchitis (J20.8 OR J40)	57	10	0	219	67 ( 23.43% )
Respiratory infection (J22 OR J98.8)	178	33	1	964	211 ( 17.94% )
Cough (R05)	506	140	4	2,743	646 ( 19.04% )
Shortness of breath (R06.2)	11	4	0	80	15 ( 15.79% )
Fever (R50.9)	659	221	6	3,480	880 ( 20.16% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	97	28	0	232	125 ( 35.01% )
Test performed, only negative results	17	18	0	91	35 ( 27.78% )
No test or unknown result	3,506	644	26	14,674	4,150 ( 22.02% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	3,031	896	27	19,963	3,927 ( 16.42% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	2,956	614	11	47	3,570 ( 98.40% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	210	112	3	1,443	322 ( 18.21% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	351	116	5	2,128	467 ( 17.96% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	486	45	-	-	531 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	45	-	-	607 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	256	87	6	0	343 ( 98.28% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,714	801	3	0	3,515 ( 99.91% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	26,079 ( 100.0% )	81.01% ( 79.96% , 82.02% )	94.95% ( 94.29% , 95.55% )
Inpatient	1,135 ( 4.35% )	90.98% ( 89.16% , 92.59% )	94.40% ( 92.87% , 95.69% )
Outpatient or Emergency Department	2,205 ( 8.46% )	82.95% ( 81.31% , 84.50% )	92.19% ( 90.92% , 93.34% )
Other	349 ( 1.34% )	91.28% ( 87.78% , 94.04% )	93.18% ( 89.94% , 95.62% )
Care Setting Reported as Unknown	7,227 ( 27.71% )	68.68% ( 66.47% , 70.83% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	12,645 ( 48.49% )	79.67% ( 78.11% , 81.18% )	94.03% ( 92.98% , 94.96% )
Male	13,370 ( 51.27% )	82.24% ( 80.80% , 83.60% )	95.79% ( 94.93% , 96.54% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	95 ( 0.36% )	75 % ( 47.62% , 92.73% )	66.67% ( 40.99% , 86.66% )
6-17	158 ( 0.61% )	75 % ( 53.29% , 90.23% )	90 % ( 68.30% , 98.77% )
18-29	1,280 ( 4.91% )	78.87% ( 74.25% , 83 % )	95.24% ( 92.14% , 97.37% )
30-39	1,807 ( 6.93% )	82.48% ( 78.89% , 85.69% )	95.44% ( 93.05% , 97.20% )
40-49	2,790 ( 10.70% )	83.99% ( 81.13% , 86.58% )	96.09% ( 94.28% , 97.45% )
50-59	4,502 ( 17.26% )	84.82% ( 82.62% , 86.85% )	95.98% ( 94.58% , 97.10% )
60-69	5,389 ( 20.66% )	83.39% ( 81.18% , 85.43% )	95.86% ( 94.48% , 96.98% )
70-79	4,964 ( 19.03% )	76.36% ( 73.48% , 79.08% )	93.84% ( 91.87% , 95.46% )
80-89	3,632 ( 13.93% )	74.30% ( 70.39% , 77.95% )	93.01% ( 90.17% , 95.23% )
90+	1,398 ( 5.36% )	73.14% ( 65.93% , 79.55% )	89.51% ( 83.29% , 94.01% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	38 ( 0.15% )	95.83% ( 78.88% , 99.89% )	100.0% ( 85.18% , 100.0% )
Asian	341 ( 1.31% )	94.27% ( 90.85% , 96.69% )	98.50% ( 96.21% , 99.59% )
Black or African American	2,123 ( 8.14% )	89.78% ( 87.64% , 91.66% )	95.82% ( 94.26% , 97.06% )
Native Hawaiian or Other Pacific Islander	4 ( 0.02% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	4,290 ( 16.45% )	80.16% ( 77.96% , 82.23% )	92.87% ( 91.26% , 94.26% )
Other/Mixed/Unknown	19,219 ( 73.70% )	77.37% ( 75.84% , 78.85% )	95.21% ( 94.29% , 96.02% )
<b>Ethnicity</b>			



**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	865 ( 3.32% )	93.52% ( 91.40% , 95.25% )	97.09% ( 95.50% , 98.24% )
Non-Hispanic	1,528 ( 5.86% )	94.80% ( 93.47% , 95.92% )	96.16% ( 94.98% , 97.13% )
Unknown	23,622 ( 90.58% )	73.57% ( 72.10% , 75.01% )	93.96% ( 93.02% , 94.81% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	525 ( 2.01% )	58.93% ( 49.24% , 68.14% )	70.21% ( 59.90% , 79.21% )
Contact and suspected exposure (Z20.828)	4,093 ( 15.69% )	63.39% ( 59.67% , 66.99% )	86.05% ( 82.73% , 88.94% )
Pneumonia (see Appendix B)	17,781 ( 68.18% )	84.26% ( 83.10% , 85.36% )	98.30% ( 97.82% , 98.71% )
Other viral pneumonia (J12.89)	14,717 ( 56.43% )	88.59% ( 87.52% , 89.60% )	99.88% ( 99.69% , 99.97% )
ARDS (J80)	1,861 ( 7.14% )	89.65% ( 86.58% , 92.22% )	97.52% ( 95.61% , 98.76% )
Sepsis (see Appendix C)	6,287 ( 24.11% )	81.55% ( 79.47% , 83.50% )	97.40% ( 96.35% , 98.21% )
Bronchitis (J20.8 OR J40)	286 ( 1.10% )	85.07% ( 74.26% , 92.60% )	100.0% ( 93.73% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,176 ( 4.51% )	84.36% ( 78.74% , 88.98% )	98.34% ( 95.23% , 99.66% )
Cough (R05)	3,393 ( 13.01% )	78.33% ( 74.95% , 81.45% )	98.06% ( 96.46% , 99.07% )
Shortness of breath (R06.2)	95 ( 0.36% )	73.33% ( 44.90% , 92.21% )	91.67% ( 61.52% , 99.79% )
Fever (R50.9)	4,366 ( 16.74% )	74.89% ( 71.88% , 77.72% )	96.63% ( 94.98% , 97.85% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	357 ( 1.37% )	77.60% ( 69.28% , 84.57% )	*****
Test performed, only negative results	126 ( 0.48% )	48.57% ( 31.38% , 66.01% )	*****
No test or unknown result	18,850 ( 72.28% )	84.48% ( 83.34% , 85.57% )	95.98% ( 95.29% , 96.59% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.02% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	23,917 ( 91.71% )	77.18% ( 75.84% , 78.49% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	3,628 ( 13.91% )	82.80% ( 81.52% , 84.03% )	95.54% ( 94.75% , 96.24% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,768 ( 6.78% )	65.22% ( 59.74% , 70.41% )	92.51% ( 88.28% , 95.58% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,600 ( 9.97% )	75.16% ( 70.98% , 79.02% )	95.38% ( 92.71% , 97.29% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	531 ( 2.04% )	91.53% ( 88.82% , 93.75% )	92.40% ( 89.79% , 94.51% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	607 ( 2.33% )	92.59% ( 90.21% , 94.54% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 0.59% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	349 ( 1.34% )	74.64% ( 69.68% , 79.16% )	91.43% ( 87.51% , 94.43% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	3,518 ( 13.49% )	77.21% ( 75.79% , 78.59% )	94.66% ( 93.78% , 95.46% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.02% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 0.67% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	4,571	1,090	28	20,543	5,661 ( 21.58% )
Inpatient	1,029	106	4	N/A	1,135
Outpatient or Emergency Department	1,820	374	12	N/A	2,194
Other	314	34	5	N/A	348
Care Setting Reported as Unknown	1,228	570	7	N/A	1,798
<b>Demographics</b>					
Sex					
Female	2,157	559	10	9,981	2,716 ( 21.37% )
Male	2,414	531	18	10,498	2,945 ( 21.88% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	12	4	0	80	16 ( 16.67% )
6-17	18	6	1	136	24 ( 14.91% )
18-29	280	75	1	929	355 ( 27.63% )
30-39	420	90	3	1,301	510 ( 28.11% )
40-49	614	118	1	2,066	732 ( 26.15% )
50-59	978	177	4	3,367	1,155 ( 25.52% )
60-69	1,019	209	8	4,181	1,228 ( 22.67% )
70-79	703	223	6	4,072	926 ( 18.51% )
80-89	399	141	3	3,116	540 ( 14.76% )
90+	128	47	1	1,231	175 ( 12.44% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	23	1	0	14	24 ( 63.16% )
Asian	263	16	0	63	279 ( 81.58% )
Black or African American	827	96	0	1,213	923 ( 43.21% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	1,107	279	1	2,927	1,386 ( 32.13% )
Other/Mixed/Unknown	2,348	698	27	16,261	3,046 ( 15.75% )
Ethnicity					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	635	45	0	187	680 ( 78.43% )
Non-Hispanic	1,276	70	1	181	1,346 ( 88.09% )
Unknown	2,662	973	27	20,111	3,635 ( 15.29% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	66	48	1	417	114 ( 21.43% )
Contact and suspected exposure (Z20.828)	439	258	6	3,422	697 ( 16.90% )
Pneumonia (see Appendix B)	3,423	648	21	13,751	4,071 ( 22.82% )
Other viral pneumonia (J12.89)	3,270	422	20	11,009	3,692 ( 25.08% )
ARDS (J80)	433	50	3	1,377	483 ( 25.93% )
Sepsis (see Appendix C)	1,198	277	6	4,839	1,475 ( 23.34% )
Bronchitis (J20.8 OR J40)	57	10	0	219	67 ( 23.43% )
Respiratory infection (J22 OR J98.8)	178	33	1	965	211 ( 17.93% )
Cough (R05)	507	143	4	2,760	650 ( 19.04% )
Shortness of breath (R06.2)	11	4	0	80	15 ( 15.79% )
Fever (R50.9)	660	226	6	3,504	886 ( 20.15% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	97	28	0	232	125 ( 35.01% )
Test performed, only negative results	17	19	0	92	36 ( 28.13% )
No test or unknown result	3,507	653	26	14,766	4,160 ( 21.95% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	3,034	913	27	20,094	3,947 ( 16.40% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	2,958	623	11	47	3,581 ( 98.41% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	211	113	3	1,457	324 ( 18.16% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	351	117	5	2,130	468 ( 17.98% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	486	46	-	-	532 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	45	-	-	607 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	256	92	6	0	348 ( 98.31% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,717	813	3	0	3,530 ( 99.92% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	26,232 ( 100.0% )	80.75% ( 79.69% , 81.77% )	95.01% ( 94.36% , 95.61% )
Inpatient	1,139 ( 4.34% )	90.66% ( 88.82% , 92.29% )	94.40% ( 92.87% , 95.69% )
Outpatient or Emergency Department	2,206 ( 8.41% )	82.95% ( 81.31% , 84.50% )	92.25% ( 90.98% , 93.39% )
Other	3,53 ( 1.35% )	90.23% ( 86.62% , 93.14% )	93.18% ( 89.94% , 95.62% )
Care Setting Reported as Unknown	7,278 ( 27.74% )	68.30% ( 66.09% , 70.45% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	12,707 ( 48.44% )	79.42% ( 77.85% , 80.92% )	94.07% ( 93.02% , 95 % )
Male	13,461 ( 51.32% )	81.97% ( 80.53% , 83.34% )	95.87% ( 95.02% , 96.61% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	96 ( 0.37% )	75 % ( 47.62% , 92.73% )	66.67% ( 40.99% , 86.66% )
6-17	161 ( 0.61% )	75 % ( 53.29% , 90.23% )	90 % ( 68.30% , 98.77% )
18-29	1,285 ( 4.90% )	78.87% ( 74.25% , 83 % )	95.24% ( 92.14% , 97.37% )
30-39	1,814 ( 6.92% )	82.35% ( 78.76% , 85.56% )	95.67% ( 93.32% , 97.37% )
40-49	2,799 ( 10.67% )	83.88% ( 81.01% , 86.47% )	96.09% ( 94.28% , 97.45% )
50-59	4,526 ( 17.25% )	84.68% ( 82.47% , 86.71% )	95.98% ( 94.58% , 97.10% )
60-69	5,417 ( 20.65% )	82.98% ( 80.76% , 85.04% )	95.86% ( 94.48% , 96.98% )
70-79	5,004 ( 19.08% )	75.92% ( 73.03% , 78.64% )	94.11% ( 92.17% , 95.69% )
80-89	3,659 ( 13.95% )	73.89% ( 69.97% , 77.55% )	93.01% ( 90.17% , 95.23% )
90+	1,407 ( 5.36% )	73.14% ( 65.93% , 79.55% )	89.51% ( 83.29% , 94.01% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	38 ( 0.14% )	95.83% ( 78.88% , 99.89% )	100.0% ( 85.18% , 100.0% )
Asian	342 ( 1.30% )	94.27% ( 90.85% , 96.69% )	98.50% ( 96.21% , 99.59% )
Black or African American	2,136 ( 8.14% )	89.60% ( 87.45% , 91.49% )	95.94% ( 94.40% , 97.16% )
Native Hawaiian or Other Pacific Islander	4 ( 0.02% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	4,314 ( 16.45% )	79.87% ( 77.66% , 81.95% )	92.87% ( 91.26% , 94.26% )
Other/Mixed/Unknown	19,334 ( 73.70% )	77.08% ( 75.55% , 78.57% )	95.29% ( 94.38% , 96.09% )
<b>Ethnicity</b>			



**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	867 ( 3.31% )	93.38% ( 91.24% , 95.13% )	97.09% ( 95.50% , 98.24% )
Non-Hispanic	1,528 ( 5.82% )	94.80% ( 93.47% , 95.92% )	96.16% ( 94.98% , 97.13% )
Unknown	23,773 ( 90.63% )	73.23% ( 71.76% , 74.67% )	94.06% ( 93.13% , 94.91% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	532 ( 2.03% )	57.89% ( 48.29% , 67.08% )	70.21% ( 59.90% , 79.21% )
Contact and suspected exposure (Z20.828)	4,125 ( 15.73% )	62.98% ( 59.28% , 66.58% )	86.25% ( 82.95% , 89.12% )
Pneumonia (see Appendix B)	17,843 ( 68.02% )	84.08% ( 82.92% , 85.19% )	98.39% ( 97.91% , 98.78% )
Other viral pneumonia (J12.89)	14,721 ( 56.12% )	88.57% ( 87.50% , 89.58% )	99.88% ( 99.69% , 99.97% )
ARDS (J80)	1,863 ( 7.10% )	89.65% ( 86.58% , 92.22% )	97.52% ( 95.61% , 98.76% )
Sepsis (see Appendix C)	6,320 ( 24.09% )	81.22% ( 79.13% , 83.18% )	97.40% ( 96.35% , 98.21% )
Bronchitis (J20.8 OR J40)	286 ( 1.09% )	85.07% ( 74.26% , 92.60% )	100.0% ( 93.73% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,177 ( 4.49% )	84.36% ( 78.74% , 88.98% )	98.34% ( 95.23% , 99.66% )
Cough (R05)	3,414 ( 13.01% )	78 % ( 74.61% , 81.13% )	98.26% ( 96.71% , 99.20% )
Shortness of breath (R06.2)	95 ( 0.36% )	73.33% ( 44.90% , 92.21% )	91.67% ( 61.52% , 99.79% )
Fever (R50.9)	4,396 ( 16.76% )	74.49% ( 71.49% , 77.33% )	96.77% ( 95.16% , 97.97% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	357 ( 1.36% )	77.60% ( 69.28% , 84.57% )	*****
Test performed, only negative results	128 ( 0.49% )	47.22% ( 30.41% , 64.51% )	*****
No test or unknown result	18,952 ( 72.25% )	84.30% ( 83.16% , 85.40% )	96 % ( 95.32% , 96.62% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.02% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	24,068 ( 91.75% )	76.87% ( 75.52% , 78.18% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	3,639 ( 13.87% )	82.60% ( 81.32% , 83.83% )	95.60% ( 94.82% , 96.30% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,784 ( 6.80% )	65.12% ( 59.66% , 70.31% )	92.95% ( 88.81% , 95.92% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,603 ( 9.92% )	75 % ( 70.82% , 78.86% )	95.38% ( 92.71% , 97.29% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	532 ( 2.03% )	91.35% ( 88.64% , 93.60% )	92.40% ( 89.79% , 94.51% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	607 ( 2.31% )	92.59% ( 90.21% , 94.54% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 0.59% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	354 ( 1.35% )	73.56% ( 68.60% , 78.12% )	91.43% ( 87.51% , 94.43% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	3,533 ( 13.47% )	76.97% ( 75.54% , 78.35% )	94.77% ( 93.89% , 95.55% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.02% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 0.67% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	4,576	1,095	28	20,601	5,671 ( 21.56% )
Inpatient	1,030	106	4	N/A	1,136
Outpatient or Emergency Department	1,822	376	12	N/A	2,198
Other	314	34	5	N/A	348
Care Setting Reported as Unknown	1,230	573	7	N/A	1,803
<b>Demographics</b>					
Sex					
Female	2,159	563	10	10,013	2,722 ( 21.36% )
Male	2,417	532	18	10,524	2,949 ( 21.86% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	12	4	0	80	16 ( 16.67% )
6-17	18	6	1	136	24 ( 14.91% )
18-29	281	76	1	932	357 ( 27.67% )
30-39	420	90	3	1,301	510 ( 28.11% )
40-49	614	118	1	2,068	732 ( 26.13% )
50-59	980	177	4	3,376	1,157 ( 25.50% )
60-69	1,020	211	8	4,188	1,231 ( 22.68% )
70-79	704	224	6	4,082	928 ( 18.50% )
80-89	399	141	3	3,137	540 ( 14.67% )
90+	128	48	1	1,237	176 ( 12.45% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	23	1	0	14	24 ( 63.16% )
Asian	263	16	0	63	279 ( 81.58% )
Black or African American	827	97	0	1,215	924 ( 43.20% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	1,107	279	1	2,939	1,386 ( 32.04% )
Other/Mixed/Unknown	2,353	702	27	16,305	3,055 ( 15.76% )
Ethnicity					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	635	45	0	187	680 ( 78.43% )
Non-Hispanic	1,276	70	1	181	1,346 ( 88.09% )
Unknown	2,667	978	27	20,169	3,645 ( 15.29% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	66	48	1	418	114 ( 21.39% )
Contact and suspected exposure (Z20.828)	439	260	6	3,429	699 ( 16.91% )
Pneumonia (see Appendix B)	3,428	652	21	13,796	4,080 ( 22.80% )
Other viral pneumonia (J12.89)	3,270	422	20	11,010	3,692 ( 25.08% )
ARDS (J80)	434	50	3	1,377	484 ( 25.97% )
Sepsis (see Appendix C)	1,198	279	6	4,848	1,477 ( 23.33% )
Bronchitis (J20.8 OR J40)	57	10	0	219	67 ( 23.43% )
Respiratory infection (J22 OR J98.8)	178	33	1	965	211 ( 17.93% )
Cough (R05)	507	143	4	2,765	650 ( 19.01% )
Shortness of breath (R06.2)	11	4	0	80	15 ( 15.79% )
Fever (R50.9)	661	227	6	3,511	888 ( 20.16% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	97	28	0	232	125 ( 35.01% )
Test performed, only negative results	17	19	0	93	36 ( 27.91% )
No test or unknown result	3,512	657	26	14,804	4,169 ( 21.94% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	3,039	918	27	20,152	3,957 ( 16.39% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	2,959	625	11	47	3,584 ( 98.41% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	211	114	3	1,461	325 ( 18.17% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	351	117	5	2,129	468 ( 17.99% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	486	46	-	-	532 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	45	-	-	607 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	258	94	6	0	352 ( 98.32% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,720	816	3	0	3,536 ( 99.92% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	26,300 ( 100.0% )	80.69% ( 79.64% , 81.71% )	95.12% ( 94.47% , 95.71% )
Inpatient	1,140 ( 4.33% )	90.67% ( 88.83% , 92.30% )	94.50% ( 92.97% , 95.77% )
Outpatient or Emergency Department	2,210 ( 8.40% )	82.89% ( 81.25% , 84.45% )	92.35% ( 91.08% , 93.48% )
Other	353 ( 1.34% )	90.23% ( 86.62% , 93.14% )	93.18% ( 89.94% , 95.62% )
Care Setting Reported as Unknown	7,302 ( 27.76% )	68.22% ( 66.01% , 70.37% )	*****
<b>Demographics</b>			
Sex			
Female	12,745 ( 48.46% )	79.32% ( 77.75% , 80.82% )	94.16% ( 93.12% , 95.08% )
Male	13,491 ( 51.30% )	81.96% ( 80.52% , 83.33% )	95.99% ( 95.15% , 96.72% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	96 ( 0.37% )	75 % ( 47.62% , 92.73% )	66.67% ( 40.99% , 86.66% )
6-17	161 ( 0.61% )	75 % ( 53.29% , 90.23% )	90 % ( 68.30% , 98.77% )
18-29	1,290 ( 4.90% )	78.71% ( 74.10% , 82.84% )	95.58% ( 92.56% , 97.62% )
30-39	1,814 ( 6.90% )	82.35% ( 78.76% , 85.56% )	95.67% ( 93.32% , 97.37% )
40-49	2,801 ( 10.65% )	83.88% ( 81.01% , 86.47% )	96.09% ( 94.28% , 97.45% )
50-59	4,537 ( 17.25% )	84.70% ( 82.50% , 86.73% )	96.17% ( 94.80% , 97.26% )
60-69	5,427 ( 20.63% )	82.86% ( 80.64% , 84.92% )	95.95% ( 94.59% , 97.06% )
70-79	5,016 ( 19.07% )	75.86% ( 72.98% , 78.58% )	94.24% ( 92.32% , 95.80% )
80-89	3,680 ( 13.99% )	73.89% ( 69.97% , 77.55% )	93.01% ( 90.17% , 95.23% )
90+	1,414 ( 5.38% )	72.73% ( 65.52% , 79.16% )	89.51% ( 83.29% , 94.01% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	38 ( 0.14% )	95.83% ( 78.88% , 99.89% )	100.0% ( 85.18% , 100.0% )
Asian	342 ( 1.30% )	94.27% ( 90.85% , 96.69% )	98.50% ( 96.21% , 99.59% )
Black or African American	2,139 ( 8.13% )	89.50% ( 87.34% , 91.40% )	95.94% ( 94.40% , 97.16% )
Native Hawaiian or Other Pacific Islander	4 ( 0.02% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	4,326 ( 16.45% )	79.87% ( 77.66% , 81.95% )	92.87% ( 91.26% , 94.26% )
Other/Mixed/Unknown	19,387 ( 73.71% )	77.02% ( 75.49% , 78.50% )	95.50% ( 94.60% , 96.28% )
Ethnicity			



**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	867 ( 3.30% )	93.38% ( 91.24% , 95.13% )	97.09% ( 95.50% , 98.24% )
Non-Hispanic	1,528 ( 5.81% )	94.80% ( 93.47% , 95.92% )	96.16% ( 94.98% , 97.13% )
Unknown	23,841 ( 90.65% )	73.17% ( 71.70% , 74.60% )	94.24% ( 93.32% , 95.07% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	533 ( 2.03% )	57.89% ( 48.29% , 67.08% )	70.21% ( 59.90% , 79.21% )
Contact and suspected exposure (Z20.828)	4,134 ( 15.72% )	62.80% ( 59.10% , 66.40% )	86.25% ( 82.95% , 89.12% )
Pneumonia (see Appendix B)	17,897 ( 68.05% )	84.02% ( 82.86% , 85.13% )	98.53% ( 98.08% , 98.91% )
Other viral pneumonia (J12.89)	14,722 ( 55.98% )	88.57% ( 87.50% , 89.58% )	99.88% ( 99.69% , 99.97% )
ARDS (J80)	1,864 ( 7.09% )	89.67% ( 86.61% , 92.23% )	97.75% ( 95.90% , 98.91% )
Sepsis (see Appendix C)	6,331 ( 24.07% )	81.11% ( 79.02% , 83.08% )	97.40% ( 96.35% , 98.21% )
Bronchitis (J20.8 OR J40)	286 ( 1.09% )	85.07% ( 74.26% , 92.60% )	100.0% ( 93.73% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,177 ( 4.48% )	84.36% ( 78.74% , 88.98% )	98.34% ( 95.23% , 99.66% )
Cough (R05)	3,419 ( 13 % )	78 % ( 74.61% , 81.13% )	98.26% ( 96.71% , 99.20% )
Shortness of breath (R06.2)	95 ( 0.36% )	73.33% ( 44.90% , 92.21% )	91.67% ( 61.52% , 99.79% )
Fever (R50.9)	4,405 ( 16.75% )	74.44% ( 71.43% , 77.28% )	96.92% ( 95.33% , 98.08% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	357 ( 1.36% )	77.60% ( 69.28% , 84.57% )	*****
Test performed, only negative results	129 ( 0.49% )	47.22% ( 30.41% , 64.51% )	*****
No test or unknown result	18,999 ( 72.24% )	84.24% ( 83.10% , 85.33% )	96.14% ( 95.46% , 96.74% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.02% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	24,136 ( 91.77% )	76.80% ( 75.45% , 78.11% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	3,642 ( 13.85% )	82.56% ( 81.28% , 83.79% )	95.64% ( 94.86% , 96.33% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,789 ( 6.80% )	64.92% ( 59.46% , 70.11% )	92.95% ( 88.81% , 95.92% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,602 ( 9.89% )	75 % ( 70.82% , 78.86% )	95.38% ( 92.71% , 97.29% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	532 ( 2.02% )	91.35% ( 88.64% , 93.60% )	92.40% ( 89.79% , 94.51% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	607 ( 2.31% )	92.59% ( 90.21% , 94.54% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 0.59% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	358 ( 1.36% )	73.30% ( 68.35% , 77.85% )	92.14% ( 88.35% , 95.01% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	3,539 ( 13.46% )	76.92% ( 75.50% , 78.30% )	94.87% ( 94 % , 95.65% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.02% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 0.67% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	3,584	653	23	14,060	4,237 ( 23.13% )
Inpatient	666	55	4	N/A	721
Outpatient or Emergency Department	1,603	250	9	N/A	1,853
Other	254	22	4	N/A	276
Care Setting Reported as Unknown	934	321	6	N/A	1,255
<b>Demographics</b>					
<b>Sex</b>					
Female	1,592	309	5	6,371	1,901 ( 22.97% )
Male	1,992	344	18	7,637	2,336 ( 23.38% )
Other/Missing	0	0	0	0	N/A
<b>Age at Hospital Admission (Years)</b>					
0-5	1	0	0	9	1 ( 10% )
6-17	5	4	1	32	9 ( 21.43% )
18-29	131	32	0	394	163 ( 29.26% )
30-39	278	44	2	783	322 ( 29.09% )
40-49	526	70	1	1,529	596 ( 28.03% )
50-59	841	126	3	2,541	967 ( 27.54% )
60-69	856	134	8	3,085	990 ( 24.25% )
70-79	572	142	4	2,799	714 ( 20.30% )
80-89	290	75	3	2,058	365 ( 15.05% )
90+	84	26	1	778	110 ( 12.37% )
Missing	0	0	0	0	N/A
<b>Race</b>					
American Indian or Alaska Native	12	0	0	10	12 ( 54.55% )
Asian	218	10	0	51	228 ( 81.72% )
Black or African American	651	53	0	792	704 ( 47.06% )
Native Hawaiian or Other Pacific Islander	2	0	0	1	2 ( 66.67% )
White	811	156	0	1,915	967 ( 33.55% )
Other/Mixed/Unknown	1,890	434	23	11,239	2,324 ( 17.11% )
<b>Ethnicity</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	533	31	0	127	564 ( 81.62% )
Non-Hispanic	927	41	0	137	968 ( 87.60% )
Unknown	2,124	581	23	13,744	2,705 ( 16.42% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	48	23	0	217	71 ( 24.65% )
Contact and suspected exposure (Z20.828)	392	190	6	2,580	582 ( 18.37% )
Pneumonia (see Appendix B)	3,452	645	22	13,901	4,097 ( 22.74% )
Other viral pneumonia (J12.89)	3,299	423	21	11,148	3,722 ( 24.99% )
ARDS (J80)	435	50	3	1,387	485 ( 25.87% )
Sepsis (see Appendix C)	1,103	210	7	4,107	1,313 ( 24.19% )
Bronchitis (J20.8 OR J40)	30	6	1	156	36 ( 18.65% )
Respiratory infection (J22 OR J98.8)	150	20	1	714	170 ( 19.21% )
Cough (R05)	433	113	3	2,203	546 ( 19.84% )
Shortness of breath (R06.2)	8	3	0	57	11 ( 16.18% )
Fever (R50.9)	572	159	5	2,750	731 ( 20.97% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	83	21	0	171	104 ( 37.82% )
Test performed, only negative results	12	12	0	57	24 ( 29.63% )
No test or unknown result	2,769	392	22	10,211	3,161 ( 23.60% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	2	1	0	1	3 ( 75% )
No test or unknown result	2,293	551	23	13,761	2,844 ( 17.10% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	2,452	392	9	32	2,844 ( 98.58% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	180	89	2	1,158	269 ( 18.82% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	351	116	5	2,091	467 ( 18.22% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	387	24	-	-	411 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	532	28	-	-	560 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	97	12	-	-	109 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	160	52	4	0	212 ( 98.15% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,084	494	2	0	2,578 ( 99.92% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	1	1	0	0	2 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	3	0	0	0	3 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	3	1	0	0	4 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	43	0	0	109	43 ( 28.29% )

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	18,320 ( 100.0% )	84.59% ( 83.47% , 85.66% )	74.50% ( 73.24% , 75.72% )
Inpatient	725 ( 3.96% )	92.37% ( 90.19% , 94.20% )	61.10% ( 58.13% , 64.01% )
Outpatient or Emergency Department	1,862 ( 10.16% )	86.51% ( 84.87% , 88.03% )	81.25% ( 79.45% , 82.95% )
Other	280 ( 1.53% )	92.03% ( 88.18% , 94.94% )	75.37% ( 70.41% , 79.88% )
Care Setting Reported as Unknown	4,909 ( 26.80% )	74.42% ( 71.91% , 76.82% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	8,277 ( 45.18% )	83.75% ( 82.01% , 85.38% )	69.43% ( 67.50% , 71.31% )
Male	9,991 ( 54.54% )	85.27% ( 83.77% , 86.69% )	79.11% ( 77.47% , 80.68% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	10 ( 0.05% )	100.0% ( 2.50% , 100.0% )	5.56% ( 0.14% , 27.29% )
6-17	42 ( 0.23% )	55.56% ( 21.20% , 86.30% )	25 % ( 8.66% , 49.10% )
18-29	557 ( 3.04% )	80.37% ( 73.43% , 86.17% )	44.56% ( 38.79% , 50.44% )
30-39	1,107 ( 6.04% )	86.34% ( 82.09% , 89.89% )	63.33% ( 58.63% , 67.84% )
40-49	2,126 ( 11.60% )	88.26% ( 85.39% , 90.73% )	82.32% ( 79.13% , 85.20% )
50-59	3,511 ( 19.16% )	86.97% ( 84.68% , 89.03% )	82.53% ( 80.06% , 84.82% )
60-69	4,083 ( 22.29% )	86.46% ( 84.17% , 88.54% )	80.53% ( 78.02% , 82.87% )
70-79	3,517 ( 19.20% )	80.11% ( 76.99% , 82.98% )	76.57% ( 73.37% , 79.57% )
80-89	2,426 ( 13.24% )	79.45% ( 74.94% , 83.48% )	67.60% ( 62.94% , 72.01% )
90+	889 ( 4.85% )	76.36% ( 67.32% , 83.94% )	58.74% ( 50.21% , 66.90% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	22 ( 0.12% )	100.0% ( 73.54% , 100.0% )	52.17% ( 30.59% , 73.18% )
Asian	279 ( 1.52% )	95.61% ( 92.08% , 97.88% )	81.65% ( 76.47% , 86.10% )
Black or African American	1,496 ( 8.17% )	92.47% ( 90.27% , 94.31% )	75.52% ( 72.51% , 78.36% )
Native Hawaiian or Other Pacific Islander	3 ( 0.02% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
White	2,882 ( 15.73% )	83.87% ( 81.40% , 86.13% )	68.04% ( 65.31% , 70.68% )
Other/Mixed/Unknown	13,586 ( 74.16% )	81.33% ( 79.68% , 82.89% )	76.70% ( 74.98% , 78.36% )
<b>Ethnicity</b>			



**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Hispanic	691 ( 3.77% )	94.50% ( 92.29% , 96.24% )	81.50% ( 78.31% , 84.40% )
Non-Hispanic	1,105 ( 6.03% )	95.76% ( 94.30% , 96.94% )	69.86% ( 67.31% , 72.32% )
Unknown	16,472 ( 89.91% )	78.52% ( 76.92% , 80.06% )	75.05% ( 73.42% , 76.64% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	288 ( 1.57% )	67.61% ( 55.45% , 78.24% )	51.06% ( 40.54% , 61.52% )
Contact and suspected exposure (Z20.828)	3,168 ( 17.29% )	67.35% ( 63.38% , 71.15% )	77.01% ( 73.11% , 80.60% )
Pneumonia (see Appendix B)	18,020 ( 98.36% )	84.26% ( 83.10% , 85.36% )	99.22% ( 98.87% , 99.49% )
Other viral pneumonia (J12.89)	14,891 ( 81.28% )	88.64% ( 87.57% , 89.64% )	*****
ARDS (J80)	1,875 ( 10.23% )	89.69% ( 86.63% , 92.25% )	97.97% ( 96.19% , 99.07% )
Sepsis (see Appendix C)	5,427 ( 29.62% )	84.01% ( 81.91% , 85.95% )	89.67% ( 87.84% , 91.32% )
Bronchitis (J20.8 OR J40)	193 ( 1.05% )	83.33% ( 67.19% , 93.63% )	52.63% ( 38.97% , 66.02% )
Respiratory infection (J22 OR J98.8)	885 ( 4.83% )	88.24% ( 82.42% , 92.66% )	82.87% ( 76.58% , 88.06% )
Cough (R05)	2,752 ( 15.02% )	79.30% ( 75.66% , 82.63% )	83.91% ( 80.46% , 86.98% )
Shortness of breath (R06.2)	68 ( 0.37% )	72.73% ( 39.03% , 93.98% )	66.67% ( 34.89% , 90.08% )
Fever (R50.9)	3,486 ( 19.03% )	78.25% ( 75.08% , 81.19% )	83.87% ( 80.89% , 86.55% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	275 ( 1.50% )	79.81% ( 70.81% , 87.04% )	93.26% ( 85.90% , 97.49% )
Test performed, only negative results	81 ( 0.44% )	50 % ( 29.12% , 70.88% )	75 % ( 47.62% , 92.73% )
No test or unknown result	13,394 ( 73.11% )	87.60% ( 86.40% , 88.73% )	75.80% ( 74.38% , 77.18% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.03% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	4 ( 0.02% )	66.67% ( 9.43% , 99.16% )	*****
No test or unknown result	16,628 ( 90.76% )	80.63% ( 79.12% , 82.06% )	89.99% ( 88.76% , 91.13% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	2,885 ( 15.75% )	86.22% ( 84.89% , 87.46% )	79.25% ( 77.78% , 80.67% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,429 ( 7.80% )	66.91% ( 60.94% , 72.51% )	79.30% ( 73.44% , 84.37% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,563 ( 13.99% )	75.16% ( 70.98% , 79.02% )	95.38% ( 92.71% , 97.29% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	411 ( 2.24% )	94.16% ( 91.44% , 96.22% )	73.57% ( 69.59% , 77.30% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	560 ( 3.06% )	95 % ( 92.85% , 96.65% )	83.13% ( 79.99% , 85.95% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	109 ( 0.59% )	88.99% ( 81.56% , 94.18% )	66.44% ( 58.16% , 74.03% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	2 ( 0.01% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	216 ( 1.18% )	75.47% ( 69.11% , 81.11% )	57.14% ( 51.12% , 63.01% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,580 ( 14.08% )	80.84% ( 79.26% , 82.34% )	72.69% ( 71.02% , 74.31% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1c. Aggregated Baseline Table for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.03% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.01% )	50 % ( 1.26% , 98.74% )	25 % ( 0.63% , 80.59% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	3 ( 0.02% )	100.0% ( 29.24% , 100.0% )	50 % ( 11.81% , 88.19% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	4 ( 0.02% )	75 % ( 19.41% , 99.37% )	42.86% ( 9.90% , 81.59% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	152 ( 0.83% )	100.0% ( 91.78% , 100.0% )	89.58% ( 77.34% , 96.53% )

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINC or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Tes*****</b>				
Total Observed	1,129	2,159	1,119	2,360
Inpatient	228	0	146	0
Outpatient or Emergency Department	210	0	169	0
Other	41	0	81	0
Care Setting Reported as Unknown	342	1,850	335	1,971
<b>Demographics</b>				
Sex				
Female	446	829	600	1,209
Male	683	1,330	519	1,151
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	0	0	21	41
6-17	0	1	10	29
18-29	31	68	46	107
30-39	68	155	96	229
40-49	142	278	85	237
50-59	226	485	162	449
60-69	289	592	217	462
70-79	226	344	227	393
80-89	115	183	197	304
90+	32	53	58	109
Missing	0	0	0	0
Race				
American Indian or Alaska Native	0	0	0	0
Asian	5	5	8	8
Black or African American	75	75	31	31
Native Hawaiian or Other Pacific Islander	0	0	0	0
White	168	169	250	250
Other/Mixed/Unknown	881	1,910	830	2,071
Ethnicity				

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	5	5	2	2
Non-Hispanic	0	0	0	0
Unknown	1,124	2,154	1,117	2,358
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	15	31	7	18
Contact and suspected exposure (Z20.828)	218	417	102	216
Pneumonia (see Appendix B)	973	1,809	521	1,025
Other viral pneumonia (J12.89)	796	1,550	62	215
ARDS (J80)	202	349	26	61
Sepsis (see Appendix C)	412	813	252	592
Bronchitis (J20.8 OR J40)	12	16	20	36
Respiratory infection (J22 OR J98.8)	207	426	34	85
Cough (R05)	341	736	247	540
Shortness of breath (R06.2)	4	11	14	44
Fever (R50.9)	409	842	228	587
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	76	0	7	0
Test performed, only negative results	8	0	37	0
No test or unknown result	737	1,850	687	1,971
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	821	1,850	731	1,971
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	155	108	159	112
<b>Codes Observed During Inpatient Stay</b>				
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	138	287	72	158

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	184	359	19	53
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	68	19	56
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	3
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	3
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	447	997	395	1,104
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	663	1,124	705	1,194
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	0	0	0	0

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	643	50	11	2,613	693 ( 20.89% )
Inpatient	140	4	0	N/A	144
Outpatient or Emergency Department	121	5	1	N/A	126
Other	24	4	1	N/A	28
Care Setting Reported as Unknown	358	37	9	N/A	395
<b>Demographics</b>					
Sex					
Female	228	22	7	1,121	250 ( 18.14% )
Male	415	28	4	1,492	443 ( 22.85% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	0	0	0	1	0 (0.00%)
18-29	14	1	0	32	15 ( 31.91% )
30-39	24	1	1	93	25 ( 21.01% )
40-49	71	2	1	246	73 ( 22.81% )
50-59	141	2	1	493	143 ( 22.45% )
60-69	185	9	2	657	194 ( 22.74% )
70-79	145	18	3	623	163 ( 20.66% )
80-89	51	15	2	352	66 ( 15.71% )
90+	12	2	1	113	14 ( 10.94% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	0	N/A
Asian	2	1	0	11	3 ( 21.43% )
Black or African American	34	1	1	197	35 ( 15.02% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	83	12	0	255	95 ( 27.14% )
Other/Mixed/Unknown	524	36	10	2,150	560 ( 20.59% )
Ethnicity					



**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	3	0	0	15	3 ( 16.67% )
Non-Hispanic	0	0	0	0	N/A
Unknown	640	50	11	2,598	690 ( 20.92% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	8	2	0	38	10 ( 20.83% )
Contact and suspected exposure (Z20.828)	156	15	2	598	171 ( 22.18% )
Pneumonia (see Appendix B)	606	47	11	2,381	653 ( 21.44% )
Other viral pneumonia (J12.89)	548	37	10	2,090	585 ( 21.79% )
ARDS (J80)	195	11	3	854	206 ( 19.38% )
Sepsis (see Appendix C)	295	21	8	1,219	316 ( 20.48% )
Bronchitis (J20.8 OR J40)	8	0	0	55	8 ( 12.70% )
Respiratory infection (J22 OR J98.8)	133	12	2	662	145 ( 17.92% )
Cough (R05)	203	12	4	837	215 ( 20.36% )
Shortness of breath (R06.2)	4	0	0	18	4 ( 18.18% )
Fever (R50.9)	272	20	2	1,083	292 ( 21.21% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	49	1	1	120	50 ( 29.24% )
Test performed, only negative results	3	1	0	7	4 ( 36.36% )
No test or unknown result	442	32	9	1,851	474 ( 20.31% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	643	50	11	2,613	693 ( 20.89% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	72	7	0	0	79 ( 100.0% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	99	9	1	414	108 ( 20.65% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	144	15	2	546	159 ( 22.49% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	11	0	0	0	11 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	272	4	0	0	276 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	360	46	1	0	406 ( 99.75% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	3,317 ( 100.0% )	92.78% ( 90.60% , 94.60% )	56.95% ( 54.01% , 59.86% )
Inpatient	144 ( 4.34% )	97.22% ( 93.04% , 99.24% )	61.40% ( 54.75% , 67.76% )
Outpatient or Emergency Department	127 ( 3.83% )	96.03% ( 90.98% , 98.70% )	57.62% ( 50.63% , 64.39% )
Other	29 ( 0.87% )	85.71% ( 67.33% , 95.97% )	58.54% ( 42.11% , 73.68% )
Care Setting Reported as Unknown	1,039 ( 31.32% )	90.63% ( 87.32% , 93.32% )	*****
<b>Demographics</b>			
Sex			
Female	1,378 ( 41.54% )	91.20% ( 86.98% , 94.40% )	51.12% ( 46.38% , 55.85% )
Male	1,939 ( 58.46% )	93.68% ( 90.99% , 95.76% )	60.76% ( 56.99% , 64.44% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	3 ( 0.09% )	N/A	N/A
6-17	1 ( 0.03% )	N/A	N/A
18-29	47 ( 1.42% )	93.33% ( 68.05% , 99.83% )	45.16% ( 27.32% , 63.97% )
30-39	119 ( 3.59% )	96 % ( 79.65% , 99.90% )	35.29% ( 24.08% , 47.83% )
40-49	320 ( 9.65% )	97.26% ( 90.45% , 99.67% )	50 % ( 41.50% , 58.50% )
50-59	637 ( 19.20% )	98.60% ( 95.04% , 99.83% )	62.39% ( 55.72% , 68.73% )
60-69	853 ( 25.72% )	95.36% ( 91.38% , 97.86% )	64.01% ( 58.19% , 69.55% )
70-79	789 ( 23.79% )	88.96% ( 83.11% , 93.32% )	64.16% ( 57.53% , 70.41% )
80-89	420 ( 12.66% )	77.27% ( 65.30% , 86.69% )	44.35% ( 35.09% , 53.91% )
90+	128 ( 3.86% )	85.71% ( 57.19% , 98.22% )	37.50% ( 21.10% , 56.31% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	N/A	N/A	N/A
Asian	14 ( 0.42% )	66.67% ( 9.43% , 99.16% )	40 % ( 5.27% , 85.34% )
Black or African American	233 ( 7.02% )	97.14% ( 85.08% , 99.93% )	45.33% ( 33.79% , 57.25% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	350 ( 10.55% )	87.37% ( 78.97% , 93.30% )	49.40% ( 41.62% , 57.21% )
Other/Mixed/Unknown	2,720 ( 82 % )	93.57% ( 91.21% , 95.46% )	59.48% ( 56.15% , 62.74% )
Ethnicity			

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	18 ( 0.54% )	100.0% ( 29.24% , 100.0% )	60 % ( 14.66% , 94.73% )
Non-Hispanic	N/A	N/A	N/A
Unknown	3,299 ( 99.46% )	92.75% ( 90.56% , 94.57% )	56.94% ( 53.99% , 59.86% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	48 ( 1.45% )	80 % ( 44.39% , 97.48% )	53.33% ( 26.59% , 78.73% )
Contact and suspected exposure (Z20.828)	771 ( 23.24% )	91.23% ( 85.94% , 95.01% )	71.56% ( 65.08% , 77.45% )
Pneumonia (see Appendix B)	3,045 ( 91.80% )	92.80% ( 90.54% , 94.66% )	62.28% ( 59.15% , 65.34% )
Other viral pneumonia (J12.89)	2,685 ( 80.95% )	93.68% ( 91.39% , 95.51% )	68.84% ( 65.50% , 72.05% )
ARDS (J80)	1,063 ( 32.05% )	94.66% ( 90.65% , 97.30% )	96.53% ( 92.99% , 98.60% )
Sepsis (see Appendix C)	1,543 ( 46.52% )	93.35% ( 90.02% , 95.84% )	71.60% ( 66.98% , 75.91% )
Bronchitis (J20.8 OR J40)	63 ( 1.90% )	100.0% ( 63.06% , 100.0% )	66.67% ( 34.89% , 90.08% )
Respiratory infection (J22 OR J98.8)	809 ( 24.39% )	91.72% ( 85.99% , 95.65% )	64.25% ( 57.31% , 70.77% )
Cough (R05)	1,056 ( 31.84% )	94.42% ( 90.45% , 97.08% )	59.53% ( 54.11% , 64.78% )
Shortness of breath (R06.2)	22 ( 0.66% )	100.0% ( 39.76% , 100.0% )	100.0% ( 39.76% , 100.0% )
Fever (R50.9)	1,377 ( 41.51% )	93.15% ( 89.62% , 95.77% )	66.50% ( 61.70% , 71.07% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	171 ( 5.16% )	98 % ( 89.35% , 99.95% )	64.47% ( 52.66% , 75.12% )
Test performed, only negative results	11 ( 0.33% )	75 % ( 19.41% , 99.37% )	37.50% ( 8.52% , 75.51% )
No test or unknown result	2,334 ( 70.36% )	93.25% ( 90.60% , 95.34% )	59.97% ( 56.33% , 63.53% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	3,317 ( 100.0% )	92.78% ( 90.60% , 94.60% )	78.32% ( 75.34% , 81.09% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	79 ( 2.38% )	91.14% ( 82.59% , 96.36% )	46.45% ( 38.41% , 54.63% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	523 ( 15.77% )	91.67% ( 84.77% , 96.12% )	71.74% ( 63.45% , 79.07% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	707 ( 21.31% )	90.57% ( 84.92% , 94.62% )	78.26% ( 71.60% , 83.99% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	11 ( 0.33% )	100.0% ( 71.51% , 100.0% )	57.89% ( 33.50% , 79.75% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	276 ( 8.32% )	98.55% ( 96.33% , 99.60% )	60.85% ( 56.15% , 65.40% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	407 ( 12.27% )	88.67% ( 85.18% , 91.58% )	54.30% ( 50.42% , 58.14% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	977	90	18	4,363	1,067 ( 19.59% )
Inpatient	215	5	3	N/A	220
Outpatient or Emergency Department	191	12	1	N/A	203
Other	37	8	1	N/A	45
Care Setting Reported as Unknown	534	65	13	N/A	599
<b>Demographics</b>					
Sex					
Female	369	41	10	1,864	410 ( 17.95% )
Male	608	49	8	2,499	657 ( 20.76% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	34	0 (0.00%)
6-17	0	0	0	16	0 (0.00%)
18-29	27	3	1	105	30 ( 22.06% )
30-39	65	4	2	213	69 ( 24.30% )
40-49	129	3	1	439	132 ( 23.08% )
50-59	212	9	2	823	221 ( 21.13% )
60-69	262	13	4	1,019	275 ( 21.19% )
70-79	184	29	5	956	213 ( 18.14% )
80-89	76	26	2	574	102 ( 15.04% )
90+	22	3	1	184	25 ( 11.90% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	0	N/A
Asian	3	1	0	16	4 ( 20% )
Black or African American	45	1	1	299	46 ( 13.29% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	109	21	0	404	130 ( 24.34% )
Other/Mixed/Unknown	820	67	17	3,644	887 ( 19.50% )
Ethnicity					



**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	3	0	0	24	3 ( 11.11% )
Non-Hispanic	0	0	0	0	N/A
Unknown	974	90	18	4,339	1,064 ( 19.63% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	16	2	0	54	18 ( 25 % )
Contact and suspected exposure (Z20.828)	225	21	3	873	246 ( 21.93% )
Pneumonia (see Appendix B)	894	78	17	3,778	972 ( 20.39% )
Other viral pneumonia (J12.89)	790	54	15	3,143	844 ( 21.09% )
ARDS (J80)	225	14	3	1,031	239 ( 18.77% )
Sepsis (see Appendix C)	393	32	9	1,749	425 ( 19.47% )
Bronchitis (J20.8 OR J40)	12	1	0	106	13 ( 10.92% )
Respiratory infection (J22 OR J98.8)	235	19	5	1,021	254 ( 19.84% )
Cough (R05)	331	20	9	1,490	351 ( 18.97% )
Shortness of breath (R06.2)	6	0	0	33	6 ( 15.38% )
Fever (R50.9)	412	34	7	1,766	446 ( 20.10% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	87	3	1	213	90 ( 29.61% )
Test performed, only negative results	9	4	0	26	13 ( 33.33% )
No test or unknown result	685	57	16	3,145	742 ( 19.01% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	977	90	18	4,363	1,067 ( 19.59% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	109	14	0	0	123 ( 100.0% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	149	12	2	606	161 ( 20.94% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	205	17	2	768	222 ( 22.38% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	1	0	0	20 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	425	11	0	0	436 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	533	78	1	0	611 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	5,448 ( 100.0% )	91.57% ( 89.73% , 93.16% )	86.54% ( 84.41% , 88.47% )
Inpatient	223 ( 4.09% )	97.73% ( 94.78% , 99.26% )	94.30% ( 90.45% , 96.93% )
Outpatient or Emergency Department	204 ( 3.74% )	94.09% ( 89.90% , 96.91% )	90.95% ( 86.23% , 94.46% )
Other	46 ( 0.84% )	82.22% ( 67.95% , 92 % )	90.24% ( 76.87% , 97.28% )
Care Setting Reported as Unknown	1,591 ( 29.20% )	89.15% ( 86.38% , 91.52% )	*****
<b>Demographics</b>			
Sex			
Female	2,284 ( 41.92% )	90 % ( 86.68% , 92.73% )	82.74% ( 78.90% , 86.13% )
Male	3,164 ( 58.08% )	92.54% ( 90.26% , 94.43% )	89.02% ( 86.43% , 91.26% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	34 ( 0.62% )	N/A	N/A
6-17	16 ( 0.29% )	N/A	N/A
18-29	136 ( 2.50% )	90 % ( 73.47% , 97.89% )	87.10% ( 70.17% , 96.37% )
30-39	284 ( 5.21% )	94.20% ( 85.82% , 98.40% )	95.59% ( 87.64% , 99.08% )
40-49	572 ( 10.50% )	97.73% ( 93.50% , 99.53% )	90.85% ( 84.85% , 95.03% )
50-59	1,046 ( 19.20% )	95.93% ( 92.41% , 98.12% )	93.81% ( 89.82% , 96.57% )
60-69	1,298 ( 23.83% )	95.27% ( 92.05% , 97.46% )	90.66% ( 86.70% , 93.75% )
70-79	1,174 ( 21.55% )	86.38% ( 81.04% , 90.69% )	81.42% ( 75.72% , 86.27% )
80-89	678 ( 12.44% )	74.51% ( 64.92% , 82.62% )	66.09% ( 56.67% , 74.65% )
90+	210 ( 3.85% )	88 % ( 68.78% , 97.45% )	68.75% ( 49.99% , 83.88% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	N/A	N/A	N/A
Asian	20 ( 0.37% )	75 % ( 19.41% , 99.37% )	60 % ( 14.66% , 94.73% )
Black or African American	346 ( 6.35% )	97.83% ( 88.47% , 99.94% )	60 % ( 48.04% , 71.15% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	534 ( 9.80% )	83.85% ( 76.37% , 89.71% )	64.88% ( 57.15% , 72.07% )
Other/Mixed/Unknown	4,548 ( 83.48% )	92.45% ( 90.51% , 94.10% )	93.08% ( 91.19% , 94.66% )
Ethnicity			

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	27 ( 0.50% )	100.0% ( 29.24% , 100.0% )	60 % ( 14.66% , 94.73% )
Non-Hispanic	N/A	N/A	N/A
Unknown	5,421 ( 99.50% )	91.54% ( 89.71% , 93.14% )	86.65% ( 84.53% , 88.59% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	72 ( 1.32% )	88.89% ( 65.29% , 98.62% )	*****
Contact and suspected exposure (Z20.828)	1,122 ( 20.59% )	91.46% ( 87.25% , 94.64% )	*****
Pneumonia (see Appendix B)	4,767 ( 87.50% )	91.98% ( 90.09% , 93.61% )	91.88% ( 89.98% , 93.52% )
Other viral pneumonia (J12.89)	4,002 ( 73.46% )	93.60% ( 91.73% , 95.16% )	99.25% ( 98.37% , 99.72% )
ARDS (J80)	1,273 ( 23.37% )	94.14% ( 90.37% , 96.76% )	*****
Sepsis (see Appendix C)	2,183 ( 40.07% )	92.47% ( 89.54% , 94.79% )	95.39% ( 92.89% , 97.20% )
Bronchitis (J20.8 OR J40)	119 ( 2.18% )	92.31% ( 63.97% , 99.81% )	100.0% ( 73.54% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,280 ( 23.49% )	92.52% ( 88.56% , 95.44% )	*****
Cough (R05)	1,850 ( 33.96% )	94.30% ( 91.34% , 96.49% )	97.07% ( 94.67% , 98.58% )
Shortness of breath (R06.2)	39 ( 0.72% )	100.0% ( 54.07% , 100.0% )	*****
Fever (R50.9)	2,219 ( 40.73% )	92.38% ( 89.51% , 94.66% )	*****
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	304 ( 5.58% )	96.67% ( 90.57% , 99.31% )	*****
Test performed, only negative results	39 ( 0.72% )	69.23% ( 38.57% , 90.91% )	*****
No test or unknown result	3,903 ( 71.64% )	92.32% ( 90.16% , 94.13% )	92.94% ( 90.85% , 94.69% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	5,448 ( 100.0% )	91.57% ( 89.73% , 93.16% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	123 ( 2.26% )	88.62% ( 81.64% , 93.64% )	70.32% ( 62.47% , 77.38% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	769 ( 14.12% )	92.55% ( 87.34% , 96.09% )	*****

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence</b>
			<b>Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	992 ( 18.21% )	92.34% ( 88.02% , 95.48% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	20 ( 0.37% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	436 ( 8 % )	97.48% ( 95.53% , 98.73% )	95.08% ( 92.64% , 96.89% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	612 ( 11.23% )	87.23% ( 84.33% , 89.78% )	80.39% ( 77.16% , 83.35% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	999	115	18	4,657	1,114 ( 19.24% )
Inpatient	216	6	3	N/A	222
Outpatient or Emergency Department	193	13	1	N/A	206
Other	37	10	1	N/A	47
Care Setting Reported as Unknown	553	86	13	N/A	639
<b>Demographics</b>					
Sex					
Female	382	52	10	2,019	434 ( 17.62% )
Male	617	63	8	2,638	680 ( 20.44% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	49	0 (0.00%)
6-17	0	0	0	23	0 (0.00%)
18-29	27	3	1	118	30 ( 20.13% )
30-39	65	4	2	221	69 ( 23.63% )
40-49	130	5	1	457	135 ( 22.77% )
50-59	215	13	2	860	228 ( 20.92% )
60-69	270	18	4	1,067	288 ( 21.19% )
70-79	187	34	5	1,014	221 ( 17.82% )
80-89	82	33	2	639	115 ( 15.21% )
90+	23	5	1	209	28 ( 11.76% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	0	N/A
Asian	4	1	0	17	5 ( 22.73% )
Black or African American	49	2	1	316	51 ( 13.86% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	115	27	0	456	142 ( 23.75% )
Other/Mixed/Unknown	831	85	17	3,868	916 ( 19.08% )
Ethnicity					



**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	3	0	0	27	3 ( 10 % )
Non-Hispanic	0	0	0	0	N/A
Unknown	996	115	18	4,630	1,111 ( 19.29% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	16	3	0	54	19 ( 26.03% )
Contact and suspected exposure (Z20.828)	226	22	3	906	248 ( 21.43% )
Pneumonia (see Appendix B)	911	95	17	3,954	1,006 ( 20.21% )
Other viral pneumonia (J12.89)	800	54	15	3,191	854 ( 21.03% )
ARDS (J80)	225	14	3	1,043	239 ( 18.60% )
Sepsis (see Appendix C)	397	40	9	1,830	437 ( 19.20% )
Bronchitis (J20.8 OR J40)	12	1	0	116	13 ( 10.08% )
Respiratory infection (J22 OR J98.8)	235	20	5	1,029	255 ( 19.78% )
Cough (R05)	335	28	9	1,571	363 ( 18.68% )
Shortness of breath (R06.2)	6	1	0	37	7 ( 15.91% )
Fever (R50.9)	417	40	7	1,845	457 ( 19.79% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	90	3	1	217	93 ( 29.90% )
Test performed, only negative results	9	6	0	30	15 ( 33.33% )
No test or unknown result	688	69	16	3,334	757 ( 18.43% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	999	115	18	4,657	1,114 ( 19.24% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	116	17	0	0	133 ( 100.0% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	149	13	2	625	162 ( 20.53% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	205	17	2	778	222 ( 22.16% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	1	0	0	20 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	430	24	0	0	454 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	550	90	1	0	640 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	5,789 ( 100.0% )	89.68% ( 87.74% , 91.40% )	88.49% ( 86.48% , 90.29% )
Inpatient	225 ( 3.89% )	97.30% ( 94.21% , 99 % )	94.74% ( 90.99% , 97.25% )
Outpatient or Emergency Department	207 ( 3.58% )	93.69% ( 89.45% , 96.60% )	91.90% ( 87.36% , 95.21% )
Other	48 ( 0.83% )	78.72% ( 64.34% , 89.30% )	90.24% ( 76.87% , 97.28% )
Care Setting Reported as Unknown	1,728 ( 29.85% )	86.54% ( 83.65% , 89.09% )	*****
<b>Demographics</b>			
Sex			
Female	2,463 ( 42.55% )	88.02% ( 84.59% , 90.92% )	85.65% ( 82.05% , 88.77% )
Male	3,326 ( 57.45% )	90.74% ( 88.30% , 92.81% )	90.34% ( 87.87% , 92.45% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	49 ( 0.85% )	N/A	N/A
6-17	23 ( 0.40% )	N/A	N/A
18-29	149 ( 2.57% )	90 % ( 73.47% , 97.89% )	87.10% ( 70.17% , 96.37% )
30-39	292 ( 5.04% )	94.20% ( 85.82% , 98.40% )	95.59% ( 87.64% , 99.08% )
40-49	593 ( 10.24% )	96.30% ( 91.57% , 98.79% )	91.55% ( 85.70% , 95.56% )
50-59	1,090 ( 18.83% )	94.30% ( 90.45% , 96.93% )	95.13% ( 91.46% , 97.55% )
60-69	1,359 ( 23.48% )	93.75% ( 90.30% , 96.25% )	93.43% ( 89.92% , 96 % )
70-79	1,240 ( 21.42% )	84.62% ( 79.17% , 89.10% )	82.74% ( 77.17% , 87.43% )
80-89	756 ( 13.06% )	71.30% ( 62.12% , 79.35% )	71.30% ( 62.12% , 79.35% )
90+	238 ( 4.11% )	82.14% ( 63.11% , 93.94% )	71.88% ( 53.25% , 86.25% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	N/A	N/A	N/A
Asian	22 ( 0.38% )	80 % ( 28.36% , 99.49% )	80 % ( 28.36% , 99.49% )
Black or African American	368 ( 6.36% )	96.08% ( 86.54% , 99.52% )	65.33% ( 53.46% , 75.96% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	598 ( 10.33% )	80.99% ( 73.55% , 87.08% )	68.45% ( 60.85% , 75.39% )
Other/Mixed/Unknown	4,801 ( 82.93% )	90.72% ( 88.65% , 92.52% )	94.32% ( 92.59% , 95.76% )
Ethnicity			

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	30 ( 0.52% )	100.0% ( 29.24% , 100.0% )	60 % ( 14.66% , 94.73% )
Non-Hispanic	N/A	N/A	N/A
Unknown	5,759 ( 99.48% )	89.65% ( 87.71% , 91.38% )	88.61% ( 86.61% , 90.41% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	73 ( 1.26% )	84.21% ( 60.42% , 96.62% )	*****
Contact and suspected exposure (Z20.828)	1,157 ( 19.99% )	91.13% ( 86.88% , 94.36% )	*****
Pneumonia (see Appendix B)	4,977 ( 85.97% )	90.56% ( 88.58% , 92.29% )	93.63% ( 91.91% , 95.08% )
Other viral pneumonia (J12.89)	4,060 ( 70.13% )	93.68% ( 91.83% , 95.21% )	*****
ARDS (J80)	1,285 ( 22.20% )	94.14% ( 90.37% , 96.76% )	*****
Sepsis (see Appendix C)	2,276 ( 39.32% )	90.85% ( 87.74% , 93.38% )	96.36% ( 94.07% , 97.95% )
Bronchitis (J20.8 OR J40)	129 ( 2.23% )	92.31% ( 63.97% , 99.81% )	100.0% ( 73.54% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,289 ( 22.27% )	92.16% ( 88.15% , 95.14% )	*****
Cough (R05)	1,943 ( 33.56% )	92.29% ( 89.04% , 94.81% )	98.24% ( 96.21% , 99.35% )
Shortness of breath (R06.2)	44 ( 0.76% )	85.71% ( 42.13% , 99.64% )	*****
Fever (R50.9)	2,309 ( 39.89% )	91.25% ( 88.27% , 93.67% )	*****
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	311 ( 5.37% )	96.77% ( 90.86% , 99.33% )	*****
Test performed, only negative results	45 ( 0.78% )	60 % ( 32.29% , 83.66% )	*****
No test or unknown result	4,107 ( 70.94% )	90.89% ( 88.61% , 92.84% )	93.35% ( 91.31% , 95.04% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	5,789 ( 100.0% )	89.68% ( 87.74% , 91.40% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	133 ( 2.30% )	87.22% ( 80.33% , 92.37% )	74.84% ( 67.25% , 81.46% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	789 ( 13.63% )	91.98% ( 86.67% , 95.66% )	*****

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,002 ( 17.31% )	92.34% ( 88.02% , 95.48% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	20 ( 0.35% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	454 ( 7.84% )	94.71% ( 92.24% , 96.58% )	96.20% ( 93.98% , 97.77% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	641 ( 11.07% )	85.94% ( 83 % , 88.54% )	82.96% ( 79.87% , 85.74% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,013	119	18	4,749	1,132 ( 19.19% )
Inpatient	218	7	3	N/A	225
Outpatient or Emergency Department	195	13	1	N/A	208
Other	37	11	1	N/A	48
Care Setting Reported as Unknown	563	88	13	N/A	651
<b>Demographics</b>					
Sex					
Female	387	54	10	2,070	441 ( 17.49% )
Male	626	65	8	2,679	691 ( 20.46% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	49	0 (0.00%)
6-17	0	0	0	23	0 (0.00%)
18-29	27	3	1	119	30 ( 20 % )
30-39	65	4	2	223	69 ( 23.47% )
40-49	132	5	1	464	137 ( 22.76% )
50-59	216	14	2	870	230 ( 20.87% )
60-69	272	20	4	1,085	292 ( 21.14% )
70-79	189	34	5	1,041	223 ( 17.57% )
80-89	87	34	2	658	121 ( 15.49% )
90+	25	5	1	217	30 ( 12.10% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	0	N/A
Asian	4	1	0	18	5 ( 21.74% )
Black or African American	52	2	1	326	54 ( 14.17% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	119	27	0	475	146 ( 23.51% )
Other/Mixed/Unknown	838	89	17	3,930	927 ( 19.02% )
Ethnicity					



**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	3	0	0	27	3 ( 10 % )
Non-Hispanic	0	0	0	0	N/A
Unknown	1,010	119	18	4,722	1,129 ( 19.24% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	16	3	0	54	19 ( 26.03% )
Contact and suspected exposure (Z20.828)	230	23	3	913	253 ( 21.64% )
Pneumonia (see Appendix B)	925	99	17	4,034	1,024 ( 20.18% )
Other viral pneumonia (J12.89)	805	54	15	3,212	859 ( 21.02% )
ARDS (J80)	227	14	3	1,052	241 ( 18.60% )
Sepsis (see Appendix C)	405	41	9	1,859	446 ( 19.27% )
Bronchitis (J20.8 OR J40)	12	1	0	117	13 ( 10 % )
Respiratory infection (J22 OR J98.8)	235	20	5	1,032	255 ( 19.74% )
Cough (R05)	338	30	9	1,592	368 ( 18.69% )
Shortness of breath (R06.2)	6	1	0	38	7 ( 15.56% )
Fever (R50.9)	423	42	7	1,860	465 ( 19.94% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	90	3	1	220	93 ( 29.62% )
Test performed, only negative results	9	6	0	30	15 ( 33.33% )
No test or unknown result	694	72	16	3,386	766 ( 18.38% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,013	119	18	4,749	1,132 ( 19.19% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	118	17	0	0	135 ( 100.0% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	151	14	2	629	165 ( 20.73% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	208	17	2	781	225 ( 22.32% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19	1	0	0	20 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	434	26	0	0	460 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	560	92	1	0	652 ( 99.85% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	5,899 ( 100.0% )	89.49% ( 87.55% , 91.21% )	89.73% ( 87.81% , 91.44% )
Inpatient	228 ( 3.87% )	96.89% ( 93.70% , 98.74% )	95.61% ( 92.08% , 97.88% )
Outpatient or Emergency Department	209 ( 3.54% )	93.75% ( 89.55% , 96.63% )	92.86% ( 88.49% , 95.95% )
Other	49 ( 0.83% )	77.08% ( 62.69% , 87.97% )	90.24% ( 76.87% , 97.28% )
Care Setting Reported as Unknown	1,777 ( 30.12% )	86.48% ( 83.61% , 89.02% )	*****
<b>Demographics</b>			
Sex			
Female	2,521 ( 42.74% )	87.76% ( 84.33% , 90.67% )	86.77% ( 83.27% , 89.77% )
Male	3,378 ( 57.26% )	90.59% ( 88.17% , 92.67% )	91.65% ( 89.32% , 93.62% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	49 ( 0.83% )	N/A	N/A
6-17	23 ( 0.39% )	N/A	N/A
18-29	150 ( 2.54% )	90 % ( 73.47% , 97.89% )	87.10% ( 70.17% , 96.37% )
30-39	294 ( 4.98% )	94.20% ( 85.82% , 98.40% )	95.59% ( 87.64% , 99.08% )
40-49	602 ( 10.21% )	96.35% ( 91.69% , 98.80% )	92.96% ( 87.43% , 96.57% )
50-59	1,102 ( 18.68% )	93.91% ( 90 % , 96.63% )	95.58% ( 92.01% , 97.86% )
60-69	1,381 ( 23.41% )	93.15% ( 89.62% , 95.77% )	94.12% ( 90.75% , 96.54% )
70-79	1,269 ( 21.51% )	84.75% ( 79.35% , 89.20% )	83.63% ( 78.15% , 88.20% )
80-89	781 ( 13.24% )	71.90% ( 63.01% , 79.69% )	75.65% ( 66.77% , 83.17% )
90+	248 ( 4.20% )	83.33% ( 65.28% , 94.36% )	78.13% ( 60.03% , 90.72% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	N/A	N/A	N/A
Asian	23 ( 0.39% )	80 % ( 28.36% , 99.49% )	80 % ( 28.36% , 99.49% )
Black or African American	381 ( 6.46% )	96.30% ( 87.25% , 99.55% )	69.33% ( 57.62% , 79.47% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	621 ( 10.53% )	81.51% ( 74.25% , 87.44% )	70.83% ( 63.34% , 77.58% )
Other/Mixed/Unknown	4,874 ( 82.62% )	90.40% ( 88.32% , 92.22% )	95.12% ( 93.48% , 96.45% )
Ethnicity			

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	30 ( 0.51% )	100.0% ( 29.24% , 100.0% )	60 % ( 14.66% , 94.73% )
Non-Hispanic	N/A	N/A	N/A
Unknown	5,869 ( 99.49% )	89.46% ( 87.52% , 91.19% )	89.86% ( 87.94% , 91.56% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	73 ( 1.24% )	84.21% ( 60.42% , 96.62% )	*****
Contact and suspected exposure (Z20.828)	1,169 ( 19.82% )	90.91% ( 86.67% , 94.15% )	*****
Pneumonia (see Appendix B)	5,075 ( 86.03% )	90.33% ( 88.36% , 92.07% )	95.07% ( 93.51% , 96.34% )
Other viral pneumonia (J12.89)	4,086 ( 69.27% )	93.71% ( 91.88% , 95.24% )	*****
ARDS (J80)	1,296 ( 21.97% )	94.19% ( 90.45% , 96.79% )	*****
Sepsis (see Appendix C)	2,314 ( 39.23% )	90.81% ( 87.74% , 93.32% )	98.30% ( 96.53% , 99.31% )
Bronchitis (J20.8 OR J40)	130 ( 2.20% )	92.31% ( 63.97% , 99.81% )	100.0% ( 73.54% , 100.0% )
Respiratory infection (J22 OR J98.8)	1,292 ( 21.90% )	92.16% ( 88.15% , 95.14% )	*****
Cough (R05)	1,969 ( 33.38% )	91.85% ( 88.57% , 94.43% )	99.12% ( 97.45% , 99.82% )
Shortness of breath (R06.2)	45 ( 0.76% )	85.71% ( 42.13% , 99.64% )	*****
Fever (R50.9)	2,332 ( 39.53% )	90.97% ( 87.99% , 93.41% )	*****
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	314 ( 5.32% )	96.77% ( 90.86% , 99.33% )	*****
Test performed, only negative results	45 ( 0.76% )	60 % ( 32.29% , 83.66% )	*****
No test or unknown result	4,168 ( 70.66% )	90.60% ( 88.31% , 92.57% )	94.17% ( 92.22% , 95.75% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	5,899 ( 100.0% )	89.49% ( 87.55% , 91.21% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	135 ( 2.29% )	87.41% ( 80.61% , 92.49% )	76.13% ( 68.63% , 82.60% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	796 ( 13.49% )	91.52% ( 86.17% , 95.28% )	*****

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence</b>
			<b>Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,008 ( 17.09% )	92.44% ( 88.18% , 95.54% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	20 ( 0.34% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	460 ( 7.80% )	94.35% ( 91.83% , 96.27% )	97.09% ( 95.08% , 98.44% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	653 ( 11.07% )	85.89% ( 82.98% , 88.47% )	84.46% ( 81.48% , 87.14% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	899	78	17	3,811	977 ( 20.33% )
Inpatient	197	5	3	N/A	202
Outpatient or Emergency Department	179	8	1	N/A	187
Other	32	6	1	N/A	38
Care Setting Reported as Unknown	491	59	12	N/A	550
<b>Demographics</b>					
Sex					
Female	336	33	9	1,568	369 ( 18.96% )
Male	563	45	8	2,243	608 ( 21.27% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	13	0 (0.00%)
6-17	0	0	0	7	0 (0.00%)
18-29	24	3	1	75	27 ( 26.21% )
30-39	56	2	2	183	58 ( 23.87% )
40-49	116	3	1	401	119 ( 22.84% )
50-59	200	6	2	755	206 ( 21.39% )
60-69	244	11	3	904	255 ( 21.94% )
70-79	174	28	5	834	202 ( 19.40% )
80-89	67	22	2	498	89 ( 15.11% )
90+	18	3	1	141	21 ( 12.88% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	0	N/A
Asian	3	1	0	15	4 ( 21.05% )
Black or African American	44	1	1	253	45 ( 15.05% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	99	19	0	331	118 ( 26.28% )
Other/Mixed/Unknown	753	57	16	3,212	810 ( 20.06% )
Ethnicity					



**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	3	0	0	20	3 ( 13.04% )
Non-Hispanic	0	0	0	0	N/A
Unknown	896	78	17	3,791	974 ( 20.37% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	14	2	0	46	16 ( 25.81% )
Contact and suspected exposure (Z20.828)	208	18	2	805	226 ( 21.88% )
Pneumonia (see Appendix B)	897	78	17	3,788	975 ( 20.40% )
Other viral pneumonia (J12.89)	793	54	15	3,152	847 ( 21.10% )
ARDS (J80)	225	14	3	1,033	239 ( 18.75% )
Sepsis (see Appendix C)	383	31	9	1,662	414 ( 19.86% )
Bronchitis (J20.8 OR J40)	11	1	0	84	12 ( 12.50% )
Respiratory infection (J22 OR J98.8)	208	19	5	867	227 ( 20.66% )
Cough (R05)	302	18	8	1,322	320 ( 19.39% )
Shortness of breath (R06.2)	6	0	0	28	6 ( 17.65% )
Fever (R50.9)	384	28	6	1,579	412 ( 20.63% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	80	3	1	187	83 ( 30.63% )
Test performed, only negative results	9	1	0	21	10 ( 32.26% )
No test or unknown result	629	51	15	2,778	680 ( 19.58% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	899	78	17	3,811	977 ( 20.33% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	100	13	0	0	113 ( 100.0% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	133	10	1	557	143 ( 20.40% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	197	17	2	744	214 ( 22.29% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	18	1	0	0	19 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	383	7	0	0	390 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	498	70	1	0	568 ( 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	4,805 ( 100.0% )	92.02% ( 90.14% , 93.64% )	79.63% ( 77.16% , 81.94% )
Inpatient	205 ( 4.27% )	97.52% ( 94.32% , 99.19% )	86.40% ( 81.26% , 90.57% )
Outpatient or Emergency Department	188 ( 3.91% )	95.72% ( 91.74% , 98.14% )	85.24% ( 79.71% , 89.74% )
Other	39 ( 0.81% )	84.21% ( 68.75% , 93.98% )	78.05% ( 62.39% , 89.44% )
Care Setting Reported as Unknown	1,387 ( 28.87% )	89.27% ( 86.38% , 91.73% )	*****
<b>Demographics</b>			
Sex			
Female	1,946 ( 40.50% )	91.06% ( 87.67% , 93.76% )	75.34% ( 71.06% , 79.27% )
Male	2,859 ( 59.50% )	92.60% ( 90.22% , 94.55% )	82.43% ( 79.36% , 85.21% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	13 ( 0.27% )	N/A	N/A
6-17	7 ( 0.15% )	N/A	N/A
18-29	103 ( 2.14% )	88.89% ( 70.84% , 97.65% )	77.42% ( 58.90% , 90.41% )
30-39	243 ( 5.06% )	96.55% ( 88.09% , 99.58% )	82.35% ( 71.20% , 90.53% )
40-49	521 ( 10.84% )	97.48% ( 92.81% , 99.48% )	81.69% ( 74.33% , 87.68% )
50-59	963 ( 20.04% )	97.09% ( 93.77% , 98.92% )	88.50% ( 83.60% , 92.35% )
60-69	1,162 ( 24.18% )	95.69% ( 92.41% , 97.83% )	84.43% ( 79.73% , 88.41% )
70-79	1,041 ( 21.66% )	86.14% ( 80.59% , 90.59% )	76.99% ( 70.95% , 82.31% )
80-89	589 ( 12.26% )	75.28% ( 65 % , 83.81% )	58.26% ( 48.70% , 67.39% )
90+	163 ( 3.39% )	85.71% ( 63.66% , 96.95% )	56.25% ( 37.66% , 73.64% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	N/A	N/A	N/A
Asian	19 ( 0.40% )	75 % ( 19.41% , 99.37% )	60 % ( 14.66% , 94.73% )
Black or African American	299 ( 6.22% )	97.78% ( 88.23% , 99.94% )	58.67% ( 46.70% , 69.92% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	449 ( 9.34% )	83.90% ( 76 % , 90.02% )	58.93% ( 51.09% , 66.45% )
Other/Mixed/Unknown	4,038 ( 84.04% )	92.96% ( 90.98% , 94.63% )	85.47% ( 82.97% , 87.73% )
Ethnicity			

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	Total Patient Count	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number (Percent)	Percent	
Hispanic	23 ( 0.48% )	100.0% ( 29.24% , 100.0% )	60 % ( 14.66% , 94.73% )
Non-Hispanic	N/A	N/A	N/A
Unknown	4782 ( 99.52% )	91.99% ( 90.11% , 93.62% )	79.72% ( 77.24% , 82.03% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	62 ( 1.29% )	87.50% ( 61.65% , 98.45% )	93.33% ( 68.05% , 99.83% )
Contact and suspected exposure (Z20.828)	1,033 ( 21.50% )	92.04% ( 87.70% , 95.21% )	95.41% ( 91.73% , 97.78% )
Pneumonia (see Appendix B)	4,780 ( 99.48% )	92 % ( 90.12% , 93.63% )	92.19% ( 90.32% , 93.80% )
Other viral pneumonia (J12.89)	4,014 ( 83.54% )	93.62% ( 91.76% , 95.17% )	99.62% ( 98.90% , 99.92% )
ARDS (J80)	1,275 ( 26.53% )	94.14% ( 90.37% , 96.76% )	*****
Sepsis (see Appendix C)	2,085 ( 43.39% )	92.51% ( 89.54% , 94.86% )	92.96% ( 90.05% , 95.24% )
Bronchitis (J20.8 OR J40)	96 ( 2 % )	91.67% ( 61.52% , 99.79% )	91.67% ( 61.52% , 99.79% )
Respiratory infection (J22 OR J98.8)	1,099 ( 22.87% )	91.63% ( 87.24% , 94.89% )	*****
Cough (R05)	1,650 ( 34.34% )	94.38% ( 91.26% , 96.63% )	88.56% ( 84.70% , 91.74% )
Shortness of breath (R06.2)	34 ( 0.71% )	100.0% ( 54.07% , 100.0% )	*****
Fever (R50.9)	1,997 ( 41.56% )	93.20% ( 90.33% , 95.44% )	93.89% ( 91.11% , 96.01% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	271 ( 5.64% )	96.39% ( 89.80% , 99.25% )	*****
Test performed, only negative results	31 ( 0.65% )	90 % ( 55.50% , 99.75% )	*****
No test or unknown result	3,473 ( 72.28% )	92.50% ( 90.26% , 94.37% )	85.35% ( 82.58% , 87.82% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	4805 ( 100.0% )	92.02% ( 90.14% , 93.64% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	113 ( 2.35% )	88.50% ( 81.13% , 93.73% )	64.52% ( 56.44% , 72.03% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	701 ( 14.59% )	93.01% ( 87.52% , 96.60% )	96.38% ( 91.75% , 98.81% )

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	Total Patient Count	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number (Percent)	Percent	
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	960 ( 19.98% )	92.06% ( 87.59% , 95.30% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	19 ( 0.40% )	94.74% ( 73.97% , 99.87% )	94.74% ( 73.97% , 99.87% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	390 ( 8.12% )	98.21% ( 96.34% , 99.28% )	85.68% ( 82.09% , 88.80% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	569 ( 11.84% )	87.68% ( 84.69% , 90.27% )	75.11% ( 71.64% , 78.36% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1d. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINCs or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test*****</b>				
Total Observed	1,742	2,815	2,419	4,437
Inpatient	384	0	544	0
Outpatient or Emergency Department	451	0	405	0
Other	53	0	180	0
Care Setting Reported as Unknown	525	2,482	715	3,855
<b>Demographics</b>				
Sex				
Female	741	1,183	1,366	2,343
Male	1,001	1,632	1,053	2,094
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	1	1	24	43
6-17	6	7	42	85
18-29	44	84	182	319
30-39	107	185	343	580
40-49	180	299	207	449
50-59	381	680	364	822
60-69	463	795	419	847
70-79	304	427	407	652
80-89	192	254	314	472
90+	64	83	117	168
Missing	0	0	0	0
Race				
American Indian or Alaska Native	0	0	0	0
Asian	7	7	3	3
Black or African American	77	79	69	73
Native Hawaiian or Other Pacific Islander	0	0	0	0
White	164	165	375	377
Other/Mixed/Unknown	1,494	2,564	1,972	3,984
Ethnicity				



**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	8	8	9	9
Non-Hispanic	0	0	0	0
Unknown	1,734	2,807	2,410	4,428
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	10	23	156	268
Contact and suspected exposure (Z20.828)	315	502	381	737
Pneumonia (see Appendix B)	1,463	2,370	688	1,523
Other viral pneumonia (J12.89)	1,327	2,164	158	641
ARDS (J80)	240	408	41	116
Sepsis (see Appendix C)	551	879	395	853
Bronchitis (J20.8 OR J40)	20	28	23	45
Respiratory infection (J22 OR J98.8)	181	342	30	114
Cough (R05)	432	693	269	613
Shortness of breath (R06.2)	6	7	17	31
Fever (R50.9)	496	824	372	851
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	142	0	25	0
Test performed, only negative results	9	0	62	0
No test or unknown result	1,262	2,482	1,760	3,855
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	1,413	2,482	1,847	3,855
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	361	196	521	237
<b>Codes Observed During Inpatient Stay</b>				

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	166	269	196	392
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	275	439	58	178
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	57	127	60	125
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	2	0	1
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	2	0	1
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	615	1,020	1,022	2,057
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection			3	3
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	2	5
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,070	1,664	1,327	2,238
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	3	5
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	2	2
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	0	0	0	0

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,647	268	33	9,173	1,915 ( 17.22% )
Inpatient	377	31	12	N/A	408
Outpatient or Emergency Department	435	50	4	N/A	485
Other	49	15	2	N/A	64
Care Setting Reported as Unknown	786	172	15	N/A	958
<b>Demographics</b>					
Sex					
Female	692	117	13	4,295	809 ( 15.81% )
Male	955	151	20	4,878	1,106 ( 18.42% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	12	0 (0.00%)
6-17	5	1	0	28	6 ( 17.65% )
18-29	37	7	1	180	44 ( 19.56% )
30-39	97	11	5	365	108 ( 22.59% )
40-49	178	14	1	674	192 ( 22.15% )
50-59	370	48	9	1,396	418 ( 22.93% )
60-69	444	61	8	1,957	505 ( 20.45% )
70-79	279	63	3	2,052	342 ( 14.27% )
80-89	176	39	4	1,781	215 ( 10.75% )
90+	61	24	2	728	85 ( 10.43% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	2	0 (0.00%)
Asian	7	0	0	40	7 ( 14.89% )
Black or African American	68	16	1	771	84 ( 9.81% )
Native Hawaiian or Other Pacific Islander	0	0	0	1	0 (0.00%)
White	139	48	0	1,372	187 ( 11.99% )
Other/Mixed/Unknown	1,433	204	32	6,987	1,637 ( 18.91% )
Ethnicity					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	7	2	0	63	9 ( 12.50% )
Non-Hispanic	0	0	0	0	N/A
Unknown	1,640	266	33	9,110	1,906 ( 17.25% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	8	12	0	118	20 ( 14.49% )
Contact and suspected exposure (Z20.828)	308	72	14	1,806	380 ( 17.27% )
Pneumonia (see Appendix B)	1,424	200	30	7,148	1,624 ( 18.45% )
Other viral pneumonia (J12.89)	1,314	133	28	5,899	1,447 ( 19.62% )
ARDS (J80)	238	27	6	1,142	265 ( 18.75% )
Sepsis (see Appendix C)	527	83	11	2,705	610 ( 18.34% )
Bronchitis (J20.8 OR J40)	18	1	0	102	19 ( 15.70% )
Respiratory infection (J22 OR J98.8)	183	19	3	1,069	202 ( 15.86% )
Cough (R05)	422	44	7	1,888	466 ( 19.74% )
Shortness of breath (R06.2)	6	2	0	60	8 ( 11.76% )
Fever (R50.9)	484	78	9	2,331	562 ( 19.37% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	176	17	3	289	193 ( 39.79% )
Test performed, only negative results	9	9	1	55	18 ( 24.32% )
No test or unknown result	1,180	166	28	5,871	1,346 ( 18.58% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,647	268	33	9,173	1,915 ( 17.22% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	329	68	2	0	397 ( 99.50% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	162	31	7	965	193 ( 16.57% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	277	38	12	1,405	315 ( 18.19% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	598	48	0	0	646 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection					N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	994	214	2	0	1,208 ( 99.83% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	11,121 ( 100.0% )	86.01% ( 84.37% , 87.53% )	94.55% ( 93.37% , 95.57% )
Inpatient	420 ( 3.78% )	92.40% ( 89.39% , 94.78% )	98.18% ( 96.28% , 99.26% )
Outpatient or Emergency Department	489 ( 4.40% )	89.69% ( 86.63% , 92.25% )	96.45% ( 94.30% , 97.96% )
Other	66 ( 0.59% )	76.56% ( 64.31% , 86.25% )	92.45% ( 81.79% , 97.91% )
Care Setting Reported as Unknown	3,931 ( 35.35% )	82.05% ( 79.47% , 84.43% )	*****
<b>Demographics</b>			
Sex	5,117 ( 46.01% )		
Female		85.54% ( 82.92% , 87.89% )	93.39% ( 91.35% , 95.07% )
Male	6,004 ( 53.99% )	86.35% ( 84.18% , 88.32% )	95.40% ( 93.92% , 96.62% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	12 ( 0.11% )	N/A	N/A
6-17	34 ( 0.31% )	83.33% ( 35.88% , 99.58% )	83.33% ( 35.88% , 99.58% )
18-29	225 ( 2.02% )	84.09% ( 69.93% , 93.36% )	84.09% ( 69.93% , 93.36% )
30-39	478 ( 4.30% )	89.81% ( 82.51% , 94.80% )	90.65% ( 83.48% , 95.43% )
40-49	867 ( 7.80% )	92.71% ( 88.07% , 95.96% )	98.89% ( 96.04% , 99.87% )
50-59	1,823 ( 16.39% )	88.52% ( 85.06% , 91.41% )	97.11% ( 94.89% , 98.55% )
60-69	2,470 ( 22.21% )	87.92% ( 84.76% , 90.63% )	95.90% ( 93.67% , 97.51% )
70-79	2,397 ( 21.55% )	81.58% ( 77.06% , 85.54% )	91.78% ( 88.10% , 94.61% )
80-89	2,000 ( 17.98% )	81.86% ( 76.05% , 86.77% )	91.67% ( 86.82% , 95.16% )
90+	815 ( 7.33% )	71.76% ( 60.96% , 81 % )	95.31% ( 86.91% , 99.02% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	2 ( 0.02% )	N/A	N/A
Asian	47 ( 0.42% )	100.0% ( 59.04% , 100.0% )	100.0% ( 59.04% , 100.0% )
Black or African American	856 ( 7.70% )	80.95% ( 70.92% , 88.70% )	88.31% ( 78.97% , 94.51% )
Native Hawaiian or Other Pacific Islander	1 ( 0.01% )	N/A	N/A
White	1,559 ( 14.02% )	74.33% ( 67.45% , 80.43% )	84.76% ( 78.32% , 89.89% )
Other/Mixed/Unknown	8,656 ( 77.83% )	87.54% ( 85.84% , 89.10% )	95.92% ( 94.79% , 96.86% )
Ethnicity			



**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	72 ( 0.65% )	77.78% ( 39.99% , 97.19% )	87.50% ( 47.35% , 99.68% )
Non-Hispanic	N/A	N/A	N/A
Unknown	1,1049 ( 99.35% )	86.04% ( 84.41% , 87.57% )	94.58% ( 93.41% , 95.60% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	138 ( 1.24% )	40 % ( 19.12% , 63.95% )	80 % ( 44.39% , 97.48% )
Contact and suspected exposure (Z20.828)	2,200 ( 19.78% )	81.05% ( 76.74% , 84.87% )	97.78% ( 95.48% , 99.10% )
Pneumonia (see Appendix B)	8,802 ( 79.15% )	87.68% ( 85.99% , 89.24% )	97.33% ( 96.37% , 98.10% )
Other viral pneumonia (J12.89)	7,374 ( 66.31% )	90.81% ( 89.20% , 92.25% )	99.02% ( 98.33% , 99.48% )
ARDS (J80)	1,413 ( 12.71% )	89.81% ( 85.52% , 93.18% )	99.17% ( 97.02% , 99.90% )
Sepsis (see Appendix C)	3,326 ( 29.91% )	86.39% ( 83.41% , 89.01% )	95.64% ( 93.59% , 97.19% )
Bronchitis (J20.8 OR J40)	121 ( 1.09% )	94.74% ( 73.97% , 99.87% )	90 % ( 68.30% , 98.77% )
Respiratory infection (J22 OR J98.8)	1,274 ( 11.46% )	90.59% ( 85.70% , 94.24% )	*****
Cough (R05)	2,361 ( 21.23% )	90.56% ( 87.53% , 93.06% )	97.69% ( 95.78% , 98.88% )
Shortness of breath (R06.2)	68 ( 0.61% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	2,902 ( 26.09% )	86.12% ( 82.98% , 88.87% )	97.58% ( 95.81% , 98.74% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	485 ( 4.36% )	91.19% ( 86.27% , 94.78% )	*****
Test performed, only negative results	74 ( 0.67% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	7,245 ( 65.15% )	87.67% ( 85.79% , 89.38% )	93.50% ( 92 % , 94.80% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,121 ( 100.0% )	86.01% ( 84.37% , 87.53% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	399 ( 3.59% )	82.87% ( 78.80% , 86.45% )	91.14% ( 87.72% , 93.86% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,165 ( 10.48% )	83.94% ( 77.98% , 88.82% )	97.59% ( 93.95% , 99.34% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,732 ( 15.57% )	87.94% ( 83.82% , 91.32% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.55% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	646 ( 5.81% )	92.57% ( 90.27% , 94.47% )	97.24% ( 95.61% , 98.38% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,210 ( 10.88% )	82.28% ( 80.01% , 84.40% )	92.90% ( 91.19% , 94.36% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,650	273	33	9,288	1,923 ( 17.10% )
Inpatient	377	33	12	N/A	410
Outpatient or Emergency Department	435	51	4	N/A	486
Other	49	15	2	N/A	64
Care Setting Reported as Unknown	789	174	15	N/A	963
<b>Demographics</b>					
Sex					
Female	695	120	13	4,345	815 ( 15.75% )
Male	955	153	20	4,943	1,108 ( 18.25% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	12	0 (0.00%)
6-17	5	1	0	28	6 ( 17.65% )
18-29	37	7	1	185	44 ( 19.13% )
30-39	97	12	5	367	109 ( 22.66% )
40-49	178	14	1	681	192 ( 21.97% )
50-59	370	48	9	1,419	418 ( 22.64% )
60-69	445	64	8	1,979	509 ( 20.39% )
70-79	281	64	3	2,078	345 ( 14.22% )
80-89	176	39	4	1,805	215 ( 10.62% )
90+	61	24	2	734	85 ( 10.35% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	2	0 (0.00%)
Asian	7	0	0	41	7 ( 14.58% )
Black or African American	69	16	1	785	85 ( 9.76% )
Native Hawaiian or Other Pacific Islander	0	0	0	1	0 (0.00%)
White	140	48	0	1,381	188 ( 11.98% )
Other/Mixed/Unknown	1,434	209	32	7,078	1,643 ( 18.77% )
Ethnicity					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	7	2	0	63	9 ( 12.50% )
Non-Hispanic	0	0	0	0	N/A
Unknown	1,643	271	33	9,225	1,914 ( 17.13% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	8	12	0	120	20 ( 14.29% )
Contact and suspected exposure (Z20.828)	308	75	14	1,837	383 ( 17.14% )
Pneumonia (see Appendix B)	1,426	202	30	7,223	1,628 ( 18.33% )
Other viral pneumonia (J12.89)	1,315	134	28	5,937	1,449 ( 19.54% )
ARDS (J80)	238	27	6	1,147	265 ( 18.69% )
Sepsis (see Appendix C)	528	87	11	2,730	615 ( 18.33% )
Bronchitis (J20.8 OR J40)	18	1	0	104	19 ( 15.45% )
Respiratory infection (J22 OR J98.8)	183	19	3	1,072	202 ( 15.82% )
Cough (R05)	422	45	7	1,904	467 ( 19.64% )
Shortness of breath (R06.2)	6	2	0	60	8 ( 11.76% )
Fever (R50.9)	484	81	9	2,354	565 ( 19.30% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	176	17	3	291	193 ( 39.63% )
Test performed, only negative results	9	9	1	55	18 ( 24.32% )
No test or unknown result	1,180	170	28	5,955	1,350 ( 18.41% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,650	273	33	9,288	1,923 ( 17.10% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	331	68	2	0	399 ( 99.50% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	162	33	7	978	195 ( 16.53% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	277	38	12	1,417	315 ( 18.06% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	598	48	0	0	646 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	997	219	2	0	1,216 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	11,244 ( 100.0% )	85.80% ( 84.16% , 87.33% )	94.72% ( 93.56% , 95.72% )
Inpatient	422 ( 3.75% )	91.95% ( 88.88% , 94.39% )	98.18% ( 96.28% , 99.26% )
Outpatient or Emergency Department	490 ( 4.36% )	89.51% ( 86.43% , 92.09% )	96.45% ( 94.30% , 97.96% )
Other	66 ( 0.59% )	76.56% ( 64.31% , 86.25% )	92.45% ( 81.79% , 97.91% )
Care Setting Reported as Unknown	3,965 ( 35.26% )	81.93% ( 79.35% , 84.31% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	5,173 ( 46.01% )	85.28% ( 82.65% , 87.64% )	93.79% ( 91.81% , 95.42% )
Male	6,071 ( 53.99% )	86.19% ( 84.02% , 88.17% )	95.40% ( 93.92% , 96.62% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	12 ( 0.11% )	N/A	N/A
6-17	34 ( 0.30% )	83.33% ( 35.88% , 99.58% )	83.33% ( 35.88% , 99.58% )
18-29	230 ( 2.05% )	84.09% ( 69.93% , 93.36% )	84.09% ( 69.93% , 93.36% )
30-39	481 ( 4.28% )	88.99% ( 81.56% , 94.18% )	90.65% ( 83.48% , 95.43% )
40-49	874 ( 7.77% )	92.71% ( 88.07% , 95.96% )	98.89% ( 96.04% , 99.87% )
50-59	1,846 ( 16.42% )	88.52% ( 85.06% , 91.41% )	97.11% ( 94.89% , 98.55% )
60-69	2,496 ( 22.20% )	87.43% ( 84.23% , 90.18% )	96.11% ( 93.93% , 97.68% )
70-79	2,426 ( 21.58% )	81.45% ( 76.94% , 85.41% )	92.43% ( 88.86% , 95.14% )
80-89	2,024 ( 18 % )	81.86% ( 76.05% , 86.77% )	91.67% ( 86.82% , 95.16% )
90+	821 ( 7.30% )	71.76% ( 60.96% , 81 % )	95.31% ( 86.91% , 99.02% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	2 ( 0.02% )	N/A	N/A
Asian	48 ( 0.43% )	100.0% ( 59.04% , 100.0% )	100.0% ( 59.04% , 100.0% )
Black or African American	871 ( 7.75% )	81.18% ( 71.24% , 88.84% )	89.61% ( 80.55% , 95.41% )
Native Hawaiian or Other Pacific Islander	1 ( 0.01% )	N/A	N/A
White	1,569 ( 13.95% )	74.47% ( 67.61% , 80.54% )	85.37% ( 79.01% , 90.39% )
Other/Mixed/Unknown	8,753 ( 77.85% )	87.28% ( 85.57% , 88.85% )	95.98% ( 94.86% , 96.92% )
<b>Ethnicity</b>			



**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	72 ( 0.64% )	77.78% ( 39.99% , 97.19% )	87.50% ( 47.35% , 99.68% )
Non-Hispanic	N/A	N/A	N/A
Unknown	11,172 ( 99.36% )	85.84% ( 84.20% , 87.37% )	94.75% ( 93.60% , 95.75% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	140 ( 1.25% )	40 % ( 19.12% , 63.95% )	80 % ( 44.39% , 97.48% )
Contact and suspected exposure (Z20.828)	2,234 ( 19.87% )	80.42% ( 76.08% , 84.27% )	97.78% ( 95.48% , 99.10% )
Pneumonia (see Appendix B)	8,881 ( 78.98% )	87.59% ( 85.89% , 89.16% )	97.47% ( 96.53% , 98.21% )
Other viral pneumonia (J12.89)	7,414 ( 65.94% )	90.75% ( 89.14% , 92.19% )	99.10% ( 98.43% , 99.53% )
ARDS (J80)	1,418 ( 12.61% )	89.81% ( 85.52% , 93.18% )	99.17% ( 97.02% , 99.90% )
Sepsis (see Appendix C)	3,356 ( 29.85% )	85.85% ( 82.85% , 88.51% )	95.83% ( 93.80% , 97.34% )
Bronchitis (J20.8 OR J40)	123 ( 1.09% )	94.74% ( 73.97% , 99.87% )	90 % ( 68.30% , 98.77% )
Respiratory infection (J22 OR J98.8)	1,277 ( 11.36% )	90.59% ( 85.70% , 94.24% )	*****
Cough (R05)	2,378 ( 21.15% )	90.36% ( 87.32% , 92.88% )	97.69% ( 95.78% , 98.88% )
Shortness of breath (R06.2)	68 ( 0.60% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	2,928 ( 26.04% )	85.66% ( 82.50% , 88.45% )	97.58% ( 95.81% , 98.74% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	487 ( 4.33% )	91.19% ( 86.27% , 94.78% )	*****
Test performed, only negative results	74 ( 0.66% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	7,333 ( 65.22% )	87.41% ( 85.52% , 89.13% )	93.50% ( 92 % , 94.80% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,244 ( 100.0% )	85.80% ( 84.16% , 87.33% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	401 ( 3.57% )	82.96% ( 78.90% , 86.52% )	91.69% ( 88.35% , 94.32% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,180 ( 10.49% )	83.08% ( 77.06% , 88.06% )	97.59% ( 93.95% , 99.34% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,744 ( 15.51% )	87.94% ( 83.82% , 91.32% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.54% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	646 ( 5.75% )	92.57% ( 90.27% , 94.47% )	97.24% ( 95.61% , 98.38% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,218 ( 10.83% )	81.99% ( 79.71% , 84.11% )	93.18% ( 91.50% , 94.61% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>Sensitivity (95% Confidence Interval)</b>	
		<b>PPV (95% Confidence Interval)</b>	
		<b>Number (Percent)</b>	
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,657	283	33	9,404	1,940 ( 17.05% )
Inpatient	379	34	12	N/A	413
Outpatient or Emergency Department	436	53	4	N/A	489
Other	49	15	2	N/A	64
Care Setting Reported as Unknown	793	181	15	N/A	974
<b>Demographics</b>					
Sex					
Female	699	126	13	4,397	825 ( 15.76% )
Male	958	157	20	5,007	1,115 ( 18.15% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	1	0	0	14	1 ( 6.67% )
6-17	5	1	0	28	6 ( 17.65% )
18-29	37	7	1	188	44 ( 18.88% )
30-39	97	13	5	372	110 ( 22.59% )
40-49	179	16	1	689	195 ( 22.03% )
50-59	370	48	9	1,429	418 ( 22.52% )
60-69	448	68	8	2,005	516 ( 20.40% )
70-79	282	65	3	2,103	347 ( 14.15% )
80-89	177	41	4	1,832	218 ( 10.61% )
90+	61	24	2	744	85 ( 10.23% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	2	0 (0.00%)
Asian	7	0	0	41	7 ( 14.58% )
Black or African American	69	17	1	798	86 ( 9.72% )
Native Hawaiian or Other Pacific Islander	0	0	0	1	0 (0.00%)
White	141	48	0	1,406	189 ( 11.85% )
Other/Mixed/Unknown	1,440	218	32	7,156	1,658 ( 18.74% )
Ethnicity					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	7	2	0	63	9 ( 12.50% )
Non-Hispanic	0	0	0	0	N/A
Unknown	1,650	281	33	9,341	1,931 ( 17.08% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	8	12	0	124	20 ( 13.89% )
Contact and suspected exposure (Z20.828)	308	78	14	1,853	386 ( 17.13% )
Pneumonia (see Appendix B)	1,430	209	30	7,290	1,639 ( 18.29% )
Other viral pneumonia (J12.89)	1,318	135	28	5,945	1,453 ( 19.57% )
ARDS (J80)	238	27	6	1,147	265 ( 18.69% )
Sepsis (see Appendix C)	531	89	11	2,747	620 ( 18.35% )
Bronchitis (J20.8 OR J40)	18	1	0	106	19 ( 15.20% )
Respiratory infection (J22 OR J98.8)	183	19	3	1,072	202 ( 15.82% )
Cough (R05)	423	47	7	1,926	470 ( 19.56% )
Shortness of breath (R06.2)	6	2	0	62	8 ( 11.43% )
Fever (R50.9)	486	84	9	2,378	570 ( 19.28% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	176	17	3	293	193 ( 39.47% )
Test performed, only negative results	9	9	1	56	18 ( 24 % )
No test or unknown result	1,184	178	28	6,021	1,362 ( 18.38% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,657	283	33	9,404	1,940 ( 17.05% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	333	70	2	0	403 ( 99.51% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	162	34	7	989	196 ( 16.44% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	277	39	12	1,420	316 ( 18.08% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	601	51	0	0	652 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,001	226	2	0	1,227 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	11,377 ( 100.0% )	85.41% ( 83.76% , 86.95% )	95.12% ( 94 % , 96.08% )
Inpatient	425 ( 3.74% )	91.77% ( 88.69% , 94.23% )	98.70% ( 96.99% , 99.58% )
Outpatient or Emergency Department	493 ( 4.33% )	89.16% ( 86.06% , 91.78% )	96.67% ( 94.57% , 98.13% )
Other	66 ( 0.58% )	76.56% ( 64.31% , 86.25% )	92.45% ( 81.79% , 97.91% )
Care Setting Reported as Unknown	4,023 ( 35.36% )	81.42% ( 78.83% , 83.81% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	5,235 ( 46.01% )	84.73% ( 82.09% , 87.11% )	94.33% ( 92.42% , 95.88% )
Male	6,142 ( 53.99% )	85.92% ( 83.74% , 87.91% )	95.70% ( 94.26% , 96.87% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	15 ( 0.13% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
6-17	34 ( 0.30% )	83.33% ( 35.88% , 99.58% )	83.33% ( 35.88% , 99.58% )
18-29	233 ( 2.05% )	84.09% ( 69.93% , 93.36% )	84.09% ( 69.93% , 93.36% )
30-39	487 ( 4.28% )	88.18% ( 80.64% , 93.55% )	90.65% ( 83.48% , 95.43% )
40-49	885 ( 7.78% )	91.79% ( 87.02% , 95.24% )	99.44% ( 96.94% , 99.99% )
50-59	1,856 ( 16.31% )	88.52% ( 85.06% , 91.41% )	97.11% ( 94.89% , 98.55% )
60-69	2,529 ( 22.23% )	86.82% ( 83.59% , 89.62% )	96.76% ( 94.71% , 98.18% )
70-79	2,453 ( 21.56% )	81.27% ( 76.76% , 85.24% )	92.76% ( 89.25% , 95.41% )
80-89	2,054 ( 18.05% )	81.19% ( 75.36% , 86.15% )	92.19% ( 87.44% , 95.56% )
90+	831 ( 7.30% )	71.76% ( 60.96% , 81 % )	95.31% ( 86.91% , 99.02% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	2 ( 0.02% )	N/A	N/A
Asian	48 ( 0.42% )	100.0% ( 59.04% , 100.0% )	100.0% ( 59.04% , 100.0% )
Black or African American	885 ( 7.78% )	80.23% ( 70.25% , 88.04% )	89.61% ( 80.55% , 95.41% )
Native Hawaiian or Other Pacific Islander	1 ( 0.01% )	N/A	N/A
White	1,595 ( 14.02% )	74.60% ( 67.78% , 80.64% )	85.98% ( 79.70% , 90.90% )
Other/Mixed/Unknown	8,846 ( 77.75% )	86.85% ( 85.13% , 88.44% )	96.39% ( 95.31% , 97.27% )
<b>Ethnicity</b>			



**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	72 ( 0.63% )	77.78% ( 39.99% , 97.19% )	87.50% ( 47.35% , 99.68% )
Non-Hispanic	N/A	N/A	N/A
Unknown	11,305 ( 99.37% )	85.45% ( 83.80% , 86.99% )	95.16% ( 94.04% , 96.12% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	144 ( 1.27% )	40 % ( 19.12% , 63.95% )	80 % ( 44.39% , 97.48% )
Contact and suspected exposure (Z20.828)	2,253 ( 19.80% )	79.79% ( 75.44% , 83.69% )	97.78% ( 95.48% , 99.10% )
Pneumonia (see Appendix B)	8,959 ( 78.75% )	87.25% ( 85.54% , 88.83% )	97.74% ( 96.85% , 98.44% )
Other viral pneumonia (J12.89)	7,426 ( 65.27% )	90.71% ( 89.10% , 92.15% )	99.32% ( 98.72% , 99.69% )
ARDS (J80)	1,418 ( 12.46% )	89.81% ( 85.52% , 93.18% )	99.17% ( 97.02% , 99.90% )
Sepsis (see Appendix C)	3,378 ( 29.69% )	85.65% ( 82.64% , 88.31% )	96.37% ( 94.45% , 97.77% )
Bronchitis (J20.8 OR J40)	125 ( 1.10% )	94.74% ( 73.97% , 99.87% )	90 % ( 68.30% , 98.77% )
Respiratory infection (J22 OR J98.8)	1,277 ( 11.22% )	90.59% ( 85.70% , 94.24% )	*****
Cough (R05)	2,403 ( 21.12% )	90 % ( 86.92% , 92.56% )	97.92% ( 96.08% , 99.04% )
Shortness of breath (R06.2)	70 ( 0.62% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	2,957 ( 25.99% )	85.26% ( 82.08% , 88.07% )	97.98% ( 96.32% , 99.03% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	489 ( 4.30% )	91.19% ( 86.27% , 94.78% )	*****
Test performed, only negative results	75 ( 0.66% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	7,411 ( 65.14% )	86.93% ( 85.02% , 88.68% )	93.82% ( 92.35% , 95.08% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,377 ( 100.0% )	85.41% ( 83.76% , 86.95% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	405 ( 3.56% )	82.63% ( 78.57% , 86.20% )	92.24% ( 88.99% , 94.78% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,192 ( 10.48% )	82.65% ( 76.61% , 87.68% )	97.59% ( 93.95% , 99.34% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,748 ( 15.36% )	87.66% ( 83.52% , 91.07% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.54% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	652 ( 5.73% )	92.18% ( 89.84% , 94.12% )	97.72% ( 96.21% , 98.75% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,229 ( 10.80% )	81.58% ( 79.30% , 83.71% )	93.55% ( 91.91% , 94.95% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	
		<b>Sensitivity (95% Confidence Interval)</b>	
		<b>Number (Percent)</b>	
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,661	287	33	9,461	1,948 ( 17.02% )
Inpatient	379	36	12	N/A	415
Outpatient or Emergency Department	439	53	4	N/A	492
Other	49	15	2	N/A	64
Care Setting Reported as Unknown	794	183	15	N/A	977
<b>Demographics</b>					
Sex					
Female	703	127	13	4,424	830 ( 15.76% )
Male	958	160	20	5,037	1,118 ( 18.11% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	1	0	0	14	1 ( 6.67% )
6-17	5	1	0	28	6 ( 17.65% )
18-29	37	8	1	189	45 ( 19.15% )
30-39	98	13	5	375	111 ( 22.61% )
40-49	179	16	1	691	195 ( 21.98% )
50-59	371	49	9	1,437	420 ( 22.51% )
60-69	449	68	8	2,017	517 ( 20.34% )
70-79	282	66	3	2,114	348 ( 14.12% )
80-89	178	42	4	1,848	220 ( 10.62% )
90+	61	24	2	748	85 ( 10.18% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	2	0 (0.00%)
Asian	7	0	0	41	7 ( 14.58% )
Black or African American	69	17	1	808	86 ( 9.61% )
Native Hawaiian or Other Pacific Islander	0	0	0	1	0 (0.00%)
White	142	48	0	1,415	190 ( 11.84% )
Other/Mixed/Unknown	1,443	222	32	7,194	1,665 ( 18.73% )
Ethnicity					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	7	2	0	63	9 ( 12.50% )
Non-Hispanic	0	0	0	0	N/A
Unknown	1,654	285	33	9,398	1,939 ( 17.05% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	8	13	0	125	21 ( 14.38% )
Contact and suspected exposure (Z20.828)	308	79	14	1,862	387 ( 17.10% )
Pneumonia (see Appendix B)	1,434	212	30	7,338	1,646 ( 18.26% )
Other viral pneumonia (J12.89)	1,318	135	28	5,949	1,453 ( 19.56% )
ARDS (J80)	238	27	6	1,149	265 ( 18.66% )
Sepsis (see Appendix C)	532	92	11	2,761	624 ( 18.37% )
Bronchitis (J20.8 OR J40)	18	1	0	107	19 ( 15.08% )
Respiratory infection (J22 OR J98.8)	183	19	3	1,072	202 ( 15.82% )
Cough (R05)	425	48	7	1,933	473 ( 19.60% )
Shortness of breath (R06.2)	6	2	0	62	8 ( 11.43% )
Fever (R50.9)	486	86	9	2,388	572 ( 19.27% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	178	17	3	295	195 ( 39.55% )
Test performed, only negative results	9	9	1	57	18 ( 23.68% )
No test or unknown result	1,185	182	28	6,045	1,367 ( 18.37% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,661	287	33	9,461	1,948 ( 17.02% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	334	70	2	0	404 ( 99.51% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	162	35	7	994	197 ( 16.44% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	277	39	12	1,423	316 ( 18.05% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	55	6	0	0	61 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	602	54	0	0	656 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,004	227	2	0	1,231 ( 99.84% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	11,442 ( 100.0% )	85.27% ( 83.61% , 86.81% )	95.35% ( 94.25% , 96.29% )
Inpatient	427 ( 3.73% )	91.33% ( 88.19% , 93.85% )	98.70% ( 96.99% , 99.58% )
Outpatient or Emergency Department	496 ( 4.33% )	89.23% ( 86.15% , 91.83% )	97.34% ( 95.40% , 98.62% )
Other	66 ( 0.58% )	76.56% ( 64.31% , 86.25% )	92.45% ( 81.79% , 97.91% )
Care Setting Reported as Unknown	4,056 ( 35.45% )	81.27% ( 78.68% , 83.67% )	*****
<b>Demographics</b>			
Sex			
Female	5,267 ( 46.03% )	84.70% ( 82.07% , 87.08% )	94.87% ( 93.03% , 96.35% )
Male	6,175 ( 53.97% )	85.69% ( 83.50% , 87.69% )	95.70% ( 94.26% , 96.87% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	15 ( 0.13% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
6-17	34 ( 0.30% )	83.33% ( 35.88% , 99.58% )	83.33% ( 35.88% , 99.58% )
18-29	235 ( 2.05% )	82.22% ( 67.95% , 92 % )	84.09% ( 69.93% , 93.36% )
30-39	491 ( 4.29% )	88.29% ( 80.81% , 93.61% )	91.59% ( 84.63% , 96.08% )
40-49	887 ( 7.75% )	91.79% ( 87.02% , 95.24% )	99.44% ( 96.94% , 99.99% )
50-59	1,866 ( 16.31% )	88.33% ( 84.87% , 91.24% )	97.38% ( 95.23% , 98.73% )
60-69	2,542 ( 22.22% )	86.85% ( 83.63% , 89.64% )	96.98% ( 94.98% , 98.34% )
70-79	2,465 ( 21.54% )	81.03% ( 76.51% , 85.02% )	92.76% ( 89.25% , 95.41% )
80-89	2,072 ( 18.11% )	80.91% ( 75.08% , 85.88% )	92.71% ( 88.07% , 95.96% )
90+	835 ( 7.30% )	71.76% ( 60.96% , 81 % )	95.31% ( 86.91% , 99.02% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	2 ( 0.02% )	N/A	N/A
Asian	48 ( 0.42% )	100.0% ( 59.04% , 100.0% )	100.0% ( 59.04% , 100.0% )
Black or African American	895 ( 7.82% )	80.23% ( 70.25% , 88.04% )	89.61% ( 80.55% , 95.41% )
Native Hawaiian or Other Pacific Islander	1 ( 0.01% )	N/A	N/A
White	1,605 ( 14.03% )	74.74% ( 67.94% , 80.75% )	86.59% ( 80.40% , 91.40% )
Other/Mixed/Unknown	8,891 ( 77.70% )	86.67% ( 84.94% , 88.26% )	96.59% ( 95.54% , 97.45% )
Ethnicity			



**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	72 ( 0.63% )	77.78% ( 39.99% , 97.19% )	87.50% ( 47.35% , 99.68% )
Non-Hispanic	N/A	N/A	N/A
Unknown	11,370 ( 99.37% )	85.30% ( 83.65% , 86.85% )	95.39% ( 94.29% , 96.33% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	146 ( 1.28% )	38.10% ( 18.11% , 61.56% )	80 % ( 44.39% , 97.48% )
Contact and suspected exposure (Z20.828)	2,263 ( 19.78% )	79.59% ( 75.22% , 83.49% )	97.78% ( 95.48% , 99.10% )
Pneumonia (see Appendix B)	9,014 ( 78.78% )	87.12% ( 85.41% , 88.70% )	98.02% ( 97.17% , 98.67% )
Other viral pneumonia (J12.89)	7,430 ( 64.94% )	90.71% ( 89.10% , 92.15% )	99.32% ( 98.72% , 99.69% )
ARDS (J80)	1,420 ( 12.41% )	89.81% ( 85.52% , 93.18% )	99.17% ( 97.02% , 99.90% )
Sepsis (see Appendix C)	3,396 ( 29.68% )	85.26% ( 82.23% , 87.95% )	96.55% ( 94.67% , 97.91% )
Bronchitis (J20.8 OR J40)	126 ( 1.10% )	94.74% ( 73.97% , 99.87% )	90 % ( 68.30% , 98.77% )
Respiratory infection (J22 OR J98.8)	1,277 ( 11.16% )	90.59% ( 85.70% , 94.24% )	*****
Cough (R05)	2,413 ( 21.09% )	89.85% ( 86.77% , 92.42% )	98.38% ( 96.69% , 99.35% )
Shortness of breath (R06.2)	70 ( 0.61% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	2,969 ( 25.95% )	84.97% ( 81.77% , 87.79% )	97.98% ( 96.32% , 99.03% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	493 ( 4.31% )	91.28% ( 86.41% , 94.84% )	*****
Test performed, only negative results	76 ( 0.66% )	50 % ( 26.02% , 73.98% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	7,440 ( 65.02% )	86.69% ( 84.77% , 88.44% )	93.90% ( 92.43% , 95.16% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	11,442 ( 100.0% )	85.27% ( 83.61% , 86.81% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	406 ( 3.55% )	82.67% ( 78.62% , 86.24% )	92.52% ( 89.30% , 95.01% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,198 ( 10.47% )	82.23% ( 76.17% , 87.30% )	97.59% ( 93.95% , 99.34% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,751 ( 15.30% )	87.66% ( 83.52% , 91.07% )	*****
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	61 ( 0.53% )	90.16% ( 79.81% , 96.30% )	96.49% ( 87.89% , 99.57% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	656 ( 5.73% )	91.77% ( 89.40% , 93.76% )	97.89% ( 96.41% , 98.87% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,233 ( 10.78% )	81.56% ( 79.28% , 83.69% )	93.83% ( 92.22% , 95.20% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,439	209	30	7,334	1,648 ( 18.29% )
Inpatient	334	18	12	N/A	352
Outpatient or Emergency Department	388	41	3	N/A	429
Other	46	11	1	N/A	57
Care Setting Reported as Unknown	671	139	14	N/A	810
<b>Demographics</b>					
Sex					
Female	572	81	12	3,299	653 ( 16.47% )
Male	867	128	18	4,035	995 ( 19.71% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	2	0	0	12	2 ( 14.29% )
18-29	25	6	1	115	31 ( 21.09% )
30-39	73	6	4	259	79 ( 23.10% )
40-49	156	11	1	567	167 ( 22.72% )
50-59	335	34	8	1,193	369 ( 23.50% )
60-69	397	54	8	1,632	451 ( 21.57% )
70-79	246	50	3	1,641	296 ( 15.26% )
80-89	153	32	3	1,375	185 ( 11.84% )
90+	52	16	2	537	68 ( 11.20% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	2	0 (0.00%)
Asian	6	0	0	29	6 ( 17.14% )
Black or African American	57	15	1	584	72 ( 10.96% )
Native Hawaiian or Other Pacific Islander	0	0	0	1	0 (0.00%)
White	108	37	0	998	145 ( 12.69% )
Other/Mixed/Unknown	1,268	157	29	5,720	1,425 ( 19.86% )
Ethnicity					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	7	2	0	49	9 ( 15.52% )
Non-Hispanic	0	0	0	0	N/A
Unknown	1,432	207	30	7,285	1,639 ( 18.30% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	5	8	0	91	13 ( 12.50% )
Contact and suspected exposure (Z20.828)	287	57	13	1,565	344 ( 17.90% )
Pneumonia (see Appendix B)	1,432	204	30	7,271	1,636 ( 18.31% )
Other viral pneumonia (J12.89)	1,321	136	28	5,979	1,457 ( 19.52% )
ARDS (J80)	240	27	6	1,157	267 ( 18.67% )
Sepsis (see Appendix C)	510	72	10	2,466	582 ( 19.03% )
Bronchitis (J20.8 OR J40)	13	0	0	79	13 ( 14.13% )
Respiratory infection (J22 OR J98.8)	165	16	3	868	181 ( 17.21% )
Cough (R05)	387	39	7	1,625	426 ( 20.70% )
Shortness of breath (R06.2)	6	2	0	53	8 ( 13.11% )
Fever (R50.9)	456	62	9	2,016	518 ( 20.37% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	154	14	3	261	168 ( 38.89% )
Test performed, only negative results	9	7	1	38	16 ( 29.09% )
No test or unknown result	1,048	126	25	4,843	1,174 ( 19.43% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	1,439	209	30	7,334	1,648 ( 18.29% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	276	46	1	0	322 ( 99.69% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	154	24	7	848	178 ( 17.23% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	275	37	12	1,382	312 ( 18.29% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	52	6	0	0	58 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	534	35	0	0	569 ( 100.0% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	853	168	2	0	1,021 ( 99.80% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	0	0	0	0	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	9,012 ( 100.0% )	87.32% ( 85.61% , 88.89% )	82.61% ( 80.74% , 84.36% )
Inpatient	364 ( 4.04% )	94.89% ( 92.04% , 96.94% )	86.98% ( 83.20% , 90.18% )
Outpatient or Emergency Department	432 ( 4.79% )	90.44% ( 87.26% , 93.05% )	86.03% ( 82.48% , 89.10% )
Other	58 ( 0.64% )	80.70% ( 68.09% , 89.95% )	86.79% ( 74.66% , 94.52% )
Care Setting Reported as Unknown	3,016 ( 33.47% )	82.84% ( 80.06% , 85.37% )	*****
<b>Demographics</b>			
<b>Sex</b>			
Female	3,964 ( 43.99% )	87.60% ( 84.82% , 90.03% )	77.19% ( 74% , 80.17% )
Male	5,048 ( 56.01% )	87.14% ( 84.89% , 89.15% )	86.61% ( 84.35% , 88.66% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	3 ( 0.03% )	N/A	N/A
6-17	14 ( 0.16% )	100.0% ( 15.81% , 100.0% )	33.33% ( 4.33% , 77.72% )
18-29	147 ( 1.63% )	80.65% ( 62.53% , 92.55% )	56.82% ( 41.03% , 71.65% )
30-39	342 ( 3.79% )	92.41% ( 84.20% , 97.16% )	68.22% ( 58.52% , 76.89% )
40-49	735 ( 8.16% )	93.41% ( 88.52% , 96.67% )	86.67% ( 80.81% , 91.27% )
50-59	1,570 ( 17.42% )	90.79% ( 87.36% , 93.53% )	87.93% ( 84.23% , 91.02% )
60-69	2,091 ( 23.20% )	88.03% ( 84.67% , 90.88% )	85.75% ( 82.22% , 88.80% )
70-79	1,940 ( 21.53% )	83.11% ( 78.34% , 87.19% )	80.92% ( 76.05% , 85.18% )
80-89	1,563 ( 17.34% )	82.70% ( 76.47% , 87.86% )	79.69% ( 73.30% , 85.14% )
90+	607 ( 6.74% )	76.47% ( 64.62% , 85.91% )	81.25% ( 69.54% , 89.92% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	2 ( 0.02% )	N/A	N/A
Asian	35 ( 0.39% )	100.0% ( 54.07% , 100.0% )	85.71% ( 42.13% , 99.64% )
Black or African American	657 ( 7.29% )	79.17% ( 67.98% , 87.84% )	74.03% ( 62.77% , 83.36% )
Native Hawaiian or Other Pacific Islander	1 ( 0.01% )	N/A	N/A
White	1,143 ( 12.68% )	74.48% ( 66.58% , 81.35% )	65.85% ( 58.05% , 73.07% )
Other/Mixed/Unknown	7,174 ( 79.60% )	88.98% ( 87.24% , 90.56% )	84.87% ( 82.95% , 86.65% )
<b>Ethnicity</b>			



**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Hispanic	58 ( 0.64% )	77.78% ( 39.99% , 97.19% )	87.50% ( 47.35% , 99.68% )
Non-Hispanic	N/A	N/A	N/A
Unknown	8,954 ( 99.36% )	87.37% ( 85.66% , 88.94% )	82.58% ( 80.72% , 84.34% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	104 ( 1.15% )	38.46% ( 13.86% , 68.42% )	50 % ( 18.71% , 81.29% )
Contact and suspected exposure (Z20.828)	1,922 ( 21.33% )	83.43% ( 79.07% , 87.20% )	91.11% ( 87.41% , 94.01% )
Pneumonia (see Appendix B)	8,937 ( 99.17% )	87.53% ( 85.83% , 89.09% )	97.88% ( 97.01% , 98.56% )
Other viral pneumonia (J12.89)	7,464 ( 82.82% )	90.67% ( 89.05% , 92.11% )	99.55% ( 99.02% , 99.83% )
ARDS (J80)	1,430 ( 15.87% )	89.89% ( 85.63% , 93.23% )	100.0% ( 98.47% , 100.0% )
Sepsis (see Appendix C)	3,058 ( 33.93% )	87.63% ( 84.68% , 90.19% )	92.56% ( 90.04% , 94.61% )
Bronchitis (J20.8 OR J40)	92 ( 1.02% )	100.0% ( 75.29% , 100.0% )	65 % ( 40.78% , 84.61% )
Respiratory infection (J22 OR J98.8)	1,052 ( 11.67% )	91.16% ( 86.04% , 94.86% )	91.16% ( 86.04% , 94.86% )
Cough (R05)	2,058 ( 22.84% )	90.85% ( 87.70% , 93.41% )	89.58% ( 86.31% , 92.30% )
Shortness of breath (R06.2)	61 ( 0.68% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	2,543 ( 28.22% )	88.03% ( 84.92% , 90.70% )	91.94% ( 89.18% , 94.18% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	432 ( 4.79% )	91.67% ( 86.41% , 95.37% )	*****
Test performed, only negative results	55 ( 0.61% )	56.25% ( 29.88% , 80.25% )	100.0% ( 66.37% , 100.0% )
No test or unknown result	6,042 ( 67.04% )	89.27% ( 87.35% , 90.98% )	83.04% ( 80.86% , 85.07% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	9,012 ( 100.0% )	87.32% ( 85.61% , 88.89% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	323 ( 3.58% )	85.71% ( 81.41% , 89.35% )	76.45% ( 71.73% , 80.74% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,033 ( 11.46% )	86.52% ( 80.61% , 91.17% )	92.77% ( 87.71% , 96.21% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	1,706 ( 18.93% )	88.14% ( 84.03% , 91.51% )	100.0% ( 98.67% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	58 ( 0.64% )	89.66% ( 78.83% , 96.11% )	91.23% ( 80.70% , 97.09% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	569 ( 6.31% )	93.85% ( 91.55% , 95.68% )	86.83% ( 83.90% , 89.40% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,023 ( 11.35% )	83.55% ( 81.13% , 85.77% )	79.72% ( 77.18% , 82.09% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1e. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between April 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINCs or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Tes*****</b>				
Total Observed	2,241	3,663	25,192	47,974
Inpatient	194	0	3,958	0
Outpatient or Emergency Department	1,069	0	5,102	0
Other	59	0	985	0
Care Setting Reported as Unknown	247	2,987	6,009	38,832
<b>Demographics</b>				
Sex				
Female	1,004	1,751	14,268	26,837
Male	1,237	1,912	10,924	21,137
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	4	13	165	359
6-17	11	32	412	825
18-29	115	334	1,675	3,910
30-39	199	408	2,899	5,988
40-49	308	530	1,882	4,617
50-59	495	820	3,218	7,991
60-69	498	749	5,065	9,747
70-79	359	465	5,573	8,325
80-89	189	237	3,347	4,802
90+	63	75	956	1,410
Missing	0	0	0	0
Race				
American Indian or Alaska Native	4	4	11	11
Asian	7	7	59	59
Black or African American	99	99	736	737
Native Hawaiian or Other Pacific Islander	0	0	0	0
White	394	398	6,312	6,314
Other/Mixed/Unknown	1,737	3,155	18,075	40,853
Ethnicity				

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	20	20	96	96
Non-Hispanic	1	1	0	0
Unknown	2,220	3,642	25,096	47,878
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	40	149	2,033	4,520
Contact and suspected exposure (Z20.828)	317	486	2,474	5,888
Pneumonia (see Appendix B)	1,685	2,184	3,090	6,719
Other viral pneumonia (J12.89)	1,418	1,823	398	1,657
ARDS (J80)	174	242	125	437
Sepsis (see Appendix C)	510	790	1,923	5,177
Bronchitis (J20.8 OR J40)	25	41	47	130
Respiratory infection (J22 OR J98.8)	117	159	68	267
Cough (R05)	351	485	836	2,275
Shortness of breath (R06.2)	6	10	77	267
Fever (R50.9)	429	662	1,645	4,440
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	58	0	58	0
Test performed, only negative results	13	0	417	0
No test or unknown result	1,498	2,987	15,579	38,832
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	1	0	0	0
Test performed, only negative results	1	0	26	0
No test or unknown result	1,567	2,987	16,028	38,832
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,486	433	10,950	5,228
<b>Codes Observed During Inpatient Stay</b>				
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	153	225	763	1,883

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	245	323	152	607
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	36	305	534
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	1
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	1
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	280	600	7,031	15,096
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	1	2
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	1	5	15
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,944	3,005	17,321	31,649
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	2	92	94
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	5	205	268
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	3	49	53
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7	11	160	238
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	1	1
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	2	2
Unknown	0	0	0	0

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,086	878	27	19,676	2,964 ( 13.08% )
Inpatient	189	59	4	N/A	248
Outpatient or Emergency Department	1,021	288	11	N/A	1,309
Other	59	30	5	N/A	89
Care Setting Reported as Unknown	817	501	7	N/A	1,318
<b>Demographics</b>					
Sex					
Female	922	443	9	9,593	1,365 ( 12.45% )
Male	1,164	435	18	10,083	1,599 ( 13.67% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	3	4	0	73	7 ( 8.75% )
6-17	10	4	1	125	14 ( 10% )
18-29	109	63	1	855	172 ( 16.73% )
30-39	185	72	3	1,238	257 ( 17.16% )
40-49	291	92	1	1,990	383 ( 16.13% )
50-59	476	141	4	3,242	617 ( 15.97% )
60-69	472	165	8	4,018	637 ( 13.66% )
70-79	323	181	5	3,917	504 ( 11.39% )
80-89	165	116	3	3,020	281 ( 8.50% )
90+	52	40	1	1,198	92 ( 7.13% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	4	0	0	13	4 ( 23.53% )
Asian	6	6	0	42	12 ( 22.22% )
Black or African American	94	40	0	994	134 ( 11.88% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	339	201	0	2,752	540 ( 16.40% )
Other/Mixed/Unknown	1,643	631	27	15,875	2,274 ( 12.51% )
Ethnicity					



**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	20	3	0	100	23 ( 18.70% )
Non-Hispanic	1	0	0	1	1 ( 50% )
Unknown	2,065	875	27	19,575	2,940 ( 13.04% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	30	28	1	390	58 ( 12.92% )
Contact and suspected exposure (Z20.828)	283	172	6	3,267	455 ( 12.20% )
Pneumonia (see Appendix B)	1,634	537	21	13,327	2,171 ( 13.99% )
Other viral pneumonia (J12.89)	1,409	347	20	10,682	1,756 ( 14.10% )
ARDS (J80)	162	40	3	1,340	202 ( 13.07% )
Sepsis (see Appendix C)	481	215	6	4,633	696 ( 13.05% )
Bronchitis (J20.8 OR J40)	24	7	0	211	31 ( 12.81% )
Respiratory infection (J22 OR J98.8)	113	32	1	958	145 ( 13.13% )
Cough (R05)	341	118	3	2,699	459 ( 14.52% )
Shortness of breath (R06.2)	6	2	0	80	8 ( 9.09% )
Fever (R50.9)	408	188	5	3,406	596 ( 14.87% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	71	25	0	228	96 ( 29.63% )
Test performed, only negative results	15	15	0	90	30 ( 25% )
No test or unknown result	1,403	519	26	14,064	1,922 ( 12% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	2,079	877	27	19,673	2,956 ( 13.05% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,416	444	11	0	1,860 ( 99.41% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	141	89	2	1,407	230 ( 14.03% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	228	89	5	2,068	317 ( 13.26% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	256	85	5	0	341 ( 98.55% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,814	784	3	0	2,598 ( 99.88% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	0	0	0	0	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
<b>Number (Percent)</b>			
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	22,667 ( 100.0% )	70.38% ( 68.70% , 72.02% )	93.08% ( 91.95% , 94.10% )
Inpatient	252 ( 1.11% )	76.21% ( 70.41% , 81.37% )	97.42% ( 94.09% , 99.16% )
Outpatient or Emergency Department	1,320 ( 5.82% )	78 % ( 75.65% , 80.22% )	95.51% ( 94.09% , 96.67% )
Other	94 ( 0.41% )	66.29% ( 55.49% , 75.97% )	100.0% ( 93.94% , 100.0% )
Care Setting Reported as Unknown	6,619 ( 29.20% )	61.99% ( 59.30% , 64.62% )	*****
<b>Demographics</b>			
Sex			
Female	10,967 ( 48.38% )	67.55% ( 64.99% , 70.03% )	91.83% ( 89.96% , 93.45% )
Male	11,700 ( 51.62% )	72.80% ( 70.54% , 74.96% )	94.10% ( 92.64% , 95.35% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	80 ( 0.35% )	42.86% ( 9.90% , 81.59% )	75 % ( 19.41% , 99.37% )
6-17	140 ( 0.62% )	71.43% ( 41.90% , 91.61% )	90.91% ( 58.72% , 99.77% )
18-29	1,028 ( 4.54% )	63.37% ( 55.70% , 70.57% )	94.78% ( 88.99% , 98.06% )
30-39	1,498 ( 6.61% )	71.98% ( 66.07% , 77.39% )	92.96% ( 88.48% , 96.10% )
40-49	2,374 ( 10.47% )	75.98% ( 71.38% , 80.17% )	94.48% ( 91.31% , 96.75% )
50-59	3,863 ( 17.04% )	77.15% ( 73.63% , 80.41% )	96.16% ( 94.07% , 97.67% )
60-69	4,663 ( 20.57% )	74.10% ( 70.51% , 77.46% )	94.78% ( 92.44% , 96.56% )
70-79	4,426 ( 19.53% )	64.09% ( 59.73% , 68.28% )	89.97% ( 86.39% , 92.88% )
80-89	3,304 ( 14.58% )	58.72% ( 52.72% , 64.53% )	87.30% ( 81.70% , 91.69% )
90+	1,291 ( 5.70% )	56.52% ( 45.78% , 66.83% )	82.54% ( 70.90% , 90.95% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	17 ( 0.07% )	100.0% ( 39.76% , 100.0% )	100.0% ( 39.76% , 100.0% )
Asian	54 ( 0.24% )	50 % ( 21.09% , 78.91% )	85.71% ( 42.13% , 99.64% )
Black or African American	1,128 ( 4.98% )	70.15% ( 61.64% , 77.74% )	94.95% ( 88.61% , 98.34% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	3,292 ( 14.52% )	62.78% ( 58.55% , 66.87% )	86.04% ( 82.22% , 89.31% )
Other/Mixed/Unknown	18,176 ( 80.19% )	72.25% ( 70.36% , 74.08% )	94.59% ( 93.42% , 95.61% )
Ethnicity			

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
Hispanic	123 ( 0.54% )	86.96% ( 66.41% , 97.22% )	100.0% ( 83.16% , 100.0% )
Non-Hispanic	2 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Unknown	22,542 ( 99.45% )	70.24% ( 68.55% , 71.89% )	93.02% ( 91.88% , 94.04% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	449 ( 1.98% )	51.72% ( 38.22% , 65.05% )	75 % ( 58.80% , 87.31% )
Contact and suspected exposure (Z20.828)	3,728 ( 16.45% )	62.20% ( 57.56% , 66.67% )	89.27% ( 85.34% , 92.46% )
Pneumonia (see Appendix B)	15,519 ( 68.47% )	75.26% ( 73.39% , 77.07% )	96.97% ( 96.04% , 97.74% )
Other viral pneumonia (J12.89)	12,458 ( 54.96% )	80.24% ( 78.30% , 82.08% )	99.37% ( 98.80% , 99.71% )
ARDS (J80)	1,545 ( 6.82% )	80.20% ( 74.03% , 85.46% )	93.10% ( 88.26% , 96.39% )
Sepsis (see Appendix C)	5,335 ( 23.54% )	69.11% ( 65.53% , 72.53% )	94.31% ( 91.94% , 96.16% )
Bronchitis (J20.8 OR J40)	242 ( 1.07% )	77.42% ( 58.90% , 90.41% )	96 % ( 79.65% , 99.90% )
Respiratory infection (J22 OR J98.8)	1,104 ( 4.87% )	77.93% ( 70.30% , 84.39% )	96.58% ( 91.48% , 99.06% )
Cough (R05)	3,161 ( 13.95% )	74.29% ( 70.04% , 78.23% )	97.15% ( 94.82% , 98.63% )
Shortness of breath (R06.2)	88 ( 0.39% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	4,007 ( 17.68% )	68.46% ( 64.56% , 72.17% )	95.10% ( 92.61% , 96.94% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	324 ( 1.43% )	73.96% ( 64 % , 82.38% )	*****
Test performed, only negative results	120 ( 0.53% )	50 % ( 31.30% , 68.70% )	*****
No test or unknown result	16,012 ( 70.64% )	73 % ( 70.95% , 74.97% )	93.66% ( 92.30% , 94.84% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.03% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	22,656 ( 99.95% )	70.33% ( 68.65% , 71.97% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,871 ( 8.25% )	76.13% ( 74.12% , 78.05% )	95.29% ( 94.09% , 96.31% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,639 ( 7.23% )	61.30% ( 54.68% , 67.63% )	92.16% ( 86.70% , 95.88% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,390 ( 10.54% )	71.92% ( 66.63% , 76.80% )	93.06% ( 89.12% , 95.91% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	346 ( 1.53% )	75.07% ( 70.13% , 79.58% )	91.43% ( 87.51% , 94.43% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,601 ( 11.47% )	69.82% ( 68.02% , 71.58% )	93.31% ( 92.11% , 94.38% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
		<b>Number (Percent)</b>	
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.03% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,089	887	27	19,837	2,976 ( 13.03% )
Inpatient	189	63	4	N/A	252
Outpatient or Emergency Department	1,024	288	11	N/A	1,312
Other	59	30	5	N/A	89
Care Setting Reported as Unknown	817	506	7	N/A	1,323
<b>Demographics</b>					
Sex					
Female	924	448	9	9,683	1,372 ( 12.40% )
Male	1,165	439	18	10,154	1,604 ( 13.62% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	3	4	0	73	7 ( 8.75% )
6-17	10	5	1	130	15 ( 10.27% )
18-29	109	64	1	879	173 ( 16.43% )
30-39	186	72	3	1,254	258 ( 17.03% )
40-49	291	92	1	2,013	383 ( 15.98% )
50-59	476	143	4	3,266	619 ( 15.92% )
60-69	472	167	8	4,044	639 ( 13.62% )
70-79	325	181	5	3,937	506 ( 11.38% )
80-89	165	118	3	3,035	283 ( 8.52% )
90+	52	41	1	1,206	93 ( 7.15% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	4	0	0	13	4 ( 23.53% )
Asian	6	6	0	42	12 ( 22.22% )
Black or African American	94	40	0	995	134 ( 11.87% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	339	202	0	2,762	541 ( 16.38% )
Other/Mixed/Unknown	1,646	639	27	16,025	2,285 ( 12.46% )
Ethnicity					



**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	20	3	0	100	23 ( 18.70% )
Non-Hispanic	1	0	0	1	1 ( 50% )
Unknown	2,068	884	27	19,736	2,952 ( 13% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	30	29	1	399	59 ( 12.85% )
Contact and suspected exposure (Z20.828)	283	175	6	3,324	458 ( 12.09% )
Pneumonia (see Appendix B)	1,634	539	21	13,384	2,173 ( 13.95% )
Other viral pneumonia (J12.89)	1,409	347	20	10,708	1,756 ( 14.07% )
ARDS (J80)	162	40	3	1,341	202 ( 13.07% )
Sepsis (see Appendix C)	481	215	6	4,671	696 ( 12.95% )
Bronchitis (J20.8 OR J40)	24	7	0	213	31 ( 12.70% )
Respiratory infection (J22 OR J98.8)	113	32	1	959	145 ( 13.12% )
Cough (R05)	341	119	3	2,719	460 ( 14.46% )
Shortness of breath (R06.2)	6	2	0	80	8 ( 9.09% )
Fever (R50.9)	408	191	5	3,433	599 ( 14.84% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	71	25	0	228	96 ( 29.63% )
Test performed, only negative results	15	15	0	91	30 ( 24.79% )
No test or unknown result	1,406	526	26	14,212	1,932 ( 11.95% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	2,082	886	27	19,834	2,968 ( 13% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,419	449	11	0	1,868 ( 99.41% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	141	90	2	1,426	231 ( 13.92% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	228	89	5	2,084	317 ( 13.18% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	256	87	6	0	343 ( 98.28% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,817	791	3	0	2,608 ( 99.89% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	0	0	0	0	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	22,840 ( 100.0% )	70.19% ( 68.52% , 71.83% )	93.22% ( 92.10% , 94.22% )
Inpatient	256 ( 1.12% )	75 % ( 69.18% , 80.22% )	97.42% ( 94.09% , 99.16% )
Outpatient or Emergency Department	1,323 ( 5.79% )	78.05% ( 75.71% , 80.26% )	95.79% ( 94.41% , 96.91% )
Other	94 ( 0.41% )	66.29% ( 55.49% , 75.97% )	100.0% ( 93.94% , 100.0% )
Care Setting Reported as Unknown	6,636 ( 29.05% )	61.75% ( 59.07% , 64.38% )	*****
<b>Demographics</b>			
Sex			
Female	11,064 ( 48.44% )	67.35% ( 64.79% , 69.83% )	92.03% ( 90.18% , 93.63% )
Male	11,776 ( 51.56% )	72.63% ( 70.38% , 74.80% )	94.18% ( 92.73% , 95.42% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	80 ( 0.35% )	42.86% ( 9.90% , 81.59% )	75 % ( 19.41% , 99.37% )
6-17	146 ( 0.64% )	66.67% ( 38.38% , 88.18% )	90.91% ( 58.72% , 99.77% )
18-29	1,053 ( 4.61% )	63.01% ( 55.35% , 70.21% )	94.78% ( 88.99% , 98.06% )
30-39	1,515 ( 6.63% )	72.09% ( 66.19% , 77.48% )	93.47% ( 89.09% , 96.48% )
40-49	2,397 ( 10.49% )	75.98% ( 71.38% , 80.17% )	94.48% ( 91.31% , 96.75% )
50-59	3,889 ( 17.03% )	76.90% ( 73.37% , 80.16% )	96.16% ( 94.07% , 97.67% )
60-69	4,691 ( 20.54% )	73.87% ( 70.28% , 77.23% )	94.78% ( 92.44% , 96.56% )
70-79	4,448 ( 19.47% )	64.23% ( 59.88% , 68.41% )	90.53% ( 87.02% , 93.35% )
80-89	3,321 ( 14.54% )	58.30% ( 52.32% , 64.11% )	87.30% ( 81.70% , 91.69% )
90+	1,300 ( 5.69% )	55.91% ( 45.24% , 66.20% )	82.54% ( 70.90% , 90.95% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	17 ( 0.07% )	100.0% ( 39.76% , 100.0% )	100.0% ( 39.76% , 100.0% )
Asian	54 ( 0.24% )	50 % ( 21.09% , 78.91% )	85.71% ( 42.13% , 99.64% )
Black or African American	1,129 ( 4.94% )	70.15% ( 61.64% , 77.74% )	94.95% ( 88.61% , 98.34% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	3,303 ( 14.46% )	62.66% ( 58.43% , 66.75% )	86.04% ( 82.22% , 89.31% )
Other/Mixed/Unknown	18,337 ( 80.28% )	72.04% ( 70.15% , 73.87% )	94.76% ( 93.61% , 95.76% )
Ethnicity			

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	123 ( 0.54% )	86.96% ( 66.41% , 97.22% )	100.0% ( 83.16% , 100.0% )
Non-Hispanic	2 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Unknown	22,715 ( 99.45% )	70.05% ( 68.37% , 71.70% )	93.15% ( 92.02% , 94.17% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	459 ( 2.01% )	50.85% ( 37.50% , 64.11% )	75 % ( 58.80% , 87.31% )
Contact and suspected exposure (Z20.828)	3,788 ( 16.58% )	61.79% ( 57.17% , 66.26% )	89.27% ( 85.34% , 92.46% )
Pneumonia (see Appendix B)	15,578 ( 68.20% )	75.20% ( 73.32% , 77 % )	96.97% ( 96.04% , 97.74% )
Other viral pneumonia (J12.89)	12,484 ( 54.66% )	80.24% ( 78.30% , 82.08% )	99.37% ( 98.80% , 99.71% )
ARDS (J80)	1,546 ( 6.77% )	80.20% ( 74.03% , 85.46% )	93.10% ( 88.26% , 96.39% )
Sepsis (see Appendix C)	5,373 ( 23.52% )	69.11% ( 65.53% , 72.53% )	94.31% ( 91.94% , 96.16% )
Bronchitis (J20.8 OR J40)	244 ( 1.07% )	77.42% ( 58.90% , 90.41% )	96 % ( 79.65% , 99.90% )
Respiratory infection (J22 OR J98.8)	1,105 ( 4.84% )	77.93% ( 70.30% , 84.39% )	96.58% ( 91.48% , 99.06% )
Cough (R05)	3,182 ( 13.93% )	74.13% ( 69.87% , 78.07% )	97.15% ( 94.82% , 98.63% )
Shortness of breath (R06.2)	88 ( 0.39% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	4,037 ( 17.68% )	68.11% ( 64.22% , 71.83% )	95.10% ( 92.61% , 96.94% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	324 ( 1.42% )	73.96% ( 64 % , 82.38% )	*****
Test performed, only negative results	121 ( 0.53% )	50 % ( 31.30% , 68.70% )	*****
No test or unknown result	16,170 ( 70.80% )	72.77% ( 70.73% , 74.75% )	93.86% ( 92.52% , 95.02% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.03% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	22,829 ( 99.95% )	70.15% ( 68.47% , 71.79% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,879 ( 8.23% )	75.96% ( 73.96% , 77.89% )	95.49% ( 94.31% , 96.49% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,659 ( 7.26% )	61.04% ( 54.42% , 67.37% )	92.16% ( 86.70% , 95.88% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,406 ( 10.53% )	71.92% ( 66.63% , 76.80% )	93.06% ( 89.12% , 95.91% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	349 ( 1.53% )	74.64% ( 69.68% , 79.16% )	91.43% ( 87.51% , 94.43% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,611 ( 11.43% )	69.67% ( 67.87% , 71.43% )	93.47% ( 92.28% , 94.53% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.03% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,092	904	27	19,968	2,996 ( 13.03% )
Inpatient	189	66	4	N/A	255
Outpatient or Emergency Department	1,025	288	11	N/A	1,313
Other	59	34	5	N/A	93
Care Setting Reported as Unknown	819	516	7	N/A	1,335
<b>Demographics</b>					
Sex					
Female	925	457	9	9,735	1,382 ( 12.42% )
Male	1,167	447	18	10,233	1,614 ( 13.60% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	3	4	0	74	7 ( 8.64% )
6-17	10	5	1	133	15 ( 10.07% )
18-29	109	64	1	884	173 ( 16.35% )
30-39	187	73	3	1,259	260 ( 17.08% )
40-49	291	93	1	2,021	384 ( 15.96% )
50-59	476	144	4	3,288	620 ( 15.85% )
60-69	472	172	8	4,066	644 ( 13.65% )
70-79	327	187	5	3,969	514 ( 11.45% )
80-89	165	121	3	3,059	286 ( 8.54% )
90+	52	41	1	1,215	93 ( 7.10% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	4	0	0	13	4 ( 23.53% )
Asian	6	6	0	43	12 ( 21.82% )
Black or African American	95	41	0	1,005	136 ( 11.92% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	339	207	0	2,781	546 ( 16.41% )
Other/Mixed/Unknown	1,648	650	27	16,126	2,298 ( 12.45% )
Ethnicity					



**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	20	3	0	101	23 ( 18.55% )
Non-Hispanic	1	0	0	1	1 ( 50% )
Unknown	2,071	901	27	19,866	2,972 ( 13% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	30	30	1	404	60 ( 12.90% )
Contact and suspected exposure (Z20.828)	284	179	6	3,350	463 ( 12.12% )
Pneumonia (see Appendix B)	1,637	547	21	13,434	2,184 ( 13.97% )
Other viral pneumonia (J12.89)	1,409	348	20	10,711	1,757 ( 14.07% )
ARDS (J80)	162	40	3	1,343	202 ( 13.05% )
Sepsis (see Appendix C)	481	220	6	4,698	701 ( 12.97% )
Bronchitis (J20.8 OR J40)	24	7	0	213	31 ( 12.70% )
Respiratory infection (J22 OR J98.8)	113	32	1	960	145 ( 13.11% )
Cough (R05)	342	122	3	2,736	464 ( 14.49% )
Shortness of breath (R06.2)	6	2	0	80	8 ( 9.09% )
Fever (R50.9)	409	196	5	3,457	605 ( 14.88% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	71	25	0	228	96 ( 29.63% )
Test performed, only negative results	15	15	0	92	30 ( 24.59% )
No test or unknown result	1,407	535	26	14,304	1,942 ( 11.93% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	2,085	903	27	19,965	2,988 ( 13% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,421	456	11	0	1,877 ( 99.42% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	142	91	2	1,440	233 ( 13.91% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	228	90	5	2,086	318 ( 13.20% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	256	92	6	0	348 ( 98.31% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,820	803	3	0	2,623 ( 99.89% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	0	0	0	0	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	22,991 ( 100.0% )	69.83% ( 68.15% , 71.47% )	93.35% ( 92.24% , 94.35% )
Inpatient	259 ( 1.13% )	74.12% ( 68.28% , 79.38% )	97.42% ( 94.09% , 99.16% )
Outpatient or Emergency Department	1,324 ( 5.76% )	78.07% ( 75.73% , 80.28% )	95.88% ( 94.51% , 96.99% )
Other	98 ( 0.43% )	63.44% ( 52.81% , 73.19% )	100.0% ( 93.94% , 100.0% )
Care Setting Reported as Unknown	6,686 ( 29.08% )	61.35% ( 58.68% , 63.97% )	*****
<b>Demographics</b>			
Sex			
Female	11,126 ( 48.39% )	66.93% ( 64.38% , 69.41% )	92.13% ( 90.29% , 93.72% )
Male	11,865 ( 51.61% )	72.30% ( 70.05% , 74.48% )	94.34% ( 92.90% , 95.56% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	81 ( 0.35% )	42.86% ( 9.90% , 81.59% )	75 % ( 19.41% , 99.37% )
6-17	149 ( 0.65% )	66.67% ( 38.38% , 88.18% )	90.91% ( 58.72% , 99.77% )
18-29	1,058 ( 4.60% )	63.01% ( 55.35% , 70.21% )	94.78% ( 88.99% , 98.06% )
30-39	1,522 ( 6.62% )	71.92% ( 66.04% , 77.30% )	93.97% ( 89.70% , 96.85% )
40-49	2,406 ( 10.46% )	75.78% ( 71.18% , 79.98% )	94.48% ( 91.31% , 96.75% )
50-59	3,912 ( 17.02% )	76.77% ( 73.25% , 80.04% )	96.16% ( 94.07% , 97.67% )
60-69	4,718 ( 20.52% )	73.29% ( 69.70% , 76.67% )	94.78% ( 92.44% , 96.56% )
70-79	4,488 ( 19.52% )	63.62% ( 59.29% , 67.79% )	91.09% ( 87.65% , 93.82% )
80-89	3,348 ( 14.56% )	57.69% ( 51.74% , 63.49% )	87.30% ( 81.70% , 91.69% )
90+	1,309 ( 5.69% )	55.91% ( 45.24% , 66.20% )	82.54% ( 70.90% , 90.95% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	17 ( 0.07% )	100.0% ( 39.76% , 100.0% )	100.0% ( 39.76% , 100.0% )
Asian	55 ( 0.24% )	50 % ( 21.09% , 78.91% )	85.71% ( 42.13% , 99.64% )
Black or African American	1,141 ( 4.96% )	69.85% ( 61.40% , 77.42% )	95.96% ( 89.98% , 98.89% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	3,327 ( 14.47% )	62.09% ( 57.87% , 66.17% )	86.04% ( 82.22% , 89.31% )
Other/Mixed/Unknown	18,451 ( 80.25% )	71.71% ( 69.82% , 73.55% )	94.88% ( 93.73% , 95.87% )
Ethnicity			

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	124 ( 0.54% )	86.96% ( 66.41% , 97.22% )	100.0% ( 83.16% , 100.0% )
Non-Hispanic	2 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Unknown	22,865 ( 99.45% )	69.68% ( 68 % , 71.33% )	93.29% ( 92.17% , 94.29% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	465 ( 2.02% )	50 % ( 36.81% , 63.19% )	75 % ( 58.80% , 87.31% )
Contact and suspected exposure (Z20.828)	3,819 ( 16.61% )	61.34% ( 56.73% , 65.80% )	89.59% ( 85.69% , 92.73% )
Pneumonia (see Appendix B)	15,639 ( 68.02% )	74.95% ( 73.08% , 76.76% )	97.15% ( 96.24% , 97.89% )
Other viral pneumonia (J12.89)	12,488 ( 54.32% )	80.19% ( 78.25% , 82.03% )	99.37% ( 98.80% , 99.71% )
ARDS (J80)	1,548 ( 6.73% )	80.20% ( 74.03% , 85.46% )	93.10% ( 88.26% , 96.39% )
Sepsis (see Appendix C)	5,405 ( 23.51% )	68.62% ( 65.04% , 72.04% )	94.31% ( 91.94% , 96.16% )
Bronchitis (J20.8 OR J40)	244 ( 1.06% )	77.42% ( 58.90% , 90.41% )	96 % ( 79.65% , 99.90% )
Respiratory infection (J22 OR J98.8)	1,106 ( 4.81% )	77.93% ( 70.30% , 84.39% )	96.58% ( 91.48% , 99.06% )
Cough (R05)	3,203 ( 13.93% )	73.71% ( 69.45% , 77.66% )	97.44% ( 95.19% , 98.82% )
Shortness of breath (R06.2)	88 ( 0.38% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	4,067 ( 17.69% )	67.60% ( 63.71% , 71.32% )	95.34% ( 92.89% , 97.13% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	324 ( 1.41% )	73.96% ( 64 % , 82.38% )	*****
Test performed, at least 1 positive result	122 ( 0.53% )	50 % ( 31.30% , 68.70% )	*****
Test performed, only negative results	16,272 ( 70.78% )	72.45% ( 70.41% , 74.43% )	93.93% ( 92.59% , 95.08% )
No test or unknown result	-	-	-
Antigen test within ±14 days from inpatient admission**	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, at least 1 positive result	6 ( 0.03% )	75 % ( 19.41% , 99.37% )	*****
Test performed, only negative results	22,980 ( 99.95% )	69.78% ( 68.10% , 71.42% )	*****
No test or unknown result	-	-	-
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,888 ( 8.21% )	75.71% ( 73.70% , 77.63% )	95.63% ( 94.46% , 96.61% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,675 ( 7.29% )	60.94% ( 54.36% , 67.25% )	92.81% ( 87.50% , 96.36% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,409 ( 10.48% )	71.70% ( 66.40% , 76.58% )	93.06% ( 89.12% , 95.91% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	354 ( 1.54% )	73.56% ( 68.60% , 78.12% )	91.43% ( 87.51% , 94.43% )
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	2,626 ( 11.42% )	69.39% ( 67.58% , 71.15% )	93.62% ( 92.44% , 94.67% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.03% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,097	909	27	20,026	3,006 ( 13.04% )
Inpatient	190	66	4	N/A	256
Outpatient or Emergency Department	1,027	290	11	N/A	1,317
Other	59	34	5	N/A	93
Care Setting Reported as Unknown	821	519	7	N/A	1,340
<b>Demographics</b>					
Sex					
Female	927	461	9	9,767	1,388 ( 12.43% )
Male	1,170	448	18	10,259	1,618 ( 13.60% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	3	4	0	74	7 ( 8.64% )
6-17	10	5	1	133	15 ( 10.07% )
18-29	110	65	1	887	175 ( 16.46% )
30-39	187	73	3	1,259	260 ( 17.08% )
40-49	291	93	1	2,023	384 ( 15.95% )
50-59	478	144	4	3,297	622 ( 15.86% )
60-69	473	174	8	4,073	647 ( 13.68% )
70-79	328	188	5	3,979	516 ( 11.47% )
80-89	165	121	3	3,080	286 ( 8.49% )
90+	52	42	1	1,221	94 ( 7.14% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	4	0	0	13	4 ( 23.53% )
Asian	6	6	0	43	12 ( 21.82% )
Black or African American	95	42	0	1,007	137 ( 11.98% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	339	207	0	2,793	546 ( 16.35% )
Other/Mixed/Unknown	1,653	654	27	16,170	2,307 ( 12.47% )
Ethnicity					



**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	20	3	0	101	23 ( 18.55% )
Non-Hispanic	1	0	0	1	1 ( 50% )
Unknown	2,076	906	27	19,924	2,982 ( 13% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	30	30	1	405	60 ( 12.88% )
Contact and suspected exposure (Z20.828)	284	181	6	3,357	465 ( 12.15% )
Pneumonia (see Appendix B)	1,642	551	21	13,479	2,193 ( 13.97% )
Other viral pneumonia (J12.89)	1,409	348	20	10,712	1,757 ( 14.07% )
ARDS (J80)	163	40	3	1,343	203 ( 13.11% )
Sepsis (see Appendix C)	481	222	6	4,707	703 ( 12.98% )
Bronchitis (J20.8 OR J40)	24	7	0	213	31 ( 12.70% )
Respiratory infection (J22 OR J98.8)	113	32	1	960	145 ( 13.11% )
Cough (R05)	342	122	3	2,741	464 ( 14.46% )
Shortness of breath (R06.2)	6	2	0	80	8 ( 9.09% )
Fever (R50.9)	410	197	5	3,464	607 ( 14.89% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	71	25	0	228	96 ( 29.63% )
Test performed, only negative results	15	15	0	93	30 ( 24.39% )
No test or unknown result	1,412	539	26	14,342	1,951 ( 11.96% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	3	1	0	2	4 ( 66.67% )
No test or unknown result	2,090	908	27	20,023	2,998 ( 13.01% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,422	458	11	0	1,880 ( 99.42% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	142	92	2	1,444	234 ( 13.93% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	228	90	5	2,085	318 ( 13.21% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	3	2	0	0	5 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	258	94	6	0	352 ( 98.32% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,823	806	3	0	2,629 ( 99.89% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	4	2	0	0	6 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	6	1	0	0	7 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	0	0	0	0	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	23,059 ( 100.0% )	69.76% ( 68.08% , 71.40% )	93.57% ( 92.48% , 94.55% )
Inpatient	260 ( 1.13% )	74.22% ( 68.40% , 79.46% )	97.94% ( 94.81% , 99.44% )
Outpatient or Emergency Department	1,328 ( 5.76% )	77.98% ( 75.64% , 80.19% )	96.07% ( 94.73% , 97.15% )
Other	98 ( 0.42% )	63.44% ( 52.81% , 73.19% )	100.0% ( 93.94% , 100.0% )
Care Setting Reported as Unknown	6,710 ( 29.10% )	61.27% ( 58.60% , 63.89% )	*****
<b>Demographics</b>			
Sex			
Female	11,164 ( 48.41% )	66.79% ( 64.24% , 69.26% )	92.33% ( 90.51% , 93.90% )
Male	11,895 ( 51.59% )	72.31% ( 70.06% , 74.48% )	94.58% ( 93.17% , 95.78% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	81 ( 0.35% )	42.86% ( 9.90% , 81.59% )	75 % ( 19.41% , 99.37% )
6-17	149 ( 0.65% )	66.67% ( 38.38% , 88.18% )	90.91% ( 58.72% , 99.77% )
18-29	1,063 ( 4.61% )	62.86% ( 55.24% , 70.03% )	95.65% ( 90.15% , 98.57% )
30-39	1,522 ( 6.60% )	71.92% ( 66.04% , 77.30% )	93.97% ( 89.70% , 96.85% )
40-49	2,408 ( 10.44% )	75.78% ( 71.18% , 79.98% )	94.48% ( 91.31% , 96.75% )
50-59	3,923 ( 17.01% )	76.85% ( 73.33% , 80.11% )	96.57% ( 94.56% , 97.99% )
60-69	4,728 ( 20.50% )	73.11% ( 69.51% , 76.49% )	94.98% ( 92.68% , 96.73% )
70-79	4,500 ( 19.52% )	63.57% ( 59.25% , 67.73% )	91.36% ( 87.97% , 94.06% )
80-89	3,369 ( 14.61% )	57.69% ( 51.74% , 63.49% )	87.30% ( 81.70% , 91.69% )
90+	1,316 ( 5.71% )	55.32% ( 44.71% , 65.59% )	82.54% ( 70.90% , 90.95% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	17 ( 0.07% )	100.0% ( 39.76% , 100.0% )	100.0% ( 39.76% , 100.0% )
Asian	55 ( 0.24% )	50 % ( 21.09% , 78.91% )	85.71% ( 42.13% , 99.64% )
Black or African American	1,144 ( 4.96% )	69.34% ( 60.90% , 76.93% )	95.96% ( 89.98% , 98.89% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	3,339 ( 14.48% )	62.09% ( 57.87% , 66.17% )	86.04% ( 82.22% , 89.31% )
Other/Mixed/Unknown	18,504 ( 80.25% )	71.65% ( 69.76% , 73.48% )	95.16% ( 94.05% , 96.12% )
Ethnicity			

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	124 ( 0.54% )	86.96% ( 66.41% , 97.22% )	100.0% ( 83.16% , 100.0% )
Non-Hispanic	2 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Unknown	22,933 ( 99.45% )	69.62% ( 67.93% , 71.27% )	93.51% ( 92.41% , 94.50% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	466 ( 2.02% )	50 % ( 36.81% , 63.19% )	75 % ( 58.80% , 87.31% )
Contact and suspected exposure (Z20.828)	3,828 ( 16.60% )	61.08% ( 56.48% , 65.53% )	89.59% ( 85.69% , 92.73% )
Pneumonia (see Appendix B)	15,693 ( 68.06% )	74.87% ( 73 % , 76.68% )	97.45% ( 96.58% , 98.15% )
Other viral pneumonia (J12.89)	12,489 ( 54.16% )	80.19% ( 78.25% , 82.03% )	99.37% ( 98.80% , 99.71% )
ARDS (J80)	1,549 ( 6.72% )	80.30% ( 74.15% , 85.53% )	93.68% ( 88.97% , 96.80% )
Sepsis (see Appendix C)	5,416 ( 23.49% )	68.42% ( 64.84% , 71.84% )	94.31% ( 91.94% , 96.16% )
Bronchitis (J20.8 OR J40)	244 ( 1.06% )	77.42% ( 58.90% , 90.41% )	96 % ( 79.65% , 99.90% )
Respiratory infection (J22 OR J98.8)	1,106 ( 4.80% )	77.93% ( 70.30% , 84.39% )	96.58% ( 91.48% , 99.06% )
Cough (R05)	3,208 ( 13.91% )	73.71% ( 69.45% , 77.66% )	97.44% ( 95.19% , 98.82% )
Shortness of breath (R06.2)	88 ( 0.38% )	75 % ( 34.91% , 96.81% )	100.0% ( 54.07% , 100.0% )
Fever (R50.9)	4,076 ( 17.68% )	67.55% ( 63.66% , 71.26% )	95.57% ( 93.17% , 97.31% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	324 ( 1.41% )	73.96% ( 64 % , 82.38% )	*****
Test performed, only negative results	123 ( 0.53% )	50 % ( 31.30% , 68.70% )	*****
No test or unknown result	16,319 ( 70.77% )	72.37% ( 70.33% , 74.35% )	94.26% ( 92.96% , 95.38% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.02% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	6 ( 0.03% )	75 % ( 19.41% , 99.37% )	*****
No test or unknown result	23,048 ( 99.95% )	69.71% ( 68.03% , 71.35% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,891 ( 8.20% )	75.64% ( 73.63% , 77.56% )	95.69% ( 94.53% , 96.67% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,680 ( 7.29% )	60.68% ( 54.11% , 66.98% )	92.81% ( 87.50% , 96.36% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,408 ( 10.44% )	71.70% ( 66.40% , 76.58% )	93.06% ( 89.12% , 95.91% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	5 ( 0.02% )	60 % ( 14.66% , 94.73% )	100.0% ( 29.24% , 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	358 ( 1.55% )	73.30% ( 68.35% , 77.85% )	92.14% ( 88.35% , 95.01% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0 % )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2,632 ( 11.41% )	69.34% ( 67.54% , 71.10% )	93.78% ( 92.61% , 94.81% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.02% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	6 ( 0.03% )	66.67% ( 22.28% , 95.67% )	100.0% ( 39.76% , 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	7 ( 0.03% )	85.71% ( 42.13% , 99.64% )	85.71% ( 42.13% , 99.64% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,653	546	23	13,654	2,199 ( 13.85% )
Inpatient	125	35	4	N/A	160
Outpatient or Emergency Department	875	195	9	N/A	1,070
Other	40	22	4	N/A	62
Care Setting Reported as Unknown	613	294	6	N/A	907
<b>Demographics</b>					
Sex					
Female	691	255	5	6,218	946 ( 13.20% )
Male	962	291	18	7,436	1,253 ( 14.39% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	9	N/A
6-17	3	4	1	31	7 ( 17.95% )
18-29	66	30	0	381	96 ( 20.13% )
30-39	137	35	2	764	172 ( 18.34% )
40-49	249	58	1	1,491	307 ( 17.07% )
50-59	413	99	3	2,484	512 ( 17.07% )
60-69	379	115	8	2,992	494 ( 14.14% )
70-79	254	118	4	2,723	372 ( 12 % )
80-89	118	65	3	2,013	183 ( 8.32% )
90+	34	22	1	766	56 ( 6.80% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	0	0	0	9	0 (0.00%)
Asian	5	4	0	33	9 ( 21.43% )
Black or African American	72	26	0	654	98 ( 13.03% )
Native Hawaiian or Other Pacific Islander	0	0	0	0	N/A
White	254	115	0	1,813	369 ( 16.91% )
Other/Mixed/Unknown	1,322	401	23	11,145	1,723 ( 13.37% )
Ethnicity					



**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	16	3	0	73	19 ( 20.65% )
Non-Hispanic	1	0	0	1	1 ( 50% )
Unknown	1,636	543	23	13,580	2,179 ( 13.81% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	19	14	0	209	33 ( 13.64% )
Contact and suspected exposure (Z20.828)	252	134	6	2,525	386 ( 13.23% )
Pneumonia (see Appendix B)	1,649	545	22	13,577	2,194 ( 13.89% )
Other viral pneumonia (J12.89)	1,420	349	21	10,844	1,769 ( 14% )
ARDS (J80)	162	40	3	1,353	202 ( 12.97% )
Sepsis (see Appendix C)	442	173	7	3,989	615 ( 13.34% )
Bronchitis (J20.8 OR J40)	18	3	1	153	21 ( 12% )
Respiratory infection (J22 OR J98.8)	92	20	1	711	112 ( 13.59% )
Cough (R05)	293	100	3	2,186	393 ( 15.22% )
Shortness of breath (R06.2)	4	1	0	57	5 ( 8.06% )
Fever (R50.9)	354	140	5	2,717	494 ( 15.36% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**					
Test performed, at least 1 positive result	61	18	0	169	79 ( 31.85% )
Test performed, only negative results	11	10	0	57	21 ( 26.92% )
No test or unknown result	1,130	327	22	9,889	1,457 ( 12.82% )
Antigen test within ±14 days from inpatient admission**					
Test performed, at least 1 positive result	4	0	0	1	4 ( 80% )
Test performed, only negative results	2	1	0	1	3 ( 75% )
No test or unknown result	1,647	545	23	13,652	2,192 ( 13.81% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,177	299	9	0	1,476 ( 99.39% )
<b>Codes Observed During Inpatient Stay</b>					
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	122	75	2	1,143	197 ( 14.68% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	228	89	5	2,047	317 ( 13.38% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	-	-	-	-	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	0	0	0	0	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	0	0	0	0	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	160	52	4	0	212 ( 98.15% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1	0	0	0	1 ( 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,484	488	2	0	1,972 ( 99.90% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2	3	0	0	5 ( 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	1	1	0	0	2 ( 100.0% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	3	1	0	0	4 ( 100.0% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	0	0	0	0	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	0	0	0	0	N/A
Unknown	0	0	0	0	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	15,876 ( 100.0% )	75.17% ( 73.31% , 76.96% )	73.76% ( 71.89% , 75.57% )
Inpatient	164 ( 1.03% )	78.13% ( 70.91% , 84.27% )	64.43% ( 57.26% , 71.16% )
Outpatient or Emergency Department	1,079 ( 6.80% )	81.78% ( 79.33% , 84.05% )	81.85% ( 79.41% , 84.12% )
Other	66 ( 0.42% )	64.52% ( 51.34% , 76.26% )	67.80% ( 54.36% , 79.38% )
Care Setting Reported as Unknown	4,452 ( 28.04% )	67.59% ( 64.43% , 70.63% )	*****
<b>Demographics</b>			
Sex			
Female	7,169 ( 45.16% )	73.04% ( 70.10% , 75.85% )	68.82% ( 65.86% , 71.68% )
Male	8,707 ( 54.84% )	76.78% ( 74.34% , 79.09% )	77.77% ( 75.35% , 80.06% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	9 ( 0.06% )	N/A	N/A
6-17	39 ( 0.25% )	42.86% ( 9.90% , 81.59% )	27.27% ( 6.02% , 60.97% )
18-29	477 ( 3 % )	68.75% ( 58.48% , 77.82% )	57.39% ( 47.83% , 66.56% )
30-39	938 ( 5.91% )	79.65% ( 72.85% , 85.40% )	68.84% ( 61.91% , 75.21% )
40-49	1,799 ( 11.33% )	81.11% ( 76.27% , 85.33% )	80.84% ( 76 % , 85.09% )
50-59	2,999 ( 18.89% )	80.66% ( 76.97% , 84 % )	83.43% ( 79.86% , 86.60% )
60-69	3,494 ( 22.01% )	76.72% ( 72.74% , 80.38% )	76.10% ( 72.11% , 79.79% )
70-79	3,099 ( 19.52% )	68.28% ( 63.28% , 72.98% )	70.75% ( 65.75% , 75.41% )
80-89	2,199 ( 13.85% )	64.48% ( 57.08% , 71.40% )	62.43% ( 55.11% , 69.36% )
90+	823 ( 5.18% )	60.71% ( 46.75% , 73.50% )	53.97% ( 40.94% , 66.61% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	9 ( 0.06% )	N/A	N/A
Asian	42 ( 0.26% )	55.56% ( 21.20% , 86.30% )	71.43% ( 29.04% , 96.33% )
Black or African American	752 ( 4.74% )	73.47% ( 63.59% , 81.88% )	72.73% ( 62.85% , 81.20% )
Native Hawaiian or Other Pacific Islander	N/A	N/A	N/A
White	2,182 ( 13.74% )	68.83% ( 63.84% , 73.53% )	64.47% ( 59.52% , 69.20% )
Other/Mixed/Unknown	12,891 ( 81.20% )	76.73% ( 74.66% , 78.70% )	76.11% ( 74.03% , 78.10% )
Ethnicity			

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	Total Patient Count	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number (Percent)	Percent	
Hispanic	92 ( 0.58% )	84.21% ( 60.42% , 96.62% )	80 % ( 56.34% , 94.27% )
Non-Hispanic	2 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Unknown	15,782 ( 99.41% )	75.08% ( 73.21% , 76.88% )	73.69% ( 71.81% , 75.52% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	242 ( 1.52% )	57.58% ( 39.22% , 74.52% )	47.50% ( 31.51% , 63.87% )
Contact and suspected exposure (Z20.828)	2,917 ( 18.37% )	65.28% ( 60.30% , 70.03% )	79.50% ( 74.63% , 83.80% )
Pneumonia (see Appendix B)	15,793 ( 99.48% )	75.16% ( 73.30% , 76.96% )	97.86% ( 97.05% , 98.50% )
Other viral pneumonia (J12.89)	12,634 ( 79.58% )	80.27% ( 78.34% , 82.10% )	*****
ARDS (J80)	1,558 ( 9.81% )	80.20% ( 74.03% , 85.46% )	93.10% ( 88.26% , 96.39% )
Sepsis (see Appendix C)	4,611 ( 29.04% )	71.87% ( 68.14% , 75.39% )	86.67% ( 83.41% , 89.50% )
Bronchitis (J20.8 OR J40)	175 ( 1.10% )	85.71% ( 63.66% , 96.95% )	72 % ( 50.61% , 87.93% )
Respiratory infection (J22 OR J98.8)	824 ( 5.19% )	82.14% ( 73.78% , 88.74% )	78.63% ( 70.09% , 85.67% )
Cough (R05)	2,582 ( 16.26% )	74.55% ( 69.95% , 78.79% )	83.48% ( 79.17% , 87.21% )
Shortness of breath (R06.2)	62 ( 0.39% )	80 % ( 28.36% , 99.49% )	66.67% ( 22.28% , 95.67% )
Fever (R50.9)	3,216 ( 20.26% )	71.66% ( 67.46% , 75.60% )	82.52% ( 78.59% , 85.99% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	248 ( 1.56% )	77.22% ( 66.40% , 85.90% )	*****
Test performed, only negative results	78 ( 0.49% )	52.38% ( 29.78% , 74.29% )	84.62% ( 54.55% , 98.08% )
No test or unknown result	11,368 ( 71.60% )	77.56% ( 75.33% , 79.68% )	75.43% ( 73.17% , 77.60% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	5 ( 0.03% )	100.0% ( 39.76% , 100.0% )	*****
Test performed, only negative results	4 ( 0.03% )	66.67% ( 9.43% , 99.16% )	*****
No test or unknown result	15,867 ( 99.94% )	75.14% ( 73.27% , 76.93% )	*****
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,485 ( 9.35% )	79.74% ( 77.60% , 81.77% )	79.21% ( 77.05% , 81.24% )
<b>Codes Observed During Inpatient Stay</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	1,342 ( 8.45% )	61.93% ( 54.76% , 68.74% )	79.74% ( 72.49% , 85.80% )

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	2,369 ( 14.92% )	71.92% ( 66.63% , 76.80% )	93.06% ( 89.12% , 95.91% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	N/A	N/A	N/A
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	2 ( 0.01% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	216 ( 1.36% )	75.47% ( 69.11% , 81.11% )	57.14% ( 51.12% , 63.01% )
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	1 ( 0.01% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	1,974 ( 12.43% )	75.25% ( 73.29% , 77.14% )	76.34% ( 74.38% , 78.21% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A

**Table 1f. Aggregated Baseline Table for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between May 1, 2020 and September 25, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.03% )	40 % ( 5.27% , 85.34% )	100.0% ( 15.81% , 100.0% )
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.01% )	50 % ( 1.26% , 98.74% )	25 % ( 0.63% , 80.59% )
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	4 ( 0.03% )	75 % ( 19.41% , 99.37% )	42.86% ( 9.90% , 81.59% )
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	N/A	N/A	N/A

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINC or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test*****</b>				
Total Observed	395	483	798	931
Inpatient	173	208	548	606
Outpatient or Emergency Department	121	131	119	123
Other	6	7	50	65
Care Setting Reported as Unknown	43	48	112	123
<b>Demographics</b>				
Sex				
Female	169	197	422	500
Male	226	286	376	431
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	0	0	18	27
6-17	1	1	6	11
18-29	9	9	38	47
30-39	16	18	50	57
40-49	43	51	58	70
50-59	85	105	104	118
60-69	98	112	178	201
70-79	85	115	180	208
80-89	44	53	117	134
90+	14	19	48	57
Missing	0	0	0	0
Race				
American Indian or Alaska Native	3	3	4	4
Asian	28	33	38	42
Black or African American	118	136	130	148
Native Hawaiian or Other Pacific Islander	2	2	1	1
White	174	218	535	621
Other/Mixed/Unknown	70	91	90	115
Ethnicity				



**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	50	63	48	58
Non-Hispanic	256	324	608	700
Unknown	89	96	142	173
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	12	14	25	26
Contact and suspected exposure (Z20.828)	68	93	159	206
Pneumonia (see Appendix B)	275	428	310	378
Other viral pneumonia (J12.89)	275	373	21	26
ARDS (J80)	100	135	14	18
Sepsis (see Appendix C)	135	219	256	308
Bronchitis (J20.8 OR J40)	10	13	9	14
Respiratory infection (J22 OR J98.8)	32	43	11	14
Cough (R05)	63	80	102	130
Shortness of breath (R06.2)	1	2	6	9
Fever (R50.9)	93	116	109	133
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	6	7	0	0
Test performed, only negative results	0	0	10	12
No test or unknown result	150	168	544	597
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	33	38	397	435
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	241	320	376	481
<b>Codes Observed During Inpatient Stay</b>				

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	23	29	28	34
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	39	48	8	9
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	17	17	24	24
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	107	120	134	150
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2	6	52	69
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	31	32	345	366

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	226	5	0	49	231 ( 82.50% )
Inpatient	93	3	0	N/A	96
Outpatient or Emergency Department	50	2	0	N/A	52
Other	3	0	0	N/A	3
Care Setting Reported as Unknown	27	0	0	N/A	27
<b>Demographics</b>					
Sex					
Female	86	2	0	19	88 ( 82.24% )
Male	140	3	0	24	143 ( 85.63% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	0	N/A
6-17	0	0	0	0	N/A
18-29	2	0	0	0	2 ( 100.0% )
30-39	6	1	0	4	7 ( 63.64% )
40-49	21	0	0	3	21 ( 87.50% )
50-59	53	2	0	7	55 ( 88.71% )
60-69	60	2	0	9	62 ( 87.32% )
70-79	47	0	0	12	47 ( 79.66% )
80-89	29	0	0	7	29 ( 80.56% )
90+	8	0	0	1	8 ( 88.89% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	1	0	0	0	1 ( 100.0% )
Asian	20	1	0	3	21 ( 87.50% )
Black or African American	69	1	0	24	70 ( 74.47% )
Native Hawaiian or Other Pacific Islander	1	0	0	0	1 ( 100.0% )
White	94	2	0	7	96 ( 93.20% )
Other/Mixed/Unknown	41	1	0	9	42 ( 82.35% )
Ethnicity					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	28	0	0	3	28 ( 90.32% )
Non-Hispanic	144	4	0	18	148 ( 89.16% )
Unknown	54	1	0	22	55 ( 71.43% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	8	0	0	3	8 ( 72.73% )
Contact and suspected exposure (Z20.828)	46	4	0	10	50 ( 83.33% )
Pneumonia (see Appendix B)	165	5	0	29	170 ( 85.43% )
Other viral pneumonia (J12.89)	180	5	0	33	185 ( 84.86% )
ARDS (J80)	88	2	0	10	90 ( 90 % )
Sepsis (see Appendix C)	100	2	0	15	102 ( 87.18% )
Bronchitis (J20.8 OR J40)	3	0	0	0	3 ( 100.0% )
Respiratory infection (J22 OR J98.8)	16	0	0	3	16 ( 84.21% )
Cough (R05)	37	1	0	9	38 ( 80.85% )
Shortness of breath (R06.2)	1	0	0	0	1 ( 100.0% )
Fever (R50.9)	60	2	0	11	62 ( 84.93% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	2	0	0	0	2 ( 100.0% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	90	1	0	32	91 ( 73.98% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	22	0	0	0	22 ( 100.0% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	140	4	0	3	144 ( 97.96% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	17	1	0	4	18 ( 81.82% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	32	1	0	11	33 ( 75 % )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	68	1	-	-	69 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	20	0	0	0	20 ( 100.0% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	280 ( 100.0% )	97.84% ( 95.02% , 99.29% )	57.22% ( 52.17% , 62.15% )
Inpatient	96 ( 34.29% )	96.88% ( 91.14% , 99.35% )	53.76% ( 46.03% , 61.35% )
Outpatient or Emergency Department	52 ( 18.57% )	96.15% ( 86.79% , 99.53% )	41.32% ( 32.45% , 50.63% )
Other	3 ( 1.07% )	100.0% ( 29.24% , 100.0% )	50 % ( 11.81% , 88.19% )
Care Setting Reported as Unknown	27 ( 9.64% )	100.0% ( 87.23% , 100.0% )	62.79% ( 46.73% , 77.02% )
<b>Demographics</b>			
Sex			
Female	107 ( 38.21% )	97.73% ( 92.03% , 99.72% )	50.89% ( 43.10% , 58.65% )
Male	167 ( 59.64% )	97.90% ( 93.99% , 99.57% )	61.95% ( 55.27% , 68.30% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	N/A	N/A	N/A
6-17	N/A	N/A	N/A
18-29	2 ( 0.71% )	100.0% ( 15.81% , 100.0% )	22.22% ( 2.81% , 60.01% )
30-39	11 ( 3.93% )	85.71% ( 42.13% , 99.64% )	37.50% ( 15.20% , 64.57% )
40-49	24 ( 8.57% )	100.0% ( 83.89% , 100.0% )	48.84% ( 33.31% , 64.54% )
50-59	62 ( 22.14% )	96.36% ( 87.47% , 99.56% )	62.35% ( 51.18% , 72.64% )
60-69	71 ( 25.36% )	96.77% ( 88.83% , 99.61% )	61.22% ( 50.85% , 70.90% )
70-79	59 ( 21.07% )	100.0% ( 92.45% , 100.0% )	55.29% ( 44.11% , 66.09% )
80-89	36 ( 12.86% )	100.0% ( 88.06% , 100.0% )	65.91% ( 50.08% , 79.51% )
90+	9 ( 3.21% )	100.0% ( 63.06% , 100.0% )	57.14% ( 28.86% , 82.34% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	1 ( 0.36% )	100.0% ( 2.50% , 100.0% )	33.33% ( 0.84% , 90.57% )
Asian	24 ( 8.57% )	95.24% ( 76.18% , 99.88% )	71.43% ( 51.33% , 86.78% )
Black or African American	94 ( 33.57% )	98.57% ( 92.30% , 99.96% )	58.47% ( 49.04% , 67.47% )
Native Hawaiian or Other Pacific Islander	1 ( 0.36% )	100.0% ( 2.50% , 100.0% )	50 % ( 1.26% , 98.74% )
White	103 ( 36.79% )	97.92% ( 92.68% , 99.75% )	54.02% ( 46.32% , 61.59% )
Other/Mixed/Unknown	51 ( 18.21% )	97.62% ( 87.43% , 99.94% )	58.57% ( 46.17% , 70.23% )
Ethnicity			



**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	31 ( 11.07% )	100.0% ( 87.66% , 100.0% )	56 % ( 41.25% , 70.01% )
Non-Hispanic	166 ( 59.29% )	97.30% ( 93.22% , 99.26% )	56.25% ( 49.94% , 62.42% )
Unknown	77 ( 27.50% )	98.18% ( 90.28% , 99.95% )	60.67% ( 49.75% , 70.87% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	11 ( 3.93% )	100.0% ( 63.06% , 100.0% )	66.67% ( 34.89% , 90.08% )
Contact and suspected exposure (Z20.828)	60 ( 21.43% )	92 % ( 80.77% , 97.78% )	67.65% ( 55.21% , 78.49% )
Pneumonia (see Appendix B)	199 ( 71.07% )	97.06% ( 93.27% , 99.04% )	60 % ( 53.95% , 65.84% )
Other viral pneumonia (J12.89)	218 ( 77.86% )	97.30% ( 93.81% , 99.12% )	65.45% ( 59.51% , 71.06% )
ARDS (J80)	100 ( 35.71% )	97.78% ( 92.20% , 99.73% )	88 % ( 79.98% , 93.64% )
Sepsis (see Appendix C)	117 ( 41.79% )	98.04% ( 93.10% , 99.76% )	74.07% ( 65.83% , 81.23% )
Bronchitis (J20.8 OR J40)	3 ( 1.07% )	100.0% ( 29.24% , 100.0% )	30 % ( 6.67% , 65.25% )
Respiratory infection (J22 OR J98.8)	19 ( 6.79% )	100.0% ( 79.41% , 100.0% )	50 % ( 31.89% , 68.11% )
Cough (R05)	47 ( 16.79% )	97.37% ( 86.19% , 99.93% )	58.73% ( 45.62% , 70.99% )
Shortness of breath (R06.2)	1 ( 0.36% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Fever (R50.9)	73 ( 26.07% )	96.77% ( 88.83% , 99.61% )	64.52% ( 53.91% , 74.17% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	2 ( 0.71% )	100.0% ( 15.81% , 100.0% )	33.33% ( 4.33% , 77.72% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	123 ( 43.93% )	98.90% ( 94.03% , 99.97% )	60 % ( 51.69% , 67.90% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	22 ( 7.86% )	100.0% ( 84.56% , 100.0% )	66.67% ( 48.17% , 82.04% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	147 ( 52.50% )	97.22% ( 93.04% , 99.24% )	58.09% ( 51.59% , 64.39% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	22 ( 7.86% )	94.44% ( 72.71% , 99.86% )	73.91% ( 51.59% , 89.77% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	44 ( 15.71% )	96.97% ( 84.24% , 99.92% )	82.05% ( 66.47% , 92.46% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.71% )	100.0% ( 15.81% , 100.0% )	11.76% ( 1.46% , 36.44% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	69 ( 24.64% )	98.55% ( 92.19% , 99.96% )	63.55% ( 53.69% , 72.64% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.71% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
	<b>Number (Percent)</b>		
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	20 ( 7.14% )	100.0% ( 83.16% , 100.0% )	64.52% ( 45.37% , 80.77% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	351	21	4	96	372 ( 78.81% )
Inpatient	141	14	0	N/A	155
Outpatient or Emergency Department	83	3	0	N/A	86
Other	5	0	1	N/A	5
Care Setting Reported as Unknown	38	2	0	N/A	40
<b>Demographics</b>					
Sex					
Female	147	9	3	41	156 ( 78 % )
Male	204	12	1	37	216 ( 85.04% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	0	0	0	0	N/A
18-29	6	1	0	2	7 ( 77.78% )
30-39	14	2	1	5	16 ( 72.73% )
40-49	39	3	0	12	42 ( 77.78% )
50-59	80	5	2	10	85 ( 87.63% )
60-69	88	4	0	15	92 ( 85.98% )
70-79	74	4	0	19	78 ( 80.41% )
80-89	38	1	0	9	39 ( 81.25% )
90+	12	0	1	1	12 ( 85.71% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	2	0	0	0	2 ( 100.0% )
Asian	27	1	0	6	28 ( 82.35% )
Black or African American	106	4	0	35	110 ( 75.86% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	151	13	3	21	164 ( 87.23% )
Other/Mixed/Unknown	63	3	1	16	66 ( 79.52% )
Ethnicity					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	44	1	0	8	45 ( 84.91% )
Non-Hispanic	226	16	4	33	242 ( 86.74% )
Unknown	81	4	0	37	85 ( 69.67% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	10	0	0	4	10 ( 71.43% )
Contact and suspected exposure (Z20.828)	59	7	0	13	66 ( 83.54% )
Pneumonia (see Appendix B)	247	15	1	41	262 ( 86.18% )
Other viral pneumonia (J12.89)	266	8	3	48	274 ( 84.31% )
ARDS (J80)	100	2	1	13	102 ( 87.93% )
Sepsis (see Appendix C)	124	8	0	22	132 ( 85.71% )
Bronchitis (J20.8 OR J40)	9	0	1	1	9 ( 81.82% )
Respiratory infection (J22 OR J98.8)	30	0	0	3	30 ( 90.91% )
Cough (R05)	57	3	0	14	60 ( 81.08% )
Shortness of breath (R06.2)	1	0	0	0	1 ( 100.0% )
Fever (R50.9)	82	3	0	19	85 ( 81.73% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	6	0	0	1	6 ( 85.71% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	138	5	1	50	143 ( 73.71% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	33	1	1	1	34 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	211	15	1	4	226 ( 97.84% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	21	1	0	7	22 ( 75.86% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	39	1	0	12	40 ( 76.92% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14	1	-	-	15 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	97	3	-	-	100 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	31	1	1	1	32 ( 94.12% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	472 ( 100.0% )	94.35% ( 91.50% , 96.47% )	88.86% ( 85.34% , 91.79% )
Inpatient	155 ( 32.84% )	90.97% ( 85.31% , 94.97% )	81.50% ( 74.90% , 86.99% )
Outpatient or Emergency Department	86 ( 18.22% )	96.51% ( 90.14% , 99.27% )	68.60% ( 59.53% , 76.73% )
Other	6 ( 1.27% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
Care Setting Reported as Unknown	41 ( 8.69% )	95 % ( 83.08% , 99.39% )	88.37% ( 74.92% , 96.11% )
<b>Demographics</b>			
<b>Sex</b>			
Female	200 ( 42.37% )	94.23% ( 89.33% , 97.33% )	86.98% ( 80.96% , 91.66% )
Male	254 ( 53.81% )	94.44% ( 90.50% , 97.10% )	90.27% ( 85.63% , 93.80% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	3 ( 0.64% )	N/A	N/A
6-17	N/A	N/A	N/A
18-29	9 ( 1.91% )	85.71% ( 42.13% , 99.64% )	66.67% ( 29.93% , 92.51% )
30-39	22 ( 4.66% )	87.50% ( 61.65% , 98.45% )	87.50% ( 61.65% , 98.45% )
40-49	54 ( 11.44% )	92.86% ( 80.52% , 98.50% )	90.70% ( 77.86% , 97.41% )
50-59	97 ( 20.55% )	94.12% ( 86.80% , 98.06% )	94.12% ( 86.80% , 98.06% )
60-69	107 ( 22.67% )	95.65% ( 89.24% , 98.80% )	89.80% ( 82.03% , 95 % )
70-79	97 ( 20.55% )	94.87% ( 87.39% , 98.59% )	87.06% ( 78.02% , 93.36% )
80-89	48 ( 10.17% )	97.44% ( 86.52% , 99.94% )	86.36% ( 72.65% , 94.83% )
90+	14 ( 2.97% )	100.0% ( 73.54% , 100.0% )	85.71% ( 57.19% , 98.22% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	2 ( 0.42% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
Asian	34 ( 7.20% )	96.43% ( 81.65% , 99.91% )	96.43% ( 81.65% , 99.91% )
Black or African American	145 ( 30.72% )	96.36% ( 90.95% , 99 % )	89.83% ( 82.91% , 94.63% )
Native Hawaiian or Other Pacific Islander	2 ( 0.42% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	188 ( 39.83% )	92.07% ( 86.83% , 95.71% )	86.78% ( 80.83% , 91.43% )
Other/Mixed/Unknown	83 ( 17.58% )	95.45% ( 87.29% , 99.05% )	90 % ( 80.48% , 95.88% )
<b>Ethnicity</b>			



**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	53 ( 11.23% )	97.78% ( 88.23% , 99.94% )	88 % ( 75.69% , 95.47% )
Non-Hispanic	279 ( 59.11% )	93.39% ( 89.49% , 96.17% )	88.28% ( 83.69% , 91.95% )
Unknown	122 ( 25.85% )	95.29% ( 88.39% , 98.70% )	91.01% ( 83.05% , 96.04% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	14 ( 2.97% )	100.0% ( 69.15% , 100.0% )	83.33% ( 51.59% , 97.91% )
Contact and suspected exposure (Z20.828)	79 ( 16.74% )	89.39% ( 79.36% , 95.63% )	86.76% ( 76.36% , 93.77% )
Pneumonia (see Appendix B)	304 ( 64.41% )	94.27% ( 90.73% , 96.76% )	89.82% ( 85.62% , 93.13% )
Other viral pneumonia (J12.89)	325 ( 68.86% )	97.08% ( 94.33% , 98.73% )	96.73% ( 93.88% , 98.49% )
ARDS (J80)	116 ( 24.58% )	98.04% ( 93.10% , 99.76% )	100.0% ( 96.38% , 100.0% )
Sepsis (see Appendix C)	154 ( 32.63% )	93.94% ( 88.41% , 97.35% )	91.85% ( 85.89% , 95.86% )
Bronchitis (J20.8 OR J40)	11 ( 2.33% )	100.0% ( 66.37% , 100.0% )	90 % ( 55.50% , 99.75% )
Respiratory infection (J22 OR J98.8)	33 ( 6.99% )	100.0% ( 88.43% , 100.0% )	93.75% ( 79.19% , 99.23% )
Cough (R05)	74 ( 15.68% )	95 % ( 86.08% , 98.96% )	90.48% ( 80.41% , 96.42% )
Shortness of breath (R06.2)	1 ( 0.21% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Fever (R50.9)	104 ( 22.03% )	96.47% ( 90.03% , 99.27% )	88.17% ( 79.82% , 93.95% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	7 ( 1.48% )	100.0% ( 54.07% , 100.0% )	100.0% ( 54.07% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	194 ( 41.10% )	96.50% ( 92.03% , 98.86% )	92 % ( 86.44% , 95.80% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	36 ( 7.63% )	97.06% ( 84.67% , 99.93% )	100.0% ( 89.42% , 100.0% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	231 ( 48.94% )	93.36% ( 89.29% , 96.24% )	87.55% ( 82.71% , 91.44% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	29 ( 6.14% )	95.45% ( 77.16% , 99.88% )	91.30% ( 71.96% , 98.93% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	52 ( 11.02% )	97.50% ( 86.84% , 99.94% )	100.0% ( 90.97% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	15 ( 3.18% )	93.33% ( 68.05% , 99.83% )	82.35% ( 56.57% , 96.20% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	100 ( 21.19% )	97 % ( 91.48% , 99.38% )	90.65% ( 83.48% , 95.43% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.42% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	34 ( 7.20% )	96.88% ( 83.78% , 99.92% )	100.0% ( 88.78% , 100.0% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	353	24	4	100	377 ( 78.38% )
Inpatient	141	15	0	N/A	156
Outpatient or Emergency Department	84	3	0	N/A	87
Other	5	0	1	N/A	5
Care Setting Reported as Unknown	39	3	0	N/A	42
<b>Demographics</b>					
Sex					
Female	149	12	3	43	161 ( 77.78% )
Male	204	12	1	39	216 ( 84.38% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	0	0	0	0	N/A
18-29	6	1	0	2	7 ( 77.78% )
30-39	14	2	1	5	16 ( 72.73% )
40-49	39	3	0	12	42 ( 77.78% )
50-59	80	6	2	12	86 ( 86 % )
60-69	89	4	0	15	93 ( 86.11% )
70-79	75	5	0	21	80 ( 79.21% )
80-89	38	1	0	9	39 ( 81.25% )
90+	12	1	1	1	13 ( 86.67% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	2	0	0	1	2 ( 66.67% )
Asian	27	1	0	6	28 ( 82.35% )
Black or African American	107	4	0	36	111 ( 75.51% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	152	16	3	22	168 ( 87.05% )
Other/Mixed/Unknown	63	3	1	17	66 ( 78.57% )
Ethnicity					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	44	1	0	8	45 ( 84.91% )
Non-Hispanic	227	18	4	34	245 ( 86.57% )
Unknown	82	5	0	40	87 ( 68.50% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	10	0	0	4	10 ( 71.43% )
Contact and suspected exposure (Z20.828)	60	8	0	14	68 ( 82.93% )
Pneumonia (see Appendix B)	248	17	1	43	265 ( 85.76% )
Other viral pneumonia (J12.89)	266	8	3	49	274 ( 84.05% )
ARDS (J80)	100	2	1	13	102 ( 87.93% )
Sepsis (see Appendix C)	124	9	0	24	133 ( 84.71% )
Bronchitis (J20.8 OR J40)	9	0	1	1	9 ( 81.82% )
Respiratory infection (J22 OR J98.8)	30	0	0	3	30 ( 90.91% )
Cough (R05)	57	3	0	14	60 ( 81.08% )
Shortness of breath (R06.2)	1	0	0	1	1 ( 50% )
Fever (R50.9)	82	3	0	19	85 ( 81.73% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	6	0	0	1	6 ( 85.71% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	139	6	1	53	145 ( 72.86% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	33	1	1	1	34 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	212	17	1	4	229 ( 97.86% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	21	1	0	7	22 ( 75.86% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	39	1	0	12	40 ( 76.92% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14	1	-	-	15 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	98	4	-	-	102 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	31	1	1	1	32 ( 94.12% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	481 ( 100.0% )	93.63% ( 90.68% , 95.88% )	89.37% ( 85.90% , 92.23% )
Inpatient	156 ( 32.43% )	90.38% ( 84.64% , 94.52% )	81.50% ( 74.90% , 86.99% )
Outpatient or Emergency Department	87 ( 18.09% )	96.55% ( 90.25% , 99.28% )	69.42% ( 60.39% , 77.47% )
Other	6 ( 1.25% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
Care Setting Reported as Unknown	43 ( 8.94% )	92.86% ( 80.52% , 98.50% )	90.70% ( 77.86% , 97.41% )
<b>Demographics</b>			
Sex			
Female	207 ( 43.04% )	92.55% ( 87.34% , 96.09% )	88.17% ( 82.32% , 92.62% )
Male	256 ( 53.22% )	94.44% ( 90.50% , 97.10% )	90.27% ( 85.63% , 93.80% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	3 ( 0.62% )	N/A	N/A
6-17	N/A	N/A	N/A
18-29	9 ( 1.87% )	85.71% ( 42.13% , 99.64% )	66.67% ( 29.93% , 92.51% )
30-39	22 ( 4.57% )	87.50% ( 61.65% , 98.45% )	87.50% ( 61.65% , 98.45% )
40-49	54 ( 11.23% )	92.86% ( 80.52% , 98.50% )	90.70% ( 77.86% , 97.41% )
50-59	100 ( 20.79% )	93.02% ( 85.43% , 97.40% )	94.12% ( 86.80% , 98.06% )
60-69	108 ( 22.45% )	95.70% ( 89.35% , 98.82% )	90.82% ( 83.28% , 95.71% )
70-79	101 ( 21 % )	93.75% ( 86.01% , 97.94% )	88.24% ( 79.43% , 94.21% )
80-89	48 ( 9.98% )	97.44% ( 86.52% , 99.94% )	86.36% ( 72.65% , 94.83% )
90+	15 ( 3.12% )	92.31% ( 63.97% , 99.81% )	85.71% ( 57.19% , 98.22% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	3 ( 0.62% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
Asian	34 ( 7.07% )	96.43% ( 81.65% , 99.91% )	96.43% ( 81.65% , 99.91% )
Black or African American	147 ( 30.56% )	96.40% ( 91.03% , 99.01% )	90.68% ( 83.93% , 95.25% )
Native Hawaiian or Other Pacific Islander	2 ( 0.42% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	193 ( 40.12% )	90.48% ( 84.99% , 94.46% )	87.36% ( 81.49% , 91.90% )
Other/Mixed/Unknown	84 ( 17.46% )	95.45% ( 87.29% , 99.05% )	90 % ( 80.48% , 95.88% )
Ethnicity			



**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	53 ( 11.02% )	97.78% ( 88.23% , 99.94% )	88 % ( 75.69% , 95.47% )
Non-Hispanic	283 ( 58.84% )	92.65% ( 88.64% , 95.59% )	88.67% ( 84.14% , 92.28% )
Unknown	127 ( 26.40% )	94.25% ( 87.10% , 98.11% )	92.13% ( 84.46% , 96.78% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	14 ( 2.91% )	100.0% ( 69.15% , 100.0% )	83.33% ( 51.59% , 97.91% )
Contact and suspected exposure (Z20.828)	82 ( 17.05% )	88.24% ( 78.13% , 94.78% )	88.24% ( 78.13% , 94.78% )
Pneumonia (see Appendix B)	309 ( 64.24% )	93.58% ( 89.93% , 96.22% )	90.18% ( 86.04% , 93.43% )
Other viral pneumonia (J12.89)	326 ( 67.78% )	97.08% ( 94.33% , 98.73% )	96.73% ( 93.88% , 98.49% )
ARDS (J80)	116 ( 24.12% )	98.04% ( 93.10% , 99.76% )	100.0% ( 96.38% , 100.0% )
Sepsis (see Appendix C)	157 ( 32.64% )	93.23% ( 87.54% , 96.86% )	91.85% ( 85.89% , 95.86% )
Bronchitis (J20.8 OR J40)	11 ( 2.29% )	100.0% ( 66.37% , 100.0% )	90 % ( 55.50% , 99.75% )
Respiratory infection (J22 OR J98.8)	33 ( 6.86% )	100.0% ( 88.43% , 100.0% )	93.75% ( 79.19% , 99.23% )
Cough (R05)	74 ( 15.38% )	95 % ( 86.08% , 98.96% )	90.48% ( 80.41% , 96.42% )
Shortness of breath (R06.2)	2 ( 0.42% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Fever (R50.9)	104 ( 21.62% )	96.47% ( 90.03% , 99.27% )	88.17% ( 79.82% , 93.95% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	7 ( 1.46% )	100.0% ( 54.07% , 100.0% )	100.0% ( 54.07% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	199 ( 41.37% )	95.86% ( 91.21% , 98.47% )	92.67% ( 87.26% , 96.28% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	36 ( 7.48% )	97.06% ( 84.67% , 99.93% )	100.0% ( 89.42% , 100.0% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	234 ( 48.65% )	92.58% ( 88.38% , 95.62% )	87.97% ( 83.18% , 91.79% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	29 ( 6.03% )	95.45% ( 77.16% , 99.88% )	91.30% ( 71.96% , 98.93% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	52 ( 10.81% )	97.50% ( 86.84% , 99.94% )	100.0% ( 90.97% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	15 ( 3.12% )	93.33% ( 68.05% , 99.83% )	82.35% ( 56.57% , 96.20% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	102 ( 21.21% )	96.08% ( 90.26% , 98.92% )	91.59% ( 84.63% , 96.08% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.42% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	34 ( 7.07% )	96.88% ( 83.78% , 99.92% )	100.0% ( 88.78% , 100.0% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	358	24	4	101	382 ( 78.44% )
Inpatient	142	15	0	N/A	157
Outpatient or Emergency Department	86	3	0	N/A	89
Other	5	0	1	N/A	5
Care Setting Reported as Unknown	39	3	0	N/A	42
<b>Demographics</b>					
Sex					
Female	152	12	3	44	164 ( 77.73% )
Male	206	12	1	39	218 ( 84.50% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	3	0 (0.00%)
6-17	0	0	0	0	N/A
18-29	6	1	0	2	7 ( 77.78% )
30-39	14	2	1	5	16 ( 72.73% )
40-49	39	3	0	12	42 ( 77.78% )
50-59	80	6	2	13	86 ( 85.15% )
60-69	91	4	0	15	95 ( 86.36% )
70-79	76	5	0	21	81 ( 79.41% )
80-89	39	1	0	9	40 ( 81.63% )
90+	13	1	1	1	14 ( 87.50% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	3	0	0	1	3 ( 75 % )
Asian	27	1	0	6	28 ( 82.35% )
Black or African American	107	4	0	36	111 ( 75.51% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	155	16	3	23	171 ( 86.80% )
Other/Mixed/Unknown	64	3	1	17	67 ( 78.82% )
Ethnicity					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	44	1	0	8	45 ( 84.91% )
Non-Hispanic	231	18	4	35	249 ( 86.46% )
Unknown	83	5	0	40	88 ( 68.75% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	10	0	0	4	10 ( 71.43% )
Contact and suspected exposure (Z20.828)	61	8	0	14	69 ( 83.13% )
Pneumonia (see Appendix B)	251	17	1	43	268 ( 85.90% )
Other viral pneumonia (J12.89)	269	8	3	49	277 ( 84.19% )
ARDS (J80)	100	2	1	13	102 ( 87.93% )
Sepsis (see Appendix C)	126	9	0	25	135 ( 84.38% )
Bronchitis (J20.8 OR J40)	10	0	1	1	10 ( 83.33% )
Respiratory infection (J22 OR J98.8)	31	0	0	3	31 ( 91.18% )
Cough (R05)	58	3	0	14	61 ( 81.33% )
Shortness of breath (R06.2)	1	0	0	1	1 ( 50 % )
Fever (R50.9)	84	3	0	19	87 ( 82.08% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	6	0	0	1	6 ( 85.71% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	139	6	1	53	145 ( 72.86% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	33	1	1	1	34 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	215	17	1	4	232 ( 97.89% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	21	1	0	7	22 ( 75.86% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	39	1	0	12	40 ( 76.92% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14	1	-	-	15 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	98	4	-	-	102 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	31	1	1	1	32 ( 94.12% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	487 ( 100.0% )	93.72% ( 90.80% , 95.93% )	90.63% ( 87.32% , 93.32% )
Inpatient	157 ( 32.24% )	90.45% ( 84.73% , 94.55% )	82.08% ( 75.54% , 87.49% )
Outpatient or Emergency Department	89 ( 18.28% )	96.63% ( 90.46% , 99.30% )	71.07% ( 62.13% , 78.95% )
Other	6 ( 1.23% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
Care Setting Reported as Unknown	43 ( 8.83% )	92.86% ( 80.52% , 98.50% )	90.70% ( 77.86% , 97.41% )
<b>Demographics</b>			
<b>Sex</b>			
Female	211 ( 43.33% )	92.68% ( 87.57% , 96.16% )	89.94% ( 84.38% , 94.03% )
Male	258 ( 52.98% )	94.50% ( 90.58% , 97.12% )	91.15% ( 86.66% , 94.51% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	3 ( 0.62% )	N/A	N/A
6-17	N/A	N/A	N/A
18-29	9 ( 1.85% )	85.71% ( 42.13% , 99.64% )	66.67% ( 29.93% , 92.51% )
30-39	22 ( 4.52% )	87.50% ( 61.65% , 98.45% )	87.50% ( 61.65% , 98.45% )
40-49	54 ( 11.09% )	92.86% ( 80.52% , 98.50% )	90.70% ( 77.86% , 97.41% )
50-59	101 ( 20.74% )	93.02% ( 85.43% , 97.40% )	94.12% ( 86.80% , 98.06% )
60-69	110 ( 22.59% )	95.79% ( 89.57% , 98.84% )	92.86% ( 85.84% , 97.08% )
70-79	102 ( 20.94% )	93.83% ( 86.18% , 97.97% )	89.41% ( 80.85% , 95.04% )
80-89	49 ( 10.06% )	97.50% ( 86.84% , 99.94% )	88.64% ( 75.44% , 96.21% )
90+	16 ( 3.29% )	92.86% ( 66.13% , 99.82% )	92.86% ( 66.13% , 99.82% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	4 ( 0.82% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Asian	34 ( 6.98% )	96.43% ( 81.65% , 99.91% )	96.43% ( 81.65% , 99.91% )
Black or African American	147 ( 30.18% )	96.40% ( 91.03% , 99.01% )	90.68% ( 83.93% , 95.25% )
Native Hawaiian or Other Pacific Islander	2 ( 0.41% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	197 ( 40.45% )	90.64% ( 85.25% , 94.56% )	89.08% ( 83.47% , 93.30% )
Other/Mixed/Unknown	85 ( 17.45% )	95.52% ( 87.47% , 99.07% )	91.43% ( 82.27% , 96.79% )
<b>Ethnicity</b>			



**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	53 ( 10.88% )	97.78% ( 88.23% , 99.94% )	88 % ( 75.69% , 95.47% )
Non-Hispanic	288 ( 59.14% )	92.77% ( 88.82% , 95.66% )	90.23% ( 85.92% , 93.58% )
Unknown	128 ( 26.28% )	94.32% ( 87.24% , 98.13% )	93.26% ( 85.90% , 97.49% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	14 ( 2.87% )	100.0% ( 69.15% , 100.0% )	83.33% ( 51.59% , 97.91% )
Contact and suspected exposure (Z20.828)	83 ( 17.04% )	88.41% ( 78.43% , 94.86% )	89.71% ( 79.93% , 95.76% )
Pneumonia (see Appendix B)	312 ( 64.07% )	93.66% ( 90.04% , 96.26% )	91.27% ( 87.29% , 94.33% )
Other viral pneumonia (J12.89)	329 ( 67.56% )	97.11% ( 94.39% , 98.75% )	97.82% ( 95.31% , 99.20% )
ARDS (J80)	116 ( 23.82% )	98.04% ( 93.10% , 99.76% )	100.0% ( 96.38% , 100.0% )
Sepsis (see Appendix C)	160 ( 32.85% )	93.33% ( 87.72% , 96.91% )	93.33% ( 87.72% , 96.91% )
Bronchitis (J20.8 OR J40)	12 ( 2.46% )	100.0% ( 69.15% , 100.0% )	100.0% ( 69.15% , 100.0% )
Respiratory infection (J22 OR J98.8)	34 ( 6.98% )	100.0% ( 88.78% , 100.0% )	96.88% ( 83.78% , 99.92% )
Cough (R05)	75 ( 15.40% )	95.08% ( 86.29% , 98.97% )	92.06% ( 82.44% , 97.37% )
Shortness of breath (R06.2)	2 ( 0.41% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Fever (R50.9)	106 ( 21.77% )	96.55% ( 90.25% , 99.28% )	90.32% ( 82.42% , 95.48% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	7 ( 1.44% )	100.0% ( 54.07% , 100.0% )	100.0% ( 54.07% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	199 ( 40.86% )	95.86% ( 91.21% , 98.47% )	92.67% ( 87.26% , 96.28% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	36 ( 7.39% )	97.06% ( 84.67% , 99.93% )	100.0% ( 89.42% , 100.0% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	237 ( 48.67% )	92.67% ( 88.53% , 95.67% )	89.21% ( 84.59% , 92.83% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	29 ( 5.95% )	95.45% ( 77.16% , 99.88% )	91.30% ( 71.96% , 98.93% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	52 ( 10.68% )	97.50% ( 86.84% , 99.94% )	100.0% ( 90.97% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	15 ( 3.08% )	93.33% ( 68.05% , 99.83% )	82.35% ( 56.57% , 96.20% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	102 ( 20.94% )	96.08% ( 90.26% , 98.92% )	91.59% ( 84.63% , 96.08% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.41% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	34 ( 6.98% )	96.88% ( 83.78% , 99.92% )	100.0% ( 88.78% , 100.0% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	321	15	4	73	336 ( 81.36% )
Inpatient	130	8	0	N/A	138
Outpatient or Emergency Department	80	3	0	N/A	83
Other	3	0	1	N/A	3
Care Setting Reported as Unknown	36	2	0	N/A	38
<b>Demographics</b>					
Sex					
Female	128	8	3	30	136 ( 80.47% )
Male	193	7	1	32	200 ( 85.84% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	1	0 (0.00%)
6-17	0	0	0	0	N/A
18-29	6	1	0	1	7 ( 87.50% )
30-39	13	2	1	5	15 ( 71.43% )
40-49	36	1	0	12	37 ( 75.51% )
50-59	77	3	2	8	80 ( 88.89% )
60-69	82	4	0	13	86 ( 86.87% )
70-79	68	2	0	13	70 ( 84.34% )
80-89	33	1	0	7	34 ( 82.93% )
90+	6	0	1	1	6 ( 75 % )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	2	0	0	0	2 ( 100.0% )
Asian	25	1	0	6	26 ( 81.25% )
Black or African American	102	4	0	29	106 ( 78.52% )
Native Hawaiian or Other Pacific Islander	2	0	0	0	2 ( 100.0% )
White	135	7	3	13	142 ( 89.87% )
Other/Mixed/Unknown	55	3	1	14	58 ( 79.45% )
Ethnicity					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	39	1	0	5	40 ( 88.89% )
Non-Hispanic	208	10	4	28	218 ( 87.20% )
Unknown	74	4	0	29	78 ( 72.90% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	10	0	0	4	10 ( 71.43% )
Contact and suspected exposure (Z20.828)	58	4	0	12	62 ( 83.78% )
Pneumonia (see Appendix B)	248	15	1	41	263 ( 86.23% )
Other viral pneumonia (J12.89)	267	8	3	48	275 ( 84.36% )
ARDS (J80)	100	2	1	13	102 ( 87.93% )
Sepsis (see Appendix C)	122	7	0	20	129 ( 86.58% )
Bronchitis (J20.8 OR J40)	9	0	1	0	9 ( 90% )
Respiratory infection (J22 OR J98.8)	25	0	0	2	25 ( 92.59% )
Cough (R05)	46	1	0	10	47 ( 82.46% )
Shortness of breath (R06.2)	1	0	0	0	1 ( 100.0% )
Fever (R50.9)	76	3	0	15	79 ( 84.04% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	5	0	0	1	5 ( 83.33% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	130	4	1	40	134 ( 76.57% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	27	0	1	1	27 ( 93.10% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	201	10	1	4	211 ( 97.69% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	21	1	0	6	22 ( 78.57% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	39	1	0	12	40 ( 76.92% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	13	1	-	-	14 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	95	3	-	-	98 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	-	-	-	-	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	-	-	-	-	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2	0	0	0	2 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	25	0	1	1	25 ( 92.59% )

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	413 ( 100.0% )	95.54% ( 92.74% , 97.48% )	81.27% ( 77.06% , 84.99% )
Inpatient	138 ( 33.41% )	94.20% ( 88.90% , 97.46% )	75.14% ( 68.02% , 81.39% )
Outpatient or Emergency Department	83 ( 20.10% )	96.39% ( 89.80% , 99.25% )	66.12% ( 56.95% , 74.47% )
Other	4 ( 0.97% )	100.0% ( 29.24% , 100.0% )	50 % ( 11.81% , 88.19% )
Care Setting Reported as Unknown	39 ( 9.44% )	94.74% ( 82.25% , 99.36% )	83.72% ( 69.30% , 93.19% )
<b>Demographics</b>			
<b>Sex</b>			
Female	169 ( 40.92% )	94.12% ( 88.74% , 97.43% )	75.74% ( 68.56% , 81.99% )
Male	233 ( 56.42% )	96.50% ( 92.92% , 98.58% )	85.40% ( 80.11% , 89.73% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	1 ( 0.24% )	N/A	N/A
6-17	N/A	N/A	N/A
18-29	8 ( 1.94% )	85.71% ( 42.13% , 99.64% )	66.67% ( 29.93% , 92.51% )
30-39	21 ( 5.08% )	86.67% ( 59.54% , 98.34% )	81.25% ( 54.35% , 95.95% )
40-49	49 ( 11.86% )	97.30% ( 85.84% , 99.93% )	83.72% ( 69.30% , 93.19% )
50-59	90 ( 21.79% )	96.25% ( 89.43% , 99.22% )	90.59% ( 82.29% , 95.85% )
60-69	99 ( 23.97% )	95.35% ( 88.52% , 98.72% )	83.67% ( 74.84% , 90.37% )
70-79	83 ( 20.10% )	97.14% ( 90.06% , 99.65% )	80 % ( 69.92% , 87.90% )
80-89	41 ( 9.93% )	97.06% ( 84.67% , 99.93% )	75 % ( 59.66% , 86.81% )
90+	8 ( 1.94% )	100.0% ( 54.07% , 100.0% )	42.86% ( 17.66% , 71.14% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	2 ( 0.48% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
Asian	32 ( 7.75% )	96.15% ( 80.36% , 99.90% )	89.29% ( 71.77% , 97.73% )
Black or African American	135 ( 32.69% )	96.23% ( 90.62% , 98.96% )	86.44% ( 78.92% , 92.05% )
Native Hawaiian or Other Pacific Islander	2 ( 0.48% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
White	158 ( 38.26% )	95.07% ( 90.11% , 98 % )	77.59% ( 70.66% , 83.55% )
Other/Mixed/Unknown	73 ( 17.68% )	94.83% ( 85.62% , 98.92% )	78.57% ( 67.13% , 87.48% )
<b>Ethnicity</b>			



**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Hispanic	45 ( 10.90% )	97.50% ( 86.84% , 99.94% )	78 % ( 64.04% , 88.47% )
Non-Hispanic	250 ( 60.53% )	95.41% ( 91.73% , 97.78% )	81.25% ( 75.92% , 85.84% )
Unknown	107 ( 25.91% )	94.87% ( 87.39% , 98.59% )	83.15% ( 73.73% , 90.25% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	14 ( 3.39% )	100.0% ( 69.15% , 100.0% )	83.33% ( 51.59% , 97.91% )
Contact and suspected exposure (Z20.828)	74 ( 17.92% )	93.55% ( 84.30% , 98.21% )	85.29% ( 74.61% , 92.72% )
Pneumonia (see Appendix B)	305 ( 73.85% )	94.30% ( 90.77% , 96.77% )	90.18% ( 86.04% , 93.43% )
Other viral pneumonia (J12.89)	326 ( 78.93% )	97.09% ( 94.35% , 98.74% )	97.09% ( 94.35% , 98.74% )
ARDS (J80)	116 ( 28.09% )	98.04% ( 93.10% , 99.76% )	100.0% ( 96.38% , 100.0% )
Sepsis (see Appendix C)	149 ( 36.08% )	94.57% ( 89.14% , 97.79% )	90.37% ( 84.10% , 94.77% )
Bronchitis (J20.8 OR J40)	10 ( 2.42% )	100.0% ( 66.37% , 100.0% )	90 % ( 55.50% , 99.75% )
Respiratory infection (J22 OR J98.8)	27 ( 6.54% )	100.0% ( 86.28% , 100.0% )	78.13% ( 60.03% , 90.72% )
Cough (R05)	57 ( 13.80% )	97.87% ( 88.71% , 99.95% )	73.02% ( 60.35% , 83.43% )
Shortness of breath (R06.2)	1 ( 0.24% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
Fever (R50.9)	94 ( 22.76% )	96.20% ( 89.30% , 99.21% )	81.72% ( 72.35% , 88.98% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	6 ( 1.45% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	175 ( 42.37% )	97.01% ( 92.53% , 99.18% )	86.67% ( 80.16% , 91.66% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	29 ( 7.02% )	100.0% ( 87.23% , 100.0% )	81.82% ( 64.54% , 93.02% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	216 ( 52.30% )	95.26% ( 91.46% , 97.70% )	83.40% ( 78.09% , 87.87% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	28 ( 6.78% )	95.45% ( 77.16% , 99.88% )	91.30% ( 71.96% , 98.93% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	52 ( 12.59% )	97.50% ( 86.84% , 99.94% )	100.0% ( 90.97% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	14 ( 3.39% )	92.86% ( 66.13% , 99.82% )	76.47% ( 50.10% , 93.19% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	98 ( 23.73% )	96.94% ( 91.31% , 99.36% )	88.79% ( 81.23% , 94.07% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	N/A	N/A	N/A
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	N/A	N/A	N/A
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	2 ( 0.48% )	100.0% ( 15.81% , 100.0% )	100.0% ( 15.81% , 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1g. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and March 31, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	27 ( 6.54% )	100.0% ( 86.28% , 100.0% )	80.65% ( 62.53% , 92.55% )

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINC or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test***</b>				
Total Observed	1,026	1,264	2,796	3,556
Inpatient	393	487	1,879	2,246
Outpatient or Emergency Department	350	366	301	349
Other	29	40	223	313
Care Setting Reported as Unknown	246	262	570	639
<b>Demographics</b>				
Sex				
Female	510	642	1,531	1,937
Male	516	622	1,265	1,619
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	0	0	28	37
6-17	1	1	38	56
18-29	31	33	221	267
30-39	80	84	357	410
40-49	111	135	234	315
50-59	235	273	348	444
60-69	240	299	514	672
70-79	189	240	529	695
80-89	111	160	382	478
90+	28	39	145	182
Missing	0	0	0	0
Race				
American Indian or Alaska Native	5	6	28	33
Asian	71	84	163	192
Black or African American	362	408	425	506
Native Hawaiian or Other Pacific Islander	3	5	3	3
White	310	426	1,823	2,349
Other/Mixed/Unknown	275	325	354	463
Ethnicity				

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	250	291	228	294
Non-Hispanic	503	677	2,089	2,698
Unknown	273	296	479	564
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	31	41	535	661
Contact and suspected exposure (Z20.828)	205	276	1,266	1,700
Pneumonia (see Appendix B)	756	1,045	543	824
Other viral pneumonia (J12.89)	808	1,009	91	129
ARDS (J80)	197	252	33	60
Sepsis (see Appendix C)	367	489	590	838
Bronchitis (J20.8 OR J40)	17	18	13	21
Respiratory infection (J22 OR J98.8)	50	60	14	16
Cough (R05)	112	150	174	248
Shortness of breath (R06.2)	3	3	10	16
Fever (R50.9)	173	207	234	334
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	19	24	3	4
Test performed, only negative results	0	0	10	13
No test or unknown result	671	759	2,116	2,501
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	153	195	1,466	1,753
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	687	878	1,786	2,398
<b>Codes Observed During Inpatient Stay</b>				

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	55	61	102	122
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	133	150	27	34
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	3	3	3	3
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	441	479	561	631
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	95	95	55	58
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	11	73	73
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	137	177	1,442	1,720
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	16	18	24	33

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	990	74	2	210	1,064 ( 83.39% )
Inpatient	332	39	1	N/A	371
Outpatient or Emergency Department	295	15	0	N/A	310
Other	22	1	0	N/A	23
Care Setting Reported as Unknown	232	19	1	N/A	251
<b>Demographics</b>					
Sex					
Female	494	36	0	90	530 ( 85.48% )
Male	496	38	2	104	534 ( 83.44% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	2	0 (0.00%)
6-17	1	0	0	0	1 ( 100.0% )
18-29	29	4	0	6	33 ( 84.62% )
30-39	76	2	0	14	78 ( 84.78% )
40-49	106	7	0	16	113 ( 87.60% )
50-59	226	13	0	36	239 ( 86.91% )
60-69	236	20	1	43	256 ( 85.33% )
70-79	181	14	1	39	195 ( 82.98% )
80-89	108	10	0	27	118 ( 81.38% )
90+	27	4	0	11	31 ( 73.81% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	2	5 ( 71.43% )
Asian	68	3	1	8	71 ( 88.75% )
Black or African American	355	13	1	116	368 ( 75.88% )
Native Hawaiian or Other Pacific Islander	3	0	0	2	3 ( 60 % )
White	294	41	0	28	335 ( 92.29% )
Other/Mixed/Unknown	265	17	0	38	282 ( 88.13% )
Ethnicity					



**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	243	8	0	27	251 ( 90.29% )
Non-Hispanic	483	39	2	46	522 ( 91.58% )
Unknown	264	27	0	121	291 ( 70.63% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	29	8	0	8	37 ( 82.22% )
Contact and suspected exposure (Z20.828)	190	44	0	44	234 ( 84.17% )
Pneumonia (see Appendix B)	744	51	2	149	795 ( 84.04% )
Other viral pneumonia (J12.89)	805	31	2	146	836 ( 84.96% )
ARDS (J80)	195	11	1	30	206 ( 86.92% )
Sepsis (see Appendix C)	359	36	2	76	395 ( 83.51% )
Bronchitis (J20.8 OR J40)	17	0	0	3	17 ( 85 % )
Respiratory infection (J22 OR J98.8)	50	1	1	17	51 ( 73.91% )
Cough (R05)	108	14	0	29	122 ( 80.79% )
Shortness of breath (R06.2)	3	0	0	0	3 ( 100.0% )
Fever (R50.9)	169	13	0	50	182 ( 78.45% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	19	0	0	3	19 ( 86.36% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	653	31	2	181	684 ( 78.89% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	148	5	0	9	153 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	652	62	1	14	714 ( 97.94% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	53	4	0	22	57 ( 72.15% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	132	10	0	35	142 ( 80.23% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	424	21	2	-	445 ( 99.55% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	135	4	0	0	139 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	1,276 ( 100.0% )	93.05% ( 91.35% , 94.50% )	96.49% ( 95.18% , 97.53% )
Inpatient	372 ( 29.15% )	89.49% ( 85.91% , 92.42% )	84.48% ( 80.51% , 87.91% )
Outpatient or Emergency Department	310 ( 24.29% )	95.16% ( 92.14% , 97.27% )	84.29% ( 80.04% , 87.94% )
Other	23 ( 1.80% )	95.65% ( 78.05% , 99.89% )	75.86% ( 56.46% , 89.70% )
Care Setting Reported as Unknown	261 ( 20.45% )	92.43% ( 88.43% , 95.38% )	94.31% ( 90.64% , 96.85% )
<b>Demographics</b>			
<b>Sex</b>			
Female	620 ( 48.59% )	93.21% ( 90.72% , 95.20% )	96.86% ( 94.96% , 98.20% )
Male	640 ( 50.16% )	92.88% ( 90.36% , 94.92% )	96.12% ( 94.08% , 97.62% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	2 ( 0.16% )	N/A	N/A
6-17	1 ( 0.08% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
18-29	39 ( 3.06% )	87.88% ( 71.80% , 96.60% )	93.55% ( 78.58% , 99.21% )
30-39	92 ( 7.21% )	97.44% ( 91.04% , 99.69% )	95 % ( 87.69% , 98.62% )
40-49	129 ( 10.11% )	93.81% ( 87.65% , 97.47% )	95.50% ( 89.80% , 98.52% )
50-59	275 ( 21.55% )	94.56% ( 90.88% , 97.07% )	96.17% ( 92.85% , 98.23% )
60-69	300 ( 23.51% )	92.19% ( 88.19% , 95.16% )	98.33% ( 95.79% , 99.54% )
70-79	235 ( 18.42% )	92.82% ( 88.25% , 96.02% )	95.77% ( 91.83% , 98.16% )
80-89	145 ( 11.36% )	91.53% ( 84.97% , 95.86% )	97.30% ( 92.30% , 99.44% )
90+	42 ( 3.29% )	87.10% ( 70.17% , 96.37% )	96.43% ( 81.65% , 99.91% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	7 ( 0.55% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	80 ( 6.27% )	95.77% ( 88.14% , 99.12% )	95.77% ( 88.14% , 99.12% )
Black or African American	485 ( 38.01% )	96.47% ( 94.03% , 98.11% )	98.07% ( 96.06% , 99.22% )
Native Hawaiian or Other Pacific Islander	5 ( 0.39% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	363 ( 28.45% )	87.76% ( 83.76% , 91.07% )	94.84% ( 91.75% , 97.02% )
Other/Mixed/Unknown	320 ( 25.08% )	93.97% ( 90.52% , 96.45% )	96.36% ( 93.41% , 98.24% )
<b>Ethnicity</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	278 ( 21.79% )	96.81% ( 93.82% , 98.61% )	97.20% ( 94.32% , 98.87% )
Non-Hispanic	570 ( 44.67% )	92.53% ( 89.93% , 94.63% )	96.02% ( 93.93% , 97.55% )
Unknown	412 ( 32.29% )	90.72% ( 86.79% , 93.80% )	96.70% ( 93.83% , 98.48% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	45 ( 3.53% )	78.38% ( 61.79% , 90.17% )	93.55% ( 78.58% , 99.21% )
Contact and suspected exposure (Z20.828)	278 ( 21.79% )	81.20% ( 75.59% , 85.99% )	92.68% ( 88.22% , 95.85% )
Pneumonia (see Appendix B)	946 ( 74.14% )	93.58% ( 91.65% , 95.19% )	98.41% ( 97.24% , 99.18% )
Other viral pneumonia (J12.89)	984 ( 77.12% )	96.29% ( 94.78% , 97.47% )	99.63% ( 98.92% , 99.92% )
ARDS (J80)	237 ( 18.57% )	94.66% ( 90.65% , 97.30% )	98.98% ( 96.38% , 99.88% )
Sepsis (see Appendix C)	473 ( 37.07% )	90.89% ( 87.61% , 93.53% )	97.82% ( 95.75% , 99.05% )
Bronchitis (J20.8 OR J40)	20 ( 1.57% )	100.0% ( 80.49% , 100.0% )	100.0% ( 80.49% , 100.0% )
Respiratory infection (J22 OR J98.8)	69 ( 5.41% )	98.04% ( 89.55% , 99.95% )	100.0% ( 92.89% , 100.0% )
Cough (R05)	151 ( 11.83% )	88.52% ( 81.50% , 93.58% )	96.43% ( 91.11% , 99.02% )
Shortness of breath (R06.2)	3 ( 0.24% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Fever (R50.9)	232 ( 18.18% )	92.86% ( 88.10% , 96.14% )	97.69% ( 94.19% , 99.37% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	22 ( 1.72% )	100.0% ( 82.35% , 100.0% )	100.0% ( 82.35% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	867 ( 67.95% )	95.47% ( 93.63% , 96.90% )	97.32% ( 95.79% , 98.40% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	162 ( 12.70% )	96.73% ( 92.54% , 98.93% )	96.73% ( 92.54% , 98.93% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	729 ( 57.13% )	91.32% ( 89.01% , 93.28% )	94.91% ( 92.99% , 96.43% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	79 ( 6.19% )	92.98% ( 83 % , 98.05% )	96.36% ( 87.47% , 99.56% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	177 ( 13.87% )	92.96% ( 87.43% , 96.57% )	99.25% ( 95.88% , 99.98% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.16% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	447 ( 35.03% )	95.28% ( 92.88% , 97.06% )	96.15% ( 93.90% , 97.74% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 7.13% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.94% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	139 ( 10.89% )	97.12% ( 92.80% , 99.21% )	98.54% ( 94.83% , 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
	<b>Number (Percent)</b>		
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 1.80% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	990	80	2	212	1,070 ( 83.33% )
Inpatient	332	41	1	N/A	373
Outpatient or Emergency Department	296	17	0	N/A	313
Other	22	1	0	N/A	23
Care Setting Reported as Unknown	232	21	1	N/A	253
<b>Demographics</b>					
Sex					
Female	493	39	0	91	532 ( 85.39% )
Male	497	41	2	105	538 ( 83.41% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	2	0 (0.00%)
6-17	1	0	0	0	1 ( 100.0% )
18-29	29	4	0	6	33 ( 84.62% )
30-39	76	3	0	14	79 ( 84.95% )
40-49	106	7	0	16	113 ( 87.60% )
50-59	226	14	0	36	240 ( 86.96% )
60-69	236	22	1	44	258 ( 85.15% )
70-79	182	14	1	40	196 ( 82.70% )
80-89	107	12	0	27	119 ( 81.51% )
90+	27	4	0	11	31 ( 73.81% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	2	5 ( 71.43% )
Asian	68	3	1	8	71 ( 88.75% )
Black or African American	356	15	1	116	371 ( 76.02% )
Native Hawaiian or Other Pacific Islander	3	0	0	2	3 ( 60 % )
White	294	45	0	30	339 ( 91.87% )
Other/Mixed/Unknown	264	17	0	38	281 ( 88.09% )
Ethnicity					



**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	243	8	0	27	251 ( 90.29% )
Non-Hispanic	483	41	2	46	524 ( 91.61% )
Unknown	264	31	0	123	295 ( 70.57% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	29	9	0	8	38 ( 82.61% )
Contact and suspected exposure (Z20.828)	191	48	0	44	239 ( 84.45% )
Pneumonia (see Appendix B)	745	54	2	151	799 ( 83.93% )
Other viral pneumonia (J12.89)	806	32	2	148	838 ( 84.82% )
ARDS (J80)	195	12	1	30	207 ( 86.97% )
Sepsis (see Appendix C)	359	40	2	76	399 ( 83.65% )
Bronchitis (J20.8 OR J40)	17	0	0	3	17 ( 85 % )
Respiratory infection (J22 OR J98.8)	50	1	1	17	51 ( 73.91% )
Cough (R05)	108	17	0	29	125 ( 81.17% )
Shortness of breath (R06.2)	3	0	0	0	3 ( 100.0% )
Fever (R50.9)	169	16	0	50	185 ( 78.72% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	19	0	0	3	19 ( 86.36% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	654	35	2	183	689 ( 78.83% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	148	5	0	9	153 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	653	66	1	14	719 ( 97.96% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	53	6	0	22	59 ( 72.84% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	133	11	0	35	144 ( 80.45% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	425	25	2	-	450 ( 99.56% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	135	4	0	0	139 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	1,284 ( 100.0% )	92.52% ( 90.78% , 94.03% )	96.49% ( 95.18% , 97.53% )
Inpatient	374 ( 29.13% )	89.01% ( 85.38% , 92 % )	84.48% ( 80.51% , 87.91% )
Outpatient or Emergency Department	313 ( 24.38% )	94.57% ( 91.45% , 96.80% )	84.57% ( 80.35% , 88.19% )
Other	23 ( 1.79% )	95.65% ( 78.05% , 99.89% )	75.86% ( 56.46% , 89.70% )
Care Setting Reported as Unknown	263 ( 20.48% )	91.70% ( 87.59% , 94.79% )	94.31% ( 90.64% , 96.85% )
<b>Demographics</b>			
Sex			
Female	623 ( 48.52% )	92.67% ( 90.11% , 94.74% )	96.67% ( 94.72% , 98.05% )
Male	645 ( 50.23% )	92.38% ( 89.80% , 94.48% )	96.32% ( 94.31% , 97.77% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	2 ( 0.16% )	N/A	N/A
6-17	1 ( 0.08% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
18-29	39 ( 3.04% )	87.88% ( 71.80% , 96.60% )	93.55% ( 78.58% , 99.21% )
30-39	93 ( 7.24% )	96.20% ( 89.30% , 99.21% )	95 % ( 87.69% , 98.62% )
40-49	129 ( 10.05% )	93.81% ( 87.65% , 97.47% )	95.50% ( 89.80% , 98.52% )
50-59	276 ( 21.50% )	94.17% ( 90.41% , 96.77% )	96.17% ( 92.85% , 98.23% )
60-69	303 ( 23.60% )	91.47% ( 87.37% , 94.58% )	98.33% ( 95.79% , 99.54% )
70-79	237 ( 18.46% )	92.86% ( 88.31% , 96.04% )	96.30% ( 92.52% , 98.50% )
80-89	146 ( 11.37% )	89.92% ( 83.05% , 94.68% )	96.40% ( 91.03% , 99.01% )
90+	42 ( 3.27% )	87.10% ( 70.17% , 96.37% )	96.43% ( 81.65% , 99.91% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	7 ( 0.55% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	80 ( 6.23% )	95.77% ( 88.14% , 99.12% )	95.77% ( 88.14% , 99.12% )
Black or African American	488 ( 38.01% )	95.96% ( 93.42% , 97.72% )	98.34% ( 96.43% , 99.39% )
Native Hawaiian or Other Pacific Islander	5 ( 0.39% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	369 ( 28.74% )	86.73% ( 82.64% , 90.15% )	94.84% ( 91.75% , 97.02% )
Other/Mixed/Unknown	319 ( 24.84% )	93.95% ( 90.49% , 96.44% )	96 % ( 92.96% , 97.99% )
Ethnicity			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	278 ( 21.65% )	96.81% ( 93.82% , 98.61% )	97.20% ( 94.32% , 98.87% )
Non-Hispanic	572 ( 44.55% )	92.18% ( 89.53% , 94.33% )	96.02% ( 93.93% , 97.55% )
Unknown	418 ( 32.55% )	89.49% ( 85.42% , 92.75% )	96.70% ( 93.83% , 98.48% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	46 ( 3.58% )	76.32% ( 59.76% , 88.56% )	93.55% ( 78.58% , 99.21% )
Contact and suspected exposure (Z20.828)	283 ( 22.04% )	79.92% ( 74.27% , 84.80% )	93.17% ( 88.81% , 96.22% )
Pneumonia (see Appendix B)	952 ( 74.14% )	93.24% ( 91.27% , 94.88% )	98.54% ( 97.41% , 99.27% )
Other viral pneumonia (J12.89)	988 ( 76.95% )	96.18% ( 94.65% , 97.37% )	99.75% ( 99.11% , 99.97% )
ARDS (J80)	238 ( 18.54% )	94.20% ( 90.09% , 96.97% )	98.98% ( 96.38% , 99.88% )
Sepsis (see Appendix C)	477 ( 37.15% )	89.97% ( 86.60% , 92.74% )	97.82% ( 95.75% , 99.05% )
Bronchitis (J20.8 OR J40)	20 ( 1.56% )	100.0% ( 80.49% , 100.0% )	100.0% ( 80.49% , 100.0% )
Respiratory infection (J22 OR J98.8)	69 ( 5.37% )	98.04% ( 89.55% , 99.95% )	100.0% ( 92.89% , 100.0% )
Cough (R05)	154 ( 11.99% )	86.40% ( 79.12% , 91.87% )	96.43% ( 91.11% , 99.02% )
Shortness of breath (R06.2)	3 ( 0.23% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Fever (R50.9)	235 ( 18.30% )	91.35% ( 86.34% , 94.98% )	97.69% ( 94.19% , 99.37% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	22 ( 1.71% )	100.0% ( 82.35% , 100.0% )	100.0% ( 82.35% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	874 ( 68.07% )	94.92% ( 93.01% , 96.44% )	97.47% ( 95.97% , 98.52% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	162 ( 12.62% )	96.73% ( 92.54% , 98.93% )	96.73% ( 92.54% , 98.93% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	734 ( 57.17% )	90.82% ( 88.47% , 92.83% )	95.05% ( 93.15% , 96.55% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	81 ( 6.31% )	89.83% ( 79.17% , 96.18% )	96.36% ( 87.47% , 99.56% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	179 ( 13.94% )	92.36% ( 86.74% , 96.13% )	100.0% ( 97.26% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.16% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	452 ( 35.20% )	94.44% ( 91.91% , 96.37% )	96.37% ( 94.17% , 97.91% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 7.09% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.93% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	139 ( 10.83% )	97.12% ( 92.80% , 99.21% )	98.54% ( 94.83% , 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 1.79% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	990	81	2	213	1,071 ( 83.28% )
Inpatient	332	42	1	N/A	374
Outpatient or Emergency Department	296	17	0	N/A	313
Other	22	1	0	N/A	23
Care Setting Reported as Unknown	232	21	1	N/A	253
<b>Demographics</b>					
Sex					
Female	493	40	0	92	533 ( 85.28% )
Male	497	41	2	105	538 ( 83.41% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	2	0 (0.00%)
6-17	1	0	0	0	1 ( 100.0% )
18-29	29	4	0	6	33 ( 84.62% )
30-39	76	3	0	14	79 ( 84.95% )
40-49	106	8	0	16	114 ( 87.69% )
50-59	226	14	0	36	240 ( 86.96% )
60-69	236	22	1	44	258 ( 85.15% )
70-79	182	14	1	41	196 ( 82.35% )
80-89	107	12	0	27	119 ( 81.51% )
90+	27	4	0	11	31 ( 73.81% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	2	5 ( 71.43% )
Asian	68	3	1	8	71 ( 88.75% )
Black or African American	356	15	1	116	371 ( 76.02% )
Native Hawaiian or Other Pacific Islander	3	0	0	2	3 ( 60 % )
White	294	45	0	30	339 ( 91.87% )
Other/Mixed/Unknown	264	18	0	39	282 ( 87.85% )
Ethnicity					



**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	243	9	0	28	252 ( 90 % )
Non-Hispanic	483	41	2	46	524 ( 91.61% )
Unknown	264	31	0	123	295 ( 70.57% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	29	9	0	8	38 ( 82.61% )
Contact and suspected exposure (Z20.828)	191	49	0	44	240 ( 84.51% )
Pneumonia (see Appendix B)	745	54	2	151	799 ( 83.93% )
Other viral pneumonia (J12.89)	806	32	2	148	838 ( 84.82% )
ARDS (J80)	195	12	1	30	207 ( 86.97% )
Sepsis (see Appendix C)	359	40	2	76	399 ( 83.65% )
Bronchitis (J20.8 OR J40)	17	0	0	3	17 ( 85 % )
Respiratory infection (J22 OR J98.8)	50	1	1	17	51 ( 73.91% )
Cough (R05)	108	17	0	29	125 ( 81.17% )
Shortness of breath (R06.2)	3	0	0	0	3 ( 100.0% )
Fever (R50.9)	169	16	0	50	185 ( 78.72% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	19	0	0	3	19 ( 86.36% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	654	35	2	184	689 ( 78.74% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	148	5	0	9	153 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	653	67	1	15	720 ( 97.83% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	53	6	0	22	59 ( 72.84% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	133	11	0	35	144 ( 80.45% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	425	25	2	-	450 ( 99.56% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	135	4	0	0	139 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	1,286 ( 100.0% )	92.44% ( 90.69% , 93.95% )	96.49% ( 95.18% , 97.53% )
Inpatient	375 ( 29.16% )	88.77% ( 85.12% , 91.79% )	84.48% ( 80.51% , 87.91% )
Outpatient or Emergency Department	313 ( 24.34% )	94.57% ( 91.45% , 96.80% )	84.57% ( 80.35% , 88.19% )
Other	23 ( 1.79% )	95.65% ( 78.05% , 99.89% )	75.86% ( 56.46% , 89.70% )
Care Setting Reported as Unknown	263 ( 20.45% )	91.70% ( 87.59% , 94.79% )	94.31% ( 90.64% , 96.85% )
<b>Demographics</b>			
<b>Sex</b>			
Female	625 ( 48.60% )	92.50% ( 89.92% , 94.58% )	96.67% ( 94.72% , 98.05% )
Male	645 ( 50.16% )	92.38% ( 89.80% , 94.48% )	96.32% ( 94.31% , 97.77% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	2 ( 0.16% )	N/A	N/A
6-17	1 ( 0.08% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
18-29	39 ( 3.03% )	87.88% ( 71.80% , 96.60% )	93.55% ( 78.58% , 99.21% )
30-39	93 ( 7.23% )	96.20% ( 89.30% , 99.21% )	95 % ( 87.69% , 98.62% )
40-49	130 ( 10.11% )	92.98% ( 86.64% , 96.92% )	95.50% ( 89.80% , 98.52% )
50-59	276 ( 21.46% )	94.17% ( 90.41% , 96.77% )	96.17% ( 92.85% , 98.23% )
60-69	303 ( 23.56% )	91.47% ( 87.37% , 94.58% )	98.33% ( 95.79% , 99.54% )
70-79	238 ( 18.51% )	92.86% ( 88.31% , 96.04% )	96.30% ( 92.52% , 98.50% )
80-89	146 ( 11.35% )	89.92% ( 83.05% , 94.68% )	96.40% ( 91.03% , 99.01% )
90+	42 ( 3.27% )	87.10% ( 70.17% , 96.37% )	96.43% ( 81.65% , 99.91% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	7 ( 0.54% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	80 ( 6.22% )	95.77% ( 88.14% , 99.12% )	95.77% ( 88.14% , 99.12% )
Black or African American	488 ( 37.95% )	95.96% ( 93.42% , 97.72% )	98.34% ( 96.43% , 99.39% )
Native Hawaiian or Other Pacific Islander	5 ( 0.39% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	369 ( 28.69% )	86.73% ( 82.64% , 90.15% )	94.84% ( 91.75% , 97.02% )
Other/Mixed/Unknown	321 ( 24.96% )	93.62% ( 90.10% , 96.17% )	96 % ( 92.96% , 97.99% )
<b>Ethnicity</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Hispanic	280 ( 21.77% )	96.43% ( 93.33% , 98.35% )	97.20% ( 94.32% , 98.87% )
Non-Hispanic	572 ( 44.48% )	92.18% ( 89.53% , 94.33% )	96.02% ( 93.93% , 97.55% )
Unknown	418 ( 32.50% )	89.49% ( 85.42% , 92.75% )	96.70% ( 93.83% , 98.48% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	46 ( 3.58% )	76.32% ( 59.76% , 88.56% )	93.55% ( 78.58% , 99.21% )
Contact and suspected exposure (Z20.828)	284 ( 22.08% )	79.58% ( 73.92% , 84.50% )	93.17% ( 88.81% , 96.22% )
Pneumonia (see Appendix B)	952 ( 74.03% )	93.24% ( 91.27% , 94.88% )	98.54% ( 97.41% , 99.27% )
Other viral pneumonia (J12.89)	988 ( 76.83% )	96.18% ( 94.65% , 97.37% )	99.75% ( 99.11% , 99.97% )
ARDS (J80)	238 ( 18.51% )	94.20% ( 90.09% , 96.97% )	98.98% ( 96.38% , 99.88% )
Sepsis (see Appendix C)	477 ( 37.09% )	89.97% ( 86.60% , 92.74% )	97.82% ( 95.75% , 99.05% )
Bronchitis (J20.8 OR J40)	20 ( 1.56% )	100.0% ( 80.49% , 100.0% )	100.0% ( 80.49% , 100.0% )
Respiratory infection (J22 OR J98.8)	69 ( 5.37% )	98.04% ( 89.55% , 99.95% )	100.0% ( 92.89% , 100.0% )
Cough (R05)	154 ( 11.98% )	86.40% ( 79.12% , 91.87% )	96.43% ( 91.11% , 99.02% )
Shortness of breath (R06.2)	3 ( 0.23% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Fever (R50.9)	235 ( 18.27% )	91.35% ( 86.34% , 94.98% )	97.69% ( 94.19% , 99.37% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	22 ( 1.71% )	100.0% ( 82.35% , 100.0% )	100.0% ( 82.35% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	875 ( 68.04% )	94.92% ( 93.01% , 96.44% )	97.47% ( 95.97% , 98.52% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	162 ( 12.60% )	96.73% ( 92.54% , 98.93% )	96.73% ( 92.54% , 98.93% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	736 ( 57.23% )	90.69% ( 88.33% , 92.72% )	95.05% ( 93.15% , 96.55% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	81 ( 6.30% )	89.83% ( 79.17% , 96.18% )	96.36% ( 87.47% , 99.56% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	179 ( 13.92% )	92.36% ( 86.74% , 96.13% )	100.0% ( 97.26% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.16% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	452 ( 35.15% )	94.44% ( 91.91% , 96.37% )	96.37% ( 94.17% , 97.91% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 7.08% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.93% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	139 ( 10.81% )	97.12% ( 92.80% , 99.21% )	98.54% ( 94.83% , 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 1.79% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	990	82	2	215	1,072 ( 83.17% )
Inpatient	332	43	1	N/A	375
Outpatient or Emergency Department	296	17	0	N/A	313
Other	22	1	0	N/A	23
Care Setting Reported as Unknown	232	21	1	N/A	253
<b>Demographics</b>					
Sex					
Female	493	41	0	92	534 ( 85.30% )
Male	497	41	2	107	538 ( 83.15% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	2	0 (0.00%)
6-17	1	0	0	0	1 ( 100.0% )
18-29	29	4	0	6	33 ( 84.62% )
30-39	76	3	0	14	79 ( 84.95% )
40-49	106	9	0	16	115 ( 87.79% )
50-59	226	14	0	38	240 ( 86.33% )
60-69	236	22	1	44	258 ( 85.15% )
70-79	182	14	1	41	196 ( 82.35% )
80-89	107	12	0	27	119 ( 81.51% )
90+	27	4	0	11	31 ( 73.81% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	5	0	0	2	5 ( 71.43% )
Asian	68	3	1	8	71 ( 88.75% )
Black or African American	356	15	1	118	371 ( 75.71% )
Native Hawaiian or Other Pacific Islander	3	0	0	2	3 ( 60 % )
White	294	45	0	30	339 ( 91.87% )
Other/Mixed/Unknown	264	19	0	39	283 ( 87.89% )
Ethnicity					



**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	243	10	0	28	253 ( 90.04% )
Non-Hispanic	483	41	2	46	524 ( 91.61% )
Unknown	264	31	0	125	295 ( 70.24% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	29	9	0	8	38 ( 82.61% )
Contact and suspected exposure (Z20.828)	191	50	0	44	241 ( 84.56% )
Pneumonia (see Appendix B)	745	54	2	153	799 ( 83.75% )
Other viral pneumonia (J12.89)	806	32	2	148	838 ( 84.82% )
ARDS (J80)	195	12	1	30	207 ( 86.97% )
Sepsis (see Appendix C)	359	40	2	76	399 ( 83.65% )
Bronchitis (J20.8 OR J40)	17	0	0	3	17 ( 85% )
Respiratory infection (J22 OR J98.8)	50	1	1	17	51 ( 73.91% )
Cough (R05)	108	17	0	29	125 ( 81.17% )
Shortness of breath (R06.2)	3	0	0	0	3 ( 100.0% )
Fever (R50.9)	169	17	0	50	186 ( 78.81% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	19	0	0	3	19 ( 86.36% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	654	35	2	186	689 ( 78.56% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	148	5	0	9	153 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	653	68	1	15	721 ( 97.83% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	53	6	0	22	59 ( 72.84% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	133	11	0	35	144 ( 80.45% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	425	25	2	-	450 ( 99.56% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	87	4	-	-	91 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11	1	-	-	12 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	135	4	0	0	139 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	13	1	0	9	14 ( 60.87% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test***</b>			
Total Observed	1,289 ( 100.0% )	92.35% ( 90.59% , 93.87% )	96.49% ( 95.18% , 97.53% )
Inpatient	376 ( 29.17% )	88.53% ( 84.87% , 91.58% )	84.48% ( 80.51% , 87.91% )
Outpatient or Emergency Department	313 ( 24.28% )	94.57% ( 91.45% , 96.80% )	84.57% ( 80.35% , 88.19% )
Other	23 ( 1.78% )	95.65% ( 78.05% , 99.89% )	75.86% ( 56.46% , 89.70% )
Care Setting Reported as Unknown	263 ( 20.40% )	91.70% ( 87.59% , 94.79% )	94.31% ( 90.64% , 96.85% )
<b>Demographics</b>			
Sex			
Female	626 ( 48.56% )	92.32% ( 89.73% , 94.43% )	96.67% ( 94.72% , 98.05% )
Male	647 ( 50.19% )	92.38% ( 89.80% , 94.48% )	96.32% ( 94.31% , 97.77% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	2 ( 0.16% )	N/A	N/A
6-17	1 ( 0.08% )	100.0% ( 2.50% , 100.0% )	100.0% ( 2.50% , 100.0% )
18-29	39 ( 3.03% )	87.88% ( 71.80% , 96.60% )	93.55% ( 78.58% , 99.21% )
30-39	93 ( 7.21% )	96.20% ( 89.30% , 99.21% )	95 % ( 87.69% , 98.62% )
40-49	131 ( 10.16% )	92.17% ( 85.66% , 96.36% )	95.50% ( 89.80% , 98.52% )
50-59	278 ( 21.57% )	94.17% ( 90.41% , 96.77% )	96.17% ( 92.85% , 98.23% )
60-69	303 ( 23.51% )	91.47% ( 87.37% , 94.58% )	98.33% ( 95.79% , 99.54% )
70-79	238 ( 18.46% )	92.86% ( 88.31% , 96.04% )	96.30% ( 92.52% , 98.50% )
80-89	146 ( 11.33% )	89.92% ( 83.05% , 94.68% )	96.40% ( 91.03% , 99.01% )
90+	42 ( 3.26% )	87.10% ( 70.17% , 96.37% )	96.43% ( 81.65% , 99.91% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	7 ( 0.54% )	100.0% ( 47.82% , 100.0% )	100.0% ( 47.82% , 100.0% )
Asian	80 ( 6.21% )	95.77% ( 88.14% , 99.12% )	95.77% ( 88.14% , 99.12% )
Black or African American	490 ( 38.01% )	95.96% ( 93.42% , 97.72% )	98.34% ( 96.43% , 99.39% )
Native Hawaiian or Other Pacific Islander	5 ( 0.39% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	369 ( 28.63% )	86.73% ( 82.64% , 90.15% )	94.84% ( 91.75% , 97.02% )
Other/Mixed/Unknown	322 ( 24.98% )	93.29% ( 89.71% , 95.91% )	96 % ( 92.96% , 97.99% )
Ethnicity			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
Hispanic	281 ( 21.80% )	96.05% ( 92.85% , 98.09% )	97.20% ( 94.32% , 98.87% )
Non-Hispanic	572 ( 44.38% )	92.18% ( 89.53% , 94.33% )	96.02% ( 93.93% , 97.55% )
Unknown	420 ( 32.58% )	89.49% ( 85.42% , 92.75% )	96.70% ( 93.83% , 98.48% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	46 ( 3.57% )	76.32% ( 59.76% , 88.56% )	93.55% ( 78.58% , 99.21% )
Contact and suspected exposure (Z20.828)	285 ( 22.11% )	79.25% ( 73.58% , 84.19% )	93.17% ( 88.81% , 96.22% )
Pneumonia (see Appendix B)	954 ( 74.01% )	93.24% ( 91.27% , 94.88% )	98.54% ( 97.41% , 99.27% )
Other viral pneumonia (J12.89)	988 ( 76.65% )	96.18% ( 94.65% , 97.37% )	99.75% ( 99.11% , 99.97% )
ARDS (J80)	238 ( 18.46% )	94.20% ( 90.09% , 96.97% )	98.98% ( 96.38% , 99.88% )
Sepsis (see Appendix C)	477 ( 37.01% )	89.97% ( 86.60% , 92.74% )	97.82% ( 95.75% , 99.05% )
Bronchitis (J20.8 OR J40)	20 ( 1.55% )	100.0% ( 80.49% , 100.0% )	100.0% ( 80.49% , 100.0% )
Respiratory infection (J22 OR J98.8)	69 ( 5.35% )	98.04% ( 89.55% , 99.95% )	100.0% ( 92.89% , 100.0% )
Cough (R05)	154 ( 11.95% )	86.40% ( 79.12% , 91.87% )	96.43% ( 91.11% , 99.02% )
Shortness of breath (R06.2)	3 ( 0.23% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Fever (R50.9)	236 ( 18.31% )	90.86% ( 85.77% , 94.59% )	97.69% ( 94.19% , 99.37% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	22 ( 1.71% )	100.0% ( 82.35% , 100.0% )	100.0% ( 82.35% , 100.0% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	877 ( 68.04% )	94.92% ( 93.01% , 96.44% )	97.47% ( 95.97% , 98.52% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	162 ( 12.57% )	96.73% ( 92.54% , 98.93% )	96.73% ( 92.54% , 98.93% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	737 ( 57.18% )	90.57% ( 88.20% , 92.60% )	95.05% ( 93.15% , 96.55% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	81 ( 6.28% )	89.83% ( 79.17% , 96.18% )	96.36% ( 87.47% , 99.56% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	179 ( 13.89% )	92.36% ( 86.74% , 96.13% )	100.0% ( 97.26% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.16% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	452 ( 35.07% )	94.44% ( 91.91% , 96.37% )	96.37% ( 94.17% , 97.91% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	91 ( 7.06% )	95.60% ( 89.13% , 98.79% )	91.58% ( 84.08% , 96.29% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	12 ( 0.93% )	91.67% ( 61.52% , 99.79% )	100.0% ( 71.51% , 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	139 ( 10.78% )	97.12% ( 92.80% , 99.21% )	98.54% ( 94.83% , 99.82% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	23 ( 1.78% )	92.86% ( 66.13% , 99.82% )	81.25% ( 54.35% , 95.95% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test***</b>					
Total Observed	852	58	2	173	910 ( 83.87% )
Inpatient	261	27	1	N/A	288
Outpatient or Emergency Department	263	14	0	N/A	277
Other	18	0	0	N/A	18
Care Setting Reported as Unknown	213	17	1	N/A	230
<b>Demographics</b>					
Sex					
Female	402	27	0	70	429 ( 85.97% )
Male	450	31	2	90	481 ( 83.94% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	0	0	0	0	N/A
6-17	0	0	0	0	N/A
18-29	15	0	0	4	15 ( 78.95% )
30-39	57	3	0	10	60 ( 85.71% )
40-49	91	6	0	14	97 ( 87.39% )
50-59	204	13	0	30	217 ( 87.85% )
60-69	219	16	1	39	235 ( 85.45% )
70-79	157	10	1	30	167 ( 84.34% )
80-89	88	7	0	23	95 ( 80.51% )
90+	21	3	0	10	24 ( 70.59% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	4	0	0	1	4 ( 80% )
Asian	63	3	1	7	66 ( 89.19% )
Black or African American	317	13	1	95	330 ( 77.46% )
Native Hawaiian or Other Pacific Islander	2	0	0	2	2 ( 50% )
White	235	29	0	26	264 ( 91.03% )
Other/Mixed/Unknown	231	13	0	29	244 ( 89.38% )
Ethnicity					



**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	210	6	0	23	216 ( 90.38% )
Non-Hispanic	412	26	2	35	438 ( 92.21% )
Unknown	230	26	0	102	256 ( 71.51% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	28	5	0	7	33 ( 82.50% )
Contact and suspected exposure (Z20.828)	185	34	0	40	219 ( 84.56% )
Pneumonia (see Appendix B)	748	54	2	151	802 ( 83.98% )
Other viral pneumonia (J12.89)	809	32	2	148	841 ( 84.86% )
ARDS (J80)	196	12	1	30	208 ( 87.03% )
Sepsis (see Appendix C)	348	27	2	66	375 ( 84.65% )
Bronchitis (J20.8 OR J40)	9	0	0	3	9 ( 75% )
Respiratory infection (J22 OR J98.8)	42	1	1	14	43 ( 74.14% )
Cough (R05)	94	12	0	26	106 ( 80.30% )
Shortness of breath (R06.2)	3	0	0	0	3 ( 100.0% )
Fever (R50.9)	160	12	0	45	172 ( 79.26% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	16	0	0	3	16 ( 84.21% )
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	571	28	2	149	599 ( 79.87% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	116	3	0	7	119 ( 94.44% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	555	56	1	14	611 ( 97.60% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	51	5	0	22	56 ( 71.79% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	132	11	0	35	143 ( 80.34% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2	-	-	-	2 ( 100.0% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	380	20	2	-	400 ( 99.50% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	79	4	-	-	83 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	10	1	-	-	11 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	105	3	0	0	108 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	0	0	0	0	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	11	0	0	7	11 ( 61.11% )

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	1,085 ( 100.0% )	93.63% ( 91.84% , 95.13% )	83.04% ( 80.60% , 85.29% )
Inpatient	289 ( 26.64% )	90.63% ( 86.65% , 93.73% )	66.41% ( 61.51% , 71.07% )
Outpatient or Emergency Department	277 ( 25.53% )	94.95% ( 91.67% , 97.21% )	75.14% ( 70.27% , 79.58% )
Other	18 ( 1.66% )	100.0% ( 81.47% , 100.0% )	62.07% ( 42.26% , 79.31% )
Care Setting Reported as Unknown	238 ( 21.94% )	92.61% ( 88.43% , 95.64% )	86.59% ( 81.68% , 90.58% )
<b>Demographics</b>			
<b>Sex</b>			
Female	499 ( 45.99% )	93.71% ( 90.97% , 95.81% )	78.82% ( 75.02% , 82.29% )
Male	573 ( 52.81% )	93.56% ( 90.98% , 95.58% )	87.21% ( 84.02% , 89.97% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	N/A	N/A	N/A
6-17	N/A	N/A	N/A
18-29	19 ( 1.75% )	100.0% ( 78.20% , 100.0% )	48.39% ( 30.15% , 66.94% )
30-39	70 ( 6.45% )	95 % ( 86.08% , 98.96% )	71.25% ( 60.05% , 80.82% )
40-49	111 ( 10.23% )	93.81% ( 87.02% , 97.70% )	81.98% ( 73.55% , 88.63% )
50-59	247 ( 22.76% )	94.01% ( 89.97% , 96.77% )	86.81% ( 81.80% , 90.86% )
60-69	275 ( 25.35% )	93.19% ( 89.18% , 96.06% )	91.25% ( 86.94% , 94.50% )
70-79	198 ( 18.25% )	94.01% ( 89.26% , 97.09% )	83.07% ( 76.95% , 88.12% )
80-89	118 ( 10.88% )	92.63% ( 85.41% , 96.99% )	79.28% ( 70.55% , 86.39% )
90+	34 ( 3.13% )	87.50% ( 67.64% , 97.34% )	75 % ( 55.13% , 89.31% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	5 ( 0.46% )	100.0% ( 39.76% , 100.0% )	80 % ( 28.36% , 99.49% )
Asian	74 ( 6.82% )	95.45% ( 87.29% , 99.05% )	88.73% ( 79 % , 95.01% )
Black or African American	426 ( 39.26% )	96.06% ( 93.36% , 97.89% )	87.57% ( 83.72% , 90.79% )
Native Hawaiian or Other Pacific Islander	4 ( 0.37% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
White	290 ( 26.73% )	89.02% ( 84.61% , 92.52% )	75.81% ( 70.64% , 80.47% )
Other/Mixed/Unknown	273 ( 25.16% )	94.67% ( 91.06% , 97.13% )	84 % ( 79.12% , 88.13% )
<b>Ethnicity</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Hispanic	239 ( 22.03% )	97.22% ( 94.05% , 98.97% )	84 % ( 78.86% , 88.32% )
Non-Hispanic	475 ( 43.78% )	94.06% ( 91.42% , 96.09% )	81.91% ( 78.26% , 85.18% )
Unknown	358 ( 33 % )	89.84% ( 85.47% , 93.26% )	84.25% ( 79.38% , 88.36% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	40 ( 3.69% )	84.85% ( 68.10% , 94.89% )	90.32% ( 74.25% , 97.96% )
Contact and suspected exposure (Z20.828)	259 ( 23.87% )	84.47% ( 78.99% , 89 % )	90.24% ( 85.33% , 93.94% )
Pneumonia (see Appendix B)	955 ( 88.02% )	93.27% ( 91.31% , 94.90% )	98.94% ( 97.93% , 99.54% )
Other viral pneumonia (J12.89)	991 ( 91.34% )	96.20% ( 94.67% , 97.38% )	*****
ARDS (J80)	239 ( 22.03% )	94.23% ( 90.14% , 96.98% )	99.49% ( 97.20% , 99.99% )
Sepsis (see Appendix C)	443 ( 40.83% )	92.80% ( 89.70% , 95.20% )	94.82% ( 92.03% , 96.85% )
Bronchitis (J20.8 OR J40)	12 ( 1.11% )	100.0% ( 66.37% , 100.0% )	52.94% ( 27.81% , 77.02% )
Respiratory infection (J22 OR J98.8)	58 ( 5.35% )	97.67% ( 87.71% , 99.94% )	84 % ( 70.89% , 92.83% )
Cough (R05)	132 ( 12.17% )	88.68% ( 81.06% , 94.01% )	83.93% ( 75.79% , 90.19% )
Shortness of breath (R06.2)	3 ( 0.28% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
Fever (R50.9)	217 ( 20 % )	93.02% ( 88.13% , 96.34% )	92.49% ( 87.49% , 95.94% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	19 ( 1.75% )	100.0% ( 79.41% , 100.0% )	84.21% ( 60.42% , 96.62% )
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	750 ( 69.12% )	95.33% ( 93.31% , 96.87% )	85.10% ( 82.17% , 87.71% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	126 ( 11.61% )	97.48% ( 92.81% , 99.48% )	75.82% ( 68.24% , 82.37% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	626 ( 57.70% )	90.83% ( 88.26% , 93 % )	80.79% ( 77.64% , 83.67% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	78 ( 7.19% )	91.07% ( 80.38% , 97.04% )	92.73% ( 82.41% , 97.98% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	178 ( 16.41% )	92.31% ( 86.65% , 96.10% )	99.25% ( 95.88% , 99.98% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	2 ( 0.18% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	402 ( 37.05% )	95 % ( 92.38% , 96.92% )	86.17% ( 82.59% , 89.25% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	83 ( 7.65% )	95.18% ( 88.12% , 98.67% )	83.16% ( 74.10% , 90.06% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	11 ( 1.01% )	90.91% ( 58.72% , 99.77% )	90.91% ( 58.72% , 99.77% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	108 ( 9.95% )	97.22% ( 92.10% , 99.42% )	76.64% ( 68.66% , 83.44% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1h. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between April 1, 2020 and April 30, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	18 ( 1.66% )	100.0% ( 71.51% , 100.0% )	68.75% ( 41.34% , 88.98% )

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINC codes or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
<b>Care Setting of "Primary" Lab Test*****</b>				
Total Observed	2,570	3,035	31,852	42,707
Inpatient	896	1,034	17,052	22,351
Outpatient or Emergency Department	904	943	6,128	6,747
Other	278	382	4,849	7,967
Care Setting Reported as Unknown	443	495	4,918	5,609
<b>Demographics</b>				
Sex				
Female	1,289	1,494	18,643	24,177
Male	1,281	1,541	13,209	18,530
Other/Missing	0	0	0	0
Age at Hospital Admission (Years)				
0-5	14	14	304	366
6-17	9	10	377	457
18-29	179	199	3,530	4,233
30-39	240	274	5,177	6,168
40-49	331	375	2,605	3,514
50-59	524	608	3,869	5,421
60-69	565	653	5,703	7,981
70-79	388	473	5,598	7,878
80-89	240	319	3,585	5,101
90+	80	110	1,104	1,588
Missing	0	0	0	0
Race				
American Indian or Alaska Native	19	24	218	315
Asian	260	311	1,720	2,158
Black or African American	763	872	5,487	6,974
Native Hawaiian or Other Pacific Islander	3	3	45	63
White	798	985	20,922	28,813
Other/Mixed/Unknown	727	840	3,460	4,384
Ethnicity				



**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Hispanic	634	733	2,227	2,796
Non-Hispanic	1,326	1,610	24,118	33,220
Unknown	610	692	5,507	6,691
<b>Codes Observed During Inpatient Stay</b>				
Asymptomatic screening (Z11.59)	54	62	7,260	9,801
Contact and suspected exposure (Z20.828)	192	228	12,695	18,782
Pneumonia (see Appendix B)	1,794	2,284	2,197	3,593
Other viral pneumonia (J12.89)	1,856	2,230	243	349
ARDS (J80)	270	363	79	132
Sepsis (see Appendix C)	720	958	3,209	5,104
Bronchitis (J20.8 OR J40)	32	38	50	72
Respiratory infection (J22 OR J98.8)	64	81	36	54
Cough (R05)	165	197	512	654
Shortness of breath (R06.2)	6	7	54	73
Fever (R50.9)	253	306	1,062	1,542
<b>Optional</b>				
<b>Other COVID Tests</b>				
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-
Test performed, at least 1 positive result	31	40	16	25
Test performed, only negative results	3	3	148	286
No test or unknown result	2,155	2,511	26,897	36,379
Antigen test within ±14 days from inpatient admission**	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0
Test performed, only negative results	0	0	0	0
No test or unknown result	981	1,185	19,259	27,281
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>				
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,608	1,958	20,794	27,662
<b>Codes Observed During Inpatient Stay</b>				

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	74	83	877	1,136
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	123	140	93	150
<b>"Primary" Lab Test Product Information****</b>				
847377 - SARS_COV_2_NS	-	-	-	-
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	526	571	2,840	3,219
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	640	649	2,272	2,407
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	6	7
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	146	149	3,474	3,775
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	1	1
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	923	1,121	19,112	26,947
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>All Nucleic Acid Amplification (NAA) Lab Tests: COVID NAA Test within ±14 Days from Hospital Admission Date for Inpatient (IP) Stay (Admitted for Any Reason)</b>				
	<b>Patients Positive</b>	<b>Lab Tests Positive</b>	<b>Patients Negative</b>	<b>Lab Tests Negative</b>
	<b>Number</b>			
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	6	8	29	67
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	4	8	23	68
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	7	7
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-
Unknown	48	48	95	199

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,478	182	1	573	2,660 ( 82.25% )
Inpatient	840	38	0	N/A	878
Outpatient or Emergency Department	795	85	1	N/A	880
Other	255	0	0	N/A	255
Care Setting Reported as Unknown	408	53	0	N/A	461
<b>Demographics</b>					
Sex					
Female	1,231	102	1	246	1,333 ( 84.37% )
Male	1,247	80	0	264	1,327 ( 83.41% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	9	0	0	6	9 ( 60% )
6-17	8	1	0	3	9 ( 75% )
18-29	171	11	0	45	182 ( 80.18% )
30-39	233	17	0	42	250 ( 85.62% )
40-49	323	25	0	45	348 ( 88.55% )
50-59	502	31	0	79	533 ( 87.09% )
60-69	547	35	0	114	582 ( 83.62% )
70-79	375	36	1	103	411 ( 79.81% )
80-89	234	20	0	57	254 ( 81.67% )
90+	76	6	0	16	82 ( 83.67% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	19	1	0	1	20 ( 95.24% )
Asian	257	10	0	20	267 ( 93.03% )
Black or African American	732	54	0	207	786 ( 79.15% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	768	71	1	146	839 ( 85.09% )
Other/Mixed/Unknown	699	46	0	135	745 ( 84.66% )
Ethnicity					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	614	40	0	86	654 ( 88.38% )
Non-Hispanic	1,275	69	1	180	1,344 ( 88.13% )
Unknown	591	71	0	244	662 ( 73.07% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	36	17	0	13	53 ( 80.30% )
Contact and suspected exposure (Z20.828)	155	76	0	72	231 ( 76.24% )
Pneumonia (see Appendix B)	1,785	99	0	317	1,884 ( 85.60% )
Other viral pneumonia (J12.89)	1,860	73	0	298	1,933 ( 86.64% )
ARDS (J80)	271	10	0	34	281 ( 89.21% )
Sepsis (see Appendix C)	717	56	0	140	773 ( 84.67% )
Bronchitis (J20.8 OR J40)	33	2	0	6	35 ( 85.37% )
Respiratory infection (J22 OR J98.8)	65	1	0	5	66 ( 92.96% )
Cough (R05)	165	21	1	24	186 ( 88.15% )
Shortness of breath (R06.2)	5	2	0	0	7 ( 100.0% )
Fever (R50.9)	251	30	1	47	281 ( 85.41% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	26	3	0	4	29 ( 87.88% )
Test performed, only negative results	2	3	0	0	5 ( 100.0% )
No test or unknown result	2,099	117	0	461	2,216 ( 82.78% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	949	10	0	129	959 ( 88.14% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,536	163	0	47	1,699 ( 97.31% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	69	22	1	17	91 ( 83.49% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	123	26	0	44	149 ( 77.20% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	485	45	-	-	530 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	44	-	-	606 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	897	10	0	0	907 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	3,234 ( 100.0% )	93.16% ( 92.13% , 94.09% )	96.42% ( 95.63% , 97.10% )
Inpatient	878 ( 27.15% )	95.67% ( 94.11% , 96.92% )	93.75% ( 91.96% , 95.24% )
Outpatient or Emergency Department	881 ( 27.24% )	90.34% ( 88.20% , 92.21% )	87.94% ( 85.64% , 89.99% )
Other	255 ( 7.88% )	100.0% ( 98.56% , 100.0% )	91.73% ( 87.84% , 94.68% )
Care Setting Reported as Unknown	590 ( 18.24% )	88.50% ( 85.23% , 91.27% )	92.10% ( 89.18% , 94.44% )
<b>Demographics</b>			
<b>Sex</b>			
Female	1,580 ( 48.86% )	92.35% ( 90.79% , 93.72% )	95.50% ( 94.22% , 96.57% )
Male	1,591 ( 49.20% )	93.97% ( 92.55% , 95.19% )	97.35% ( 96.31% , 98.16% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	15 ( 0.46% )	100.0% ( 66.37% , 100.0% )	64.29% ( 35.14% , 87.24% )
6-17	12 ( 0.37% )	88.89% ( 51.75% , 99.72% )	88.89% ( 51.75% , 99.72% )
18-29	227 ( 7.02% )	93.96% ( 89.44% , 96.94% )	95.53% ( 91.38% , 98.05% )
30-39	292 ( 9.03% )	93.20% ( 89.34% , 95.99% )	97.08% ( 94.08% , 98.82% )
40-49	393 ( 12.15% )	92.82% ( 89.58% , 95.30% )	97.58% ( 95.29% , 98.95% )
50-59	612 ( 18.92% )	94.18% ( 91.85% , 96.01% )	95.80% ( 93.71% , 97.35% )
60-69	696 ( 21.52% )	93.99% ( 91.74% , 95.78% )	96.81% ( 95.01% , 98.10% )
70-79	515 ( 15.92% )	91.24% ( 88.08% , 93.79% )	96.65% ( 94.34% , 98.20% )
80-89	311 ( 9.62% )	92.13% ( 88.10% , 95.12% )	97.50% ( 94.64% , 99.08% )
90+	98 ( 3.03% )	92.68% ( 84.75% , 97.27% )	95 % ( 87.69% , 98.62% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	21 ( 0.65% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
Asian	287 ( 8.87% )	96.25% ( 93.22% , 98.19% )	98.85% ( 96.67% , 99.76% )
Black or African American	993 ( 30.71% )	93.13% ( 91.13% , 94.80% )	95.94% ( 94.28% , 97.22% )
Native Hawaiian or Other Pacific Islander	4 ( 0.12% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	986 ( 30.49% )	91.54% ( 89.45% , 93.33% )	96.24% ( 94.68% , 97.45% )
Other/Mixed/Unknown	880 ( 27.21% )	93.83% ( 91.85% , 95.44% )	96.15% ( 94.48% , 97.43% )
<b>Ethnicity</b>			



**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	740 ( 22.88% )	93.88% ( 91.76% , 95.59% )	96.85% ( 95.17% , 98.06% )
Non-Hispanic	1,525 ( 47.16% )	94.87% ( 93.55% , 95.98% )	96.15% ( 94.97% , 97.12% )
Unknown	906 ( 28.01% )	89.27% ( 86.66% , 91.53% )	96.89% ( 95.18% , 98.11% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	66 ( 2.04% )	67.92% ( 53.68% , 80.08% )	66.67% ( 52.53% , 78.91% )
Contact and suspected exposure (Z20.828)	303 ( 9.37% )	67.10% ( 60.63% , 73.12% )	80.73% ( 74.43% , 86.05% )
Pneumonia (see Appendix B)	2,201 ( 68.06% )	94.75% ( 93.64% , 95.71% )	99.50% ( 99.05% , 99.77% )
Other viral pneumonia (J12.89)	2,231 ( 68.99% )	96.22% ( 95.27% , 97.03% )	*****
ARDS (J80)	315 ( 9.74% )	96.44% ( 93.55% , 98.28% )	*****
Sepsis (see Appendix C)	913 ( 28.23% )	92.76% ( 90.70% , 94.48% )	99.58% ( 98.79% , 99.91% )
Bronchitis (J20.8 OR J40)	41 ( 1.27% )	94.29% ( 80.84% , 99.30% )	*****
Respiratory infection (J22 OR J98.8)	71 ( 2.20% )	98.48% ( 91.84% , 99.96% )	*****
Cough (R05)	211 ( 6.52% )	88.71% ( 83.26% , 92.87% )	100.0% ( 97.79% , 100.0% )
Shortness of breath (R06.2)	7 ( 0.22% )	71.43% ( 29.04% , 96.33% )	83.33% ( 35.88% , 99.58% )
Fever (R50.9)	329 ( 10.17% )	89.32% ( 85.11% , 92.68% )	99.21% ( 97.17% , 99.90% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	33 ( 1.02% )	89.66% ( 72.65% , 97.81% )	83.87% ( 66.27% , 94.55% )
Test performed, only negative results	5 ( 0.15% )	40 % ( 5.27% , 85.34% )	66.67% ( 9.43% , 99.16% )
No test or unknown result	2,677 ( 82.78% )	94.72% ( 93.71% , 95.61% )	97.40% ( 96.64% , 98.03% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	1,088 ( 33.64% )	98.96% ( 98.09% , 99.50% )	96.74% ( 95.43% , 97.76% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,746 ( 53.99% )	90.41% ( 88.91% , 91.77% )	95.52% ( 94.39% , 96.48% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV)</b>	<b>Sensitivity (95% Confidence Interval)</b>
		<b>(95% Confidence Interval)</b>	<b>Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	109 ( 3.37% )	75.82% ( 65.72% , 84.19% )	93.24% ( 84.93% , 97.77% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	193 ( 5.97% )	82.55% ( 75.49% , 88.27% )	100.0% ( 97.05% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	530 ( 16.39% )	91.51% ( 88.80% , 93.74% )	92.21% ( 89.57% , 94.35% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	606 ( 18.74% )	92.74% ( 90.38% , 94.68% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 4.79% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	907 ( 28.05% )	98.90% ( 97.98% , 99.47% )	97.18% ( 95.90% , 98.15% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>			
	<b>Total Patient Count</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.15% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 5.44% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,479	184	1	575	2,663 ( 82.22% )
Inpatient	840	39	0	N/A	879
Outpatient or Emergency Department	795	86	1	N/A	881
Other	255	0	0	N/A	255
Care Setting Reported as Unknown	409	53	0	N/A	462
<b>Demographics</b>					
Sex					
Female	1,232	102	1	246	1,334 ( 84.38% )
Male	1,247	82	0	265	1,329 ( 83.38% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	9	0	0	6	9 ( 60% )
6-17	8	1	0	3	9 ( 75% )
18-29	171	11	0	45	182 ( 80.18% )
30-39	233	17	0	42	250 ( 85.62% )
40-49	323	25	0	45	348 ( 88.55% )
50-59	502	32	0	79	534 ( 87.11% )
60-69	547	36	0	115	583 ( 83.52% )
70-79	376	36	1	103	412 ( 79.84% )
80-89	234	20	0	57	254 ( 81.67% )
90+	76	6	0	16	82 ( 83.67% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	19	1	0	1	20 ( 95.24% )
Asian	257	10	0	20	267 ( 93.03% )
Black or African American	732	54	0	208	786 ( 79.07% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	768	72	1	146	840 ( 85.11% )
Other/Mixed/Unknown	700	47	0	135	747 ( 84.69% )
Ethnicity					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	615	41	0	86	656 ( 88.41% )
Non-Hispanic	1,275	70	1	180	1,345 ( 88.14% )
Unknown	591	71	0	245	662 ( 72.99% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	36	17	0	13	53 ( 80.30% )
Contact and suspected exposure (Z20.828)	155	78	0	72	233 ( 76.39% )
Pneumonia (see Appendix B)	1,786	100	0	317	1,886 ( 85.61% )
Other viral pneumonia (J12.89)	1,861	74	0	298	1,935 ( 86.65% )
ARDS (J80)	271	10	0	34	281 ( 89.21% )
Sepsis (see Appendix C)	717	56	0	141	773 ( 84.57% )
Bronchitis (J20.8 OR J40)	33	3	0	6	36 ( 85.71% )
Respiratory infection (J22 OR J98.8)	65	1	0	5	66 ( 92.96% )
Cough (R05)	165	21	1	24	186 ( 88.15% )
Shortness of breath (R06.2)	5	2	0	0	7 ( 100.0% )
Fever (R50.9)	251	30	1	47	281 ( 85.41% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	26	3	0	4	29 ( 87.88% )
Test performed, only negative results	2	3	0	0	5 ( 100.0% )
No test or unknown result	2,100	118	0	462	2,218 ( 82.76% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	949	10	0	129	959 ( 88.14% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,537	165	0	47	1,702 ( 97.31% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	69	22	1	17	91 ( 83.49% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	123	27	0	44	150 ( 77.32% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	486	45	-	-	531 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	45	-	-	607 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	897	10	0	0	907 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	3,239 ( 100.0% )	93.09% ( 92.06% , 94.02% )	96.46% ( 95.67% , 97.14% )
Inpatient	879 ( 27.14% )	95.56% ( 93.98% , 96.83% )	93.75% ( 91.96% , 95.24% )
Outpatient or Emergency Department	882 ( 27.23% )	90.24% ( 88.09% , 92.12% )	87.94% ( 85.64% , 89.99% )
Other	255 ( 7.87% )	100.0% ( 98.56% , 100.0% )	91.73% ( 87.84% , 94.68% )
Care Setting Reported as Unknown	591 ( 18.25% )	88.53% ( 85.26% , 91.29% )	92.33% ( 89.44% , 94.63% )
<b>Demographics</b>			
Sex			
Female	1,581 ( 48.81% )	92.35% ( 90.80% , 93.72% )	95.58% ( 94.31% , 96.63% )
Male	1,594 ( 49.21% )	93.83% ( 92.40% , 95.06% )	97.35% ( 96.31% , 98.16% )
Other/Missing	N/A	N/A	N/A
Age at Hospital Admission (Years)			
0-5	15 ( 0.46% )	100.0% ( 66.37% , 100.0% )	64.29% ( 35.14% , 87.24% )
6-17	12 ( 0.37% )	88.89% ( 51.75% , 99.72% )	88.89% ( 51.75% , 99.72% )
18-29	227 ( 7.01% )	93.96% ( 89.44% , 96.94% )	95.53% ( 91.38% , 98.05% )
30-39	292 ( 9.02% )	93.20% ( 89.34% , 95.99% )	97.08% ( 94.08% , 98.82% )
40-49	393 ( 12.13% )	92.82% ( 89.58% , 95.30% )	97.58% ( 95.29% , 98.95% )
50-59	613 ( 18.93% )	94.01% ( 91.65% , 95.87% )	95.80% ( 93.71% , 97.35% )
60-69	698 ( 21.55% )	93.83% ( 91.55% , 95.64% )	96.81% ( 95.01% , 98.10% )
70-79	516 ( 15.93% )	91.26% ( 88.11% , 93.81% )	96.91% ( 94.66% , 98.39% )
80-89	311 ( 9.60% )	92.13% ( 88.10% , 95.12% )	97.50% ( 94.64% , 99.08% )
90+	98 ( 3.03% )	92.68% ( 84.75% , 97.27% )	95 % ( 87.69% , 98.62% )
Missing	N/A	N/A	N/A
Race			
American Indian or Alaska Native	21 ( 0.65% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
Asian	287 ( 8.86% )	96.25% ( 93.22% , 98.19% )	98.85% ( 96.67% , 99.76% )
Black or African American	994 ( 30.69% )	93.13% ( 91.13% , 94.80% )	95.94% ( 94.28% , 97.22% )
Native Hawaiian or Other Pacific Islander	4 ( 0.12% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	987 ( 30.47% )	91.43% ( 89.33% , 93.23% )	96.24% ( 94.68% , 97.45% )
Other/Mixed/Unknown	882 ( 27.23% )	93.71% ( 91.72% , 95.34% )	96.29% ( 94.64% , 97.54% )
Ethnicity			



**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	742 ( 22.91% )	93.75% ( 91.62% , 95.48% )	97 % ( 95.36% , 98.19% )
Non-Hispanic	1,526 ( 47.11% )	94.80% ( 93.47% , 95.92% )	96.15% ( 94.97% , 97.12% )
Unknown	907 ( 28 % )	89.27% ( 86.66% , 91.53% )	96.89% ( 95.18% , 98.11% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	66 ( 2.04% )	67.92% ( 53.68% , 80.08% )	66.67% ( 52.53% , 78.91% )
Contact and suspected exposure (Z20.828)	305 ( 9.42% )	66.52% ( 60.07% , 72.55% )	80.73% ( 74.43% , 86.05% )
Pneumonia (see Appendix B)	2,203 ( 68.01% )	94.70% ( 93.59% , 95.67% )	99.55% ( 99.12% , 99.81% )
Other viral pneumonia (J12.89)	2,233 ( 68.94% )	96.18% ( 95.22% , 96.99% )	*****
ARDS (J80)	315 ( 9.73% )	96.44% ( 93.55% , 98.28% )	*****
Sepsis (see Appendix C)	914 ( 28.22% )	92.76% ( 90.70% , 94.48% )	99.58% ( 98.79% , 99.91% )
Bronchitis (J20.8 OR J40)	42 ( 1.30% )	91.67% ( 77.53% , 98.25% )	*****
Respiratory infection (J22 OR J98.8)	71 ( 2.19% )	98.48% ( 91.84% , 99.96% )	*****
Cough (R05)	211 ( 6.51% )	88.71% ( 83.26% , 92.87% )	100.0% ( 97.79% , 100.0% )
Shortness of breath (R06.2)	7 ( 0.22% )	71.43% ( 29.04% , 96.33% )	83.33% ( 35.88% , 99.58% )
Fever (R50.9)	329 ( 10.16% )	89.32% ( 85.11% , 92.68% )	99.21% ( 97.17% , 99.90% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	33 ( 1.02% )	89.66% ( 72.65% , 97.81% )	83.87% ( 66.27% , 94.55% )
Test performed, only negative results	5 ( 0.15% )	40 % ( 5.27% , 85.34% )	66.67% ( 9.43% , 99.16% )
No test or unknown result	2,680 ( 82.74% )	94.68% ( 93.66% , 95.58% )	97.45% ( 96.69% , 98.07% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	1,088 ( 33.59% )	98.96% ( 98.09% , 99.50% )	96.74% ( 95.43% , 97.76% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1749 ( 54 % )	90.31% ( 88.80% , 91.67% )	95.58% ( 94.46% , 96.54% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	109 ( 3.37% )	75.82% ( 65.72% , 84.19% )	93.24% ( 84.93% , 97.77% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	194 ( 5.99% )	82 % ( 74.90% , 87.79% )	100.0% ( 97.05% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	531 ( 16.39% )	91.53% ( 88.82% , 93.75% )	92.40% ( 89.79% , 94.51% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	607 ( 18.74% )	92.59% ( 90.21% , 94.54% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 4.79% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	907 ( 28 % )	98.90% ( 97.98% , 99.47% )	97.18% ( 95.90% , 98.15% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.15% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 5.43% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,479	186	1	575	2,665 ( 82.23% )
Inpatient	840	40	0	N/A	880
Outpatient or Emergency Department	795	86	1	N/A	881
Other	255	0	0	N/A	255
Care Setting Reported as Unknown	409	54	0	N/A	463
<b>Demographics</b>					
Sex					
Female	1,232	102	1	246	1,334 ( 84.38% )
Male	1,247	84	0	265	1,331 ( 83.40% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	9	0	0	6	9 ( 60% )
6-17	8	1	0	3	9 ( 75% )
18-29	171	11	0	45	182 ( 80.18% )
30-39	233	17	0	42	250 ( 85.62% )
40-49	323	25	0	45	348 ( 88.55% )
50-59	502	33	0	79	535 ( 87.13% )
60-69	547	37	0	115	584 ( 83.55% )
70-79	376	36	1	103	412 ( 79.84% )
80-89	234	20	0	57	254 ( 81.67% )
90+	76	6	0	16	82 ( 83.67% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	19	1	0	1	20 ( 95.24% )
Asian	257	10	0	20	267 ( 93.03% )
Black or African American	732	55	0	208	787 ( 79.10% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	768	72	1	146	840 ( 85.11% )
Other/Mixed/Unknown	700	48	0	135	748 ( 84.71% )
Ethnicity					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	615	42	0	86	657 ( 88.43% )
Non-Hispanic	1,275	70	1	180	1,345 ( 88.14% )
Unknown	591	72	0	245	663 ( 73.02% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	36	18	0	13	54 ( 80.60% )
Contact and suspected exposure (Z20.828)	155	79	0	72	234 ( 76.47% )
Pneumonia (see Appendix B)	1,786	101	0	317	1,887 ( 85.62% )
Other viral pneumonia (J12.89)	1,861	74	0	298	1,935 ( 86.65% )
ARDS (J80)	271	10	0	34	281 ( 89.21% )
Sepsis (see Appendix C)	717	57	0	141	774 ( 84.59% )
Bronchitis (J20.8 OR J40)	33	3	0	6	36 ( 85.71% )
Respiratory infection (J22 OR J98.8)	65	1	0	5	66 ( 92.96% )
Cough (R05)	165	21	1	24	186 ( 88.15% )
Shortness of breath (R06.2)	5	2	0	0	7 ( 100.0% )
Fever (R50.9)	251	30	1	47	281 ( 85.41% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	26	3	0	4	29 ( 87.88% )
Test performed, only negative results	2	4	0	0	6 ( 100.0% )
No test or unknown result	2,100	118	0	462	2,218 ( 82.76% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	949	10	0	129	959 ( 88.14% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,537	167	0	47	1,704 ( 97.32% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	69	22	1	17	91 ( 83.49% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	123	27	0	44	150 ( 77.32% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	486	46	-	-	532 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	45	-	-	607 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	897	10	0	0	907 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	3,241 ( 100.0% )	93.02% ( 91.99% , 93.96% )	96.46% ( 95.67% , 97.14% )
Inpatient	880 ( 27.15% )	95.45% ( 93.86% , 96.73% )	93.75% ( 91.96% , 95.24% )
Outpatient or Emergency Department	882 ( 27.21% )	90.24% ( 88.09% , 92.12% )	87.94% ( 85.64% , 89.99% )
Other	255 ( 7.87% )	100.0% ( 98.56% , 100.0% )	91.73% ( 87.84% , 94.68% )
Care Setting Reported as Unknown	592 ( 18.27% )	88.34% ( 85.06% , 91.12% )	92.33% ( 89.44% , 94.63% )
<b>Demographics</b>			
<b>Sex</b>			
Female	1,581 ( 48.78% )	92.35% ( 90.80% , 93.72% )	95.58% ( 94.31% , 96.63% )
Male	1,596 ( 49.24% )	93.69% ( 92.25% , 94.94% )	97.35% ( 96.31% , 98.16% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	15 ( 0.46% )	100.0% ( 66.37% , 100.0% )	64.29% ( 35.14% , 87.24% )
6-17	12 ( 0.37% )	88.89% ( 51.75% , 99.72% )	88.89% ( 51.75% , 99.72% )
18-29	227 ( 7 % )	93.96% ( 89.44% , 96.94% )	95.53% ( 91.38% , 98.05% )
30-39	292 ( 9.01% )	93.20% ( 89.34% , 95.99% )	97.08% ( 94.08% , 98.82% )
40-49	393 ( 12.13% )	92.82% ( 89.58% , 95.30% )	97.58% ( 95.29% , 98.95% )
50-59	614 ( 18.94% )	93.83% ( 91.45% , 95.72% )	95.80% ( 93.71% , 97.35% )
60-69	699 ( 21.57% )	93.66% ( 91.37% , 95.50% )	96.81% ( 95.01% , 98.10% )
70-79	516 ( 15.92% )	91.26% ( 88.11% , 93.81% )	96.91% ( 94.66% , 98.39% )
80-89	311 ( 9.60% )	92.13% ( 88.10% , 95.12% )	97.50% ( 94.64% , 99.08% )
90+	98 ( 3.02% )	92.68% ( 84.75% , 97.27% )	95 % ( 87.69% , 98.62% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	21 ( 0.65% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
Asian	287 ( 8.86% )	96.25% ( 93.22% , 98.19% )	98.85% ( 96.67% , 99.76% )
Black or African American	995 ( 30.70% )	93.01% ( 91 % , 94.69% )	95.94% ( 94.28% , 97.22% )
Native Hawaiian or Other Pacific Islander	4 ( 0.12% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	987 ( 30.45% )	91.43% ( 89.33% , 93.23% )	96.24% ( 94.68% , 97.45% )
Other/Mixed/Unknown	883 ( 27.24% )	93.58% ( 91.58% , 95.23% )	96.29% ( 94.64% , 97.54% )
<b>Ethnicity</b>			



**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	743 ( 22.93% )	93.61% ( 91.46% , 95.35% )	97 % ( 95.36% , 98.19% )
Non-Hispanic	1,526 ( 47.08% )	94.80% ( 93.47% , 95.92% )	96.15% ( 94.97% , 97.12% )
Unknown	908 ( 28.02% )	89.14% ( 86.52% , 91.41% )	96.89% ( 95.18% , 98.11% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	67 ( 2.07% )	66.67% ( 52.53% , 78.91% )	66.67% ( 52.53% , 78.91% )
Contact and suspected exposure (Z20.828)	306 ( 9.44% )	66.24% ( 59.79% , 72.27% )	80.73% ( 74.43% , 86.05% )
Pneumonia (see Appendix B)	2,204 ( 68 % )	94.65% ( 93.53% , 95.62% )	99.55% ( 99.12% , 99.81% )
Other viral pneumonia (J12.89)	2,233 ( 68.90% )	96.18% ( 95.22% , 96.99% )	*****
ARDS (J80)	315 ( 9.72% )	96.44% ( 93.55% , 98.28% )	*****
Sepsis (see Appendix C)	915 ( 28.23% )	92.64% ( 90.56% , 94.37% )	99.58% ( 98.79% , 99.91% )
Bronchitis (J20.8 OR J40)	42 ( 1.30% )	91.67% ( 77.53% , 98.25% )	*****
Respiratory infection (J22 OR J98.8)	71 ( 2.19% )	98.48% ( 91.84% , 99.96% )	*****
Cough (R05)	211 ( 6.51% )	88.71% ( 83.26% , 92.87% )	100.0% ( 97.79% , 100.0% )
Shortness of breath (R06.2)	7 ( 0.22% )	71.43% ( 29.04% , 96.33% )	83.33% ( 35.88% , 99.58% )
Fever (R50.9)	329 ( 10.15% )	89.32% ( 85.11% , 92.68% )	99.21% ( 97.17% , 99.90% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	33 ( 1.02% )	89.66% ( 72.65% , 97.81% )	83.87% ( 66.27% , 94.55% )
Test performed, only negative results	6 ( 0.19% )	33.33% ( 4.33% , 77.72% )	66.67% ( 9.43% , 99.16% )
No test or unknown result	2,680 ( 82.69% )	94.68% ( 93.66% , 95.58% )	97.45% ( 96.69% , 98.07% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	1,088 ( 33.57% )	98.96% ( 98.09% , 99.50% )	96.74% ( 95.43% , 97.76% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,751 ( 54.03% )	90.20% ( 88.69% , 91.57% )	95.58% ( 94.46% , 96.54% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	109 ( 3.36% )	75.82% ( 65.72% , 84.19% )	93.24% ( 84.93% , 97.77% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	194 ( 5.99% )	82 % ( 74.90% , 87.79% )	100.0% ( 97.05% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	532 ( 16.41% )	91.35% ( 88.64% , 93.60% )	92.40% ( 89.79% , 94.51% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	607 ( 18.73% )	92.59% ( 90.21% , 94.54% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 4.78% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	907 ( 27.99% )	98.90% ( 97.98% , 99.47% )	97.18% ( 95.90% , 98.15% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.15% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 5.43% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	2,479	186	1	575	2,665 ( 82.23% )
Inpatient	840	40	0	N/A	880
Outpatient or Emergency Department	795	86	1	N/A	881
Other	255	0	0	N/A	255
Care Setting Reported as Unknown	409	54	0	N/A	463
<b>Demographics</b>					
Sex					
Female	1,232	102	1	246	1,334 ( 84.38% )
Male	1,247	84	0	265	1,331 ( 83.40% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	9	0	0	6	9 ( 60% )
6-17	8	1	0	3	9 ( 75% )
18-29	171	11	0	45	182 ( 80.18% )
30-39	233	17	0	42	250 ( 85.62% )
40-49	323	25	0	45	348 ( 88.55% )
50-59	502	33	0	79	535 ( 87.13% )
60-69	547	37	0	115	584 ( 83.55% )
70-79	376	36	1	103	412 ( 79.84% )
80-89	234	20	0	57	254 ( 81.67% )
90+	76	6	0	16	82 ( 83.67% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	19	1	0	1	20 ( 95.24% )
Asian	257	10	0	20	267 ( 93.03% )
Black or African American	732	55	0	208	787 ( 79.10% )
Native Hawaiian or Other Pacific Islander	3	0	0	1	3 ( 75% )
White	768	72	1	146	840 ( 85.11% )
Other/Mixed/Unknown	700	48	0	135	748 ( 84.71% )
Ethnicity					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	615	42	0	86	657 ( 88.43% )
Non-Hispanic	1,275	70	1	180	1,345 ( 88.14% )
Unknown	591	72	0	245	663 ( 73.02% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	36	18	0	13	54 ( 80.60% )
Contact and suspected exposure (Z20.828)	155	79	0	72	234 ( 76.47% )
Pneumonia (see Appendix B)	1,786	101	0	317	1,887 ( 85.62% )
Other viral pneumonia (J12.89)	1,861	74	0	298	1,935 ( 86.65% )
ARDS (J80)	271	10	0	34	281 ( 89.21% )
Sepsis (see Appendix C)	717	57	0	141	774 ( 84.59% )
Bronchitis (J20.8 OR J40)	33	3	0	6	36 ( 85.71% )
Respiratory infection (J22 OR J98.8)	65	1	0	5	66 ( 92.96% )
Cough (R05)	165	21	1	24	186 ( 88.15% )
Shortness of breath (R06.2)	5	2	0	0	7 ( 100.0% )
Fever (R50.9)	251	30	1	47	281 ( 85.41% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	26	3	0	4	29 ( 87.88% )
Test performed, only negative results	2	4	0	0	6 ( 100.0% )
No test or unknown result	2,100	118	0	462	2,218 ( 82.76% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	949	10	0	129	959 ( 88.14% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,537	167	0	47	1,704 ( 97.32% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	69	22	1	17	91 ( 83.49% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	123	27	0	44	150 ( 77.32% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	486	46	-	-	532 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	562	45	-	-	607 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	131	24	-	-	155 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	897	10	0	0	907 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5	0	0	0	5 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	47	0	0	129	47 ( 26.70% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	3,241 ( 100.0% )	93.02% ( 91.99% , 93.96% )	96.46% ( 95.67% , 97.14% )
Inpatient	880 ( 27.15% )	95.45% ( 93.86% , 96.73% )	93.75% ( 91.96% , 95.24% )
Outpatient or Emergency Department	882 ( 27.21% )	90.24% ( 88.09% , 92.12% )	87.94% ( 85.64% , 89.99% )
Other	255 ( 7.87% )	100.0% ( 98.56% , 100.0% )	91.73% ( 87.84% , 94.68% )
Care Setting Reported as Unknown	592 ( 18.27% )	88.34% ( 85.06% , 91.12% )	92.33% ( 89.44% , 94.63% )
<b>Demographics</b>			
<b>Sex</b>			
Female	1,581 ( 48.78% )	92.35% ( 90.80% , 93.72% )	95.58% ( 94.31% , 96.63% )
Male	1,596 ( 49.24% )	93.69% ( 92.25% , 94.94% )	97.35% ( 96.31% , 98.16% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	15 ( 0.46% )	100.0% ( 66.37% , 100.0% )	64.29% ( 35.14% , 87.24% )
6-17	12 ( 0.37% )	88.89% ( 51.75% , 99.72% )	88.89% ( 51.75% , 99.72% )
18-29	227 ( 7 % )	93.96% ( 89.44% , 96.94% )	95.53% ( 91.38% , 98.05% )
30-39	292 ( 9.01% )	93.20% ( 89.34% , 95.99% )	97.08% ( 94.08% , 98.82% )
40-49	393 ( 12.13% )	92.82% ( 89.58% , 95.30% )	97.58% ( 95.29% , 98.95% )
50-59	614 ( 18.94% )	93.83% ( 91.45% , 95.72% )	95.80% ( 93.71% , 97.35% )
60-69	699 ( 21.57% )	93.66% ( 91.37% , 95.50% )	96.81% ( 95.01% , 98.10% )
70-79	516 ( 15.92% )	91.26% ( 88.11% , 93.81% )	96.91% ( 94.66% , 98.39% )
80-89	311 ( 9.60% )	92.13% ( 88.10% , 95.12% )	97.50% ( 94.64% , 99.08% )
90+	98 ( 3.02% )	92.68% ( 84.75% , 97.27% )	95 % ( 87.69% , 98.62% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	21 ( 0.65% )	95 % ( 75.13% , 99.87% )	100.0% ( 82.35% , 100.0% )
Asian	287 ( 8.86% )	96.25% ( 93.22% , 98.19% )	98.85% ( 96.67% , 99.76% )
Black or African American	995 ( 30.70% )	93.01% ( 91 % , 94.69% )	95.94% ( 94.28% , 97.22% )
Native Hawaiian or Other Pacific Islander	4 ( 0.12% )	100.0% ( 29.24% , 100.0% )	100.0% ( 29.24% , 100.0% )
White	987 ( 30.45% )	91.43% ( 89.33% , 93.23% )	96.24% ( 94.68% , 97.45% )
Other/Mixed/Unknown	883 ( 27.24% )	93.58% ( 91.58% , 95.23% )	96.29% ( 94.64% , 97.54% )
<b>Ethnicity</b>			



**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Hispanic	743 ( 22.93% )	93.61% ( 91.46% , 95.35% )	97 % ( 95.36% , 98.19% )
Non-Hispanic	1,526 ( 47.08% )	94.80% ( 93.47% , 95.92% )	96.15% ( 94.97% , 97.12% )
Unknown	908 ( 28.02% )	89.14% ( 86.52% , 91.41% )	96.89% ( 95.18% , 98.11% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	67 ( 2.07% )	66.67% ( 52.53% , 78.91% )	66.67% ( 52.53% , 78.91% )
Contact and suspected exposure (Z20.828)	306 ( 9.44% )	66.24% ( 59.79% , 72.27% )	80.73% ( 74.43% , 86.05% )
Pneumonia (see Appendix B)	2,204 ( 68 % )	94.65% ( 93.53% , 95.62% )	99.55% ( 99.12% , 99.81% )
Other viral pneumonia (J12.89)	2,233 ( 68.90% )	96.18% ( 95.22% , 96.99% )	*****
ARDS (J80)	315 ( 9.72% )	96.44% ( 93.55% , 98.28% )	*****
Sepsis (see Appendix C)	915 ( 28.23% )	92.64% ( 90.56% , 94.37% )	99.58% ( 98.79% , 99.91% )
Bronchitis (J20.8 OR J40)	42 ( 1.30% )	91.67% ( 77.53% , 98.25% )	*****
Respiratory infection (J22 OR J98.8)	71 ( 2.19% )	98.48% ( 91.84% , 99.96% )	*****
Cough (R05)	211 ( 6.51% )	88.71% ( 83.26% , 92.87% )	100.0% ( 97.79% , 100.0% )
Shortness of breath (R06.2)	7 ( 0.22% )	71.43% ( 29.04% , 96.33% )	83.33% ( 35.88% , 99.58% )
Fever (R50.9)	329 ( 10.15% )	89.32% ( 85.11% , 92.68% )	99.21% ( 97.17% , 99.90% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	33 ( 1.02% )	89.66% ( 72.65% , 97.81% )	83.87% ( 66.27% , 94.55% )
Test performed, only negative results	6 ( 0.19% )	33.33% ( 4.33% , 77.72% )	66.67% ( 9.43% , 99.16% )
No test or unknown result	2,680 ( 82.69% )	94.68% ( 93.66% , 95.58% )	97.45% ( 96.69% , 98.07% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	1,088 ( 33.57% )	98.96% ( 98.09% , 99.50% )	96.74% ( 95.43% , 97.76% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,751 ( 54.03% )	90.20% ( 88.69% , 91.57% )	95.58% ( 94.46% , 96.54% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>		
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	109 ( 3.36% )	75.82% ( 65.72% , 84.19% )	93.24% ( 84.93% , 97.77% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	194 ( 5.99% )	82 % ( 74.90% , 87.79% )	100.0% ( 97.05% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	532 ( 16.41% )	91.35% ( 88.64% , 93.60% )	92.40% ( 89.79% , 94.51% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	607 ( 18.73% )	92.59% ( 90.21% , 94.54% )	87.81% ( 85.02% , 90.25% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	155 ( 4.78% )	84.52% ( 77.84% , 89.82% )	89.73% ( 83.62% , 94.13% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	907 ( 27.99% )	98.90% ( 97.98% , 99.47% )	97.18% ( 95.90% , 98.15% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
			<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	5 ( 0.15% )	100.0% ( 47.82% , 100.0% )	83.33% ( 35.88% , 99.58% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	176 ( 5.43% )	100.0% ( 92.45% , 100.0% )	97.92% ( 88.93% , 99.95% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
<b>Care Setting of "Primary" Lab Test*****</b>					
Total Observed	1,931	107	0	406	2,038 ( 83.39% )
Inpatient	541	20	0	N/A	561
Outpatient or Emergency Department	728	55	0	N/A	783
Other	214	0	0	N/A	214
Care Setting Reported as Unknown	321	27	0	N/A	348
<b>Demographics</b>					
Sex					
Female	901	54	0	153	955 ( 86.19% )
Male	1,030	53	0	201	1,083 ( 84.35% )
Other/Missing	0	0	0	0	N/A
Age at Hospital Admission (Years)					
0-5	1	0	0	0	1 ( 100.0% )
6-17	2	0	0	1	2 ( 66.67% )
18-29	65	2	0	13	67 ( 83.75% )
30-39	141	9	0	19	150 ( 88.76% )
40-49	277	12	0	38	289 ( 88.38% )
50-59	428	27	0	57	455 ( 88.87% )
60-69	477	19	0	93	496 ( 84.21% )
70-79	318	24	0	76	342 ( 81.82% )
80-89	172	10	0	45	182 ( 80.18% )
90+	50	4	0	12	54 ( 81.82% )
Missing	0	0	0	0	N/A
Race					
American Indian or Alaska Native	12	0	0	1	12 ( 92.31% )
Asian	213	6	0	18	219 ( 92.41% )
Black or African American	579	27	0	138	606 ( 81.45% )
Native Hawaiian or Other Pacific Islander	2	0	0	1	2 ( 66.67% )
White	557	41	0	102	598 ( 85.43% )
Other/Mixed/Unknown	568	33	0	94	601 ( 86.47% )
Ethnicity					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Hispanic	517	28	0	54	545 ( 90.98% )
Non-Hispanic	926	41	0	136	967 ( 87.67% )
Unknown	488	38	0	164	526 ( 76.23% )
<b>Codes Observed During Inpatient Stay</b>					
Asymptomatic screening (Z11.59)	29	9	0	8	38 ( 82.61% )
Contact and suspected exposure (Z20.828)	140	56	0	55	196 ( 78.09% )
Pneumonia (see Appendix B)	1,803	100	0	324	1,903 ( 85.45% )
Other viral pneumonia (J12.89)	1,879	74	0	304	1,953 ( 86.53% )
ARDS (J80)	273	10	0	34	283 ( 89.27% )
Sepsis (see Appendix C)	661	37	0	118	698 ( 85.54% )
Bronchitis (J20.8 OR J40)	12	3	0	3	15 ( 83.33% )
Respiratory infection (J22 OR J98.8)	58	0	0	3	58 ( 95.08% )
Cough (R05)	140	13	0	17	153 ( 90% )
Shortness of breath (R06.2)	4	2	0	0	6 ( 100.0% )
Fever (R50.9)	218	19	0	33	237 ( 87.78% )
<b>Optional</b>					
<b>Other COVID Tests</b>					
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-	-	-
Test performed, at least 1 positive result	22	3	0	2	25 ( 92.59% )
Test performed, only negative results	1	2	0	0	3 ( 100.0% )
No test or unknown result	1,639	65	0	322	1,704 ( 84.11% )
Antigen test within ±14 days from inpatient admission**	-	-	-	-	-
Test performed, at least 1 positive result	0	0	0	0	N/A
Test performed, only negative results	0	0	0	0	N/A
No test or unknown result	646	6	0	109	652 ( 85.68% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>					
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,275	93	0	32	1,368 ( 97.71% )
<b>Codes Observed During Inpatient Stay</b>					

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	58	14	0	15	72 ( 82.76% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	123	27	0	44	150 ( 77.32% )
<b>"Primary" Lab Test Product Information****</b>					
847377 - SARS_COV_2_NS	-	-	-	-	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	-	-	-	-	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	-	-	-	-	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	387	24	-	-	411 ( 100.0% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	532	28	-	-	560 ( 100.0% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	-	-	-	-	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	-	-	-	-	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	97	12	-	-	109 ( 100.0% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	-	-	-	-	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	-	-	-	-	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	-	-	-	-	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	600	6	0	0	606 ( 100.0% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>					
	<b>Lab Positive***</b>	<b>Lab Negative***</b>	<b>Lab, No Results</b>	<b>No Lab</b>	<b>Patients with Lab Result</b>
	<b>Number</b>				<b>Number (Percent)</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	-	-	-	-	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	-	-	-	-	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	3	0	0	0	3 ( 100.0% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	0	0	0	0	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	-	-	-	-	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	-	-	-	-	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	-	-	-	-	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	-	-	-	-	N/A
Unknown	43	0	0	109	43 ( 28.29% )

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
<b>Care Setting of "Primary" Lab Test*****</b>			
Total Observed	2,444 ( 100.0% )	94.75% ( 93.69% , 95.68% )	75.14% ( 73.42% , 76.80% )
Inpatient	561 ( 22.95% )	96.43% ( 94.55% , 97.81% )	60.38% ( 57.09% , 63.60% )
Outpatient or Emergency Department	783 ( 32.04% )	92.98% ( 90.95% , 94.66% )	80.53% ( 77.80% , 83.06% )
Other	214 ( 8.76% )	100.0% ( 98.29% , 100.0% )	76.98% ( 71.58% , 81.80% )
Care Setting Reported as Unknown	457 ( 18.70% )	92.24% ( 88.91% , 94.82% )	72.46% ( 68.05% , 76.57% )
<b>Demographics</b>			
<b>Sex</b>			
Female	1,108 ( 45.34% )	94.35% ( 92.69% , 95.72% )	69.90% ( 67.31% , 72.39% )
Male	1,284 ( 52.54% )	95.11% ( 93.65% , 96.31% )	80.41% ( 78.12% , 82.55% )
Other/Missing	N/A	N/A	N/A
<b>Age at Hospital Admission (Years)</b>			
0-5	1 ( 0.04% )	100.0% ( 2.50% , 100.0% )	7.14% ( 0.18% , 33.87% )
6-17	3 ( 0.12% )	100.0% ( 15.81% , 100.0% )	22.22% ( 2.81% , 60.01% )
18-29	80 ( 3.27% )	97.01% ( 89.63% , 99.64% )	36.31% ( 29.27% , 43.82% )
30-39	169 ( 6.91% )	94 % ( 88.92% , 97.22% )	58.75% ( 52.24% , 65.04% )
40-49	327 ( 13.38% )	95.85% ( 92.86% , 97.84% )	83.69% ( 79.26% , 87.50% )
50-59	512 ( 20.95% )	94.07% ( 91.48% , 96.05% )	81.68% ( 78.10% , 84.90% )
60-69	589 ( 24.10% )	96.17% ( 94.08% , 97.68% )	84.42% ( 81.17% , 87.32% )
70-79	418 ( 17.10% )	92.98% ( 89.74% , 95.45% )	81.96% ( 77.76% , 85.66% )
80-89	227 ( 9.29% )	94.51% ( 90.13% , 97.33% )	71.67% ( 65.51% , 77.28% )
90+	66 ( 2.70% )	92.59% ( 82.11% , 97.94% )	62.50% ( 50.96% , 73.08% )
Missing	N/A	N/A	N/A
<b>Race</b>			
American Indian or Alaska Native	13 ( 0.53% )	100.0% ( 73.54% , 100.0% )	63.16% ( 38.36% , 83.71% )
Asian	237 ( 9.70% )	97.26% ( 94.13% , 98.99% )	81.92% ( 76.70% , 86.40% )
Black or African American	744 ( 30.44% )	95.54% ( 93.58% , 97.04% )	75.88% ( 72.69% , 78.88% )
Native Hawaiian or Other Pacific Islander	3 ( 0.12% )	100.0% ( 15.81% , 100.0% )	66.67% ( 9.43% , 99.16% )
White	700 ( 28.64% )	93.14% ( 90.81% , 95.04% )	69.80% ( 66.48% , 72.97% )
Other/Mixed/Unknown	695 ( 28.44% )	94.51% ( 92.37% , 96.19% )	78.13% ( 74.94% , 81.08% )
<b>Ethnicity</b>			



**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Hispanic	599 ( 24.51% )	94.86% ( 92.66% , 96.56% )	81.55% ( 78.30% , 84.49% )
Non-Hispanic	1,103 ( 45.13% )	95.76% ( 94.29% , 96.94% )	69.83% ( 67.28% , 72.30% )
Unknown	690 ( 28.23% )	92.78% ( 90.22% , 94.84% )	80 % ( 76.60% , 83.10% )
<b>Codes Observed During Inpatient Stay</b>			
Asymptomatic screening (Z11.59)	46 ( 1.88% )	76.32% ( 59.76% , 88.56% )	53.70% ( 39.61% , 67.38% )
Contact and suspected exposure (Z20.828)	251 ( 10.27% )	71.43% ( 64.56% , 77.64% )	72.92% ( 66.05% , 79.06% )
Pneumonia (see Appendix B)	2,227 ( 91.12% )	94.75% ( 93.65% , 95.70% )	*****
Other viral pneumonia (J12.89)	2,257 ( 92.35% )	96.21% ( 95.27% , 97.01% )	*****
ARDS (J80)	317 ( 12.97% )	96.47% ( 93.60% , 98.29% )	*****
Sepsis (see Appendix C)	816 ( 33.39% )	94.70% ( 92.77% , 96.24% )	91.81% ( 89.56% , 93.70% )
Bronchitis (J20.8 OR J40)	18 ( 0.74% )	80 % ( 51.91% , 95.67% )	37.50% ( 21.10% , 56.31% )
Respiratory infection (J22 OR J98.8)	61 ( 2.50% )	100.0% ( 93.84% , 100.0% )	90.63% ( 80.70% , 96.48% )
Cough (R05)	170 ( 6.96% )	91.50% ( 85.91% , 95.40% )	84.85% ( 78.45% , 89.95% )
Shortness of breath (R06.2)	6 ( 0.25% )	66.67% ( 22.28% , 95.67% )	66.67% ( 22.28% , 95.67% )
Fever (R50.9)	270 ( 11.05% )	91.98% ( 87.76% , 95.10% )	86.17% ( 81.29% , 90.17% )
<b>Optional</b>			
<b>Other COVID Tests</b>			
Antibody laboratory test (IgM, IgG, IgA, any combination or total, or neutralizing) observed within -7 days prior to hospitalization through end of patient record**	-	-	-
Test performed, at least 1 positive result	27 ( 1.10% )	88 % ( 68.78% , 97.45% )	70.97% ( 51.96% , 85.78% )
Test performed, only negative results	3 ( 0.12% )	33.33% ( 0.84% , 90.57% )	33.33% ( 0.84% , 90.57% )
No test or unknown result	2,026 ( 82.90% )	96.19% ( 95.16% , 97.04% )	76.06% ( 74.20% , 77.84% )
Antigen test within ±14 days from inpatient admission**	-	-	-
Test performed, at least 1 positive result	N/A	N/A	N/A
Test performed, only negative results	N/A	N/A	N/A
No test or unknown result	761 ( 31.14% )	99.08% ( 98.01% , 99.66% )	65.85% ( 62.79% , 68.82% )
<b>Codes Observed Within ±5 Days of Diagnostic Specimen Collection</b>			
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	1,400 ( 57.28% )	93.20% ( 91.74% , 94.48% )	79.29% ( 77.23% , 81.25% )
<b>Codes Observed During Inpatient Stay</b>			

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	
Z20.828 (contact and suspected exposure) AND [R05 (cough) OR R06.2 (shortness of breath) OR R50.9 (fever)]	87 ( 3.56% )	80.56% ( 69.53% , 88.94% )	78.38% ( 67.28% , 87.11% )
Z20.828 (contact and suspected exposure) AND [J12.89 (other viral pneumonia) OR J20.8 (acute bronchitis) OR J40 (bronchitis, NOS) OR J22 (lower or acute respiratory infection) OR J98.8 (respiratory infection, NOS) OR J80 (ARDS)]	194 ( 7.94% )	82 % ( 74.90% , 87.79% )	100.0% ( 97.05% , 100.0% )
<b>"Primary" Lab Test Product Information****</b>			
847377 - SARS_COV_2_NS	N/A	N/A	N/A
85008 - Blood Count; Blood Smear, Microscopic Examination Without Manual	N/A	N/A	N/A
87635A - Coronavirus 2019-Ncov Panel (N1, N2, N3), Qualitative, NAA	N/A	N/A	N/A
87635K - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-PCR	411 ( 16.82% )	94.16% ( 91.44% , 96.22% )	73.57% ( 69.59% , 77.30% )
87635M - SARS-CoV-2, Qualitative, NAA (COVID-19), KP Lab	560 ( 22.91% )	95 % ( 92.85% , 96.65% )	83.13% ( 79.99% , 85.95% )
87635P - SARS-CoV-2, (COVID-19), RNA, Qualitative RT-NAA	N/A	N/A	N/A
87635R - SARS-CoV-2, NAA (COVID-19), POCT	N/A	N/A	N/A
87635T - SARS-CoV-2, Qualitative, Rapid NAA (COVID-19)	109 ( 4.46% )	88.99% ( 81.56% , 94.18% )	66.44% ( 58.16% , 74.03% )
87635Y - SARS-CoV-2, NAA (COVID-19), Home Collection Test	N/A	N/A	N/A
94306-8 - SARS-CoV-2 (COVID-19) RNA Panel - Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94307-6 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N1	N/A	N/A	N/A
94308-4 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By Nucleic Acid Amplification Using CDC Primer-Probe Set N2	N/A	N/A	N/A
94309-2 - SARS-CoV-2 (COVID-19) RNA [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94314-2 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94316-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94500-6 - SARS-CoV-2 (COVID-19) RNA [presence] In Respiratory Specimen By NAA With Probe Detection	606 ( 24.80% )	99.01% ( 97.86% , 99.64% )	65.01% ( 61.83% , 68.08% )
94505-5 - SARS-CoV-2 (COVID-19) IgG Ab [units/Volume] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A

**Table 1i. Aggregated Baseline Table for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020**

<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR ARDS (J80)]*</b>			
	<b>Total Patient Count</b>	<b>PPV (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>
	<b>Number (Percent)</b>	<b>Percent</b>	<b>Percent</b>
94507-1 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum, Plasma Or Blood By Rapid Immunoassay	N/A	N/A	N/A
94531-1 - SARS-CoV-2 (COVID-19) RNA Panel - Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94533-7 - SARS-CoV-2 (COVID-19) N Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94534-5 - SARS-CoV-2 (COVID-19) RdRp Gene [presence] In Respiratory Specimen By NAA With Probe Detection	N/A	N/A	N/A
94559-2 - SARS-CoV-2 (COVID-19) ORF1ab Region [presence] In Respiratory Specimen By NAA With Probe Detection	3 ( 0.12% )	100.0% ( 29.24% , 100.0% )	50 % ( 11.81% , 88.19% )
94563-4 - SARS-CoV-2 (COVID-19) IgG Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94564-2 - SARS-CoV-2 (COVID-19) IgM Ab [presence] In Serum Or Plasma By Immunoassay	N/A	N/A	N/A
94565-9 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Non-Probe Detection	N/A	N/A	N/A
94641-8 - SARS-CoV-2 (COVID-19) S Gene [presence] In Unspecified Specimen By NAA With Probe Detection	N/A	N/A	N/A
94759-8 - SARS-CoV-2 (COVID-19) RNA [presence] In Nasopharynx By NAA With Probe Detection	N/A	N/A	N/A
Unknown	152 ( 6.22% )	100.0% ( 91.78% , 100.0% )	89.58% ( 77.34% , 96.53% )

\*Includes only the first algorithm-qualifying inpatient stay per algorithm per patient.

\*\* COVID NAA, antibody, and antigen tests are identified using LOINC's or any other identifier available in the data.

\*\*\*Any NAA result in 14 days prior through 14 days after inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per encounter - positive if patient had at least one positive NAA result; negative if all NAA results are negative (during test window, from any type of specimen/site).

"Primary" test result will be the first positive molecular test within the ±14-day window, or the last negative molecular test within the ±14-day window among patients with no positive test.

\*\*\*\*Only the "primary" lab test, as defined above, is described

\*\*\*\*\*Sensitivity not calculated because algorithm cohort NAA-positive patient count is larger than laboratory result cohort NAA-positive patient count. This is a result of a different visit being used to describe characteristics among the lab-based cohort and the algorithm-based cohort.

\*\*\*\*\*Sum across care settings does not equal total observed because care setting was not reported for some patients.

**Table 2a. Summary of Outcomes for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and October 17, 2020, by Time Period**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>						
<b>Total Nucleic Acid Amplification (NAA) Positive Patients</b>	<b>Total Patients Observed</b>	<b>Lab Test Positive***</b>	<b>Total Lab Results Known</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>	
<b>Number</b>	<b>Number</b>	<b>Number</b>	<b>Number (Percent)</b>	<b>Number (Percent)</b>	<b>Number (Percent)</b>	
<b>All Times</b>						
9,103	41,895	8,070	9,527 (22.74%)	84.71% ( 83.97% , 85.42% )	88.65% ( 87.98% , 89.30% )	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
1,524	3,597	869	924 (25.69%)	94.05% ( 92.32% , 95.48% )	57.02% ( 54.49% , 59.52% )	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
2,768	12,397	2,637	2,979 (24.03%)	88.52% ( 87.32% , 89.64% )	95.27% ( 94.41% , 96.03% )	
<b>Time C: May 1, 2020 - October 17, 2020</b>						
4,811	25,901	4,564	5,624 (21.71%)	81.15% ( 80.11% , 82.17% )	94.87% ( 94.20% , 95.47% )	
<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>						
<b>All Times</b>						
9,103	44,527	8,536	10,071 (22.62%)	84.76% ( 84.04% , 85.46% )	93.77% ( 93.26% , 94.26% )	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
1,524	5,920	1,328	1,439 (24.31%)	92.29% ( 90.78% , 93.61% )	87.14% ( 85.35% , 88.78% )	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
2,768	12,528	2,640	2,993 (23.89%)	88.21% ( 87.00% , 89.34% )	95.38% ( 94.53% , 96.13% )	
<b>Time C: May 1, 2020 - October 17, 2020</b>						
4,811	26,079	4,568	5,639 (21.62%)	81.01% ( 79.96% , 82.02% )	94.95% ( 94.29% , 95.55% )	
<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>						
<b>All Times</b>						
9,103	45,165	8,570	10,163 (22.5%)	84.33% ( 83.60% , 85.03% )	94.14% ( 93.64% , 94.62% )	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
1,524	6,270	1,352	1,491 (23.78%)	90.68% ( 89.09% , 92.11% )	88.71% ( 87.02% , 90.26% )	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
2,768	12,663	2,647	3,011 (23.78%)	87.91% ( 86.69% , 89.05% )	95.63% ( 94.80% , 96.36% )	
<b>Time C: May 1, 2020 - October 17, 2020</b>						
4,811	26,232	4,571	5,661 (21.58%)	80.75% ( 79.69% , 81.77% )	95.01% ( 94.36% , 95.61% )	
<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>						

**Table 2a. Summary of Outcomes for Algorithm Cohorts from All Participating Sentinel Data Partners in the Sentinel Distributed Database (SDD) between February 20, 2020 and October 17, 2020, by Time Period**

	Total Patients Observed		Lab Test	Total Lab Results Known	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number		Positive***			
	Number		Number (Percent)			
<b>All Times</b>	9,103	45,417	8,598	10,205 (22.47%)	84.25% ( 83.53% , 84.95% )	94.45% (93.96% , 94.91% )
<b>Time A: February 20, 2020 - March 31, 2020</b>	1,524	6,386	1,371	1,514 (23.71%)	90.55% ( 88.97% , 91.98% )	89.96% ( 88.34% , 91.42% )
<b>Time B: April 1, 2020 - April 30, 2020</b>	2,768	12,731	2,651	3,020 (23.72%)	87.78% ( 86.56% , 88.93% )	95.77% ( 94.96% , 96.49% )
<b>Time C: May 1, 2020 - October 17, 2020</b>	4,811	26,300	4,576	5,671 (21.56%)	80.69% ( 79.64% , 81.71% )	95.12% ( 94.47% , 95.71% )
<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>						
<b>All Times</b>	9,103	33,635	7,095	8,108 (24.11%)	87.51% ( 86.77% , 88.22% )	77.94% (77.08% , 78.79% )
<b>Time A: February 20, 2020 - March 31, 2020</b>	1,524	5,218	1,220	1,313 (25.16%)	92.92% ( 91.39% , 94.25% )	80.05% ( 77.96% , 82.03% )
<b>Time B: April 1, 2020 - April 30, 2020</b>	2,768	10,097	2,291	2,558 (25.33%)	89.56% ( 88.31% , 90.72% )	82.77% ( 81.31% , 84.16% )
<b>Time C: May 1, 2020 - October 17, 2020</b>	4,811	18,320	3,584	4,237 (23.13%)	84.59% ( 83.47% , 85.66% )	74.50% ( 73.24% , 75.72% )

\*Includes only the first algorithm-qualifying inpatient (IP) stay per algorithm per patient.

\*\* Diagnosis codes provided.

\*\*\*Any NAA result in 14 days prior through 14 days after admission for the inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per IP stay - positive if patient had at least one positive RT-NAA result; negative if all RT-NAA results are negative.

**Table 2b. Summary of Outcomes for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020, by Time Period**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>						
<b>Total Nucleic Acid Amplification (NAA) Positive Patients</b>	<b>Total Patients Observed</b>	<b>Lab Test Positive***</b>	<b>Total Lab Results Known</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>	
<b>Number</b>			<b>Number (Percent)</b>			
<b>All Times</b>						
5,112	37,105	4,376	5,572 (15.02%)	78.54% ( 77.43% , 79.61%)	85.60% (84.61% , 86.55%)	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
1,129	3,317	643	693 (20.89%)	92.78% ( 90.60% , 94.60%)	56.95% ( 54.01% , 59.86%)	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
1,742	11,121	1,647	1,915 (17.22%)	86.01% ( 84.37% , 87.53%)	94.55% ( 93.37% , 95.57%)	
<b>Time C: May 1, 2020 - September 25, 2020</b>						
2,241	22,667	2,086	2,964 (13.08%)	70.38% ( 68.70% , 72.02%)	93.08% ( 91.95% , 94.10%)	
<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>						
<b>All Times</b>						
5,112	39,532	4,716	5,966 (15.09%)	79.05% ( 77.99% , 80.07%)	92.25% (91.49% , 92.97%)	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
1,129	5,448	977	1,067 (19.59%)	91.57% ( 89.73% , 93.16%)	86.54% ( 84.41% , 88.47%)	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
1,742	11,244	1,650	1,923 (17.1%)	85.80% ( 84.16% , 87.33%)	94.72% ( 93.56% , 95.72%)	
<b>Time C: May 1, 2020 - September 25, 2020</b>						
2,241	22,840	2,089	2,976 (13.03%)	70.19% ( 68.52% , 71.83%)	93.22% ( 92.10% , 94.22%)	
<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>						
<b>All Times</b>						
5,112	40,157	4,748	6,050 (15.07%)	78.48% ( 77.42% , 79.51%)	92.88% ( 92.14% , 93.57%)	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
1,129	5,789	999	1,114 (19.24%)	89.68% ( 87.74% , 91.40%)	88.49% ( 86.48% , 90.29%)	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
1,742	11,377	1,657	1,940 (17.05%)	85.41% ( 83.76% , 86.95%)	95.12% ( 94 % , 96.08%)	
<b>Time C: May 1, 2020 - September 25, 2020</b>						
2,241	22,991	2,092	2,996 (13.03%)	69.83% ( 68.15% , 71.47%)	93.35% ( 92.24% , 94.35%)	
<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>						

**Table 2b. Summary of Outcomes for Algorithm Cohorts from All Participating National Insurers in the Sentinel Distributed Database (SDD) between February 20, 2020 and September 25, 2020, by Time Period**

	Total Patients Observed		Lab Test Positive***	Total Lab Results Known	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number		Number	Number (Percent)	Number (Percent)	Number (Percent)
	Number	Number	Number	Number (Percent)	Number (Percent)	Number (Percent)
<b>All Times</b>	5,112	40,400	4,771	6,086 (15.06%)	78.39% ( 77.34% , 79.42% )	93.33% (92.61% , 94.00% )
<b>Time A: February 20, 2020 - March 31, 2020</b>	1,129	5,899	1,013	1,132 (19.19%)	89.49% ( 87.55% , 91.21% )	89.73% ( 87.81% , 91.44% )
<b>Time B: April 1, 2020 - April 30, 2020</b>	1,742	11,442	1,661	1,948 (17.02%)	85.27% ( 83.61% , 86.81% )	95.35% ( 94.25% , 96.29% )
<b>Time C: May 1, 2020 - September 25, 2020</b>	2,241	23,059	2,097	3,006 (13.04%)	69.76% ( 68.08% , 71.40% )	93.57% ( 92.48% , 94.55% )
<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>						
<b>All Times</b>	5,112	29,693	3,991	4,824 (16.25%)	82.73% ( 81.64% , 83.79% )	78.07% (76.91% , 79.20% )
<b>Time A: February 20, 2020 - March 31, 2020</b>	1,129	4,805	899	977 (20.33%)	92.02% ( 90.14% , 93.64% )	79.63% ( 77.16% , 81.94% )
<b>Time B: April 1, 2020 - April 30, 2020</b>	1,742	9,012	1,439	1,648 (18.29%)	87.32% ( 85.61% , 88.89% )	82.61% ( 80.74% , 84.36% )
<b>Time C: May 1, 2020 - September 25, 2020</b>	2,241	15,876	1,653	2,199 (13.85%)	75.17% ( 73.31% , 76.96% )	73.76% ( 71.89% , 75.57% )

\*Includes only the first algorithm-qualifying inpatient (IP) stay per algorithm per patient.

\*\* Diagnosis codes provided.

\*\*\*Any NAA result in 14 days prior through 14 days after admission for the inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per IP stay - positive if patient had at least one positive RT-NAA result; negative if all RT-NAA results are negative.

**Table 2c. Summary of Outcomes for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and October 17, 2020, by Time Period**

<b>Algorithm 1: Inpatient (IP) Stay with Code U07.1*</b>						
<b>Total Nucleic Acid Amplification (NAA) Positive Patients</b>	<b>Total Patients Observed</b>	<b>Lab Test Positive***</b>	<b>Total Lab Results Known</b>	<b>Positive Predictive Value (PPV) (95% Confidence Interval)</b>	<b>Sensitivity (95% Confidence Interval)</b>	
<b>Number</b>			<b>Number (Percent)</b>			
<b>All Times</b>						
3,991	4,790	3,694	3,955 (82.57%)	93.40% ( 92.58% , 94.15% )	92.56% ( 91.70% , 93.35% )	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
395	280	226	231 (82.5%)	97.84% ( 95.02% , 99.29% )	57.22% ( 52.17% , 62.15% )	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
1,026	1,276	990	1,064 (83.39%)	93.05% ( 91.35% , 94.50% )	96.49% ( 95.18% , 97.53% )	
<b>Time C: May 1, 2020 - October 17, 2020</b>						
2,570	3,234	2,478	2,660 (82.25%)	93.16% ( 92.13% , 94.09% )	96.42% ( 95.63% , 97.10% )	
<b>Algorithm 2: IP Stay with Any of Codes U07.1, B97.29*</b>						
<b>All Times</b>						
3,991	4,995	3,820	4,105 (82.18%)	93.06% ( 92.24% , 93.82% )	95.72% ( 95.04% , 96.32% )	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
395	472	351	372 (78.81%)	94.35% ( 91.50% , 96.47% )	88.86% ( 85.34% , 91.79% )	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
1,026	1,284	990	1,070 (83.33%)	92.52% ( 90.78% , 94.03% )	96.49% ( 95.18% , 97.53% )	
<b>Time C: May 1, 2020 - October 17, 2020</b>						
2,570	3,239	2,479	2,663 (82.22%)	93.09% ( 92.06% , 94.02% )	96.46% ( 95.67% , 97.14% )	
<b>Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2*</b>						
<b>All Times</b>						
3,991	5,008	3,822	4,113 (82.13%)	92.92% ( 92.10% , 93.69% )	95.77% ( 95.09% , 96.37% )	
<b>Time A: February 20, 2020 - March 31, 2020</b>						
395	481	353	377 (78.38%)	93.63% ( 90.68% , 95.88% )	89.37% ( 85.90% , 92.23% )	
<b>Time B: April 1, 2020 - April 30, 2020</b>						
1,026	1,286	990	1,071 (83.28%)	92.44% ( 90.69% , 93.95% )	96.49% ( 95.18% , 97.53% )	
<b>Time C: May 1, 2020 - October 17, 2020</b>						
2,570	3,241	2,479	2,665 (82.23%)	93.02% ( 91.99% , 93.96% )	96.46% ( 95.67% , 97.14% )	
<b>Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21*</b>						



**Table 2c. Summary of Outcomes for Algorithm Cohorts from All Participating Integrated Delivery Systems in the Sentinel Distributed Database (SDD) between February 20, 2020 and October 17, 2020, by Time Period**

	Total Patients Observed		Lab Test Positive***	Total Lab Results Known	PPV (95% Confidence Interval)	Sensitivity (95% Confidence Interval)
	Number		Number (Percent)			
<b>All Times</b>	3,991	5,017	3,827	4,119 (82.1%)	92.91% ( 92.08% , 93.68% )	95.89% ( 95.23% , 96.49% )
<b>Time A: February 20, 2020 - March 31, 2020</b>	395	487	358	382 (78.44%)	93.72% ( 90.80% , 95.93% )	90.63% ( 87.32% , 93.32% )
<b>Time B: April 1, 2020 - April 30, 2020</b>	1,026	1,289	990	1,072 (83.17%)	92.35% ( 90.59% , 93.87% )	96.49% ( 95.18% , 97.53% )
<b>Time C: May 1, 2020 - October 17, 2020</b>	2,570	3,241	2,479	2,665 (82.23%)	93.02% ( 91.99% , 93.96% )	96.46% ( 95.67% , 97.14% )
<b>Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]*</b>						
<b>All Times</b>	3,991	3,942	3,104	3,284 (83.31%)	94.52% ( 93.68% , 95.27% )	77.77% ( 76.45% , 79.06% )
<b>Time A: February 20, 2020 - March 31, 2020</b>	395	413	321	336 (81.36%)	95.54% ( 92.74% , 97.48% )	81.27% ( 77.06% , 84.99% )
<b>Time B: April 1, 2020 - April 30, 2020</b>	1,026	1,085	852	910 (83.87%)	93.63% ( 91.84% , 95.13% )	83.04% ( 80.60% , 85.29% )
<b>Time C: May 1, 2020 - October 17, 2020</b>	2,570	2,444	1,931	2,038 (83.39%)	94.75% ( 93.69% , 95.68% )	75.14% ( 73.42% , 76.80% )

\*Includes only the first algorithm-qualifying inpatient (IP) stay per algorithm per patient.

\*\* Diagnosis codes provided.

\*\*\*Any NAA result in 14 days prior through 14 days after admission for the inpatient encounter during which the COVID diagnosis codes were recorded.

Includes one test result per IP stay - positive if patient had at least one positive RT-NAA result; negative if all RT-NAA results are negative.

**Table 3. Descriptive Summary of Outpatient Encounters Meeting the COVID-19 Claims Algorithms in the Sentinel Distributed Database (SDD) between May 1, 2020 and October 17, 2020\***

	Algorithm 1: Inpatient (IP) Stay with Code U07.1**	Algorithm 2: IP Stay with Any of Codes U07.1, B97.29**	Algorithm 3: IP Stay with Any of Codes U07.1, B97.29, B34.2**	Algorithm 4: IP Stay with Any of Codes U07.1, B97.29, B34.2, J12.81, B97.21**	Algorithm 5: IP Stay with Codes [U07.1 OR B97.29] and [Pneumonia*** OR Acute Respiratory Distress Syndrome (ARDS) (J80)]**
	Number				
<b>Total Patients Observed</b>	173,733	186,619	198,563	202,917	8,649
<b>Patient History</b>					
No history of hospitalization in prior 30 days (look back for discharge date in prior 30 days)	164,649	177,424	189,177	193,436	5,681
Positive COVID NAA diagnostic test in ±7 days from outpatient encounter	46,395	48,097	49,225	49,387	1,863
<b>Codes Observed During Outpatient Encounter</b>					
Asymptomatic screening (Z11.59)	8,082	8,559	9,197	9,407	74
Contact and suspected exposure (Z20.828)	30,524	38,053	41,918	42,543	383
Pneumonia (see Appendix B)	6,213	6,379	6,473	6,955	8,262
Other viral pneumonia (J12.89)	3,672	3,765	3,760	3,754	5,020
ARDS (J80)	210	217	218	220	271
Sepsis (see Appendix C)	441	445	453	454	276
Bronchitis (J20.8 OR J40)	974	1,115	1,133	1,148	48
Respiratory infection (J22 OR J98.8)	6,787	10,351	10,450	10,454	174
Cough (R05)	16,483	22,503	23,327	23,574	836
Shortness of breath (R06.2)	319	352	377	383	33
Fever (R50.9)	218	218	223	224	30
Procedure code for PCR test (U0001, U0002, U0003, U0004, 87635, 87426)	57,822	64,564	69,375	71,349	549

\*Optional table including results from two of the six participating DPs.

\*\*Includes only the first algorithm-qualifying outpatient encounter per algorithm per patient.

\*\*\* Based on provided diagnosis codes.

**Appendix A. Most Recent Lab Data Dates for Each Data Partner (DP) up to the Request End Date (October 17, 2020)**

<b>DP ID</b>	<b>Most Recent Lab Data</b>
IDS01	09/30/2020
IDS02	10/05/2020
IDS03	10/13/2020
IDS04	10/17/2020
Claims01	09/15/2020
Claims02	09/25/2020

**Appendix B. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Pneumonia in this Request**

Code	Description	Code Category	Code Type
<b>Pneumonia</b>			
J12	Viral pneumonia, not elsewhere classified	Diagnosis	ICD-10-CM
J12.81	Pneumonia due to SARS-associated coronavirus	Diagnosis	ICD-10-CM
J12.89	Other viral pneumonia	Diagnosis	ICD-10-CM
J12.9	Viral pneumonia, unspecified	Diagnosis	ICD-10-CM
J13	Pneumonia due to Streptococcus pneumoniae	Diagnosis	ICD-10-CM
J14	Pneumonia due to Hemophilus influenzae	Diagnosis	ICD-10-CM
J15	Bacterial pneumonia, not elsewhere classified	Diagnosis	ICD-10-CM
J15.0	Pneumonia due to Klebsiella pneumoniae	Diagnosis	ICD-10-CM
J15.1	Pneumonia due to Pseudomonas	Diagnosis	ICD-10-CM
J15.20	Pneumonia due to staphylococcus, unspecified	Diagnosis	ICD-10-CM
J15.211	Pneumonia due to Methicillin susceptible Staphylococcus aureus	Diagnosis	ICD-10-CM
J15.212	Pneumonia due to Methicillin resistant Staphylococcus aureus	Diagnosis	ICD-10-CM
J15.29	Pneumonia due to other staphylococcus	Diagnosis	ICD-10-CM
J15.3	Pneumonia due to streptococcus, group B	Diagnosis	ICD-10-CM
J15.4	Pneumonia due to other streptococci	Diagnosis	ICD-10-CM
J15.5	Pneumonia due to Escherichia coli	Diagnosis	ICD-10-CM
J15.6	Pneumonia due to other Gram-negative bacteria	Diagnosis	ICD-10-CM
J15.7	Pneumonia due to Mycoplasma pneumoniae	Diagnosis	ICD-10-CM
J15.8	Pneumonia due to other specified bacteria	Diagnosis	ICD-10-CM
J15.9	Unspecified bacterial pneumonia	Diagnosis	ICD-10-CM
J16	Pneumonia due to other infectious organisms, not elsewhere classified	Diagnosis	ICD-10-CM
J16.8	Pneumonia due to other specified infectious organisms	Diagnosis	ICD-10-CM
J17	Pneumonia in diseases classified elsewhere	Diagnosis	ICD-10-CM
J18.0	Bronchopneumonia, unspecified organism	Diagnosis	ICD-10-CM
J18.1	Lobar pneumonia, unspecified organism	Diagnosis	ICD-10-CM
J18.8	Other pneumonia, unspecified organism	Diagnosis	ICD-10-CM
J18.9	Pneumonia, unspecified organism	Diagnosis	ICD-10-CM
J95.851	Ventilator associated pneumonia	Diagnosis	ICD-10-CM

**Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Sepsis in this Request**

Code	Description	Code Category	Code Type
<b>Sepsis</b>			
A02.1	Salmonella sepsis	Diagnosis	ICD-10-CM
A20.7	Septicemic plague	Diagnosis	ICD-10-CM
A22.7	Anthrax sepsis	Diagnosis	ICD-10-CM
A26.7	Erysipelothrix sepsis	Diagnosis	ICD-10-CM
A32.7	Listerial sepsis	Diagnosis	ICD-10-CM
A40	Streptococcal sepsis	Diagnosis	ICD-10-CM
A40.0	Sepsis due to streptococcus, group A	Diagnosis	ICD-10-CM
A40.1	Sepsis due to streptococcus, group B	Diagnosis	ICD-10-CM
A40.3	Sepsis due to Streptococcus pneumoniae	Diagnosis	ICD-10-CM
A40.8	Other streptococcal sepsis	Diagnosis	ICD-10-CM
A40.9	Streptococcal sepsis, unspecified	Diagnosis	ICD-10-CM
A41	Other sepsis	Diagnosis	ICD-10-CM
A41.0	Sepsis due to Staphylococcus aureus	Diagnosis	ICD-10-CM
A41.01	Sepsis due to Methicillin susceptible Staphylococcus aureus	Diagnosis	ICD-10-CM
A41.02	Sepsis due to Methicillin resistant Staphylococcus aureus	Diagnosis	ICD-10-CM
A41.0Z16	Sepsis due to Staphylococcus aureus Infection with drug resistant microorganisms	Diagnosis	ICD-10-CM
A41.1	Sepsis due to other specified staphylococcus	Diagnosis	ICD-10-CM
A41.2	Sepsis due to unspecified staphylococcus	Diagnosis	ICD-10-CM
A41.3	Sepsis due to Hemophilus influenzae	Diagnosis	ICD-10-CM
A41.4	Sepsis due to anaerobes	Diagnosis	ICD-10-CM
A41.5	Sepsis due to other Gram-negative organisms	Diagnosis	ICD-10-CM
A41.50	Gram-negative sepsis, unspecified	Diagnosis	ICD-10-CM
A41.51	Sepsis due to Escherichia coli [E. coli]	Diagnosis	ICD-10-CM
A41.52	Sepsis due to Pseudomonas	Diagnosis	ICD-10-CM
A41.53	Sepsis due to Serratia	Diagnosis	ICD-10-CM
A41.59	Other Gram-negative sepsis	Diagnosis	ICD-10-CM
A41.8	Other specified sepsis	Diagnosis	ICD-10-CM
A41.81	Sepsis due to Enterococcus	Diagnosis	ICD-10-CM
A41.89	Other specified sepsis	Diagnosis	ICD-10-CM
A41.9	Sepsis, unspecified organism	Diagnosis	ICD-10-CM
A42.7	Actinomycotic sepsis	Diagnosis	ICD-10-CM
A54.86	Gonococcal sepsis	Diagnosis	ICD-10-CM
B37.7	Candidal sepsis	Diagnosis	ICD-10-CM
I26.01	Septic pulmonary embolism with acute cor pulmonale	Diagnosis	ICD-10-CM
I26.90	Septic pulmonary embolism without acute cor pulmonale	Diagnosis	ICD-10-CM
I76	Septic arterial embolism	Diagnosis	ICD-10-CM
P36	Bacterial sepsis of newborn	Diagnosis	ICD-10-CM
P36.0	Sepsis of newborn due to streptococcus, group B	Diagnosis	ICD-10-CM
P36.1	Sepsis of newborn due to other and unspecified streptococci	Diagnosis	ICD-10-CM
P36.10	Sepsis of newborn due to unspecified streptococci	Diagnosis	ICD-10-CM
P36.19	Sepsis of newborn due to other streptococci	Diagnosis	ICD-10-CM

**Appendix C. List of International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Diagnosis Codes Used to Define Sepsis in this Request**

<b>Code</b>	<b>Description</b>	<b>Code Category</b>	<b>Code Type</b>
P36.2	Sepsis of newborn due to Staphylococcus aureus	Diagnosis	ICD-10-CM
P36.3	Sepsis of newborn due to other and unspecified staphylococci	Diagnosis	ICD-10-CM
P36.30	Sepsis of newborn due to unspecified staphylococci	Diagnosis	ICD-10-CM
P36.39	Sepsis of newborn due to other staphylococci	Diagnosis	ICD-10-CM
P36.4	Sepsis of newborn due to Escherichia coli	Diagnosis	ICD-10-CM
P36.5	Sepsis of newborn due to anaerobes	Diagnosis	ICD-10-CM
P36.8	Other bacterial sepsis of newborn	Diagnosis	ICD-10-CM
P36.9	Bacterial sepsis of newborn, unspecified	Diagnosis	ICD-10-CM
R65.2	Severe sepsis	Diagnosis	ICD-10-CM
R65.20	Severe sepsis without septic shock	Diagnosis	ICD-10-CM
R65.21	Severe sepsis with septic shock	Diagnosis	ICD-10-CM
T81.12	Postprocedural septic shock	Diagnosis	ICD-10-CM
T81.12XA	Postprocedural septic shock, initial encounter	Diagnosis	ICD-10-CM
T81.12XD	Postprocedural septic shock, subsequent encounter	Diagnosis	ICD-10-CM
T81.12XS	Postprocedural septic shock, sequela	Diagnosis	ICD-10-CM
T81.44	Sepsis following a procedure	Diagnosis	ICD-10-CM
T81.44XA	Sepsis following a procedure, initial encounter	Diagnosis	ICD-10-CM
T81.44XD	Sepsis following a procedure, subsequent encounter	Diagnosis	ICD-10-CM
T81.44XS	Sepsis following a procedure, sequela	Diagnosis	ICD-10-CM

**Appendix D. List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Nucleic Acid Amplification (NAA) Diagnostic Tests in this Request**

Code	Short Name	Long Common Name
<b>COVID Nucleic Acid Amplification (NAA) Diagnostic Tests</b>		
95521-1	SARS-CoV-2 N gene # Resp NAA+probe	SARS-CoV-2 (COVID-19) N gene [# /volume] (viral load) in Respiratory specimen by NAA with probe detection
94510-5	SARS-CoV-2 N gene Ct XXX Qn NAA+probe	SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection
94311-8	SARS-CoV-2 N gene Ct XXX Qn NAA N1	SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N1
94312-6	SARS-CoV-2 N gene Ct XXX Qn NAA N2	SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N2
95522-9	SARS-CoV-2 N gene Resp NAA+probe-Log#	SARS-CoV-2 (COVID-19) N gene [Log # /volume] (viral load) in Respiratory specimen by NAA with probe detection
94760-6	SARS-CoV-2 N gene Nph QI NAA+probe	SARS-CoV-2 (COVID-19) N gene [Presence] in Nasopharynx by NAA with probe detection
95409-9	SARS-CoV-2 N gene Nose QI NAA+probe	SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection
94533-7	SARS-CoV-2 N gene Resp QI NAA+probe	SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by NAA with probe detection
94756-4	SARS-CoV-2 N gene Resp QI NAA N1	SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1
94757-2	SARS-CoV-2 N gene Resp QI NAA N2	SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N2
95425-5	SARS-CoV-2 N gene Sal QI NAA+probe	SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection
94766-3	SARS-CoV-2 N gene SerPI QI NAA+probe	SARS-CoV-2 (COVID-19) N gene [Presence] in Serum or Plasma by NAA with probe detection
94316-7	SARS-CoV-2 N gene XXX QI NAA+probe	SARS-CoV-2 (COVID-19) N gene [Presence] in Unspecified specimen by NAA with probe detection
94307-6	SARS-CoV-2 N gene XXX QI NAA N1	SARS-CoV-2 (COVID-19) N gene [Presence] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N1
94308-4	SARS-CoV-2 N gene XXX QI NAA N2	SARS-CoV-2 (COVID-19) N gene [Presence] in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N2
94644-2	SARS-CoV-2 ORF1ab Ct Resp Qn NAA+probe	SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Respiratory specimen by NAA with probe detection
94511-3	SARS-CoV-2 ORF1ab Ct XXX Qn NAA+probe	SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Unspecified specimen by NAA with probe detection
94559-2	SARS-CoV-2 ORF1ab Resp QI NAA+probe	SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Respiratory specimen by NAA with probe detection
95824-9	SARS-CoV-2 ORF1ab Sal QI NAA+probe	SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection
94639-2	SARS-CoV-2 ORF1ab XXX QI NAA+probe	SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Unspecified specimen by NAA with probe detection
94646-7	SARS-CoV-2 RdRp Ct Resp Qn NAA+probe	SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection
94645-9	SARS-CoV-2 RdRp Ct XXX Qn NAA+probe	SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection
94534-5	SARS-CoV-2 RdRp Resp QI NAA+probe	SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Respiratory specimen by NAA with probe detection
94314-2	SARS-CoV-2 RdRp XXX QI NAA+probe	SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Unspecified specimen by NAA with probe detection
94745-7	SARS-CoV-2 RNA Ct Resp Qn NAA+probe	SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory specimen by NAA with probe detection

**Appendix D. List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Nucleic Acid Amplification (NAA) Diagnostic Tests in this Request**

<b>Code</b>	<b>Short Name</b>	<b>Long Common Name</b>
94746-5	SARS-CoV-2 RNA Ct XXX Qn NAA+probe	SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Unspecified specimen by NAA with probe detection
94819-0	SARS-CoV-2 RNA XXX NAA+probe-Log#	SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Unspecified specimen by NAA with probe detection
94565-9	SARS-CoV-2 RNA Nph Ql NAA+non-probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection
94759-8	SARS-CoV-2 RNA Nph Ql NAA+probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection
95406-5	SARS-CoV-2 RNA Nose Ql NAA+probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection
95608-6	SARS-CoV-2 RNA Resp Ql NAA+non-probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with non-probe detection
94500-6	SARS-CoV-2 RNA Resp Ql NAA+probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory specimen by NAA with probe detection
94845-5	SARS-CoV-2 RNA Sal Ql NAA+probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by NAA with probe detection
94660-8	SARS-CoV-2 RNA SerPl Ql NAA+probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Serum or Plasma by NAA with probe detection
94309-2	SARS-CoV-2 RNA XXX Ql NAA+probe	SARS-CoV-2 (COVID-19) RNA [Presence] in Unspecified specimen by NAA with probe detection
94531-1	SARS-CoV-2 RNA Pnl Resp NAA+probe	SARS-CoV-2 (COVID-19) RNA panel - Respiratory specimen by NAA with probe detection
95826-4	SARS-CoV-2 RNA Pnl Sal NAA+probe	SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection
94306-8	SARS-CoV-2 RNA Pnl XXX NAA+probe	SARS-CoV-2 (COVID-19) RNA panel - Unspecified specimen by NAA with probe detection
94642-6	SARS-CoV-2 S gene Ct Resp Qn NAA+probe	SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Respiratory specimen by NAA with probe detection
94643-4	SARS-CoV-2 S gene Ct XXX Qn NAA+probe	SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Unspecified specimen by NAA with probe detection
94640-0	SARS-CoV-2 S gene Resp Ql NAA+probe	SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory specimen by NAA with probe detection
94767-1	SARS-CoV-2 S gene SerPl Ql NAA+probe	SARS-CoV-2 (COVID-19) S gene [Presence] in Serum or Plasma by NAA with probe detection
94641-8	SARS-CoV-2 S gene XXX Ql NAA+probe	SARS-CoV-2 (COVID-19) S gene [Presence] in Unspecified specimen by NAA with probe detection



**Appendix E. List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Antibody Tests in this Request**


Code	Short Name	Long Common Name
<b>COVID Antibody Tests</b>		
94661-6	SARS-CoV-2 Ab SerPI-Imp	SARS-CoV-2 (COVID-19) Ab [Interpretation] in Serum or Plasma
95825-6	SARS-CoV-2 Ab DBS QI IA	SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay
94762-2	SARS-CoV-2 Ab SerPI QI IA	SARS-CoV-2 (COVID-19) Ab [Presence] in Serum or Plasma by Immunoassay
94769-7	SARS-CoV-2 Ab SerPI IA-aCnc	SARS-CoV-2 (COVID-19) Ab [Units/volume] in Serum or Plasma by Immunoassay
94504-8	SARS-CoV-2 Ab Pnl SerPI IA	SARS-CoV-2 (COVID-19) Ab panel - Serum or Plasma by Immunoassay
94503-0	SARS-CoV-2 Ab Pnl SerPIBld IA.rapid	SARS-CoV-2 (COVID-19) Ab panel - Serum, Plasma or Blood by Rapid immunoassay
94562-6	SARS-CoV-2 IgA SerPI QI IA	SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum or Plasma by Immunoassay
94768-9	SARS-CoV-2 IgA SerPIBld QI IA.rapid	SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay
95427-1	SARS-CoV-2 IgA Titr SerPI IF	SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence
94720-0	SARS-CoV-2 IgA SerPI IA-aCnc	SARS-CoV-2 (COVID-19) IgA Ab [Units/volume] in Serum or Plasma by Immunoassay
95125-1	SARS-CoV-2 IgA+IgM SerPI QI IA	SARS-CoV-2 (COVID-19) IgA+IgM [Presence] in Serum or Plasma by Immunoassay
94761-4	SARS-CoV-2 IgG DBS QI IA	SARS-CoV-2 (COVID-19) IgG Ab [Presence] in DBS by Immunoassay
94563-4	SARS-CoV-2 IgG SerPI QI IA	SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum or Plasma by Immunoassay
94507-1	SARS-CoV-2 IgG SerPIBld QI IA.rapid	SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay
95429-7	SARS-CoV-2 IgG Titr SerPI IF	SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence
94505-5	SARS-CoV-2 IgG SerPI IA-aCnc	SARS-CoV-2 (COVID-19) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay
94547-7	SARS-CoV-2 IgG+IgM SerPI QI IA	SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay
95542-7	SARS-CoV-2 IgG+IgM SerPIBld QI IA.rapid	SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay
95416-4	SARS-CoV-2 IgM DBS QI IA	SARS-CoV-2 (COVID-19) IgM Ab [Presence] in DBS by Immunoassay
94564-2	SARS-CoV-2 IgM SerPI QI IA	SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum or Plasma by Immunoassay
94508-9	SARS-CoV-2 IgM SerPIBld QI IA.rapid	SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay
95428-9	SARS-CoV-2 IgM Titr SerPI IF	SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence
94506-3	SARS-CoV-2 IgM SerPI IA-aCnc	SARS-CoV-2 (COVID-19) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay
95411-5	SARS-CoV-2 NAb Ser QI pVNT	SARS-CoV-2 (COVID-19) neutralizing antibody [Presence] in Serum by pVNT
95410-7	SARS-CoV-2 NAb Titr Ser pVNT	SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT

**Appendix F. List of Logical Observation Identifiers Names and Codes (LOINC) Terminology Used to Define COVID Antigen Tests in this Request**


<b>Code</b>	<b>Short Name</b>	<b>Long Common Name</b>
<b>COVID Antigen Tests</b>		
95209-3	SARS-CoV+SARS-CoV-2 Ag Resp Ql IA.rapid	SARS-CoV+SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay
94558-4	SARS-CoV-2 Ag Resp Ql IA.rapid	SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory specimen by Rapid immunoassay

Appendix G. Design Diagrams Detailing the Study Parameters for this Request for each of the Three Time Periods Assessed

Time Period A:



Time Period B:



Appendix G. Design Diagrams Detailing the Study Parameters for this Request for each of the Three Time Periods Assessed

Time Period C:

